U.S. patent application number 11/320229 was filed with the patent office on 2006-05-18 for drug efflux pump inhibitor.
This patent application is currently assigned to Daiichi Pharmaceutical Co., Ltd.. Invention is credited to Aesop Cho, Haruko Kawato, Kiyoshi Nakayama, Masami Ohtsuka, Monica Palme, William Watkins, Jason Zhang.
Application Number | 20060106034 11/320229 |
Document ID | / |
Family ID | 25286829 |
Filed Date | 2006-05-18 |
United States Patent
Application |
20060106034 |
Kind Code |
A1 |
Nakayama; Kiyoshi ; et
al. |
May 18, 2006 |
Drug efflux pump inhibitor
Abstract
A medicament for preventive and/or therapeutic treatment of a
microbial infection which comprises as an active ingredient a
compound represented by the following general formula (I): ##STR1##
wherein, R.sup.1 and R.sup.2 represent hydrogen atom, a halogen
atom, hydroxyl group or the like, W.sup.1 represents --CH.dbd.CH--,
--CH.sub.2O--, --CH.sub.2CH.sub.2-- or the like; R.sup.3 represents
hydrogen atom, a halogen atom, hydroxyl group or an amino group;
R.sup.4 represents hydrogen atom, a group of --OZ.sub.0-4R.sup.5
(Z.sub.0-4 represents an alkylene group, a fluorine-substituted
alkylene group or a single bond, and R.sup.5 represents a cyclic
alkyl group, an aryl group or the like); W.sup.2 represents a
single bond or --C(R.sup.8).dbd.C(R.sup.9)-(R.sup.8 and R.sup.9
represent hydrogen atom, a halogen atom, a lower alkyl group or the
like, Q represents an acidic group, but W.sup.2 and Q may together
form vinylidenethiazolidinedione or an equivalent heterocyclic
ring; m and n represent an integer of 0 to 2, and q represents an
integer of 0 to 3.
Inventors: |
Nakayama; Kiyoshi;
(Funabashi-shi, JP) ; Ohtsuka; Masami; (Tokyo,
JP) ; Kawato; Haruko; (Tokyo, JP) ; Watkins;
William; (Sunnyvale, CA) ; Zhang; Jason;
(Foster City, CA) ; Palme; Monica; (San Jose,
CA) ; Cho; Aesop; (Mountain View, CA) |
Correspondence
Address: |
GREENBLUM & BERNSTEIN, P.L.C.
1950 ROLAND CLARKE PLACE
RESTON
VA
20191
US
|
Assignee: |
Daiichi Pharmaceutical Co.,
Ltd.
Tokyo
MA
Trine Pharmaceuticals, Inc.
Waltham
|
Family ID: |
25286829 |
Appl. No.: |
11/320229 |
Filed: |
December 29, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09842234 |
Apr 26, 2001 |
|
|
|
11320229 |
Dec 29, 2005 |
|
|
|
Current U.S.
Class: |
514/259.41 |
Current CPC
Class: |
A61K 31/519 20130101;
A61K 31/427 20130101; A61K 31/4745 20130101; A61K 31/496 20130101;
A61K 31/5025 20130101; A61K 31/549 20130101; C12Q 1/18 20130101;
A61K 31/55 20130101; C07D 417/12 20130101; A61K 31/5377 20130101;
A61K 45/06 20130101; C07D 417/06 20130101; A61K 31/4709 20130101;
C07D 471/04 20130101 |
Class at
Publication: |
514/259.41 |
International
Class: |
A61K 31/519 20060101
A61K031/519 |
Claims
1. A method for therapeutic treatment of microbial infection
comprising administering to a mammal in need thereof a
therapeutically effective amount of a compound represented by the
following formula (I) or a physiologically acceptable salt, or a
hydrate thereof: ##STR36## wherein, R.sup.1 and R.sup.2 each
independently represent hydrogen atom, a halogen atom, hydroxyl
group, a group of OZ.sub.1-6 (the group of OZ.sub.1-6 represents an
alkyl group having 1-6 carbon atoms or a fluoroalkyl group having
1-6 carbon atoms, which bonds via the oxygen atom), a group of
S(O).sub.nZ.sub.1-4 (Z.sub.1-4 represents an alkyl group having 1-4
carbon atoms or a fluoroalkyl group having 1-4 carbon atoms or an
alkylene group derived therefrom), a group of N(R.sup.12)(R.sup.13)
(R.sup.12 and R.sup.13 each independently represent hydrogen atom,
an alkyl group having 1-4 carbon atoms or a fluoroalkyl group
having 1-4 carbon atoms), a group of Z.sub.1-8 which may be
substituted (Z.sub.1-8 represents an alkyl group having 1-8 carbon
atoms or a fluoroalkyl group having 1-8 carbon atoms), a 5- to
7-membered cyclic alkyl group, an aryl group, a heteroaryl group,
or a 4- to 7-membered saturated or partially saturated heterocyclic
group (the cyclic alkyl group, aryl group, heteroaryl group and
heterocyclic group may have one to three substituents selected from
the group consisting of a halogen atom, hydroxyl group, a group of
OZ.sub.1-4, a group of S(O).sub.nZ.sub.1-4, a group of
N(R.sup.12)(R.sup.13), a group of Z.sub.1-4, carboxyl group, a
group of CO.sub.2Z.sub.1-4, group of CONH.sub.2, a group of
CONH(Z.sub.1-4) and a group of CON(Z.sub.1-4)(Z.sub.1-4)); W.sup.1
represents a group selected from the group consisting of
--CH.dbd.CH--, --N(R.sup.12)CO--, --CON(R.sup.12)--, --CH.sub.2O--
and --CH.sub.2CH.sub.2-- (each of the aforementioned groups binds
to the thiazole ring at the left end); R.sup.3 represents hydrogen
atom, a halogen atom, hydroxyl group or an amino group; R.sup.4
represents a group selected from the group consisting of hydrogen
atom, a group of --OZ.sub.0-4R.sup.5 (Z.sub.0-4 represents an
alkylene group having 1-4 carbon atoms, a fluorine-substituted
alkylene group having 1-4 carbon atoms or a single bond, and
R.sup.5 represents a 5- to 7-membered cyclic alkyl group, an aryl
group, a heteroaryl group or a 4- to 7-membered saturated or
partially saturated heterocyclic group (the cyclic alkyl group,
aryl group, heteroaryl group and heterocyclic group may have one to
three substituents selected from the group consisting of a halogen
atom, hydroxyl group, a group of OZ.sub.1-4, a group of
S(O).sub.nZ.sub.1-4, a group of N(R.sup.12)(R.sup.13), a group of
Z.sub.1-4, carboxyl group, a group of CO.sub.2Z.sub.1-4, group of
CONH.sub.2, a group of CONH(Z.sub.1-4) and a group of
CON(Z.sub.1-4)(Z.sub.1-4)), a group of
--S(O).sub.nZ.sub.0-4R.sup.5, a group of --N(R.sup.6)(R.sup.7)
{R.sup.6 and R.sup.7 each independently represent hydrogen atom or
Z.sub.1-4, or they may bind to each other to form a saturated or
unsaturated 5- to 7-membered ring (the ring may contain one or two
hetero atoms as ring constituting atoms), and R.sup.6 and R.sup.7
may have one to three substituents selected from the group
consisting of a halogen atom, hydroxyl group, a group of
OCON(R.sup.12)(R.sup.13), a group of CON(R.sup.12)(R.sup.13), a
group of N(R.sup.12)CON(R.sup.12)(R.sup.13), a group of Z.sub.1-4,
a group of OZ.sub.1-4, a group S(O).sub.nZ.sub.1-4, group of
CH.sub.2OH, a group of (CH.sub.2).sub.mN(R.sup.12)(R.sup.13),
carboxyl group, cyano group, a group of
CO-Z.sub.1-4(R.sup.10)--N(R.sup.12)(R.sup.13) (R.sup.10 is a
substituent corresponding to a side chain on an amino acid carbon
or a group of -Z.sub.1-4-R.sup.11 (R.sup.11 represents a
substituent which forms a quaternary salt) and a group of ##STR37##
a 5- or 6-membered aryl group which may be substituted and a 5- or
6-membered unsaturated heterocyclic group which may be substituted;
W.sup.2 represents a single bond or --C(R.sup.8).dbd.C(R.sup.9)--
(R.sup.8 and R.sup.9 each independently represent hydrogen atom, a
halogen atom, a lower alkyl group, an alkoxy group, cyano group,
carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group
or a group of N(R.sup.12)(R.sup.13)), Q represents an acidic group,
and W.sup.2 and Q may bind together to form
vinylidenethiazolidinedione in E- or Z-configuration or an
equivalent heterocyclic ring; m and n each independently represent
an integer of 0 to 2, and q represents an integer of 0 to 3.
2. The method according to claim 1, further comprising
administering at least one antimicrobial agent.
3. The method according to claim 2, wherein the compound is an
active ingredient in a composition.
4. The method according to claim 3, wherein the at least one
antimicrobial agent is simultaneously administered with the
composition.
5. The method according to claim 3, wherein the at least one
antimicrobial agent is separately administered from the
composition.
6. The method according to claim 3, wherein the at least one
antimicrobial agent is successively administered with the
composition.
7. The method according to claim 1 wherein the mammal is a
human.
8. The method according to claim 1 wherein the microbial infection
comprises an infection by bacteria having a genetically homologous
drug efflux pump to Pseudomonas aeruginosa
9. A method for preventive treatment of a microbial infection
comprising administering to a mammal a preventively effective
amount of a compound represented by the following formula (I) or a
physiologically acceptable salt, or a hydrate thereof: ##STR38##
wherein, R.sup.1 and R.sup.2 each independently represent hydrogen
atom, a halogen atom, hydroxyl group, a group of OZ.sub.1-6 (the
group of OZ.sub.1-6 represents an alkyl group having 1-6 carbon
atoms or a fluoroalkyl group having 1-6 carbon atoms, which bonds
via the oxygen atom), a group of S(O).sub.nZ.sub.1-4 (Z.sub.1-4
represents an alkyl group having 1-4 carbon atoms or a fluoroalkyl
group having 1-4 carbon atoms or an alkylene group derived
therefrom), a group of N(R.sup.12)(R.sup.13) (R.sup.12 and R.sup.13
each independently represent hydrogen atom, an alkyl group having
1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms), a
group of Z.sub.1-8 which may be substituted (Z.sub.1-8 represents
an alkyl group having 1-8 carbon atoms or a fluoroalkyl group
having 1-8 carbon atoms), a 5- to 7-membered cyclic alkyl group, an
aryl group, a heteroaryl group, or a 4- to 7-membered saturated or
partially saturated heterocyclic group (the cyclic alkyl group,
aryl group, heteroaryl group and heterocyclic group may have one to
three substituents selected from the group consisting of a halogen
atom, hydroxyl group, a group of OZ.sub.1-4, a group of
S(O).sub.nZ.sub.1-4, a group of N(R.sup.12)(R.sup.13), a group of
Z.sub.1-4, carboxyl group, a group of CO.sub.2Z.sub.1-4, group of
CONH.sub.2, a group of CONH(Z.sub.1-4) and a group of
CON(Z.sub.1-4)(Z.sub.1-4)); W.sup.1 represents a group selected
from the group consisting of --CH.dbd.CH--, --N(R.sup.12)CO--,
--CON(R.sup.12)--, --CH.sub.2O-- and --CH.sub.2CH.sub.2-- (each of
the aforementioned groups binds to the thiazole ring at the left
end); R.sup.3 represents hydrogen atom, a halogen atom, hydroxyl
group or an amino group; R.sup.4 represents a group selected from
the group consisting of hydrogen atom, a group of
--OZ.sub.0-4R.sup.5 (Z.sub.0-4 represents an alkylene group having
1-4 carbon atoms, a fluorine-substituted alkylene group having 1-4
carbon atoms or a single bond, and R.sup.5 represents a 5- to
7-membered cyclic alkyl group, an aryl group, a heteroaryl group or
a 4- to 7-membered saturated or partially saturated heterocyclic
group (the cyclic alkyl group, aryl group, heteroaryl group and
heterocyclic group may have one to three substituents selected from
the group consisting of a halogen atom, hydroxyl group, a group of
OZ.sub.1-4, a group of S(O).sub.nZ.sub.1-4, a group of
N(R.sup.12)(R.sup.13), a group of Z.sub.1-4, carboxyl group, a
group of CO.sub.2Z.sub.1-4, group of CONH.sub.2, a group of
CONH(Z.sub.1-4) and a group of CON(Z.sub.1-4)(Z.sub.1-4)), a group
of --S(O).sub.nZ.sub.0-4R.sup.5, a group of --N(R.sup.6)(R.sup.7)
{R.sup.6 and R.sup.7 each independently represent hydrogen atom or
Z.sub.1-4, or they may bind to each other to form a saturated or
unsaturated 5- to 7-membered ring (the ring may contain one or two
hetero atoms as ring constituting atoms), and R.sup.6 and R.sup.7
may have one to three substituents selected from the group
consisting of a halogen atom, hydroxyl group, a group of
OCON(R.sup.12)(R.sup.13), a group of CON(R.sup.12)(R.sup.13), a
group of N(R.sup.12)CON(R.sup.12)(R.sup.13), a group of Z.sub.1-4,
a group of OZ.sub.1-4, a group S(O).sub.nZ.sub.1-4, group of
CH.sub.2OH, a group of (CH.sub.2).sub.mN(R.sup.12)(R.sup.13),
carboxyl group, cyano group, a group of
CO-Z.sub.1-4(R.sup.10)--N(R.sup.12)(R.sup.13) (R.sup.10 is a
substituent corresponding to a side chain on an amino acid carbon
or a group of -Z.sub.1-4-R.sup.11 (R.sup.11 represents a
substituent which forms a quaternary salt) and a group of ##STR39##
a 5- or 6-membered aryl group which may be substituted and a 5- or
6-membered unsaturated heterocyclic group which may be substituted;
W.sup.2 represents a single bond or --C(R.sup.8).dbd.C(R.sup.9)--
(R.sup.8 and R.sup.9 each independently represent hydrogen atom, a
halogen atom, a lower alkyl group, an alkoxy group, cyano group,
carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group
or a group of N(R.sup.12)(R.sup.13)), Q represents an acidic group,
and W.sup.2 and Q may bind together to form
vinylidenethiazolidinedione in E- or Z-configuration or an
equivalent heterocyclic ring; m and n each independently represent
an integer of 0 to 2, and q represents an integer of 0 to 3.
10. The method according to claim 9, further comprising
administering at least one antimicrobial agent.
11. The method according to claim 10, wherein the compound is an
active ingredient in a composition.
12. The method according to claim 11, wherein the at least one
antimicrobial agent is simultaneously administered with the
composition.
13. The method according to claim 11, wherein the at least one
antimicrobial agent is separately administered from the
composition.
14. The method according to claim 11, wherein the at least one
antimicrobial agent is successively administered with the
composition.
15. The method according to claim 9 wherein the mammal is a
human.
16. The method according to claim 9 wherein the microbial infection
comprises an infection by microorganisms selected from Pseudomonas
aeruginosa and bacteria having a genetically homologous drug efflux
pump to Pseudomonas aeruginosa.
17. A method for therapeutic treatment of a microbial infection
comprising administering to a mammal in need thereof a
therapeutically effective amount of a compound represented by the
following formula (I) or a physiologically acceptable salt, or a
hydrate thereof: ##STR40## wherein, R.sup.1 and R.sup.2 each
independently represent hydrogen atom, a halogen atom, hydroxyl
group, a group of OZ.sub.1-6 (the group of OZ.sub.1-6 represents an
alkyl group having 1-6 carbon atoms or a fluoroalkyl group having
1-6 carbon atoms, which bonds via the oxygen atom), a group of
S(O).sub.nZ.sub.1-4 (Z.sub.1-4 represents an alkyl group having 1-4
carbon atoms or a fluoroalkyl group having 1-4 carbon atoms or an
alkylene group derived therefrom), a group of N(R.sup.12)(R.sup.13)
(R.sup.12 and R.sup.13 each independently represent hydrogen atom,
an alkyl group having 1-4 carbon atoms or a fluoroalkyl group
having 1-4 carbon atoms), a group of Z.sub.1-8 which may be
substituted (Z.sub.1-8 represents an alkyl group having 1-8 carbon
atoms or a fluoroalkyl group having 1-8 carbon atoms), a 5- to
7-membered cyclic alkyl group, an aryl group, a heteroaryl group,
or a 4- to 7-membered saturated or partially saturated heterocyclic
group (the cyclic alkyl group, aryl group, heteroaryl group and
heterocyclic group may have one to three substituents selected from
the group consisting of a halogen atom, hydroxyl group, a group of
OZ.sub.1-4, a group of S(O).sub.nZ.sub.1-4, a group of
N(R.sup.12)(R.sup.13), a group of Z.sub.1-4, carboxyl group, a
group of CO.sub.2Z.sub.1-4, group of CONH.sub.2, a group of
CONH(Z.sub.1-4) and a group of CON(Z.sub.1-4)(Z.sub.1-4)); W.sup.1
represents a group selected from the group consisting of
--CH.dbd.CH--, --N(R.sup.12)CO--, --CON(R.sup.12)--, --CH.sub.2O--
and --CH.sub.2CH.sub.2-- (each of the aforementioned groups binds
to the thiazole ring at the left end); R.sup.3 represents hydrogen
atom, a halogen atom, hydroxyl group or an amino group; R.sup.4
represents a group selected from the group consisting of hydrogen
atom, a group of --OZ.sub.0-4R.sup.5 (Z.sub.0-4 represents an
alkylene group having 1-4 carbon atoms, a fluorine-substituted
alkylene group having 1-4 carbon atoms or a single bond, and
R.sup.5 represents a 5- to 7-membered cyclic alkyl group, an aryl
group, a heteroaryl group or a 4- to 7-membered saturated or
partially saturated heterocyclic group (the cyclic alkyl group,
aryl group, heteroaryl group and heterocyclic group may have one to
three substituents selected from the group consisting of a halogen
atom, hydroxyl group, a group of OZ.sub.1-4, a group of
S(O).sub.nZ.sub.1-4, a group of N(R.sup.12)(R.sup.13), a group of
Z.sub.1-4, carboxyl group, a group of CO.sub.2Z.sub.1-4, group of
CONH.sub.2, a group of CONH(Z.sub.1-4) and a group of
CON(Z.sub.1-4)(Z.sub.1-4)), a group of
--S(O).sub.nZ.sub.0-4R.sup.5, a group of --N(R.sup.6)(R.sup.7)
{R.sup.6 and R.sup.7 each independently represent hydrogen atom or
Z.sub.1-4, or they may bind to each other to form a saturated or
unsaturated 5- to 7-membered ring (the ring may contain one or two
hetero atoms as ring constituting atoms), and R.sup.6 and R.sup.7
may have one to three substituents selected from the group
consisting of a halogen atom, hydroxyl group, a group of
OCON(R.sup.12)(R.sup.13), a group of CON(R.sup.12)(R.sup.13), a
group of N(R.sup.12)CON(R.sup.12)(R.sup.13), a group of Z.sub.1-4,
a group of OZ.sub.1-4, a group S(O).sub.nZ.sub.1-4, group of
CH.sub.2OH, a group of (CH.sub.2).sub.mN(R.sup.12)(R.sup.13),
carboxyl group, cyano group, a group of
CO-Z.sub.1-4(R.sup.10)--N(R.sup.12)(R.sup.13) (R.sup.10 is a
substituent corresponding to a side chain on an amino acid carbon
or a group of -Z.sub.1-4-R.sup.11 (R.sup.11 represents a
substituent which forms a quaternary salt) and a group of ##STR41##
a 5- or 6-membered aryl group which may be substituted and a 5- or
6-membered unsaturated heterocyclic group which may be substituted;
W.sup.2 represents a single bond or --C(R.sup.8).dbd.C(R.sup.9)--
(R.sup.8 and R.sup.9 each independently represent hydrogen atom, a
halogen atom, a lower alkyl group, an alkoxy group, cyano group,
carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group
or a group of N(R.sup.12)(R.sup.13)), Q represents an acidic group,
and W.sup.2 and Q may bind together to form
vinylidenethiazolidinedione in E- or Z-configuration or an
equivalent heterocyclic ring; m and n each independently represent
an integer of 0 to 2, and q represents an integer of 0 to 3;
R.sup.14 represents hydrogen atom, Z.sub.1-4, Z.sub.1-4R.sup.5 or
Z.sub.1-4OR.sup.5; and X represents C--H and Y represents C--H or
nitrogen atom.
18. The method according to claim 17, further comprising
administering at least one antimicrobial agent.
19. The method according to claim 18, wherein the compound is an
active ingredient in a composition.
20. The method according to claim 17, wherein the microbial
infection comprises an infection by bacteria having a genetically
homologous drug efflux pump to Pseudomonas aeruginosa.
21. The method according to claim 17, wherein the at least one
antimicrobial agent and the compound are present in a
composition.
22. A method for preventive treatment of a microbial infection
comprising administering to a mammal a preventively effective
amount of a compound represented by the following formula (I) or a
physiologically acceptable salt, or a hydrate thereof: ##STR42##
wherein, R.sup.1 and R.sup.2 each independently represent hydrogen
atom, a halogen atom, hydroxyl group, a group of OZ.sub.1-6 (the
group of OZ.sub.1-6 represents an alkyl group having 1-6 carbon
atoms or a fluoroalkyl group having 1-6 carbon atoms, which bonds
via the oxygen atom), a group of S(O).sub.nZ.sub.1-4 (Z.sub.0-4
represents an alkyl group having 1-4 carbon atoms or a fluoroalkyl
group having 1-4 carbon atoms or an alkylene group derived
therefrom), a group of N(R.sup.12)(R.sup.13) (R.sup.12 and R.sup.13
each independently represent hydrogen atom, an alkyl group having
1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms), a
group of Z.sub.1-8 which may be substituted (Z.sub.1-8 represents
an alkyl group having 1-8 carbon atoms or a fluoroalkyl group
having 1-8 carbon atoms), a 5- to 7-membered cyclic alkyl group, an
aryl group, a heteroaryl group, or a 4- to 7-membered saturated or
partially saturated heterocyclic group (the cyclic alkyl group,
aryl group, heteroaryl group and heterocyclic group may have one to
three substituents selected from the group consisting of a halogen
atom, hydroxyl group, a group of OZ.sub.1-4, a group of
S(O).sub.nZ.sub.1-4, a group of N(R.sup.12)(R.sup.13), a group of
Z.sub.1-4, carboxyl group, a group of CO.sub.2Z.sub.1-4, group of
CONH.sub.2, a group of CONH(Z.sub.1-4) and a group of
CON(Z.sub.1-4)(Z.sub.1-4)); W.sup.1 represents a group selected
from the group consisting of --CH.dbd.CH--, --N(R.sup.12)CO--,
--CON(R.sup.12)--, --CH.sub.2O-- and --CH.sub.2CH.sub.2-- (each of
the aforementioned groups binds to the thiazole ring at the left
end); R.sup.3 represents hydrogen atom, a halogen atom, hydroxyl
group or an amino group; R.sup.4 represents a group selected from
the group consisting of hydrogen atom, a group of
--OZ.sub.0-4R.sup.5 (Z.sub.0-4 represents an alkylene group having
1-4 carbon atoms, a fluorine-substituted alkylene group having 1-4
carbon atoms or a single bond, and R.sup.5 represents a 5- to
7-membered cyclic alkyl group, an aryl group, a heteroaryl group or
a 4- to 7-membered saturated or partially saturated heterocyclic
group (the cyclic alkyl group, aryl group, heteroaryl group and
heterocyclic group may have one to three substituents selected from
the group consisting of a halogen atom, hydroxyl group, a group of
OZ.sub.1-4, a group of S(O).sub.nZ.sub.1-4, a group of
N(R.sup.12)(R.sup.13), a group of Z.sub.1-4, carboxyl group, a
group of CO.sub.2Z.sub.1-4, group of CONH.sub.2, a group of
CONH(Z.sub.1-4) and a group of CON(Z.sub.1-4)(Z.sub.1-4)), a group
of --S(O).sub.nZ.sub.0-4R.sup.5, a group of --N(R.sup.6)(R.sup.7)
{R.sup.6 and R.sup.7 each independently represent hydrogen atom or
Z.sub.1-4, or they may bind to each other to form a saturated or
unsaturated 5- to 7-membered ring (the ring may contain one or two
hetero atoms as ring constituting atoms), and R.sup.6 and R.sup.7
may have one to three substituents selected from the group
consisting of a halogen atom, hydroxyl group, a group of
OCON(R.sup.12)(R.sup.13), a group of CON(R.sup.12)(R.sup.13), a
group of N(R.sup.12)CON(R.sup.12)(R.sup.13), a group of Z.sub.1-4,
a group of OZ.sub.1-4, a group S(O).sub.nZ.sub.1-4, group of
CH.sub.2OH, a group of (CH.sub.2).sub.mN(R.sup.12)(R.sup.13),
carboxyl group, cyano group, a group of
CO-Z.sub.1-4(R.sup.10)--N(R.sup.12)(R.sup.13) (R.sup.10 is a
substituent corresponding to a side chain on an amino acid carbon
or a group of -Z.sub.1-4-R.sup.11 (R.sup.1 represents a substituent
which forms a quaternary salt) and a group of ##STR43## a 5- or
6-membered aryl group which may be substituted and a 5- or
6-membered unsaturated heterocyclic group which may be substituted;
W.sup.2 represents a single bond or --C(R.sup.8).dbd.C(R.sup.9)--
(R.sup.8 and R.sup.9 each independently represent hydrogen atom, a
halogen atom, a lower alkyl group, an alkoxy group, cyano group,
carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group
or a group of N(R.sup.12)(R.sup.13)), Q represents an acidic group,
and W.sup.2 and Q may bind together to form
vinylidenethiazolidinedione in E- or Z-configuration or an
equivalent heterocyclic ring; m and n each independently represent
an integer of 0 to 2, and q represents an integer of 0 to 3;
R.sup.14 represents hydrogen atom, Z.sub.1-4, Z.sub.1-4R.sup.5 or
Z.sub.1-4OR.sup.5; and X represents C--H and Y represents C--H or
nitrogen atom.
23. The method according to claim 22, wherein the compound is an
active ingredient in a composition.
24. The method according to claim 22, wherein the microbial
infection comprises an infection by microorganisms selected from
Pseudomonas aeruginosa and bacteria having a genetically homologous
drug efflux pump to Pseudomonas aeruginosa.
25. The method according to claim 22, wherein the at least one
antimicrobial agent and the compound are present in a composition.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of application Ser. No.
09/842,234, filed Apr. 26, 2001, the disclosure of which is
incorporated by reference herein in its entirety.
TECHNICAL FIELD
[0002] The present invention relates to a medicament useful for
preventive and therapeutic treatment of microbial infectious
diseases.
BACKGROUND ART
[0003] For preventive or therapeutic treatment of infectious
diseases caused by microorganisms, various antibacterial agents
have so far been developed, and drugs such as .beta.-lactam
antibiotics (penicillins, cephems, monobactams, carbapenems, and
penems), aminoglycosides, quinolones, macrolides, tetracyclines,
rifamycins, chloramphenicols, and phosphomycins have been
practically used. However, with the increase of clinically used
amount of antibacterial agents, remarkable numbers of resistant
bacterial strains to these antibacterial agents have emerged, which
becomes a serious problem in the treatment of infectious
diseases.
[0004] Examples of problematic bacteria, which cause particularly
intractable or serious infectious diseases among those caused by
resistant bacteria, include Pseudomonas aeruginosa and
methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial
agents effective against these bacteria have been limited so far,
and it is not certain whether or not therapeutic efficacy of the
currently available drugs will be expected in the future. In
particular, no drug is available at present by which specifically
high efficacy against resistant Pseudomonas aeruginosa can be
achieved. With the increase of aged population and the
popularization of sophisticated medical technologies including
human organ transplantation and anti-cancer treatments, infections
frequently occurring particularly in patients with reduced
immunity, i.e., so-called opportunistic infections, have become an
extremely serious problem in the clinical field, and under the
circumstances, early developments of measures against the resistant
bacteria are desired.
[0005] Recently, the presence of drug efflux pumps has recognized
as a bacterial excretion mechanism of drugs through researches on
resistance acquiring mechanisms of resistant bacteria. In earlier
researches, a pump that specifically excretes a tetracycline
antibacterial agent from bacterial cells was identified in 1980 by
the group of Levy, and the discovery was noted as a major factor of
the resistance to tetracycline (L. McMurry, Proc. Natl. Acad. Sci.
U.S.A., 77, 3974, 1980). Furthermore, based on recent researches,
the presence of multidrug-excreting drug efflux pumps was reported
in Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis,
Staphylococcus bacteria, Diplococcus pneumoniae, and Neisseria
gonorrhoeae. Four multidrug efflux pumps have so far been reported
as homological drug efflux pumps deriving from Pseudomonas
aeruginosa, and they have been considered as a cause of low drug
sensitivity inherent to Pseudomonas aeruginosa (K. Poole et al., J.
Bacteriol., 175, 7363, 1993; K. Poole et al., M. Microbiol., 21,
713, 1996; T. Kohler et al., M. Microbiol., 23, 345, 1997; T. Mine
et al., Antimicrob. Agents Chemother., 43, 415, 1999).
[0006] The drug efflux pumps of Pseudomonas aeruginosa excrete
various drugs including .beta.-lactams, tetracyclines,
chloramphenicols, and quinolones, to which the drug resistance of
Pseudomonas aeruginosa is attributable.
[0007] In order to overcome the problem, it will be effective to
invent an antibacterial agent that has a novel structure, by which
resistance acquisition due to a drug efflux pump, one of factors of
resistance acquisition, can be avoided, or develop an agent for a
combinational use with currently available antibacterial agents
that can restore their efficacy by inhibiting functions of drug
efflux pumps.
DISCLOSURE OF THE INVENTION
[0008] Therefore, an object of the present invention is to provide
a novel medicament for the treatment of infectious diseases that
improves therapeutic efficacy of an agent against pathogenic
microorganisms, in particular, a medicament that acts on a
microorganism with acquired resistance to an antimicrobial agent,
and eliminates the resistance of the bacteria by inhibiting a drug
efflux pump so as to improve preventive and/or therapeutic effect
of the antimicrobial agent.
[0009] In order to achieve the aforementioned object, the inventors
of the present invention conducted various researches to search for
compounds that eliminate resistance to an antimicrobial drug of
Pseudomonas aeruginosa that has acquired the resistance. As a
result, they found that the compounds represented by the following
general formula (I) or (II) had the desired activity, and thus
achieved the present invention.
[0010] The present invention thus provides a medicament for
preventive and/or therapeutic treatment of microbial infections,
which comprises as an active ingredient a compound represented by
the following general formula (I) or a physiologically acceptable
salt thereof, or a hydrate thereof: ##STR2## wherein, R.sup.1 and
R.sup.2 each independently represent hydrogen atom, a halogen atom,
hydroxyl group, a group of OZ.sub.1-6 (the group of OZ.sub.1-6
represents an alkyl group having 1-6 carbon atoms or a fluoroalkyl
group having 1-6 carbon atoms, which bonds via the oxygen atom), a
group of S(O).sub.nZ.sub.1-4 (Z.sub.1-4 represents an alkyl group
having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon
atoms or an alkylene group derived therefrom), a group of
N(R.sup.12)(R.sup.13) (R.sup.12 and R.sup.13 each independently
represent hydrogen atom, an alkyl group having 1-4 carbon atoms or
a fluoroalkyl group having 1-4 carbon atoms), a group of Z.sub.1-8
which may be substituted (Z.sub.1-8 represents an alkyl group
having 1-8 carbon atoms or a fluoroalkyl group having 1-8 carbon
atoms), a 5- to 7-membered cyclic alkyl group, an aryl group, a
heteroaryl group, or a 4- to 7-membered saturated or partially
saturated heterocyclic group (the cyclic alkyl group, aryl group,
heteroaryl group and heterocyclic group may have one to three
substituents selected from the group consisting of a halogen atom,
hydroxyl group, a group of OZ.sub.1-4, a group of
S(O).sub.nZ.sub.1-4, a group of N(R.sup.12)(R.sup.13), a group of
Z.sub.1-4, carboxyl group, a group of CO.sub.2Z.sub.1-4, group of
CONH.sub.2, a group of CONH(Z.sub.1-4) and a group of
CON(Z.sub.1-4)(Z.sub.1-4)); W.sup.1 represents a group selected
from the group consisting of --CH.dbd.CH--, --N(R.sup.12)CO--,
--CON(R.sup.12)--, --CH.sub.2O-- and --CH.sub.2CH.sub.2-- (each of
the aforementioned groups binds to the thiazole ring at the left
end); R.sup.3 represents hydrogen atom, a halogen atom, hydroxyl
group or an amino group; R.sup.4 represents a group selected from
the group consisting of hydrogen atom, a group of
--OZ.sub.0-4R.sup.5 (Z.sub.0-4 represents an alkylene group having
1-4 carbon atoms, a fluorine-substituted alkylene group having 1-4
carbon atoms or a single bond, and R.sup.5 represents a 5- to
7-membered cyclic alkyl group, an aryl group, a heteroaryl group or
a 4- to 7-membered saturated or partially saturated heterocyclic
group (the cyclic alkyl group, aryl group, heteroaryl group and
heterocyclic group may have one to three substituents selected from
the group consisting of a halogen atom, hydroxyl group, a group of
OZ.sub.1-4, a group of S(O).sub.nZ.sub.1-4, a group of
N(R.sup.12)(R.sup.13), a group of Z.sub.1-4, carboxyl group, a
group of CO.sub.2Z.sub.1-4, group of CONH.sub.2, a group of
CONH(Z.sub.1-4) and a group of CON(Z.sub.1-4)(Z.sub.1-4)), a group
of --S(O).sub.nZ.sub.0-4R.sup.5, a group of --N(R.sup.6)(R.sup.7)
(R.sup.6 and R.sup.7 each independently represent hydrogen atom or
Z.sub.1-4, or they may bind to each other to form a saturated or
unsaturated 5- to 7-membered ring (the ring may contain one or two
hetero atoms as ring constituting atoms), and R.sup.6 and R.sup.7
may have one to three substituents selected from the group
consisting of a halogen atom, hydroxyl group, a group of
OCON(R.sup.12)(R.sup.13), a group of CON(R.sup.12)(R.sup.13), a
group of N(R.sup.12)CON(R.sup.12)(R.sup.13), a group of Z.sub.1-4,
a group of OZ.sub.1-4, a group S(O).sub.nZ.sub.1-4, group of
CH.sub.2OH, a group of (CH.sub.2).sub.mN(R.sup.12)(R.sup.13),
carboxyl group, cyano group, a group of
CO-Z.sub.1-4(R.sup.10)--N(R.sup.12)(R.sup.13) (R.sup.10 is a
substituent corresponding to a side chain on an amino acid carbon
or a group of -Z.sub.1-4-R.sup.11 (R.sup.11 represents a
substituent which forms a quaternary salt) and a group of ##STR3##
a 5- or 6-membered aryl group which may be substituted and a 5- or
6-membered unsaturated heterocyclic group which may be substituted;
W.sup.2 represents a single bond or --C(R.sup.8).dbd.C(R.sup.9)--
(R.sup.8 and R.sup.9 each independently represent hydrogen atom, a
halogen atom, a lower alkyl group, an alkoxy group, cyano group,
carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group
or a group of N(R.sup.12)(R.sup.13)), Q represents an acidic group,
and W.sup.2 and Q may bind together to form
vinylidenethiazolidinedione in E- or Z-configuration or an
equivalent heterocyclic ring; m and n each independently represent
an integer of 0 to 2, and q represents an integer of 0 to 3.
[0011] As other aspects of the present invention, provided are a
medicament for eliminating resistance of a microorganism with
acquired drug resistance, which comprises a compound represented by
the aforementioned general formula (I) or a physiologically
acceptable salt thereof as an active ingredient; and a medicament
for enhancing effect of an antimicrobial agent, which comprises a
compound represented by the aforementioned general formula (I) or a
physiologically acceptable salt thereof as an active ingredient.
The aforementioned medicaments wherein the microorganism is
Pseudomonas aeruginosa are preferred embodiments of the present
invention. The present invention also provides a pharmaceutical
composition for preventive and/or therapeutic treatment of
microbial infections, which comprises a compound represented by the
aforementioned general formula (I) or a physiologically acceptable
salt thereof together with an antimicrobial agent.
[0012] As further aspects of the present invention, provided are a
method for preventive and/or therapeutic treatment of microbial
infections, which comprises the step of administering to a mammal
including human a preventively and/or therapeutically effective
amount of a compound represented by the aforementioned general
formula (I) or a physiologically acceptable salt thereof; a method
for eliminating resistance of a microorganism with acquired
resistance to an antimicrobial agent, which comprises the step of
contacting with the microorganism an effective amount of a compound
represented by the aforementioned general formula (I) or a
physiologically acceptable salt thereof; a method for inhibiting
acquisition of resistance to an antimicrobial agent by a
microorganism, which comprises the step of contacting with a
microorganism an effective amount of a compound represented by the
aforementioned general formula (I) or a physiologically acceptable
salt thereof; a method for enhancing sensitivity of a microorganism
to an antimicrobial agent, which comprises the step of contacting
with a microorganism an effective amount of a compound represented
by the aforementioned general formula (I) or a physiologically
acceptable salt thereof; and a method for improving effect of an
antimicrobial agent, which comprises the step of administering to a
mammal including human an effective amount of a compound
represented by the aforementioned general formula (I) or a
physiologically acceptable salt thereof. The compounds represented
by the aforementioned general formula (I) or physiologically
acceptable salts thereof are usually administered with one or more
of antimicrobial agents simultaneously or separately, or
successively. The present invention also provides a use of the
compounds represented by the aforementioned general formula (I) or
physiologically acceptable salts thereof for the manufacture of the
aforementioned medicaments.
[0013] In addition to the aforementioned inventions, the present
invention also provides a medicament for preventive and/or
therapeutic treatment of microbial infections, which comprises as
an active ingredient a compound represented by the following
general formula (I), a physiologically acceptable salt thereof, or
hydrates thereof ##STR4##
[0014] In the formula, R.sup.1, R.sup.2, R.sup.3, R.sup.4, W.sup.1,
W.sup.2 and Q have the same meanings as those defined above;
R.sup.14 represents hydrogen atom, Z.sub.1-4, Z.sub.1-4R.sup.5 or
Z.sub.1-4OR.sup.5; and X and Y each independently represent C--H or
nitrogen atom.
BEST MODE FOR CARRYING OUT THE INVENTION
[0015] In the specification, the "alkyl group" means a linear,
branched or cyclic alkyl group or an alkyl group consisting of a
combination thereof. The same is applied to an alkyl moiety of a
substituent having the alkyl moiety (for example, fluoroalkyl
group).
[0016] In the general formula (I), R.sup.1 is preferably an alkyl
group. Examples of the alkyl group include a linear or branched
alkyl group having 1-8 carbon atoms (for example, methyl group,
ethyl group, n-propyl group, isopropyl group, n-butyl group,
isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group
and the like), and a cyclic alkyl group having 3-8 carbon atoms,
preferably 3-6 carbon atoms (for example, cyclopropyl group,
cyclobutyl group, cyclopentyl group, cyclohexyl group and the
like). The cyclic alkyl group may have another alkyl group or a
halogen atom, hydroxyl group or the like on the ring. R.sup.1 is
also preferably an aryl group, a heteroaryl group or a heterocyclic
group. The aryl group may preferably has a 5- or 6-membered ring.
As the heterocyclic group, a heterocyclic group having 3-8,
preferably 3-6, of ring constituting atoms can be used, and the
ring may be saturated or partially saturated. As a substituent that
binds to the heterocyclic group, for example, an alkyl group or a
halogen atom is preferred.
[0017] R.sup.2 is preferably hydrogen atom or a halogen atom.
[0018] W.sup.1 is preferably a linking group having a length of two
atoms, and --CH.dbd.CH--, --N(R.sup.12)CO--, --CON(R.sup.12)--,
--CH.sub.2O-- and --CH.sub.2CH.sub.2-- are more preferred.
[0019] R.sup.3 is preferably hydrogen atom, a halogen atom, amino
group or hydroxyl group.
[0020] R.sup.4 is preferably hydrogen atom, --OZ.sub.0-4R.sup.5 or
--N(R.sup.6)(R.sup.7).
[0021] R.sup.5 is preferably a 5- or 6-membered aryl group, 5- to
7-membered alicyclic group, 4- to 7-membered saturated heterocyclic
group, or 5- or 6-membered unsaturated heterocyclic group, which
may be substituted, and more preferably a 4- to 7-membered
saturated heterocyclic group or a 5- or 6-membered unsaturated
heterocyclic group.
[0022] R.sup.6 and R.sup.7 represent hydrogen atom, an alkyl group
having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon
atoms, or they bind to each other to form a saturated or
unsaturated 5- to 7-membered ring. The ring may contain one or two
hetero atoms as atoms constituting the ring. R.sup.6 and R.sup.7
may have one to three substituents selected from the group shown as
follows: a halogen atom, hydroxyl group, a group of
OCON(R.sup.12)(R.sup.13), a group of CON(R.sup.12)(R.sup.13), a
group of N(R.sup.12)CON(R.sup.12)(R.sup.13), a group of Z.sub.1-4,
a group of OZ.sub.1-4, a group S(O).sub.nZ.sub.1-4, a group of
CH.sub.2OH, a group of (CH.sub.2).sub.mN(R.sup.12)(R.sup.13),
carboxyl group, cyano group, a group of
CO-Z.sub.1-4(R.sup.10)--N(R.sup.12)(R.sup.13) and a group of
##STR5## wherein R.sup.10 is a substituent on .alpha.-carbon atom
of an amino acid, or a group comprising an alkyl group or a
fluoroalkyl group having 1-4 carbon atoms and a quaternary salt
such as ##STR6## substituted at the terminal of said alkyl or
fluoroalkyl group (in the definitions of the aforementioned
substituents, R.sup.12 and R.sup.13 represent hydrogen atom, an
alkyl group or a fluoroalkyl group having 1-4 carbon atoms, n
independently represents an integer of 0 to 2, and q represents an
integer of 0 to 3).
[0023] More preferably, R.sup.6 and R.sup.7 form a piperidine ring
or the like and said ring has a substituent such as fluorine atom,
hydroxyl group, a group of OCON(R.sup.12)(R.sup.13) and a group of
CON(R.sup.12)(R.sup.13) on the ring. The ring formed by R.sup.6 and
R.sup.7 bound to each other is preferably a piperazine ring, and
preferred examples include a piperazine ring of which 4-position
(nitrogen atom not bound to the pyridopyrimidine ring) is
substituted with an alkyl group or a fluoroalkyl group having 1-4
carbon atoms, or with other substituent such as
CO-Z.sub.1-4(R.sup.10)--N(R.sup.12)(R.sup.13) and ##STR7##
[0024] W.sup.2 is preferably a single bond or a group represented
by --C(R.sup.8).dbd.C(R.sup.9)--. R.sup.8 and R.sup.9 each
independently represent hydrogen atom, a halogen atom, a lower
alkyl group, an alkoxy group, cyano group, carboxyl group,
hydroxymethyl group, cyanomethyl group, vinyl group or a group of
N(R.sup.12)(R.sup.13), more preferably hydrogen atom, a halogen
atom or a lower alkyl group.
[0025] Q represents an acidic group, preferably an acidic group
which is carboxyl group, 1,2,3,4-tetrazol-5-yl group or an
equivalent thereof. However, type of the acidic group is not
particularly limited, and said group may be any one of cyclic or
non-cyclic, or a combination thereof. Examples include a lower
alkoxy group, hydroxyl group, carboxyl group, N-cyanocarboxamido
group, a methanesulfonylamido group having 1-3 fluorine atoms,
--CONH-(5-tetrazolyl) group, 5-tetrazolyl group which may be
substituted, 1,2,3-triazolyl group which may be substituted,
2,4-dioxothiazolidin-5-ylidenyl group which may be substituted,
4-oxo-2-thioxothiazolidin-5-ylidenyl group which may be
substituted, 5-oxo-4-tetrazolyl group which may be substituted,
3-(5-oxo)-[1.2.4]oxadiazolidinyl group which may be substituted,
2-(3,5-dioxo)-[1.2.4]oxadiazolidinyl group which may be
substituted, 5-(3-oxo)-[1.2.4]oxadiazolidinyl group which may be
substituted, 3-(5-oxo)-[1.2.4]isoxazolidyl group which may be
substituted or the like. More preferred examples include carboxyl
group, 5-tetrazolyl group which may be substituted,
N-cyanocarboxamido group, a methanesulfonylamido group that has 1-3
fluorine atoms, --CONH-(5-tetrazolyl) group or the like.
[0026] For R.sup.1, R.sup.2, R.sup.3, R.sup.4, W.sup.1, W.sup.2 and
Q of the compounds represented by the general formula (II), those
explained as for R.sup.1, R.sup.2, R.sup.3, R.sup.4, W.sup.1,
W.sup.2 and Q in the aforementioned general formula (I) can be
preferably used, respectively.
[0027] R.sup.14 is preferably an alkyl group having 1-4 carbon
atoms or a fluoroalkyl group having 1-4 carbon atoms.
[0028] The compounds represented by the aforementioned general
formula (I) can be produced by the following methods. ##STR8##
[0029] As shown in Scheme 1, Compound 3 can be obtained by heating
Aminopyridine derivative 1 and malonic acid or an ester of malonic
acid in a solvent such as toluene and xylene. As the ester of
malonic acid, Ester 2 as a phenol ester substituted with an
electron-withdrawing group such as a halogen atom can be used. An
alkyl ester can also be used. By formylating Compound 3 with
Vilsmeier's reagent prepared from phosphorus oxychloride or oxalyl
chloride and dimethylformamide (DMF), Aldehyde 4 can be obtained.
By subjecting Compound 4 to the Wittig reaction or Horner-Emons
reaction, Acrylic acid derivative 5 can be synthesized. Where the
Wittig reaction is employed, Compound 5 can be obtained by reacting
an alkyloxycarbomethylene-triphenylphosphorane which may be
substituted with the aldehyde compound in an inert solvent such as
tetrahydrofuran, DMF or methylene chloride. Where the Horner-Emons
reaction is employed, the target compound can be synthesized by
reacting the aldehyde compound with a dialkylphosphonoacetic acid
ester which may be substituted at the 2-position in the presence of
a base in an inert solvent such as THF and DMF. Compound 7 having
amino group at the 2-position as a linker can be obtained by
converting the hydroxyl group at the 2-position of Compound 5 into
tosyl group, mesyl group, diphenylphosphoric acid ester or the
like, and then replacing the resulting group with an amine. The
ester group of the acrylic acid moiety can be hydrolyzed in the
final step to obtain Compound I-A. As the ester group, a lower
alkyl ester such as those of methyl group and ethyl group,
tert-butyl ester, benzyl ester, allyl ester and so forth can be
used, and they can be hydrolyzed by hydrolysis under an alkaline or
acidic condition, catalytic reduction or a method by using a metal
catalyst such as palladium.
[0030] Further, Compound I-A can also be synthesized by the method
shown in Scheme 2. Compound 9 can be obtained by converting the
hydroxyl group at the 2-position of Compound 3 into tosyl group,
mesyl group, diphenylphosphoric acid ester or the like and then
replacing the resulting group with an amine. The resulting product
can be formylated with Vilsmeier's reagent prepared from phosphorus
oxychloride or oxalyl chloride and dimethylformamide to obtain
Aldehyde 10. By subjecting Compound 10 to the Wittig reaction or
Horner-Emons reaction, Acrylic acid derivative 7 can be
synthesized. Where the Wittig reaction is employed, Compound 7 can
be obtained by reacting an
alkyloxycarbomethylenetriphenylphosphorane which may be substituted
with the aldehyde compound in an inert solvent such as THF, DMF,
toluene or methylene chloride. Where the Horner-Emons reaction is
employed, the target compound can be synthesized by reacting the
aldehyde compound with a dialkylphosphonoacetic acid ester which
may be substituted at the 2-position in the presence of a base in
an inert solvent such as THF and DMF.
[0031] According to this synthetic scheme, various primary or
secondary amines can be reacted with Compound 6 to synthesize
variety of 2-substituted derivatives by the multiple parallel
synthesis method in a liquid phase. ##STR9##
[0032] A compound in which a substituent is introduced at the
2-position of the pyridopyrimidine ring as a linker can be
synthesized by the method shown in Scheme 3.
[0033] Compound 11 can be synthesized by reacting Compound 5 with
an alkylating agent in the presence of a base. The ester portion of
the resulting Compound 11 can be hydrolyzed to obtain Compound I-B
in a manner similar to that for the aforementioned compound having
a nitrogen atom as a linker. ##STR10##
[0034] Compound I-B can also be synthesized by the method shown in
Scheme 4, i.e., by alkylation of Compound 3 with an alkylating
agent and subsequent formylation, olefination and deprotection of
the ester portion. ##STR11##
[0035] Compound 1 used for the aforementioned synthesis can be
synthesized as follows.
[0036] For example, Compound 1-A of which W portion is an amide
bond can be synthesized by condensing an aminothiazole derivative,
which is a known compound or can be synthesized by a known method,
and a 2-aminopyridine-4-carboxylic acid derivative of which amino
group is protected by a usual method used for a reaction of forming
a peptide bond, and deprotecting the protective group of the amino
group. ##STR12##
[0037] Compound 1-B of which W portion is a double bond can be
synthesized by condensing 2-Methylthiazole derivative 17, which is
a known compound or can be synthesized by a known method, and
2-Aminopyridine-4-carbaldehyde derivative 18 of which amino group
is protected under a condition for the Knoevenagel reaction, and
removing the protective group of the amino group. As for the
condition of the Knoevenagel reaction, the reaction can also be
performed by heating in acetic anhydride or in the presence of a
base such as piperidine and piperazine and in the co-presence of an
acid such as acetic acid. ##STR13##
[0038] An anion that can be obtained by treating
2-Amino-4-methylpyridine derivative 20 of which amino group is
protected with a strong base such as n-BuLi and an aldehyde are
reacted, and then the resulting hydroxyl group can be subjected to
tosylation, mesylation or the like, or the resulting product is
converted into a halogenated compound such as by chlorination or
bromination. The resulting product is then subjected to elimination
reaction using a base such as DBU to obtain Double bond-containing
derivative 23. By removing its amino protective group, Compound 1-C
can be synthesized. ##STR14##
[0039] Compound 1-D of which W portion is an ether bond can be
synthesized by condensing Thiazolemethyl halide 24, which is a
known compound or can be synthesized by a known method, and
4-Hydroxypyridine-2-carboxylic acid ester 25 in the presence of a
base, hydrolyzing the ester portion of the resulting Compound 26,
and then converting the produced carboxylic acid into Amine
derivative 28 by employing the Curtius rearrangement or the like.
Amino compound 1-D can also be obtained by first converting the
carboxylic acid into a condensation product with hydrazine, then
converting the resulting product into an acid azide with a nitrous
acid salt or a derivative thereof, further subjecting the resulting
product to a rearrangement reaction and, if required, removing the
protective group of the amino group. ##STR15##
[0040] Compound 1-E, where W portion is ethylene, can be
synthesized by reacting an anion, obtained by treating
2-Amino-4-methylpyridine derivative 20 of which amino group is
protected with a strong base such as n-BuLi, with Thiazolemethyl
halide 24 to obtain a condensation product and then removing the
protective group of the amino group. ##STR16##
[0041] As shown in Scheme 10, Compound 1-E can also be synthesized
by reacting an anion, obtained by treating 2-Amino-4-methylpyridine
derivative 20 of which amino group is protected with a strong base
such as n-BuLi, with Halogenoacetic acid derivative 30 to obtain a
condensation product, converting the ester portion into an amide,
then converting the resulting product into a thioamide compound by
using Lawesson's reagent, diphosphorous pentasulfide or the like
and condensing the product with a haloketone compound.
##STR17##
[0042] A compound of which W portion is a triple bond can be
synthesized by the synthetic methods described in WO9633181
published Oct. 24, 1996.
[0043] The compound represented by the general formula (II) can be
synthesized by the method shown in Scheme 11. ##STR18##
[0044] Amide derivative 35 can be obtained by converting
N-Alkyl-quinolone-carboxylic acid derivative 34 described in
PCT/JP00/07565 into a mixed acid anhydride, and then reacting the
resulting product with ammonia or an ethylamine having an
electron-withdrawing group (EWG) such as cyanoethylamine and
3-aminopropanoic acid ester. The alkylamide derivative can be
converted into Compound 36 by treatment with sodium azide and
trifluoromethanesulfonic acid anhydride in an acetonitrile solvent
to form a tetrazole ring. Then, the product can be converted into
Tetrazole compound II-A by treatment with DUB in an inert solvent
such as methylene chloride or treatment with a base such as sodium
methoxide in an alcohol.
[0045] Further, Tetrazole compound II-A can similarly be obtained
by subjecting Carbamoyl derivative 35 to dehydration reaction to
obtain Cyano derivative 37 and treating the resulting compound with
sodium azide and aluminum chloride in dimethylformamide. Similarly,
Tetrazole compound II-A can be produced by subjecting Carboxylic
acid 34 having a cinnolin-4-one or naphthylidin-4-one structure to
the same treatment. ##STR19##
[0046] As shown in Scheme 12, where a derivative having a
cinnolin-4-one structure is desired, Compound 38, which is a known
compound or can be easily derived from a known compound, can be
converted into a diazo compound by treating the amino group with
sodium nitrite, and the resulting product can be reacted with a
malonic acid ester to obtain Compound 39 (R.sup.5.dbd.H). An
electrophilic regent such as an alkyl halide can be reacted with
the nitrogen atom of the resulting Compound 39 (R.sup.5.dbd.H) by
using a base such as sodium hydride and potassium carbonate in a
solvent such as DMF and THF, and then the product can be heated in
a solvent such as Dowtherm A and PPA and treated under an ordinary
hydrolysis condition to obtain Carboxylic acid 41. The Carboxylic
acid 41 obtained can be subjected to a treatment similar to the
aforementioned treatment (Scheme 11) to produce Tetrazole compound
II-B. ##STR20##
[0047] As shown in Scheme 13, when W portion is --CH.sub.2O--,
Compound 42 can be converted into an alkoxide by treatment with a
strong base such as sodium hydride in DMF or THF, and the alkoxide
can be reacted with Compound 43, which is a known compound or can
be synthesized by a known method (Japanese Patent Un-examined
Publication (Kokai) No. 57-144264 or 60-197686), to obtain Compound
44. Subsequently, Compound 44 can be converted into a carboxylic
acid by hydrolysis and subjected to a treatment similar to the
aforementioned treatment (Scheme 11) to produce Tetrazole compound
II-C.
[0048] As for the aforementioned production of cinnolin-4-one
derivative, a method wherein 3-chloro-4-fluoroaniline is used as a
starting material is compared with a method wherein
3,4-difluoroaniline is used, 3,4-difluoroaniline will give much
higher yield of cinnolin-4-one-3-carboxylic acid as for the thermal
cyclization reaction performed in a solvent such as Dowtherm A and
PPA in the production of the known Compound 43 and selectivity of
the substitution of the alkoxide shown in Scheme 13. ##STR21##
[0049] As shown in Scheme 14, where the compound in which W is an
olefin is desired, Compound 45, which is a known compound or can be
synthesized by a known method, can be esterified and then subjected
to treatment with an oxidizing agent such as selenium dioxide, and
the resulting Aldehyde derivative 46 and Compound 47 can be
subjected to the Wittig reaction and further subjecting the adduct
to addition of ammonia to obtain Carbamoyl compound 49. The
resulting Carbamoyl derivative 49 can be converted into Tetrazole
compound II-D by using the same method as in Scheme 11.
[0050] The synthetic intermediates and the target compounds in the
aforementioned preparations can be isolated and purified by using
methods for isolation and purification ordinarily used in the field
of organic synthetic chemistry, for example, neutralization,
filtration, extraction, drying, concentration, recrystallization,
various chromatographic techniques and the like. The synthetic
intermediates may be used in subsequent reactions without
purification. When a salt of compound of the general formula (I) or
(II) is desired, a product obtained in the form of a salt may be
purified without any treatment. When a product is obtained in a
free form, a salt can be formed by dissolving or suspending the
product in a suitable organic solvent, and then adding an acid or
base. It is also possible to convert a compound represented by the
general formula (I) or (II) obtained in the form of a salt into a
compound in a free form, and then convert the result into an
appropriate salt.
[0051] Although it is not intended to be bound by any specific
theory, the compounds represented by the general formula (I) have
an activity for inhibiting drug efflux pumps of microorganisms.
More specifically, the compounds represented by the general formula
(I) can act on a microorganism with acquired resistance to an
antimicrobial agent to inhibit its drug efflux pump, and eliminate
the resistance of the microorganism. In addition, the compounds
represented by the general formula (I) can act on a microorganism
to inhibit a drug efflux pump, thereby suppress the acquisition of
resistance to an antimicrobial agent by a microorganism. Therefore,
the medicament of the present invention that comprises a compound
represented by the general formula (I) as an active ingredient is
useful for preventive and/or therapeutic treatment of microbial
infections, generally by a combinational administration with an
antimicrobial agent. The medicament of the present invention is
extremely useful as a medicament for preventive and/or therapeutic
treatment of, in particular, infectious diseases caused by a
microorganism with acquired resistance to one or more antimicrobial
agents.
[0052] Methods for using the medicament of the present invention
are not particularly limited. Examples include a method of
administering one or more antimicrobial agents, and also
administering the medicament of the present invention
simultaneously, separately, or successively to enhance the activity
of the antimicrobial agent(s); and a method of preparing a
pharmaceutical composition comprising one or more antimicrobial
agents and the medicament of the present invention (so-called a
compound drug) and the administering the composition.
[0053] Kinds of microbial infections that are applicable by the
medicament of the present invention are not particularly limited.
Bacteria are suitable as target microorganisms. The medicament of
the present invention can be used for various infections by
microorganisms including Gram-positive or Gram-negative bacteria,
aerobic or anaerobic bacteria and the like. The medicament of the
present invention can most suitably be used for infections by
Pseudomonas aeruginosa with acquired resistance to one or more
antimicrobial agents, or infections by Pseudomonas aeruginosa with
low sensitivity to antimicrobial agents. The medicament of the
present invention can be used for microbial infections of mammals
including human.
[0054] Drugs having variety of structures have been known as
antimicrobial agents, and various drugs are clinically used. Kinds
of antimicrobial agents that can be administered in combination
with the medicament of the present invention are not particularly
limited, and examples include, for example, penicillin (penam)
antibiotics, cephalosporin (cephem) antibiotics, oxacephem
antibiotics, penem antibiotics, carbapenem antibiotics, monobactam
antibiotics, aminoglycoside antibiotics, macrolide antibiotics,
chloramphenicol antibiotics, tetracycline antibiotics, glycopeptide
antibiotics, phosphomycin antibiotics, lincomycin antibiotics,
sulfonamide preparations, p-aminosalicylic acid preparations,
isonicotinic acid hydrazide preparations, quinolone synthetic
antimicrobial agents and the like. However, antimicrobial agents
are not limited to these examples. When a pharmaceutical
composition comprising one or more antimicrobial agents together
with the medicament of the present invention is manufactured, the
antimicrobial agents exemplified above can also be used.
[0055] As the active ingredient of the medicament of the present
invention, a substance selected from the group consisting of the
compounds represented by the formula (I) and pharmaceutically
acceptable salts thereof, and hydrates thereof and solvates thereof
can be used. Two or more of the substances may be used in
combination. The aforementioned substance, per se, may be
administered as the medicament of the present invention. Generally,
however, it is desirable that the substance is administered in the
form of a pharmaceutical composition comprising one or more of the
aforementioned substances as the active ingredient together with
one or more pharmaceutical additives. The pharmaceutical
composition may optionally be added with one or more of other
pharmaceutically active ingredients such as the aforementioned
antimicrobial agents and .beta.-lactamase inhibitors.
[0056] A pharmaceutical composition for the use of administration
in vivo can be readily prepared by mixing one or more of the
aforementioned substances as the active ingredient and one or more
pharmaceutically acceptable additives for pharmaceutical
preparations according to methods for formulation ordinarily used
in the field of manufacturing pharmacy. The route of administration
of the medicament of the present invention is not particularly
limited; however, it is desirable to appropriately chose the most
effective administration route for preventive and/or therapeutic
treatment of a target infectious disease. Examples of
pharmaceutical compositions suitable for oral administration
include, for example, capsules, powders, tablets, granules,
subtilized granules, emulsions, syrups, solutions, suspensions and
the like. Examples of pharmaceutical compositions suitable for
parenteral administration include, for example, inhalants, sprays,
intrarectal preparations, injections, drip infusions, ointments,
creams, transdermal preparations, transmucosal preparations, eye
drops, nasal drops, ear drops, tape preparations, patches and the
like. However, the forms of the medicament of the present invention
are not limited to these examples.
[0057] Among the pharmaceutical compositions suitable for oral
administration, liquid preparations such as emulsions and syrups
can be prepared by using pharmaceutical additives including water;
saccharides such as sucrose, sorbitol, fructose; glycols such as
polyethylene glycol and propylene glycol; oils such as sesame oil,
olive oil and soybean oil; antiseptics such as p-hydroxybenzoic
acid esters; flavors such as strawberry flavor and peppermint and
the like. Solid preparations such as capsules, tablets, powders and
granules can be prepared by using excipients such as lactose,
glucose, sucrose and mannitol; disintegrating agents such as starch
and sodium alginate; lubricants such as magnesium stearate and
talc; binders such as polyvinyl alcohol, hydroxypropylcellulose and
gelatin; surfactants such as fatty acid esters; plasticizers such
as glycerin and the like.
[0058] Among the pharmaceutical compositions suitable for
parenteral administration, liquid preparations such as injections,
drip infusions and eye drops can preferably be prepared as
sterilized isotonic liquid preparations. For example, injections
can be prepared by using an aqueous medium such as a solution of
sodium chloride, a solution of glucose, or a mixture of saline and
glucose solution. The intrarectal preparations can be prepared
generally in the form of suppositories by using carriers such as
cacao butter, hydrogenated fat and hydrogenated carboxylic acid.
For the preparation of sprays, a non-irritable carrier can be used
that enables fine dispersion and enhances absorption of the
aforementioned substances as the active ingredient. Examples of
such a carrier include lactose, glycerin and the like. Aerosols,
dry powders or the like can also be chosen as the form of
preparation. However, pharmaceutical additives used for the
manufacture of the medicament of the present invention are not
limited to those mentioned above, and any additives available for
those skilled in the art can be used.
[0059] A dose and frequency of administration of the medicament of
the present invention are not particularly limited, and a suitable
dose can be chosen depending on the type and severity of a
microbial infection, the presence or absence of an underlying
disease, the age and body weight of a patient and the like.
EXAMPLES
[0060] The present invention will be explained more specifically
with reference to the examples. However, the scope of the present
invention is not limited to the following examples.
Example 1
(E)-3-[8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidino)--
4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoic acid
(A) Methyl
3-{2-[(tert-butoxycarbonyl)amino]-4-pyridyl}propanoate
[0061] tert-Butyl N-(4-methyl-2-pyridyl)carbamate (5 g, 24.0 mmol)
was dissolved in tetrahydrofuran (120 ml), cooled to -78.degree.
C., and then added dropwise with n-butyl lithium (40 ml, 60 mmol).
Then, the reaction solution was warmed and stirred at room
temperature. The reaction mixture was stirred for 1 hour, then
again cooled to -78.degree. C., and added dropwise with methyl
bromoacetate (3.4 ml) dissolved in tetrahydrofuran (10 ml). After
the reaction mixture was stirred for 30 minutes, the reaction was
stopped with saturated brine and the reaction mixture was extracted
with ethyl acetate. The resulting organic layer was dried over
sodium sulfate and concentrated under reduced pressure, and the
residue was purified by silica gel column chromatography
(chloroform:ethyl acetate=3:1.fwdarw.5:1) to obtain 3.95 g (59%) of
the title compound as pale yellow crystals.
[0062] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.53 (9H, s), 2.67 (2H, t,
J=7.81 Hz), 2.95 (2H, t, J=7.81 Hz), 3.68 (3H, s), 6.82 (1H, dd,
J=1.22, 5.13 Hz), 7.84 (1H, s), 8.13 (1H, d, J=5.13 Hz)
(B) 3-{2-[(tert-Butoxycarbonyl)amino]-4-pyridyl)propanoic acid
[0063] Methyl
3-{2-[(tert-butoxycarbonyl)amino]-4-pyridyl}propanoate (30.65 g,
0.11 mol) dissolved in methanol (200 ml) was added with 1 N aqueous
sodium hydroxide (164 ml) and stirred at room temperature for 21
hours. After the solvent was evaporated under reduced pressure and
the residue was washed with diethyl ether, the resulting aqueous
layer was added with concentrated hydrochloric acid until pH of the
layer became 1. The solution was washed with ethyl acetate, and the
resulting aqueous layer was neutralized by further adding sodium
hydroxide. The solution was extracted with
chloroform:methanol=10:1, and the resulting organic layer was dried
over sodium sulfate and concentrated under reduced pressure to
obtain 11.16 g (38%) of the title compound as yellow crystals
without purification.
[0064] .sup.1H-NMR (CD.sub.3OD).delta.: 1.54 (9H, s), 2.67 (2H, t,
J=7.59 Hz), 2.95 (2H, t, J=7.59 Hz), 6.90 (1H, d, J=5.14 Hz), 7.80
(1H, s), 8.08 (1H, d, J=5.14 Hz)
[0065] EI/MS; m/z: 267 (M.sup.++1)
(C) tert-Butyl N-[4-(3-amino-3-oxopropyl)-2-pyridyl]carbamate
[0066] 3-{2-[(tert-Butoxycarbonyl)amino]-4-pyridyl}propanoic acid
(11.16 g, 41.92 mmol) dissolved in tetrahydrofuran (200 ml) was
added with triethylamine (9 ml, 62.89 mmol), cooled with ice, and
then added dropwise with ethyl chloroformate (6 ml, 62.89 mmol).
The reaction mixture was stirred for 10 minutes, and then added
with aqueous ammonia (50 ml) dissolved in tetrahydrofuran (50 ml)
at 0.degree. C. The reaction mixture was stirred for 20 minutes
under ice cooling, and then the solvent was evaporated under
reduced pressure. The resulting residue was washed with water and
extracted with chloroform. The resulting organic layer was washed
with saturated brine, and the organic layer was dried over sodium
sulfate and concentrated under reduced pressure to obtain 11.794 g
(100%) of the title compound as brown crystals without
purification.
[0067] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.53 (9H, s), 2.57 (2H, t,
J=8.05 Hz), 2.97 (2H, t, J=8.05 Hz), 5.40 (2H, br), 6.84 (1H, dd,
J=1.46, 5.13 Hz), 7.83 (1H, s), 8.13 (1H, d, J=5.13 Hz)
[0068] EI/MS; m/z: 266 (M.sup.++1)
(D) tert-Butyl
N-[4-(3-amino-3-thioxopropyl)-2-pyridyl]carbamate
[0069] Under argon atmosphere, tert-butyl
N-[4-(3-amino-3-oxopropyl)-2-pyridyl]-carbamate (11.79 g, 44.44
mmol) dissolved in tetrahydrofuran (100 ml) was added with
Lawesson's reagent (9 g, 22.22 mmol) and stirred at 70-80.degree.
C. for 30 minutes. After the reaction mixture was returned to room
temperature, the solvent was evaporated under reduced pressure and
the resulting residue was purified by silica gel column
chromatography (chloroform.fwdarw.chloroform:methanol=20:1) to
obtain 9.544 g (76%) of the title compound as pale yellow
crystals.
[0070] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.53 (9H, s), 2.89 (2H, t,
J=8.30 Hz), 3.09 (2H, t, J=8.30 Hz), 6.94 (1H, d, J=5.13 Hz), 7.75
(1H, s), 8.08 (1H, d, J=5.13 Hz)
[0071] EI/MS; m/z: 282 (M.sup.++1)
(E) 2-Bromo-1-cyclobutyl-1-ethanone
[0072] 1-Cyclobutyl-1-ethanone (500 mg, 5.1 mmol) dissolved in
methanol (5 ml) was added with bromine (0.3 ml, 5.6 mmol) and
stirred at room temperature for 1 hour. The resulting ocher
reaction mixture was added with water (3 ml) under ice cooling, and
then gradually added with potassium carbonate (350 mg). The mixture
was extracted with dichloromethane, and the resulting organic layer
was neutralized with saturated aqueous sodium hydrogencarbonate and
washed with saturated brine. The resulting organic layer was dried
over magnesium sulfate and concentrated under reduced pressure to
obtain 867 mg (96%) of the title compound without purification.
[0073] .sup.1H-NMR (CDCl.sub.3) .delta.:1.88 (1H,m), 2.00 (1H,m),
2.20-2.37 (4H,m), 3.60 (1H, qu, J=8.53 Hz), 3.88 (2H, s)
(F)
8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]p-
yrimidin-4-one
[0074] tert-Butyl N-[4-(3-amino-3-thioxopropyl)-2-pyridyl]carbamate
(1.38 g, 4.9 mmol) dissolved in ethanol was added with
2-bromo-1-cyclobutyl-1-ethanone (867 mg, 4.9 mmol) and refluxed at
100.degree. C. for 1 hour. The resulting reaction solution was
cooled to room temperature, then neutralized with saturated aqueous
sodium hydrogencarbonate and extracted with chloroform. The
resulting organic layer was washed with saturated brine, dried over
magnesium sulfate and concentrated under reduced pressure.
[0075] The resulting oily compound was added with dichloromethane
(50 ml) and slowly added dropwise with trifluoroacetic acid (50 ml)
under ice cooling. Then, the reaction solution was warmed to room
temperature and stirred 1 hour. The resulting solution was
neutralized with saturated sodium hydrogencarbonate and extracted
with chloroform. The organic layer was washed with saturated brine,
and the resulting organic layer was dried over magnesium sulfate
and concentrated under reduced pressure.
[0076] The brown oily residue (1.37 g) was added with xylene (7 ml)
and trichlorophenyl malonate (2.7 g, 5.83 mmol) and refluxed by
heating at 140.degree. C. for 1 hour, and the solvent was
evaporated under reduced pressure. The resulting oily compound was
purified by silica gel chromatography (ethyl acetate
chloroform:methanol=30:1.fwdarw.10:1.fwdarw.5:1) to obtain 657 mg
(41% for the three steps) of the title compound as pale yellow
crystals.
[0077] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.91 (1H,m), 2.01 (1H, qu,
J=8.79 Hz), 2.22 (2H, d qu, J=2.44, 8.79 Hz), 2.34 (2H, tq, J=2.44,
8.79 Hz), 3.39 (4H, dd, J=6.84, 20.75 Hz), 3.63 (1H, qu, J=8.79
Hz), 5.33 (1H, s), 6.76 (1H, s), 7.11 (1H, dd, J=1.71, 7.08 Hz),
7.40 (1H, s), 9.02 (1H, d, J=7.08 Hz)
(G)
8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidino)-4H--
pyrido-[1,2-a]pyrimidin-4-one
[0078]
8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4H-pyrido[1,2-
-a]pyrimidin-4-one (120 mg, 0.366 mmol) dissolved in
tetrahydrofuran (4 ml) and dimethylformamide (1 ml) was added with
4-dimethylaminopyridine (60 mg, 0.475 mmol) and p-tolunenesulfonyl
chloride (77 mg, 0.402 mmol) at room temperature and stirred for 30
minutes. The solvent was evaporated under reduced pressure, and the
residue was washed with water and extracted with chloroform. The
resulting organic layer was dried over magnesium sulfate and
concentrated under reduced pressure.
[0079] The resulting oily compound was added with dimethylformamide
(3 ml) and 3-hydroxypiperidine (45 mg, 0.44 mmol), and stirred at
60.degree. C. for 40 hours. The solvent was evaporated under
reduced pressure, and then the residue was purified by silica gel
column chromatography (chloroform.fwdarw.chloroform:methanol=20:1)
to obtain 103 mg (68% for the two steps) of the title compound as
oil.
[0080] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.56 (1H, m), 1.66 (1H,
m), 1.62-2.09 (4H, m), 2.23 (2H, d qu, J=2.20, 9.03 Hz), 2.35 (2H,
m), 3.15 (2H, t, J=7.32 Hz), 3.35 (2H, t, J=7.32 Hz), 3.37 (1H, m),
3.48 (1H, m), 3.63 (1H, qu, J=9.03 Hz), 3.68 (1H, m), 3.84 (1H, m),
3.99 (1H, dd, J=2.93, 13.18 Hz), 5.64 (1H, s), 6.71 (1H, dd,
J=1.71, 7.32 Hz), 6.76 (1H, s), 7.10 (1H, s), 8.76 (1H, d, J=7.32
Hz)
[0081] EI/MS; m/z: 411 (M.sup.++1)
(H)
2-(3-{[1-(tert-Butyl)-1,1-dimethylsilyl]oxy}piperidino)-8-[2-(4-cyclob-
utyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one
[0082]
8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidino)-
-4H-pyrido[1, 2-a]pyrimidin-4-one (103 mg, 0.251 mmol) dissolved in
dichloromethane (3 ml) was added with imidazole (51 mg, 0.753 mmol)
and tert-butyldimethylsilyl chloride (57 mg, 0.376 mmol) under ice
cooling and stirred for 1 hour. Then, as the reaction did not
progress, the reaction mixture was warmed to room temperature and
further added with imidazole and tert-butyldimethylsilyl chloride
so that the reaction was completed. The reaction solution was
diluted with chloroform, washed with water, dried over magnesium
sulfate and then concentrated under reduced pressure. The resulting
residue was purified by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=20:1) to obtain 128 mg (97%)
of the title compound as an orange oily substance.
[0083] .sup.1H-NMR (CDCl.sub.3) .delta.: 0.87 (9H, s), 0.92 (6H,
s), 1.53 (2H, m), 1.80-2.09 (4H, m), 2.23 (2H, m), 2.34 (2H, m),
3.02 (2H, m), 3.14 (2H, t, J=8.04 Hz), 3.35 (2H, t, J=8.04 Hz),
3.64 (2H, m), 4.00 (1H, brd), 4.20 (1H, brd), 5.59 (1H, s), 6.69
(1H, dd, J=1.95, 7.31 Hz), 6.75 (1H, s), 7.06 (1H, s), 8.76 (1H, d,
J=7.31 Hz)
[0084] EI/MS; m/z: 525 (M.sup.++1)
(I)
1-{8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl}-3-formyl-4-oxo-4H-pyrido-
[1,2-a]-pyrimidin-2-yl}-3-piperidyl formate
[0085] Under ice cooling, dimethylformamide (2 ml) was added with
phosphorus oxychloride (34 .mu.l, 0.366 mmol), and then the
reaction solution was added dropwise with
2-(3-{[1-(tert-butyl)-1,1-dimethylsilyl]oxy}piperidino)-8-[2-(4-cyclobuty-
l1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one (128 mg,
0.244 mmol) dissolved in dimethylformamide under ice cooling. Then
the reaction solution was warmed to room temperature. After 2
hours, the reaction solution was further added with phosphorus
oxychloride (34 .mu.l) at room temperature and stirred at room
temperature for 20 minutes. The solvent was evaporated under
reduced pressure, and the resulting residue was neutralized by
adding saturated aqueous sodium hydrogencarbonate and extracted
with ethyl acetate and chloroform. The organic layer collected was
washed with saturated brine, dried over magnesium sulfate and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=20:1) to obtain 69 mg (61%)
of the title compound as a yellow oily substance.
[0086] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.25-2.09 (6H, m), 2.22
(2H, dqu, J=2.45, 9.06 Hz), 2.34 (2H, m), 3.18 (2H, t, J=7.83 Hz),
3.36 (2H, t, J=7.83 Hz), 3.65 (3H, m), 3.82 (1H, dd, J=6.37, 13.47
Hz), 3.91 (1H, dd, J=3.18, 13.47 Hz), 5.07 (1H, m), 6.77 (1H, dd,
J=1.71, 7.34 Hz), 6.77 (1H, s), 7.07 (1H, s), 7.98 (1H, s), 8.72
(1H, d, J=7.34 Hz), 10.08 (1H, s)
[0087] EI/MS; m/z: 467 (M.sup.++1)
(J) tert-Butyl
(E)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-formyloxy-piperidi-
no)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0088]
1-{8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-3-formyl-4-oxo-4H-py-
rido[1,2-a]py rimidin-2-yl}-3-piperidylformate (69 mg, 0.148 mmol)
dissolved in tetrahydrofuran (3 ml) was added with
(tert-butoxycarbonylmethylene)triphenylphosphorane (84 mg, 0.222
mmol) and refluxed at 100.degree. C. After 7 hours, the reaction
solution was further added with the phosphorane (90 mg) and further
refluxed for 11 hours. Then the phosphorane (90 mg) was further
added, and after 5 hours, the phosphorane (89 mg) was further
added. The reaction solution was refluxed for 10 hours, then added
with the phosphorane (90 mg) and refluxed for 5 hours. The reaction
solution was returned to room temperature, and the solvent was
evaporated under reduced pressure. The residue was purified by thin
layer silica gel chromatography (chloroform:methanol=30:1) to
obtain 94 mg of the title compound as yellow crystals in a mixture
with triphenylphosphine oxide.
[0089] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.51 (9H, s), 1.89-2.04
(6H, m), 2.22 (2H, m), 2.34 (2H, m), 3.19 (2H, t, J=7.81 Hz), 3.36
(2H, t, J=7.81 Hz), 3.53-3.68 (4H, m), 3.79 (1H, dd, J=3.42, 13.67
Hz), 5.13 (1H, m), 6.76 (1H, s), 6.84 (1H, dd, J=1.95, 7.32 Hz),
7.06 (1H, d, J=15.63 Hz), 7.20 (1H, s), 7.65 (1H, d, J=15.63 Hz),
8.08 (1H, s), 8.85 (1H, d, J=7.32 Hz)
(K) tert-Butyl
(E)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidino)-
-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0090] tert-Butyl
(E)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-formyloxy-piperidi-
no)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (95 mg,
0.168 mmol) dissolved in methanol (4 ml) was added with sodium
methoxide (4 mg, 0.074 mmol) under ice cooling and stirred for 45
minutes under ice cooling. Then the reaction solution was further
added with sodium methoxide (4 mg), and after 5 minutes, further
added with sodium methoxide (10 mg). After the reaction solution
was stirred for 15 minutes, the reaction was stopped with saturated
brine and added with chloroform for extraction. The organic layer
was dried over magnesium sulfate and concentrated under reduced
pressure, and the residue was purified by thin layer silica gel
chromatography (chloroform:methanol=20:1) to obtain 76 mg (84%) of
the title compound as yellow crystals in a mixture with
triphenylphosphine oxide.
[0091] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.51 (9H, s), 1.82-2.08
(6H, m), 2.17-2.25 (2H, m), 2.32-2.36 (2H, m), 3.19 (2H, t, J=7.32
Hz), 3.36 (2H, t, J=7.32 Hz), 3.53-3.65 (4H, m), 3.92 (1H, d,
J=13.92 Hz), 4.01 (1H, s), 6.77 (1H, s), 6.86 (1H, dd, J=1.95, 7.32
Hz), 7.03 (1H, d, J=15.63 Hz), 7.19 (1H, s), 7.62 (1H, d, J=15.63
Hz), 8.85 (1H, d, J=7.32 Hz)
[0092] EI/MS; m/z: 537 (M.sup.++1)
(L)
(E)-3-[8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidi-
no)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoic acid
[0093] tert-Butyl
(E)-3-[8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxy-piperidino-
)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (76 mg, 0.142
mmol) was added with formic acid (3 ml) and stirred at room
temperature for 2 hours and 30 minutes. After the formic acid was
evaporated under reduced pressure, the residue was purified by thin
layer silica gel chromatography (chloroform:methanol=15:1) to
obtain 39 mg (55% for the three steps) of the title compound as
yellow crystals.
[0094] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.25 (1H, m), 1.52 (1H,
m), 1.83-2.08 (4H, m), 2.21 (2H, d qu, J=2.44, 8.30 Hz), 2.36 (2H,
tq, J=2.93, 8.30 Hz), 3.19 (2H, t, J=7.32 Hz), 3.36 (2H, t, J=7.32
Hz), 3.63 (4H, m), 3.88 (1H, d, J=13.43 Hz), 4.02 (1H, brd), 6.76
(1H, s), 6.86 (1H, dd, J=2.71, 7.32 Hz), 7.06 (1H, d, J=15.63 Hz),
7.19 (1H, s), 7.65 (1H, d, J=15.63 Hz), 8.84 (1H, d, J=7.32 Hz)
[0095] EI/MS; m/z: 481 (M.sup.++1)
Example 2
(E)-3-{8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A)
8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2--
a]pyrimidin-4-one
[0096]
8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4H-pyrido[1,2-
-a]-pyrimidin-4-one (302 mg, 0.925 mmol) dissolved in
tetrahydrofuran (14 ml) and dimethylformamide (6 ml) was added with
4-dimethylaminopyridine (150 mg, 1.20 mmol) and p-tolunenesulfonyl
chloride (194 mg, 1.02 mmol) and stirred at room temperature for 20
minutes.
[0097] After the solvent was evaporated under reduced pressure, the
residue was diluted with chloroform and washed with water. The
resulting organic layer was dried over magnesium sulfate and
concentrated under reduced pressure.
[0098] The residue was dissolved in dimethylformamide (2 ml), added
with morpholine (1 ml, 11.5 mmol) and stirred at 70.degree. C. for
3 hours. After the reaction solution was returned to room
temperature, the solvent was evaporated under reduced pressure and
the residue was purified by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=20:1) to obtain 351 mg of
the title compound as pale yellow crystals as a substance
containing dimethylformamide.
[0099] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.92 (1H, m), 2.02 (1H,
m), 2.23 (2H, m), 2.35 (2H, m), 3.16 (2H, t, J=8.32 Hz), 3.35 (2H,
t, J=8.32 Hz), 3.66 (4H, t, J=5.38 Hz), 3.70 (1H, m), 3.78 (4H, t,
J=5.38 Hz), 5.57 (1H, s), 6.74 (1H, dd, J=2.94, 7.09 Hz), 6.76 (1H,
s), 7.13 (1H, s), 8.78 (1H, d, J=7.09 Hz)
[0100] EI/MS; m/z: 397 (M.sup.++1)
(B)
8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrid-
o[1,2-a]-pyrimidine-3-carbaldehyde
[0101] Reactions were performed in the same manner as in Example 1,
(I) by using
8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrid-
o[1,2-a]pyrimidin-4-one (346 mg, 0.8726 mmol) to obtain 305 mg
(82%) of the title compound as ocher solid.
[0102] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.92-2.96 (6H, m), 3.19
(2H, t, J=7.34 Hz), 3.36 (2H, t, J=7.34 Hz), 3.68 (1H, m)3.73 (4H,
t, J=5.14 Hz), 3.82 (4H, t, J=5.14 Hz), 6.77 (1H, s), 6.78 (1H, dd,
J=1.96, 7.34 Hz), 7.08 (1H, s), 8.74 (1H, d, J=7.34 Hz), 10.01 (1H,
s)
[0103] EI/MS; m/z: 425 (M.sup.++1)
(C) tert-Butyl
(E)-3-{8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-p-
yrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0104] Reactions were performed in the same manner as in Example 1,
(J) by using
8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-
-pyrido[1,2-a]-pyrimidin-3-carbaldehyde (100 mg, 0.2356 mmol) to
obtain 127 mg (100%) of the title compound as a yellow oily
substance in a mixture with triphenylphosphine oxide.
[0105] .sup.1H-NMR (CDCl.sub.3) .delta.: 2.02 (1H, m), 2.20 (1H,
m), 2.23 (2H, m), 2.34 (2H, m), 3.20 (2H, t, J=7.08 Hz), 3.37 (2H,
t, J=7.08 Hz), 3.60 (4H, t, J=4.39 Hz), 3.63 (1H, m), 3.83 (4H, t,
J=4.39 Hz), 6.76 (1H, s), 6.85 (1H, dd, J=1.71, 7.32 Hz), 7.05 (1H,
d, J=15.63 Hz), 7.21 (1H, s), 7.64 (1H, d, J=15.63 Hz), 8.86 (1H,
d, J=7.32 Hz)
[0106] EI/MS; m/z: 523 (M.sup.++1)
(D)
(E)-3-{8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4-
H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0107] Reactions were performed in the same manner as in Example 1,
(L) by using tert-butyl
(E)-3-{8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-p-
yrido[1,2-a]pyrimidin-3-yl}-2-propenoate (127 mg, 0.2430 mmol) to
obtain 82.7 mg (73%) of the title compound as yellow crystals.
[0108] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.92 (1H, m), 2.01 (1H,
m), 2.22 (2H, m), 2.34 (2H, m), 3.19 (2H, t, J=8.06 Hz), 3.37 (2H,
t, J=8.06 Hz), 3.61 (4H, s), 3.64 (1H, m), 3.81 (4H, s), 6.76 (1H,
s), 6.86 (1H, dd, J=1.47, 7.32 Hz), 7.08 (1H, d, J=15.63 Hz), 7.19
(1H, s), 7.64 (1H, d, J=15.63 Hz), 8.87 (1H, d, J=7.32 Hz)
[0109] EI/MS; m/z: 467 (M.sup.++1).
[0110] IR (cm.sup.-1): 2962, 2850, 1680, 1647, 1516, 1444
Example 3
(E)-3-{8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoic acid
(A) Ethyl
(E)-3-{8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoate
[0111]
8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-p-
yrido[1,2-a]pyrimidin-3-carbaldehyde (100 mg, 0.236 mmol) dissolved
in toluene (2 ml) was added with
(carbethoxyethylidene)triphenylphosphorane (102 mg, 0.283 mmol) and
refluxed by heating at 130.degree. C. Then the regent was added
until the reaction was completed, and 7 equivalents of the regent
was finally added. After the reaction mixture was stirred for 4
days, the solvent was evaporated under reduced pressure, and the
resulting residue was purified by thin layer silica gel
chromatography (chloroform:methanol=40:1) to obtain 443 mg of
yellow crystals in a mixture with triphenylphosphine oxide.
[0112] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (3H, t, J=7.08 Hz),
1.88 (3H, s), 1.90 (1H, m), 2.05 (1H, m), 2.23 (2H, m), 2.35 (2H,
m), 3.20 (2H, t, J=7.81 Hz), 3.37 (2H, t, J=7.81 Hz), 3.57 (4H, t,
J=4.88 Hz), 3.64 (1H, m), 3.73 (4H, t, J=4.88 Hz), 4.25 (2H, q,
J=7.08 Hz), 6.77 (1H, s), 6.82 (1H, d, J=7.33 Hz), 7.21 (1H, s),
7.57 (1H, s), 8.84 (1H, d, J=7.33 Hz)
(B)
(E)-3-{8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4-
H-pyrido-[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoic acid
[0113] Ethyl
(E)-3-{8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-p-
yrido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoate (120 mg, 0.236
mmol) dissolved in methanol (5 ml) was added dropwise with 1 N
aqueous sodium hydroxide (2 ml) under ice cooling. The reaction
solution was stirred for 10 minutes and then warmed to room
temperature because the reaction did not progress. The reaction
solution was stirred for 45 minutes, then further added with 1 N
aqueous sodium hydroxide (2 ml), and after 1 hour, further added
with 1 N aqueous sodium hydroxide (2 ml). The solvent was
evaporated under reduced pressure, and the resulting sodium salt of
the title compound was dissolved in 1,4-dioxane, added with 4 N
hydrochloric acid (6 ml) and stirred. Then the reaction solution
was concentrated under reduced pressure, and the residue was
neutralized with saturated aqueous sodium hydrogencarbonate and
extracted with chloroform and methanol. The organic layer was dried
over magnesium sulfate and concentrated under reduced pressure. The
resulting residue was purified by thin layer silica gel
chromatography (chloroform:methanol=30:1) to obtain 75 mg (66%) of
the title compound as yellow crystals.
[0114] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.84 (3H, s), 1.91 (1H,
m), 2.02 (1H, hex, J=9.06 Hz), 2.22 (2H, d qu, J=2.21, 9.06 Hz),
2.34 (2H, q, J=8.57 Hz), 3.16 (2H, t, J=8.08 Hz), 3.36 (2H, t,
J=8.08 Hz), 3.56 (4H, s), 3.64 (1H, qu, J=8.57 Hz), 3.70 (4H, s),
6.76 (1H, s), 6.80 (1H, dd, J=1.22, 7.10 Hz), 7.16 (1H, s), 7.57
(1H, s), 8.83 (1H, d, J=7.10 Hz)
[0115] EI/MS; m/z: 481 (M.sup.++1)
[0116] IR (cm.sup.-1): 2958, 2919, 2850, 1666, 1641, 1440, 1251,
1115
Example 4
(E)-3-{8-[2-(4-Ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido--
[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) 4-[2-(4-Ethyl-1,3-thiazol-2-yl)ethyl]-2-pyridinamine
[0117] tert-Butyl N-[4-(3-amino-3-thioxopropyl)-2-pyridyl]carbamate
(590 mg, 2.10 mmol) dissolved in ethanol (20 ml) was added with
1-bromo-2-butanone (0.23 ml, 2.10 mmol) and refluxed by heating at
100.degree. C. The reaction solution was stirred for 1 hour and
then returned to room temperature. The solvent was evaporated under
reduced pressure, and the residue was diluted with chloroform. The
mixture was washed with saturated aqueous sodium hydrogencarbonate
and dried over sodium sulfate, and concentrated under reduced
pressure.
[0118] The resulting residue was added with dichloromethane (20 ml)
and added dropwise with trifluoroacetic acid (20 ml) under ice
cooling. Then the reaction solution was warmed to room temperature
and stirred for 15 hours. The trifluoroacetic acid was evaporated
under reduced pressure, and the residue was neutralized with
saturated sodium hydrogencarbonate and extracted with chloroform.
The organic layer was washed with saturated brine and the collected
organic layer was dried over magnesium sulfate and concentrated
under reduced pressure. The resulting residue without purification
gave 477 mg (98%) of the title compound as an orange oily
substance.
[0119] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (3H, t, J=7.59 Hz),
2.78 (2H, dq, J=0.98, 7.59 Hz), 2.98 (2H, t, J=8.33 Hz), 3.25 (2H,
t, J=8.33 Hz), 6.37 (1H, s), 6.52 (1H, dd, J=1.23, 5.39 Hz), 6.72
(1H, s), 7.93 (1H, d, J=5.39 Hz)
(B)
8-[2-(4-Ethyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]pyrimi-
din-4-one
[0120] 4-[2-(4-Ethyl-1,3-thiazol-2-yl)ethyl]-2-pyridinamine (480
mg, 2.044 mmol) dissolved in xylene (10 ml) was added with
trichlorophenyl malonate (1 g, 2.160 mmol) and refluxed by heating
at 140.degree. C. The reaction solution was stirred for 3 hours and
returned to room temperature. The solvent was evaporated under
reduced pressure and the resulting residue was purified by silica
gel column chromatography
(chloroform.fwdarw.chloroform:methanol=80:1.fwdarw.50:1.fwdarw.5:1)
to obtain 135 mg (22%) of orange crystals.
[0121] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (3H, t, J=7.57 Hz),
2.78 (2H, q, J=7.57 Hz), 3.36 (4H, dd, J=6.35, 17.82 Hz), 5.33 (1H,
s), 6.76 (1H, s), 7.09 (1H, d, J=7.08 Hz), 7.39 (1H, s), 9.02 (1H,
d, J=7.08 Hz)
[0122] EI/MS; m/z: 302 (M.sup.++1)
(C)
8-[2-(4-Ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyr-
imidin-4-one
[0123] Reactions were performed in the same manner as in Example 2,
(A) by using
8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]-
pyrimidin-4-one (135 mg, 0.4480 mmol) as a starting material to
obtain 120 mg (72%) of the title compound as pale yellow
crystals.
[0124] .sup.1H-NMR(CDCl.sub.3) .delta.: 1.29 (3H, t, J=7.57 Hz),
2.78 (2H, dq, J=0.977, 7.57 Hz), 3.16 (2H, t, J=8.06 Hz), 3.34 (2H,
t, J=8.06 Hz), 3.64 (4H, t, J=5.13 Hz), 3.77 (4H, t, J=5.13 Hz),
5.57 (1H, s), 6.74 (1H, d, J=0.977 Hz), 6.74 (1H, dd, J=1.953, 7.08
Hz), 7.12 (1H, d, J=1.953 Hz), 8.79 (1H, d, J=7.08 Hz)
[0125] EI/MS; m/z: 371 (M.sup.++1)
(D)
8-[2-(4-Ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-
-a]-pyrimidine-3-carbaldehyde
[0126] Reactions were performed in the same manner as in Example 1,
(I) by using
8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-
-a]pyrimidin-4-one (120 mg, 0.324 mmol) to obtain 116 mg (90%) of
the title compound.
[0127] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (3H, t, J=7.57 Hz),
2.78 (2H, q, J=7.57 Hz), 3.19 (2H, t, J=7.08 Hz), 3.35 (2H, t,
J=7.08 Hz), 3.73 (4H, t, J=4.15 Hz), 3.82 (4H, t, J=4.15 Hz), 6.76
(1H, s), 6.78 (1H, dd, J=1.71, 7.32 Hz), 7.07 (1H, d, J=1.71 Hz),
8.74 (1H, d, J=7.32 Hz), 10.11 (1H, s)
[0128] EI/MS; m/z: 399 (M.sup.++1)
(E) tert-Butyl
(E)-3-{8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido-
[1,2-a]pyrimidin-3-yl}-2-propenoate
[0129] Reactions were performed in the same manner as in Example 1,
(J) by using
8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyri-
do[1,2-a]pyrimidine-3-carbaldehyde (116 mg, 0.2911 mmol) to obtain
the title compound as yellow crystals in a mixture with
triphenylphosphine oxide.
[0130] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (3H, t, J=7.57 Hz),
1.51 (9H, s), 2.78 (2H, q, J=7.57 Hz), 3.20 (2H, t, J=7.08 Hz),
3.36 (2H, t, J=7.08 Hz), 3.60 (4H, t, J=4.88 Hz), 3.83 (4H, t,
J=4.88 Hz), 6.74 (1H, s), 6.85 (1H, dd, J=1.71, 7.32 Hz), 7.05 (1H,
d, J=15.87 Hz), 7.20 (1H, s), 7.68 (1H, d, J=15.87 Hz), 8.87 (1H,
d, J=7.32 Hz)
(F)
(E)-3-{8-[2-(4-Ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyr-
ido[1,2-a]-pyrimidin-3-yl}-2-propenoic acid
[0131] Reactions were performed in the same manner as in Example 1,
(L) by using tert-butyl
(E)-3-{8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido-
-[1,2-a]pyrimidin-3-yl}-2-propenoate (144 mg, 0.290 mmol) to obtain
93 mg (73%) of the title compound as yellow crystals.
[0132] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (3H, t, J=7.57 Hz),
2.79 (2H, q, J=7.57 Hz), 3.21 (2H, t, J=7.08 Hz), 3.38 (2H, t,
J=7.08 Hz), 3.63 (4H, t, J=6.15 Hz), 3.83 (4H, t, J=6.15 Hz), 6.75
(1H, s), 6.87 (1H, dd, J=1.47, 7.32 Hz), 7.09 (1H, d, J=15.63 Hz),
7.21 (1H, s), 7.68 (1H, d, J=15.63 Hz), 8.87 (1H, d, J=7.32 Hz)
[0133] EI/MS; m/z: 441 (M.sup.++1)
[0134] IR (cm.sup.-1): 2964, 2919, 2850, 1681, 1517, 1444
Example 5
(E)-3-{2-(3-Hydroxypiperidino)-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) 4-Methoxy-2-pyridinecarbonitrile
[0135] 4-Methoxypyridine-N-oxide hydrate (1 g, 6.99 mmol) dissolved
in dichloromethane (4 ml) was added with trimethylsilyl cyanide (1
ml, 7.69 mmol) and subsequently added dropwise with
N,N-dimethylcarbamoyl chloride (0.8 ml, 9.09 mmol) under ice
cooling. The reaction solution was warmed to room temperature,
stirred for 1 hour, and then added further with trimethylsilyl
cyanide (0.2 ml, 1.40 mmol). The reaction solution was stirred for
19 hours, then added with 10% potassium carbonate (2 ml). The
mixture was diluted with ethyl acetate, washed with saturated brine
and dried over magnesium sulfate, and then concentrated under
reduced pressure. The resulting crystals were washed with hexane to
obtain 560 mg (60%) of the title compound as pink crystals without
purification.
[0136] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.92 (3H, s), 7.02 (1H,
dd, J=2.44, 5.86 Hz), 7.22 (1H, d, J=2.44 Hz), 8.51 (1H, d, J=5.86
Hz)
(B) 4-Hydroxy-2-pyridinecarbonitrile
[0137] 4-Methoxy-2-pyridinecarbonitrile (544 mg, 4.055 mmol) was
added with 47% hydrobromic acid (6 ml) and refluxed by heating at
130.degree. C. The reaction solution was stirred for 22 hours,
returned to room temperature, and then concentrated under reduced
pressure. The residue was subjected to azeotropy with toluene and
diethyl ether to remove excessive hydrobromic acid. The resulting
white crystals were washed with diethyl ether to obtain 1.47 g of
the title compound containing hydrogen bromide without
purification.
[0138] .sup.1H-NMR (CD.sub.3OD) .delta.:7.48 (1H, dd, J=2.44, 6.83
Hz), 7.81 (1H, d, J=2.44 Hz), 8.63 (1H, d, J=6.83 Hz)
(C) Ethyl 4-hydroxy-2-pyridinecarboxylate
[0139] 4-Hydroxy-2-pyridinecarbonitrile (25.48 g, 0.2121 mol)
dissolved in ethanol (400 ml) was added with concentrated
hydrochloric acid (40 ml) and refluxed by heating at 110.degree. C.
for 6 days. The reaction solution was returned to room temperature,
evaporated under reduced pressure and added with
chloroform:methanol=20:1. After insoluble crystals were removed by
filtration, the resulting filtrate was concentrated under reduced
pressure. The resulting residue was purified by silica gel column
chromatography (chloroform:methanol=20:1.fwdarw.10:1) to obtain
22.4 g (63% for the two steps) of the title compound as yellow
crystals.
[0140] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.32 (3H, t, J=7.32 Hz),
4.52 (2H, q, J=7.32 Hz), 7.18 (1H, dd, J=2.69, 6.84 Hz), 7.58 (1H,
d, J=2.69 Hz), 8.36 (1H, d, J=6.84 Hz)
[0141] EI/MS; m/z: 168 (M.sup.++1)
(D) 2-(Chloromethyl)-4-isopropyl-1,3-thiazole
[0142] (4-Isopropyl-1,3-thiazol-2-yl)methanol (10 g, 63.6011 mmol)
dissolved in dichloromethane (60 ml) was added with thionyl
chloride (7 ml, 95.40 mmol) under ice cooling, and then the
reaction solution was returned to room temperature and stirred for
20 minutes. The reaction solution was concentrated under reduced
pressure, and the residue was subjected to azeotropy with toluene
and then diluted with diethyl ether, and further neutralized with
saturated aqueous sodium hydrogencarbonate. The organic layer was
washed with saturated brine, then dried over magnesium sulfate and
concentrated under reduced pressure. The title compound was
obtained as the residue without purification (11 g, 100%).
[0143] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.30 (6H, d, J=7.08 Hz),
3.09 (1H, qu, J=7.08 Hz), 4.83 (2H, s), 6.91 (1H, s)
[0144] EI/MS; m/z: 176 (M.sup.++1)
(E) Ethyl
4-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinecarboxylate
[0145] Ethyl 4-hydroxy-2-pyridinecarboxylate (19.5 g, 0.057 mol)
dissolved in dimethylformamide (200 ml) was added with a solution
of 2-(chloromethyl)-4-isopropyl-1,3-thiazole (11 g, 0.063 mol) in
dimethylformamide (150 ml). The mixture was added with potassium
iodide (9.5 g) and potassium carbonate (12 g) at room temperature,
then heated to 110.degree. C. and stirred for 1 hour. The reaction
solution was returned to room temperature, and the solvent was
evaporated under reduced pressure. The residue was diluted with
chloroform and washed with water. The resulting organic layer was
washed with saturated brine, and the organic layer was dried over
magnesium sulfate and concentrated under reduced pressure. The
residue was purified by silica gel chromatography (chloroform) to
obtain 8.049 g (46%) of the title compound.
[0146] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.32 (6H, d, J=6.86 Hz),
1.44 (3H, t, J=7.10 Hz), 3.12 (1H, qu, J=6.86 Hz), 4.47 (2H, q,
J=7.10 Hz), 5.44 (2H, s), 6.94 (1H, s), 7.09 (1H, dd, J=2.694, 5.63
Hz), 7.80 (1H, d, J=2.694 Hz), 8.58 (1H, d, J=5.63 Hz)
[0147] EI/MS; m/z: 307 (M.sup.++1)
(F) 4-[(4-Isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinecarboxylic
acid
[0148] Ethyl
4-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinecarboxylate
(7.44 g, 24.28 mmol) dissolved in ethanol (50 ml) was added
dropwise with 1 N sodium hydroxide (27 ml, 26.70 mmol) at room
temperature, and stirred at room temperature for 1 hour and 30
minutes. The solvent was evaporated under reduced pressure, and the
resulting Na salt crystals were washed with ethyl acetate.
[0149] The crystals were added with 4 N hydrochloric acid (27 ml)
and 1,4-dioxane (40 ml), stirred and concentrated under reduced
pressure. The residue was subjected to azeotropy with toluene, and
the solvent was completely evaporated. The resulting crystals were
filtered with chloroform:methanol=10:1, and the filtrate was
concentrated under reduced pressure. The resulting pale yellow
crystals were purified by silica gel column chromatography
(chloroform:methanol=20:1.fwdarw.10:1.fwdarw.5:1) to obtain 6.7 g
(100%) of the title compound as white crystals.
[0150] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.37 (6H, d, J=6.83 Hz),
3.22 (1H, qu, J=6.83 Hz), 5.96 (2H, s), 7.54 (1H, s), 7.92 (1H, dd,
J=2.68, 6.83 Hz), 8.22 (1H, d, J=2.68 Hz), 8.80 (1H, d, J=6.83
Hz)
[0151] EI/MS; m/z: 279 (M.sup.++1).
(G) tert-Butyl
N-{4-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridyl}carbamate
[0152]
4-[(4-Isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinecarboxylic acid
(50 mg, 0.18 mmol) was added with toluene (12 ml), triethylamine
(63 .mu.l, 0.45 mmol) and diphenyl phosphorylazide (78 .mu.l, 0.36
mmol) and refluxed by heating at 140.degree. C. for 7 hours. The
reaction solution was returned to room temperature, added with
tert-butanol (12 ml) and refluxed again by heating at 140.degree.
C. The reaction solution was stirred for 18 hours and then returned
to room temperature, and the solvent was evaporated under reduced
pressure. The residue was purified by thin layer silica gel
chromatography (chloroform:methanol=40:1) to obtain 33 mg (53%) of
the title compound.
[0153] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.32 (6H, d, J=6.86 Hz),
1.53 (9H, s), 3.11 (1H, qu, J=6.86 Hz), 5.40 (2H, s), 6.60 (1H, dd,
J=2.45, 5.88 Hz), 6.91 (1H, s), 7.73 (1H, s), 8.15 (1H, dd, J=2.45,
5.88 Hz)
[0154] EI/MS; m/z: 350 (M.sup.++1)
(H) 4-[(4-Isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinamine
[0155] tert-Butyl
N-{4-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridyl}carbamate
(706 mg, 2.202 mmol) dissolved in dichloromethane (20 ml) was added
dropwise with trifluoroacetic acid (20 ml) under ice cooling, then
warmed to room temperature and stirred for 2 hours. The reaction
solution was concentrated under reduced pressure, diluted with
chloroform, then neutralized with saturated aqueous sodium
hydrogencarbonate and extracted with chloroform. The organic layer
was dried over magnesium sulfate and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography
(chloroform.fwdarw.chloroform:methanol=50:1.fwdarw.30:1.fwdarw.20:1)
to obtain 331 mg (66%) of the title compound.
[0156] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.32 (6H, d, J=6.83 Hz),
3.11 (1H, qu, J=6.83 Hz), 5.31 (2H, s), 6.08 (1H, d, J=1.95 Hz),
6.35 (1H, dd, J=1.95, 5.85 Hz), 6.91 (1H, s), 7.91 (1H, d, J=5.85
Hz)
(I)
2-Hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4H-pyrido[1,2-a]py-
rimidin-4-one
[0157] 4-[(4-Isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinamine
(378 mg, 1.52 mmol) dissolved in xylene (15 ml) was added with
trichlorophenyl malonate (750 mg, 1.62 mmol) and refluxed by
heating at 140.degree. C. for 1 hour and 30 minutes. The reaction
solution was returned to room temperature and concentrated under
reduced pressure, and the residue was purified by silica gel column
chromatography
(chloroform.fwdarw.chloroform:methanol=100:1.fwdarw.80:1.fwdarw.50:1)
to obtain 307 mg (64%) of the title compound.
[0158] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (6H, d, J=6.84 Hz),
3.15 (1H, qu, J=6.84 Hz), 5.23 (1H, s), 5.60 (2H, s), 6.95 (1H, dd,
J=2.44, 7.57 Hz), 7.01 (1H, s), 7.06 (1H, d, J=2.44 Hz), 8.99 (1H,
d, J=7.57 Hz)
[0159] EI/MS; m/z: 318 (M.sup.++1)
(J)
2-Hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4-oxo-4H-pyrido[1,-
2-a]-pyrimidine-3-carbaldehyde
[0160] Dimethylformamide (3 ml) was added with phosphorus
oxychloride (130 .mu.l, 1.42 mmol) under ice cooling, and further
added dropwise with
2-hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4H-pyrido[1,2-a]pyrim-
idin-4-one (300 mg, 0.945 mmol) dissolved in dimethylformamide (6
ml) under ice cooling. Then, the reaction solution was returned to
room temperature and stirred for 1 hour. The reaction was stopped
with saturated aqueous sodium hydrogencarbonate, and the reaction
solution was extracted with chloroform. The resulting organic layer
was washed with saturated brine, dried over sodium sulfate and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=50:1.fwdarw.30:1.fwdarw.10:1)
to obtain 45 mg (14%) of the title compound.
[0161] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.32 (6H, d, J=6.84 Hz),
3.13 (1H, qu, J=6.84 Hz), 5.50 (2H, s), 6.94 (1H, d, J=6.85 Hz),
6.99 (2H, s), 8.92 (1H, d, J=6.85 Hz), 10.13 (1H, s)
[0162] EI/MS; m/z: 346 (M.sup.++1)
(K) tert-Butyl
(E)-3-{2-hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4-oxo-4H-pyrid-
o[1,2-a]pyrimidin-3-yl}-2-propenoate
[0163]
2-Hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4-oxo-4H-pyrid-
o[1,2-a]pyr imidin-3-carbaldehyde (45 mg, 0.13 mmol) dissolved in
tetrahydrofuran (2 ml) and dimethylformamide (1 ml) was added with
(tert-butoxycarbonylmethylene)triphenyl-phosphorane (60 mg, 0.16
mmol) and refluxed by heating at 100.degree. C. for 2 hours. The
reaction solution was returned to room temperature and concentrated
under reduced pressure, and the residue was purified by thin layer
silica gel chromatography (chloroform:methanol=20:1) to obtain 36
mg (62%) of the title compound.
[0164] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.26 (6H, d, J=6.86 Hz),
1.44 (9H, s), 3.08 (1H, qu, J=6.86 Hz), 5.57 (2H, s), 6.82 (1H, d,
J=15.92 Hz), 6.90 (1H, d, J=7.83 Hz), 6.96 (1H, s), 7.01 (1H, s),
7.69 (1H, d, J=15.92 Hz), 8.95 (1H, d, J=7.83 Hz)
[0165] EI/MS; m/z: 444 (M.sup.++1)
(L) tert-Butyl
(E)-3-{2-(3-hydroxypiperidino)-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]--
4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0166] Reactions were performed in the same manner as in Example 1,
(G) by using tert-butyl
(E)-3-{2-hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4-oxo-4H-pyrid-
o-[1,2-a]pyrimidin-3-yl}-2-propenoate (26 mg, 0.059 mmol) to obtain
24 mg (78%) of the title compound as yellow oily compound.
[0167] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (6H, d, J=7.08 Hz),
1.51 (9H, s), 1.60 (2H, m), 1.83 (2H, m), 3.14 (1H, qu, J=7.08 Hz),
3.56 (3H, m), 3.92 (1H, dd, J=3.91,13.67 Hz), 4.02 (1H, m), 5.44
(2H, s), 6.75 (1H, dd, J=2.68, 7.32 Hz), 6.76 (1H, s), 6.97 (1H,
s), 6.98 (1H, d, J=15.62 Hz), 7.48 (1H, d, J=15.62 Hz), 8.86 (1H,
d, J=7.32 Hz)
[0168] EI/MS; m/z: 527 (M.sup.++1)
(M)
(E)-3-{2-(3-Hydroxypiperidino)-8-[(4-isopropyl-1,3-thiazol-2-yl)methox-
y]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0169] tert-Butyl
(E)-3-{2-(3-hydroxypiperidino)-8-[(4-isopropyl-1,3-thiazol-2-yl)-methoxy]-
-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (24 mg, 0.046
mmol) was added with a mixture of 4 N hydrochloric acid and dioxane
(1 ml) and stirred at room temperature for 3 hours. The reaction
solution was concentrated under reduced pressure, and the residue
was purified by thin layer silica gel chromatography
(chloroform:methanol=15:1) to obtain 24 mg (100%) of the title
compound as yellow crystals.
[0170] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.33 (6H, d, J=7.08 Hz),
1.57 (1H, m), 1.69 (1H, m), 1.89 (1H, m), 2.07 (1H, m), 3.14 (1H,
qu, J=7.08 Hz), 3.16 (1H, m), 3.17 (1H, m), 3.82 (2H, m), 4.04 (1H,
d, J=9.52 Hz), 5.54 (2H, s), 6.87 (1H, d, J=7.81 Hz), 6.92 (1H, d,
J=15.38 Hz), 6.95 (1H, s), 7.18 (1H, s), 7.61 (1H, d, J=15.38 Hz),
8.81 (1H, d, J=7.81 Hz)
[0171] EI/MS; m/z: 471 (M.sup.++1)
Example 6
(E)-3-{8-[2-(4-Ethyl-2-thienyl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]--
pyrimidin-3-yl}-2-propenoic acid
(A) 4-Ethyl-2-thiophenecarbaldehyde
[0172] 3-Ethylthiophene (2 g, 17.8 mmol) dissolved in diethyl ether
(18 ml) was added with a solution of n-butyl lithium in hexane (1.5
M, 14 ml, 21.4 mmol) at room temperature and refluxed by heating at
60.degree. C. for 15 minutes. The reaction solution was returned to
room temperature and added dropwise with dimethylformamide (2 ml,
23.2 mmol) dissolved in diethyl ether. After the reaction solution
was stirred for 2 hours at room temperature, the reaction was
stopped with saturated aqueous ammonium chloride, and the reaction
solution was extracted with chloroform. The collected organic layer
was washed with saturated brine, then dried over magnesium sulfate
and concentrated under reduced pressure.
[0173] The residue was purified by silica gel column chromatography
(hexane:ethyl acetate=20:1.fwdarw.10:1) to obtain 2 g (80%) of the
title compound.
[0174] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.27 (3H, t, J=7.59 Hz),
2.68 (2H, q, J=7.59 Hz), 7.39 (1H, s), 7.63 (1H, s), 9.87 (1H,
s)
(B) (4-Ethyl-2-thienyl)methanol
[0175] 4-Ethyl-2-thiophenecarbaldehyde (1 g, 7.13 mmol) dissolved
in methanol (7 ml) was added with sodium borohydride (135 mg, 3.57
mmol) under ice cooling, stirred for 10 minutes and then further
added with sodium borohydride (150 mg, 3.96 mmol) at 0.degree. C.
After the reaction solution was stirred under ice cooling for 30
minutes, the reaction was stopped with saturated aqueous ammonium
chloride and the reaction solution was extracted with chloroform.
The organic layer collected was dried over magnesium sulfate and
concentrated under reduced pressure to obtain 1 g (100%) of the
title compound without purification.
[0176] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.22 (3H, t, J=7.56 Hz),
2.59 (2H, q, J=7.56 Hz), 4.75 (2H, s), 6.86 (2H, s)
(C) tert-Butyl
N-{4-[2-(3-bromo-4-ethyl-2-thienyl)ethyl]-2-pyridyl}carbamate
[0177] (4-Ethyl-2-thienyl)methanol (1 g, 7.03 mmol) dissolved in
dichloromethane (7 ml) was added with thionyl bromide (0.8 ml,
10.55 mmol) under ice cooling and then warmed to room temperature.
The reaction solution was stirred for 20 minutes and then
concentrated under reduced pressure, and the residue was
neutralized by adding saturated aqueous sodium hydrogencarbonate
and extracted with diethyl ether. The organic layer was washed with
saturated brine, dried over magnesium sulfate and concentrated
under reduced pressure. The residue was used in the subsequent
reaction without purification.
[0178] tert-Butyl N-(4-methyl-2-pyridyl)carbamate (800 mg, 3.84
mmol) dissolved in tetrahydrofuran (15 ml) was cooled to
-78.degree. C. and then added dropwise with a solution of n-butyl
lithium in hexane (1.5 M, 6.4 ml, 9.6 mmol). The reaction solution
was stirred at room temperature for 1 hour, then cooled to
-78.degree. C. again and added dropwise with a solution of the
above obtained 3-bromo-2-(bromomethyl)-4-ethylthiophene in
tetrahydrofuran (14 ml). After the reaction solution was stirred at
-78.degree. C. for 1 hour and the reaction was stopped with
saturated brine, the reaction solution was extracted with ethyl
acetate. The organic layer collected was dried over magnesium
sulfate and concentrated under reduced pressure. The resulting
residue was purified by silica gel column chromatography
(chloroform) to obtain 1.3 g (85%) of the title compound.
[0179] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.15 (3H, t, J=7.57 Hz),
1.55 (9H, s), 2.52 (2H, q, J=7.57 Hz), 2.92 (2H, t, J=8.55 Hz),
3.04 (2H, t, J=8.55 Hz), 6.50 (1H, s), 6.77 (1H, d, J=5.13 Hz),
7.87 (1H, s), 8.18 (1H, d, J=5.13 Hz)
[0180] EI/MS; m/z: 411 (M+)
(D) 4-[2-(3-Bromo-4-ethyl-2-thienyl)ethyl]-2-pyridylamine
[0181] tert-Butyl
N-{4-[2-(3-bromo-4-ethyl-2-thienyl)ethyl]-2-pyridyl}carbamate (1.34
g, 4.04 mmol) dissolved in dichloromethane (40 ml) was added with
trifluoroacetic acid (40 ml) at 0.degree. C. and stirred at
0.degree. C. for 3 hours. The reaction solution was concentrated
under reduced pressure, neutralized with saturated sodium
hydrogencarbonate and extracted with chloroform, and then the
organic layer was dried over magnesium sulfate and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (chloroform:ethyl acetate=3:1.fwdarw.1:1
ethyl acetate only) to obtain 524 mg (56%) of the title
compound.
[0182] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.12 (3H, t, J=7.56 Hz),
2.48 (2H, q, J=7.56 Hz), 2.79 (2H, t, J=7.56 Hz), 3.01 (2H, t,
J=7.56 Hz), 6.40 (1H, s), 6.46 (1H, d, J=5.36 Hz), 6.53 (1H, s),
7.76 (1H, d, J=5.36 Hz)
[0183] EI/MS; m/z: 310 (M.sup.+-1)
(E)
8-[2-(3-Bromo-4-ethyl-2-thienyl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]pyrim-
idin-4-one
[0184] Reactions were performed in the same manner as in Example 4,
(B) by using 4-[2-(3-bromo-4-ethyl-2-thienyl)ethyl]-2-pyridylamine
as a starting material. After the reaction was completed, the
reaction solution was concentrated under reduced pressure and the
crystals in the resulting turbid solution was removed by
filtration. The filtrate was concentrated under reduced pressure,
and the resulting residue was purified by silica gel column
chromatography (chloroform.fwdarw.chloroform:ethyl
acetate=1:1.fwdarw.ethyl acetate.fwdarw.ethyl
acetate:methanol=50:1.fwdarw.30:1 .fwdarw.10:1) to obtain 180 mg
(38%) of the title compound.
[0185] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.14 (3H, t, J=7.56 Hz),
2.49 (2H, q, J=7.56 Hz), 3.15 (4H, s), 5.31 (1H, s), 6.53 (1H, s),
7.12 (1H, d, J=7.07 Hz), 7.24 (1H, s), 8.98 (1H, d, J=7.07 Hz)
(F)
8-[2-(4-Ethyl-2-thienyl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-o-
ne
[0186]
8-[2-(3-Bromo-4-ethyl-2-thienyl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]p-
yrimidin-4-one (96 mg, 0.25 mmol) dissolved in toluene (6 ml) was
added with tributyltin hydride (75 .mu.l 1) and
2,2-azobisisobutyronitrile (4 mg, 0.025 mmol) and refluxed by
heating at 140.degree. C. Then 2,2-azobisisobutyronitrile and
tributyltin hydride were further added until the reaction was
completed while the progress of the reaction was monitored by
LC-MS. 34 mg (0.22 mmol) of 2,2-azobisisobutyronitrile and 350
.mu.l (1.30 mmol) of tributyltin hydride were used. The reaction
solution was returned to room temperature and the reaction was
stopped with an aqueous solution of potassium fluoride. The
reaction solution was extracted with ethyl acetate, and the organic
layer was washed with saturated brine. Then, the aqueous layer was
extracted with ethyl acetate. The organic layer collected was dried
over magnesium sulfate and concentrated under reduced pressure. The
residue was purified by thin layer silica gel chromatography
(chloroform:methanol=20:1) to obtain 119 mg of the title compound
with contained impurities.
[0187] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (3H, t, J=7.32 Hz),
2.56 (2H, q, J=7.32 Hz), 3.04 (2H, t, J=8.06 Hz), 3.17 (2H, t,
J=8.06 Hz), 5.34 (1H, s), 5.63 (1H, s), 6.74 (1H, d, J=4.88 Hz),
7.04 (1H, d, J=7.08 Hz), 7.35 (1H, s), 9.02 (1H, d, J=7.08 Hz)
[0188] ES-MS: 301 (M.sup.++1)
(G)
8-[2-(4-Ethyl-2-thienyl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin--
4-one
[0189] Reactions were performed in the same manner as in Example 2,
(A) by using
8-[2-(4-ethyl-2-thienyl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]pyrimid-
in-4-one (122 mg, 0.406 mmol) as a starting material. As a result,
122 mg of the title compound was obtained as a yellow oily
substance in a mixture with impurities.
[0190] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20 (3H, t, J=7.57 Hz),
2.56 (2H, q, J=7.57 Hz), 3.01 (2H, t, J=7.32 Hz), 3.16 (2H, t,
J-7.32 Hz), 3.66 (4H, t, J=4.88 Hz), 3.78 (4H, t, J=4.88 Hz), 5.62
(1H, s), 6.64 (1H, s), 6.73 (2H, m), 7.11 (1H, s), 8.79 (1H, d,
J=7.08 Hz)
[0191] ES-MS; m/z: 370 (M.sup.++1)
(H)
8-[2-(4-Ethyl-2-thienyl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyri-
midin-3-carbaldehyde
[0192] Reactions were performed in the same manner as in Example 1,
(I) by using
8-[2-(4-ethyl-2-thienyl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyri-
midin-4-one (122 mg, 0.33 mmol) as a starting material. As a
result, 52 mg (40% for the three steps) of the title compound in
orange color was obtained.
[0193] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20 (3H, t, J=7.56 Hz),
2.56 (2H, q, J=7.56 Hz), 3.02 (2H, t, J=8.04 Hz), 3.17 (2H, t,
J=8.04 Hz), 3.73 (4H, d, J=4.88 Hz), 3.82 (4H, d, J=4.88 Hz), 6.64
(1H, s), 6.74 (1H, s), 6.76 (1H, dd, J=1.95, 7.07 Hz), 7.03 (1H,
s), 8.74 (1H, d, J=7.07 Hz), 10.11 (1H, s)
[0194] EI/MS; m/z: 398 (M.sup.++1)
(I) tert-Butyl
(E)-3-{8-[2-(4-ethyl-2-thienyl)ethyl]-2-morpholino-4-oxo-4H-pyrido-[1,2-a-
]pyrimidin-3-yl]-2-propenoate
[0195] Reactions were performed in the same manner as in Example 1,
(J) by using
8-[2-(4-ethyl-2-thienyl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2--
a]pyrimidine-3-carbaldehyde (52 mg, 0.13 mmol) as a starting
material. As a result, 65 mg of the title compound was obtained as
an orange oily substance in a mixture with triphenylphosphine
oxide.
[0196] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20 (3H, t, J=7.59 Hz),
1.51 (9H, s), 2.56 (2H, q, J=7.59 Hz), 3.04 (2H, t, J=8.08 Hz),
3.17 (2H, t, J=8.08 Hz), 3.60 (4H, t, J=4.41 Hz), 3.83 (4H, t,
J=4.41 Hz), 6.63 (1H, s), 6.73 (1H, s), 6.82 (1H, dd, J=1.96, 7.35
Hz), 7.05 (1H, d, J=15.68 Hz), 7.17 (1H, s), 7.69 (1H, d, J=15.68
Hz), 8.87 (1H, d, J=7.35 Hz)
[0197] EI/MS; m/z: 496 (M.sup.++1)
(J)
(E)-3-{8-[2-(4-Ethyl-2-thienyl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-
-a]-pyrimidin-3-yl}-2-propenoic acid
[0198] Reactions were performed in the same manner as in Example 1,
(L) by using tert-butyl
(E)-3-{8-[2-(4-ethyl-2-thienyl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]-
-pyrimidin-3-yl}-2-propenoate (65 mg, 0.13 mmol) as a starting
material. As a result, 32 mg (56%) of yellow crystals were
obtained.
[0199] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20 (3H, t, J=7.57 Hz),
2.56 (2H, q, J=7.57 Hz), 3.05 (2H, t, J=7.81 Hz), 3.18 (2H, t,
J=7.81 Hz), 3.63 (4H, t, J=4.40 Hz), 3.84 (4H, t, J=4.40 Hz), 6.63
(1H, s), 6.74 (1H, s), 6.84 (1H, dd, J=1.95, 7.32 Hz), 7.11 (1H, d,
J=15.38 Hz), 7.18 (1H, s), 7.69 (1H, d, J=15.38 Hz), 8.88 (1H, d,
J=7.32 Hz)
[0200] EI/MS; m/z: 440 (M.sup.++1)
Example 7
(E)-3-[8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-morpholino-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) 2-(Acetylamino)isonicotinic acid
[0201] N1-(4-Methyl-2-pyridyl)acetamide (25 g, 0.168 mol) suspended
in water (250 ml) was added with potassium permanganate (76.1 g,
0.50 mol) at 100.degree. C. over 1 hour and then stirred for 40
minutes. The reaction solution was returned to room temperature,
and black crystals were removed by filtration. The resulting
filtrate was added with 12 N hydrochloric acid until pH of the
solution became 3 to 4. After the reaction solution was stirred for
about 15 minutes, the deposited white crystals were collected by
filtration, washed with water, and dried by using a vacuum pump to
obtain 7.65 g (25%) of the title compound without purification.
[0202] .sup.1H-NMR (CD.sub.3OD) .delta.: 2.20 (3H, s), 7.59 (1H,
dd, J=1.47, 5.13 Hz), 8.42 (1H, dd, J=0.73, 5.13 Hz), 8.63 (1H,
s)
[0203] EI/MS; m/z: 179 (M+)
(B)
N4-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-(acetylamino)isonicotinamide
[0204] 2-(Acetylamino)isonicotinic acid (500 mg, 2.8 mmol) was
added dropwise with thionyl chloride (15 ml, 68.5 mmol) at room
temperature, warmed to 80.degree. C. and stirred for 30 minutes.
The reaction solution was returned to room temperature,
concentrated under reduced pressure, and the residue was subjected
to azeotropy with toluene to evaporate excessive thionyl chloride.
The resulting yellow crystals was added to a mixed solution of
pyridine (0.25 ml), dichloromethane (5 ml) and
4-(tert-butyl)-1,3-thiazol-2-amine (525 mg, 3.35 mmol) under ice
cooling. The mixture was stirred at 0.degree. C. for 30 minutes,
then warmed to room temperature, and further stirred for 2 hours
and 30 minutes. The reaction solution was added with water and
extracted with chloroform. The organic layer was dried over
magnesium sulfate and concentrated under reduced pressure. The
resulting residue was purified by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=80:1.fwdarw.50:1) to obtain
545.8 mg (61%) of the title compound.
[0205] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.31 (9H, s), 2.26 (3H,
s), 6.61 (1H, s), 7.63 (1H, dd, J=0.49, 5.14 Hz), 8.44 (1H, d,
J=5.14 Hz), 8.51 (1H, brd), 8.72 (1H, s)
[0206] EI/MS; m/z: 319 (M.sup.++1)
(C)N4-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-aminoisonicotinamide
[0207]
N4-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-(acetylamino)isonicotinamid-
e (546 mg) dissolved in ethanol (12 ml) was added dropwise with
concentrated hydrochloric acid (1.2 ml) at room temperature and
stirred at 80-90.degree. C. for 1 hour. The reaction solution was
returned to room temperature, concentrated under reduced pressure,
neutralized with 1 N sodium hydroxide and extracted with
chloroform. The organic layer was dried over magnesium sulfate and
concentrated under reduced pressure, and the resulting residue was
purified by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=60:1.fwdarw.20:1) to obtain
247.2 mg (52%) of the title compound as white crystals.
[0208] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.33 (9H, s), 6.63 (1H, d,
J=0.73 Hz), 7.05 (1H, t, J=0.73 Hz), 7.09 (1H, ddd, J=0.73, 1.46,
5.36 Hz), 8.13 (1H, dd, J=0.73, 5.36 Hz)
[0209] EI/MS; m/z: 275 (M.sup.+-1)
(D)
N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-pyrido[1-
,2-a]-pyrimidine-8-carboxamide
[0210] N4-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-aminoisonicotinamide
(200 mg, 0.724 mmol) was added with xylene (20 ml) and
trichlorophenyl malonate (370 mg, 0.796 mmol) and refluxed by
heating at 130.degree. C. The reaction solution was stirred for 1
hour, then returned to room temperature and concentrated under
reduced pressure. The resulting orange crystals was taken by
filtration, washed with chloroform, dried under reduced pressure to
obtain 209 mg (84%) of the title compound as orange crystals
without purification.
[0211] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.31 (9H, s),3.45 (2H,
m), 6.88 (1H, s), 7.77 (1H, d, J=7.08 Hz), 8.02 (1H, s), 8.99 (1H,
d, J=7.08 Hz)
[0212] EI/MS; m/z: 345 (M.sup.++1)
(E)
N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-morpholino-4-oxo-4H-pyrido[1,2--
a]-pyrimidine-8-carboxamide
[0213] Reactions were performed in the same manner as in Example 2,
(A) by using
N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-py-
rido[1,2-a]pyrimidine-8-carboxamide (209 mg, 0.607 mmol). The
resulting crude product was purified by silica gel column
chromatography (chloroform:methanol=50:1.fwdarw.30:1) to obtain 147
mg of the title compound in a mixture with byproducts.
[0214] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.36 (9H, s), 3.46 (4H, t,
J=4.64 Hz), 3.58 (4H, t, J=4.64 Hz), 5.71 (1H, s), 6.64 (1H, s),
7.51 (1H, d, J=7.57 Hz), 7.99 (1H, s), 8.89 (1H, d, J=7.57 Hz)
[0215] EI/MS; m/z: 414 (M.sup.++1)
(F)
N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-3-formyl-2-morpholino-4-oxo-4H-py-
rido[1,2-a]-pyrimidine-8-carboxamide
[0216] Dimethylformamide (1 ml) was added dropwise with phosphorus
oxychloride (66 .mu.l, 0.712 mmol) under ice cooling, then warmed
to room temperature, and stirred for 15 minutes. The reaction
solution was cooled to 0.degree. C. with ice, added with
N8-[4-(tertbutyl)-1,3-thiazol-2-yl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]py-
rimidine-8-c arboxamide (147 mg, 0.356 mmol) dissolved in
dimethylformamide (4 ml) under ice cooling, and stirred at
0.degree. C. for 2 hours and 30 minutes. The reaction solution was
neutralized with saturated aqueous sodium hydrogencarbonate and
concentrated under reduced pressure. The resulting residue was
added with chloroform for extraction, and the organic layer was
dried over magnesium sulfate and concentrated under reduced
pressure. The resulting residue was purified by thin layer silica
gel chromatography (chloroform:methanol=40:1) to obtain 98.2 mg of
the title compound as yellow crystals in a mixture with
dimethylformamide.
[0217] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.34 (9H, s), 3.78 (4H, d,
J=4.88 Hz), 3.82 (4H, d, J=4.88 Hz), 6.59 (1H, s), 7.44 (1H, dd,
J=1.71, 7.32 Hz), 7.86 (1H, s), 8.87 (1H, d, J=7.32 Hz), 10.16 (1H,
s)
[0218] EI/MS; m/z: 442 (M.sup.++1)
(G) Methyl
(E)-3-[8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-m-
orpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0219]
N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-3-formyl-2-morpholino-4-oxo-4-
H-pyrido-[1,2-a]pyrimidine-8-carboxamide (98.2 mg, 0.223 mmol) was
added with tetrahydrofuran (6 ml), lithium chloride (30 mg, 0.669
mmol) and
bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)-phosphonate (142
.mu.l, 0.669 mmol), then added dropwise with
1,8-diazabicyclo[5.4.0]undec-7-ene (92 .mu.g 1,0.669 mmol) at room
temperature, stirred at room temperature for 1 hour, and further
added with
bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)-phosphonate (75
.mu.l) and 1,8-diaza-bicyclo[5.4.0]undec-7-ene (45 .mu.l). The
reaction solution was further stirred at room temperature for 30
minutes and concentrated under reduced pressure. The resulting
residue was purified by thin layer silica gel chromatography
(chloroform:methanol=40:1) to obtain 145.8 mg of the title compound
in a mixture with 1,8-diazabicyclo[5.4.0]undec-7-ene.
[0220] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.35 (9H, s), 3.70 (4H,
m), 3.78 (4H, m), 3.86 (3H, s), 6.62 (1H, s), 7.12 (1H, d, J=15.63
Hz), 7.41 (1H, s), 7.58 (1H, d, J=7.57 Hz), 7.59 (1H, d, J=15.63
Hz), 8.98 (1H, d, J=7.57 Hz)
[0221] EI/MS; m/z: 498 (M.sup.++1)
(H)
(E)-3-[8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-morpholi-
no-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoic acid
[0222] Methyl
(E)-3-[8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-morpholino--
4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (145.8 mg, 0.293
mmol) was added with methanol (2 ml), tetrahydrofuran (5 ml) and
water (1 ml), and then added dropwise with 1 N sodium hydroxide (1
ml) at room temperature. After the reaction solution was stirred at
room temperature for 1 hour, the solution was further added with 1
N sodium hydroxide (2 ml) and further stirred at room temperature
for 15 hours. The reaction solution was added with 1 N hydrochloric
acid until pH of the solution became 4 and extracted with
chloroform. The organic layer was dried over magnesium sulfate and
concentrated under reduced pressure. The resulting residue was
purified by thin layer silica gel chromatography
(chloroform:methanol=20:1) to obtain 15.4 mg (5% for the four
steps) of the title compound as yellow crystals.
[0223] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.27 (9H, s), 3.70 (4H,
m), 3.78 (4H, m), 6.54 (1H, brd), 6.93 (1H, d, J=15.38 Hz), 7.48
(1H, d, J=15.38 Hz), 7.78 (1H, d, J=7.08 Hz), 8.05 (1H, s), 8.88
(1H, d, J=7.08 Hz)
[0224] ES-MS: 484 (M.sup.++1), 482 (M.sup.+-1)
Example 8
(E)-3-[8-{[(4-Cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-hydroxy-pip-
eridino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoic acid
(A) 4-Cyclobutyl-1,3-thiazol-2-amine
[0225] Thiourea (2.3 g, 30.0 mmol) was dissolved in ethanol (100
ml), added with 2-bromo-1-cyclobutyl-1-ethanone synthesized in the
same manner as in Example 1, (E), and then heated to 100.degree. C.
The reaction solution was stirred for 1 hour, then returned to room
temperature, neutralized with saturated sodium hydrogencarbonate
and extracted with chloroform. The collected organic layer was
washed with saturated brine, dried over magnesium sulfate and then
concentrated under reduced pressure.
[0226] The title compound was obtained as the residue without
purification as a brown oily substance (5.4 g, 100%).
[0227] .sup.1H-NMR (CDCl.sub.3) .delta. 1.86 (1H, m), 1.98 (1H, qu,
J=9.31 Hz), 2.12-2.37 (4H, m), 3.38 (1H, qu, J=8.08 Hz), 5.36 (2H,
brd), 6.07 (1H, s)
(B)
N4-(4-Cyclobutyl-1,3-thiazol-2-yl)-2-(acetylamino)isonicotinamide
[0228] Reactions were performed in the same manner as in Example 7,
(B) by using 2-(acetylamino)isonicotinic acid (3.3 g, 18.42 mmol)
as the starting material and 4-cyclobutyl-1,3-thiazol-2-amine (3 g,
18.42 mmol) to obtain 3.76 g (65%) of the title compound.
[0229] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.91 (1H, m), 2.03 (1H,
qu, J=9.03 Hz),2.15-2.42 (4H, m), 2.23 (3H, s), 3.55 (1H, qu,
J=8.55 Hz), 6.63 (1H, s), 7.56 (1H, d, J=5.13 Hz), 8.37 (1H, s),
8.66 (1H, s)
[0230] EI/MS; m/z: 317 (M.sup.++1)
(C) N4-(4-Cyclobutyl-1,3-thiazol-2-yl)-2-aminoisonicotinamide
[0231] Reactions were performed in the same manner as in Example 7,
(C) by using
N4-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(acetylamino)isonicotinamid- e
(3.76 g, 11.9 mmol) to obtain 1.73 g (53%) of the title
compound.
[0232] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.94-2.37 (6H, m), 3.58
(1H, qu, J=8.57 Hz), 6.67 (1H, s), 7.07 (1H, s), 7.09 (1H, d,
J=5.14 Hz), 8.10 (1H, d, J=5.14 Hz)
[0233] EI/MS; m/z: 273 (M.sup.+-1)
(D)
N8-(4-Cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-
-a]-pyrimidine-8-carboxamide
[0234] Reactions were performed in the same manner as in Example 7,
(D) by using
N4-(4-cyclobutyl-1,3-thiazol-2-yl)-2-aminoisonicotinamide (1.73 g,
6.3 mmol) to obtain 1.85 g (86%) of the title compound as brown
solid.
[0235] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.85-1.98 (2H, m),
2.16-2.27 (4H, m), 3.47 (2H, m), 3.57 (1H, m), 6.91 (1H, s), 7.74
(1H, d, J=7.35 Hz), 8.27 (1H, s), 8.97 (1H, d, J=7.35 Hz)
[0236] EI/MS; m/z: 343 (M.sup.++1)
(E)
N8-(4-Cyclobutyl-1,3-thiazol-2-yl)-2-(3-hydroxypiperidino)-4-oxo-4H-py-
rido-[1,2-a]pyrimidine-8-carboxamide
[0237]
N8-(4-Cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxo-3,4-dihydro-2H-pyrido-
[1,2-a]-pyrimidine-8-carboxamide (100 mg, 0.29 mmol) was added with
acetonitrile (2 ml) and dimethylformamide (1 ml), cooled to
-10.degree. C. with ice, then added with diphenyl chlorophosphate
(0.2 ml, 0.96 mmol), and further added dropwise with
diisopropylethylamine (0.3 ml, 1.74 mmol). The reaction solution
was stirred at -10.degree. C. for 30 minutes, then added with
3-hydroxypiperidine (90 mg, 0.89 mmol), warmed to room temperature,
and then further warmed to 80.degree. C. As the reaction was not
completed, the reaction solution was further added with
3-hydroxypiperidine (60 mg), stirred for 1 hour, and further added
with 3-hydroxypiperidine (70 mg). After the disappear of the
starting material was observed, the reaction was stopped with
saturated aqueous sodium hydrogencarbonate, and the reaction
solution was extracted with chloroform. The organic layer was dried
over magnesium sulfate and concentrated under reduced pressure. The
resulting residue was purified by thin layer silica gel
chromatography (chloroform:methanol=15:1) to obtain 85.2 mg (69%)
of the title compound as yellow crystals.
[0238] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.60-2.06 (6H, m),
2.21-2.35 (4H, m), 3.57 (4H, m), 3.95 (2H, m), 5.75 (1H, s), 6.62
(1H, s), 7.28 (1H, dd, J=1.71, 7.56 Hz), 7.74 (1H, s), 8.87 (1H, d,
J=7.56 Hz)
[0239] EI/MS; m/z: 426 (M.sup.++1)
(F)
N8-(4-Cyclobutyl-1,3-thiazol-2-yl)-3-formyl-2-(3-hydroxypiperidino)-4--
oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
[0240] Reactions were performed in the same manner as in Example 7,
(F) by using
N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(3-hydroxypiperidino)-4-oxo-
-4H-pyrido[1,2-a]-pyrimidine-8-carboxamide (85.2 mg, 0.20 mmol) to
obtain 27.5 mg (30%) of the title compound.
[0241] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.84-2.38 (10H, m),
3.43-3.63 (4H, m), 3.90 (1H, m), 4.08 (1H, m), 6.61 (1H, s), 7.39
(1H, d, J=7.07 Hz), 7.82 (1H, s), 8.87 (1H, d.J=7.07 Hz), 10.09
(1H, s)
[0242] EI/MS; m/z: 454 (M.sup.++1)
(G) Methyl
(E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3--
hydroxy-piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0243] Reactions were performed in the same manner as in Example 7,
(G) by using
N8-(4-cyclobutyl-1,3-thiazol-2-yl)-3-formyl-2-(3-hydroxypiperidi-
no)-4-oxo-4H-pyrido-[1,2-a]pyrimidine-8-carboxamide (27.5 mg, 0.061
mmol) to obtain 16.3 mg (53%) of the title compound.
[0244] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.91 (5H, m), 2.06 (1H,
m), 2.20 (2H, m), 2.38 (2H, m), 3.61 (4H, m), 3.68 (3H, s), 3.88
(1H, m), 4.04 (1H, m), 6.60 (1H, s), 7.14 (1H, d, J=15.63 Hz), 7.47
(1H.dd, J=1.95, 7.57 Hz), 7.57 (1H, d, J=15.63 Hz), 7.94 (1H, s),
8.99 (1H, d, J=7.57 Hz)
[0245] EI/MS; m/z: 610 (M.sup.++1)
(H)
(E)-3-[8-{[(4-Cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-hydroxy-
piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoic
acid
[0246] Reactions were performed in the same manner as in Example 7,
(H) by using methyl
(E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-hydroxy-pi-
peridino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (16.3
mg, 0.032 mmol) to obtain 11 mg (69%) of the title compound as
orange crystals.
[0247] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.59-2.08 (6H, m),
2.27-2.37 (4H, m), 3.62 (3H, s), 3.87 (2H, m), 4.08 (1H, d, J=12.21
Hz), 6.69 (1H, s), 7.09 (1H, d, J=15.87 Hz), 7.48 (1H, d, J=15.87
Hz), 7.60 (1H, dd, J=1.95, 7.32 Hz), 8.07 (1H, s), 8.94 (1H, d,
J=7.32 Hz)
[0248] EI/MS; m/z: 496 (M.sup.++1)
Example 9
(E)-3-[8-{[(4-Cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(4-methyl-pipe-
razino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoic acid
(A)
N8-(4-Cyclobutyl-1,3-thiazol-2-yl)-2-(4-methylpiperazino)-4-oxo-4H-pyr-
ido[1,2-a]-pyrimidine-8-carboxamide
[0249] Reactions were performed in the same manner as in Example 8,
(E) by using
N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxo-3,4-dihydro-2H-pyri-
do[1,2-a]pyrimidine-* 8-carboxamide (60 mg, 0.174 mmol) and
N-methylpiperazine (60 .mu.l, 0.52 mmol) as regents to obtain 51.2
mg (69%) of the title compound.
[0250] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.94 (1H, m), 2.04 (1H,
m), 2.23 (2H, m), 2.34 (2H, m), 2.35 (3H, s), 2.50 (4H, t, J=5.13
Hz), 3.57 (1H, qu, J=8.30 Hz), 3.72 (4H, brd), 5.68 (1H, s), 6.63
(1H, s), 7.30 (1H.dd, J=1.95, 7.32 Hz), 7.80 (1H, s), 8.95 (1H, d,
J=7.32 Hz)
[0251] EI/MS; m/z: 425 (M.sup.++1)
(B) Methyl
(E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(4--
methyl-piperazino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0252] Reactions were performed in the same manner as in Example 7,
(F) by using
N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(4-methylpiperazino)-4-oxo--
4H-pyrido[1,2-a]-pyrimidine-8-carboxamide (51.2 mg, 0.1206 mmol),
and the product was used without purification to perform reactions
in the same manner as in Example 7,(d) to obtain 24.7 mg (40% for
the two steps) of the title compound.
[0253] .sup.1H-NMR (CDCl.sub.3) .delta. 1.94 (1H, m), 2.05 (1H, m),
2.23 (2H, m), 2.34 (3H, s), 2.35 (2H, m), 2.54 (4H, m), 3.58 (1H,
qu, J=8.54 Hz), 3.68 (4H, m), 3.81 (3H, s), 6.62 (1H, s), 7.16 (1H,
d, J=15.63 Hz), 7.43 (1H, dd, J=1.95, 7.57 Hz), 7.57 (1H, d,
J=15.63 Hz), 7.88 (1H, s), 8.99 (1H, d, J=7.57 Hz)
[0254] EI/MS; m/z: 509 (M.sup.++1)
(C)
(E)-3-{[8-[(4-Cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(4-methylp-
iperazino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoic
acid
[0255] Reactions were performed in the same manner as in Example 7,
(H) by using methyl
(E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(4-methyl-pip-
erazino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (24.7
mg, 0.049 mmol) to obtain 14.1 mg (59%) of the title compound in
yellow color.
[0256] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.96-2.38 (6H, m), 2.37
(3H, s), 2.61 (4H, m), 3.59 (1H, m), 3.67 (4H, m), 6.66 (1H, s),
7.08 (1H, d, J=15.63 Hz), 7.48 (1H, d, J=15.63 Hz), 7.61 (1H.dd,
J=1.71, 7.57 Hz), 8.09 (1H, s), 8.96 (1H, d, J=7.57 Hz)
[0257] EI/MS; m/z: 495 (M.sup.++1)
Example 10
N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-4-oxo-3-(2H-1,2,3,4-tetrazol-5-yl)-4H-
-pyrido[1,2-a]pyrimidine-8-carboxamide
(A) Ethyl
2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetate
[0258] Ethyl 1H-tetrazole-5-acetate (30 g, 0.192 mol) was dissolved
in dimethylformamide (100 ml), cooled with ice, and added with
potassium carbonate (32 g, 0.231 mol). The mixture was added
dropwise with 4-methoxybenzochloride (31 ml, 0.231 mol) and stirred
at room temperature for 21 hours. The reaction solution was
concentrated under reduced pressure and subjected to azeotropy with
toluene. The resulting residue was diluted with ethyl acetate and
washed with water, and the compound dissolved in the aqueous layer
was extracted with ethyl acetate. The organic layer collected was
dried over magnesium sulfate. The organic layer was concentrated
under reduced pressure, and then the residue was purified by silica
gel column chromatography (hexane:ethyl acetate=2:1) to obtain 24 g
(46%) of the title compound as a colorless transparent
substance.
[0259] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.25 (3H, t, J=7.07 Hz),
3.79 (3H, s), 3.93 (2H, s), 4.18 (2H, qu, J=7.07 Hz), 5.68 (2H, s),
6.88 (2H, d, J=8.78 Hz), 7.31 (2H, d, J=8.78 Hz)
[0260] EI/MS; m/z: 275 (M.sup.+-1)
(B) Ethyl
3-(dimethylamino)-2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-y-
l]-2-propenoate
[0261] Dimethylformamide dimethylacetal (13 ml, 97.3 mmol) was
dissolved in ethyl
2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetate (24 g, 88.4
mmol) and heated to 100.degree. C. for 3 hours with stirring. The
reaction solution was purified by silica gel column chromatography
(hexane:ethyl acetate=3:1.fwdarw.1:1.fwdarw.1:3) to obtain 14 g
(48%) of yellow crystals.
[0262] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.26 (3H, t, J=7.07 Hz),
2.04 (6H, s), 3.79 (3H, s), 4.11 (2H, qu, J=7.07 Hz), 5.70 (2H, s),
6.86 (2H, d, J=9.02 Hz), 7.30 (2H, d, J=9.02 Hz), 7.73 (1H, s)
[0263] EI/MS; m/z: 332 (M.sup.++1)
(C) Ethyl 2-aminoisonicotinate
[0264] 2-(Acetylamino)isonicotinic acid (13 g, 73.60 mmol)
synthesized by the method of Example 7, (A) was added with ethanol
(50 ml) and toluene (150 ml) and heated to 100-110.degree. C. The
mixture was added dropwise with concentrated sulfuric acid (7 ml)
and heated for 11 hour with stirring. The reaction solution was
returned to room temperature and poured into saturated aqueous
sodium hydrogencarbonate cooled with ice. The mixture was extracted
with chloroform and the collected organic layer was dried over
magnesium sulfate and concentrated under reduced pressure to obtain
7.6 g (23% for the two steps) of the title compound as pale yellow
crystals without purification.
[0265] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.39 (3H, t, J=7.07 Hz),
4.37 (2H, qu, J=7.07 Hz), 4.63 (2H, brd), 7.07 (1H, s), 7.17 (1H,
dd, J=0.98, 5.12 Hz), 8.18 (1H, d, J=5.12 Hz)
[0266] EI/MS; m/z: 165 (M.sup.+-1)
(D) Ethyl
3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido-
[1,2-a]-pyrimidine-8-carboxylate
[0267] Ethyl 2-aminoisonicotinate (6.5 g, 39.23 mmol) was added
with acetic acid (500 ml) and ethyl
3-(dimethylamino)-2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-2-prop-
enoate (13 g, 39.23 mmol) and refluxed by heating at 130.degree. C.
for 5 hours. The reaction solution was returned to room temperature
and poured into water, and this was extracted with chloroform. The
resulting organic layer was washed with saturated brine, and the
collected organic layer was dried over magnesium sulfate. The
organic layer was concentrated under reduced pressure and subjected
to azeotropy with toluene, and the resulting residue was purified
by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=80:1.fwdarw.50:1.fwdarw.30:1)
to obtain 8.6 g of the title compound.
[0268] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.45 (3H, t, J=7.08 Hz),
3.79 (3H, s), 4.49 (2H,q, J=7.08 Hz), 5.82 (2H, s)6.89 (2H, d,
J=8.54 Hz), 7.30 (2H, d, J=8.54 Hz), 7.74 (1H, d, J=6.59 Hz), 8.39
(1H, s), 9.28 (1H, s), 9.29 (1H, d, J=6.59 Hz)
[0269] EI/MS; m/z: 407 (M.sup.++1)
(E)
3-[2-(4-Methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a-
]-pyrimidine-8-carboxylic acid
[0270] Ethyl
3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]-p-
yrimidine-8-carboxylate (8.6 g, 21.1 mmol) was dissolved in
tetrahydrofuran (170 ml) and added dropwise with 0.5 N aqueous
sodium hydroxide (65 ml) at room temperature. The reaction solution
was stirred for 1 hour and 30 minutes, then added with 1 N
hydrochloric acid (55 ml) and water (250 ml) under ice cooling and
warmed to room temperature with stirring. The deposited yellow
crystals were taken by filtration, washed with water, dissolved in
ethanol and concentrated under reduced pressure. The resulting
crystals were dried under reduced pressure to obtain 4 g (27% for
the two steps) of the title compound without purification.
[0271] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.81 (3H, s), 5.83 (2H,
s), 6.92 (2H, d, J=8.55 Hz), 7.43 (2H, d, J=8.55 Hz), 7.83 (1H, dd,
J=1.22, 7.32 Hz), 8.40 (1H, s), 9.23 (1H, s), 9.31 (1H, d, J=7.32
Hz)
[0272] EI/MS; m/z: 379 (M.sup.++1)
(F)
N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-4-oxo-3-(2H-1,2,3,4-tetrazol-5-yl-
)-4H-pyrido-[1,2-a]pyrimidine-8-carboxamide
[0273]
3-[2-(4-Methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1-
,2-a]-pyrimidine-8-carboxylic acid (40 mg, 0.114 mmol) was added
with dimethylformamide (2 ml), 4-(tert-butyl)-1,3-thiazol-2-amine
(20 mg, 0.125 mmol), 1-hydroxybenzotriazole (20 mg, 0.136 mmol) and
4-dimethylaminopyridine (21 mg, 0.170 mmol) at room temperature,
then added with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (35 mg, 0.170 mmol) at room temperature, and stirred
at room temperature for 24 hours. The reaction solution was added
dropwise with 1 N hydrochloric acid (3 ml) at room temperature, and
the deposited yellow crystals were taken by filtration and washed
with water. The crystals were dissolved in chloroform and ethanol,
concentrated under reduced pressure, and dried to obtain the title
compound as yellow crystals without purification. The product was
dissolved in anisole (0.2 ml) and trifluoroacetic acid (5 ml),
stirred at room temperature for 5 hours, and added with water. The
deposited yellow crystals were collected by filtration and washed
with water, and the resulting crystals were dissolved in chloroform
and ethanol and concentrated under reduced pressure. The crude
crystals was added with ethanol, taken by filtration and washed
with diethyl ether to obtain 28 mg (67% for the two steps) of the
title compound as yellow crystals.
[0274] .sup.1H-NMR (CD.sub.3OD) .delta. 1.38 (9H, s), 6.66 (1H, s),
8.10 (1H, d, J=8.30 Hz), 8.57 (1H, s), 9.38 (1H, d, J=8.30 Hz),
9.39 (1H, s)
[0275] EI/MS; m/z: 397 (M.sup.++1)
Example 11
N8-[4-(4-Pyridyl)-1,3-thiazol-2-yl]-4-oxo-3-(2H-1,2,3,4-tetrazol-5-yl)-4H--
pyrido[1,2-a]pyrimidine-8-carboxamide
(A) 2-Bromo-1-(4-pyridyl)-1-ethanone
[0276] 4-Acetylpyridine (3.62 g, 29.9 mmol) was added with acetic
acid (30 ml) and 47% hydrobromic acid (5.3 ml) at room temperature,
subsequently added dropwise with bromine (1.6 ml in total) four
times at an interval of 5 minutes, stirred at room temperature for
2 hours and 30 minutes. The mixture was further added with bromine
(1.6 ml), and stirred at room temperature for 20 hours. The
reaction solution was filtered, and the resulting crystals were
washed with diethyl ether and dried to obtain 12.43 g of the title
compound as a salt of hydrogen bromide in the form of orange
crystals without purification.
[0277] .sup.1H-NMR (CD.sub.3OD) .delta.: 3.73 (2H, dd, J=1.21,28.76
Hz), 8.26 (2H, d, J=6.83 Hz), 8.89 (2H, d, J=6.83 Hz)
[0278] EI/MS; m/z: 279 (M.sup.+-1)
(B) 4-(4-Pyridyl)-1,3-thiazol-2-amine
[0279] Reactions were performed in the same manner as in Example 8,
(A) by using 2-bromo-1-(4-pyridyl)-1-ethanone (1 g, 3.56 mmol) to
obtain 410 mg (65%) of the title compound.
[0280] .sup.1H-NMR (CD.sub.3OD) .delta.: 7.26 (1H, s), 7.80 (2H, d,
J=6.35 Hz), 8.50 (2H, d, J=6.35 Hz)
[0281] EI/MS; m/z: 176 (M.sup.+-1)
(C)
N8-[4-(4-Pyridyl)-1,3-thiazol-2-yl]-4-oxo-3-(2H-1,2,3,4-tetrazol-5-yl)-
-4H-pyrido-[1,2-a]pyrimidine-8-carboxamide
[0282] Reactions were performed in the same manner as in Example
10, (F) by using
3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido-
[1,2-a]pyrimidine-8-c arboxylic acid (120 mg, 0.32 mmol) and
4-(4-pyridyl)-1,3-thiazol-2-amine (62 mg, 0.35 mmol) to obtain 35.7
mg (27% for the two steps) of the title compound as orange
crystals.
[0283] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 8.03 (3H, m), 8.29 (1H,
s), 8.66 (1H, d, J=0.977 Hz), 8.73 (2H, d, J=5.62 Hz), 9.29 (1H,
s), 9.32 (1H, d, J=6.54 Hz)
[0284] ES-MS; m/z: 418 (M.sup.++1)
[0285] IR (cm.sup.-1): 1668, 1633, 1567, 1492, 1288
Example 12
N8-(1,3-Benzothiazol-2-yl)-4-oxo-3-(2H-1,2,3,4-tetrazol-5-yl)-4H-pyrido-[1-
,2-a]pyrimidine-8-carboxamide
[0286] Reactions were performed in the same manner as in Example
10, (F) by using
3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido-
[1,2-a]pyrimidine-8-c arboxylic acid (60 mg, 0.16 mmol) and
2-aminobenzothiazole (30 mg, 0.17 mmol) to obtain 2 mg (3% for the
two steps) of an orange compound.
[0287] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 7.39 (1H, t, J=7.57 Hz),
7.52 (1H, t, J=7.57 Hz), 7.78 (1H, d, J=7.57 Hz), 8.05 (2H, d,
J=7.57 Hz), 8.61 (1H, s), 9.28 (1H, s), 9.31 (1H, d, J=7.57 Hz)
[0288] ES-MS; m/z: 391 (M.sup.++1)
Example 13
N8-(4-Cyclobutyl-1,3-thiazol-2-yl)-2-(4-methylpiperazino)-4-oxo-4H-pyrido[-
1,2-a]pyrimidine-8-carboxamide
[0289] Reactions were performed in the same manner as in Example 9,
(A) by using
N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxo-3,4-dihydro-2H-pyri-
do[1,2-a]pyrimidine-8-carboxamide (40 mg, 0.12 mmol), and the
resulting compound was added with 4 N hydrochloric acid solution in
dioxane (2 ml) and stirred to obtain 12 mg (24%) of the title
compound as hydrochloride. NMR for free form and Mass:
[0290] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.94 (1H, m), 2.04 (1H,
m), 2.23 (2H, m), 2.34 (2H, m), 2.35 (3H, s), 2.50 (4H, t, J=5.13
Hz), 3.57 (1H, qu, J=8.30 Hz), 3.72 (4H, brd), 5.68 (1H, s), 6.63
(1H, s), 7.30 (1H.dd, J=1.95, 7.32 Hz), 7.80 (1H, s), 8.95 (1H, d,
J=7.32 Hz)
[0291] EI/MS; m/z: 425 (M.sup.++1)
Example 14
N8-(4-Isopropyl-1,3-thiazol-2-yl)-4-oxo-3-(2H-1,2,3,4-tetrazol-5-yl)-4H-py-
rido[1,2-a]pyrimidine-8-carboxamide
[0292] (A)
N8-(4-Isopropyl-1,3-thiazol-2-yl)-3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetra-
zol-5-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
[0293]
3-[2-(4-Methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1-
,2-a]-pyrimidine-8-carboxylic acid (250 mg, 0.66 mmol) was
dissolved in dimethylformamide (6 ml), added with
N,N-carbonylbis-1H-imidazole (abbreviated as "CDI" hereinafter, 160
mg, 0.991 mmol) and heated to 90.degree. C. with stirring. After 1
hour and 30 minutes, the reaction solution was further added with
CDI (170 mg), further stirred for 1 hour, and then further added
with CDI (170 mg). The reaction solution was stirred further 2
hours, then returned to room temperature, added with
4-isopropyl-1,3-thiazol-2-amine hydrobromide (1.32 mmol) and
stirred at room temperature for 2 hours and 30 minutes. The
reaction solution was added with 2 N hydrochloric acid (7 ml), and
the deposited crystals were collected by filtration and washed with
water. The resulting yellow crystals were dissolved in chloroform
and washed with saturated brine, and the collected organic layer
was dried over magnesium sulfate and concentrated under reduced
pressure to obtain the title compound as yellow crystals without
purification.
[0294] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.34 (6H, d, J=6.83 Hz),
3.00 (1H, qu, J=6.83 Hz), 3.80 (3H, s), 5.85 (2H, s), 6.63 (1H, s),
6.92 (2H, d, J=8.78 Hz), 7.44 (2H, d, J=8.78 Hz), 8.04 (1H, dd,
J=1.46, 7.56 Hz), 8.50 (1H, s), 9.20 (1H, s), 9.34 (1H, d, J=7.56
Hz)
[0295] EI/MS; m/z: 503 (M.sup.++1)
(B)
N8-(4-Isopropyl-1,3-thiazol-2-yl)-4-oxo-3-(2H-1,2,3,4-tetrazol-5-yl)-4-
H-pyrido-[1,2-a]pyrimidine-8-carboxamide
[0296]
N8-(4-Isopropyl-1,3-thiazol-2-yl)-3-[2-(4-methoxybenzyl)-2H-1,2,3,-
4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
(330 mg, 0.66 mmol) was added with trifluoroacetic acid (10 ml) at
room temperature and stirred for 3 days. The reaction solution was
poured into ice water, and the deposited yellow crystals were
collected by filtration, washed with water, then dissolved in
chloroform and ethanol, and concentrated under reduced pressure.
The resulting yellow crystals were suspended in a small amount of
ethanol, and the crystals were taken by filtration and washed with
diethyl ether to obtain 54 mg (21% for the two steps) of the title
compound as yellow crystals.
[0297] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.27 (6H, d, J=6.84 Hz),
2.93 (1H, m), 6.90 (1H, s), 8.02 (1H, d, J=7.08 Hz), 8.55 (1H, s),
9.26 (1H, s), 9.29 (1H, d, J=7.08 Hz)
[0298] ES-MS; m/z: 383 (M.sup.++1)
Example 15
(E)-3-(2-{3-[(Aminocarbonyl)oxy]piperidino}-8-{[(4-cyclobutyl-1,3-thiazol--
2-yl)amino]carbonyl}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-propenoic
acid
(A)
1-(8-{[(4-Cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-3-formyl-4-oxo-4-
H-pyrido-[1,2-a]pyrimidin-2-yl)-3-piperidyl formate
[0299] Reactions were performed in the same manner as in Example 7,
(F) by using
N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(3-hydroxypiperidino)-4-oxo-
-4H-pyrido[1,2-a]-pyrimidine-8-carboxamide (85 mg, 0.20 mmol) to
obtain 21 mg (22%) of the title compound.
[0300] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.92-2.41 (10H, m),
3.58-3.68 (3H, m), 3.93 (2H, m), 5.10 (1H, m), 6.61 (1H, s), 7.39
(1H, dd, J=1.95, 7.31 Hz), 7.79 (1H, d, J=1.95 Hz), 8.01 (1H, s),
8.89 (1H, d, J=7.31 Hz), 10.14 (1H, s)
[0301] EI/MS; m/z: 482 (M.sup.++1)
(B) tert-Butyl
(E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-formyloxy--
piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0302] Reactions were performed in the same manner as in Example 1,
(J) by using
1-(8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-3-formyl-4-
-oxo-4H-pyrido[1,2-a]-pyrimidin-2-yl)-3-piperidyl formate (36 mg,
0.075 mmol), and the resulting reaction solution was purified by
thin layer silica gel chromatography (chloroform:methanol=30:1) to
obtain 35 mg of the title compound as orange crystals in a mixture
with triphenylphosphine oxide.
[0303] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.52 (9H, s), 1.94-2.00
(6H, m), 2.23-2.34 (4H, m), 3.57-3.83 (5H, m), 5.15 (1H, m), 6.62
(1H, s), 7.09 (1H, d, J=15.63 Hz), 7.48 (1H, dd, J=1.71, 7.32 Hz),
7.49 (1H, d, J=15.63 Hz), 7.91 (1H, s), 8.09 (1H, s), 8.98 (1H, d,
J=7.32 Hz)
(C) tert-Butyl
(E)-3-[8-{([(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-hydroxy-p-
iperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0304] Reactions were performed in the same manner as in Example 1,
(K) by using tert-butyl
(E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-formyloxy--
piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (35
mg, 0.060 mmol), and the resulting crude crystals were purified by
thin layer silica gel chromatography (chloroform:methanol=40:1) to
obtain 16 mg (40% for the two steps) of the title compound as
yellow crystals.
[0305] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.52 (9H, s), 1.72-2.07
(6H, m), 2.17-2.38 (4H, m), 3.60 (4H, m), 3.80 (1H, m), 4.02 (1H,
m), 6.61 (1H, s), 7.10 (1H, d, J=15.60 Hz), 7.48 (1H, dd, J=1.71,
7.31 Hz), 7.49 (1H, d, J=15.60 Hz), 7.97 (1H, s), 9.00 (1H, d,
J=7.31 Hz)
[0306] EI/MS; m/z: 552 (M.sup.++1)
(D) tert-Butyl
(E)-3-(2-{3-[(aminocarbonyl)oxy]piperidino}-8-{[(4-cyclobutyl-1,3-thiazol-
-2-yl)amino]carbonyl}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-propenoate
[0307] tert-Butyl
(E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-hydroxypip-
eridino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (16 mg,
0.029 mmol) was dissolved in ethyl acetate (3 ml), added with
trichloroacetyl isocyanate (10 .mu.l) under ice cooling, stirred at
0.degree. C. for 1 hour, then further added with trichloroacetyl
isocyanate (10 .mu.l), and further stirred for 30 minutes. Then,
the reaction solution was concentrated under reduced pressure, and
the resulting residue was added with methanol (2 ml), water (0.2
ml) and sodium formate (12 mg) at room temperature and stirred at
room temperature for 7 hours. The reaction solution was
concentrated under reduced pressure, and the residue was purified
by thin layer silica gel chromatography (chloroform:methanol=30:1)
to obtain 20 mg of the title compound.
[0308] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.51 (9H, s), 1.90-2.36
(10H, m), 3.36-3.77 (4H, m), 4.04 (1H, m), 4.92 (1H, m), 6.62 (1H,
s), 7.10 (1H, d, J=15.38 Hz), 7.54 (1H, d, J=7.57 Hz), 7.60 (1H, d,
J=15.38 Hz), 8.07 (1H, s), 9.00 (1H, d, J=7.57 Hz)
[0309] EI/MS; m/z: 595 (M.sup.++1)
(E)
(E)-3-(2-{3-[(Aminocarbonyl)oxy]piperidino)-8-{([(4-cyclobutyl-1,3-thi-
azol-2-yl)-amino]carbonyl}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propeno-
ic acid
[0310] tert-Butyl
(E)-3-(2-{3-[(aminocarbonyl)oxy]piperidino}-8-{[(4-cyclobutyl-1,3-thiazol-
-2-yl)amino]carbonyl}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
(20 mg, 0.034 mmol) was added with a mixed solution of 4 N
hydrochloric acid and dioxane (1.5 ml) at room temperature and
stirred for 2 hours. The reaction solution was concentrated under
reduced pressure, and the resulting residue was purified by thin
layer silica gel chromatography (chloroform:methanol=10:1) to
obtain 9 mg (58% for the two steps) of the title compound as yellow
crystals.
[0311] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.68 (2H, m), 1.94-2.10
(4H, m), 2.23 (2H, m), 2.38 (2H, m), 3.39-3.72 (4H, m), 3.98 (1H,
dd, J=5.86, 11.70 Hz), 4.86 (1H, m), 6.64 (1H, s), 7.10 (1H, d,
J=15.63 Hz), 7.56 (1H, d, J=7.32 Hz), 7.68 (1H, d, J=15.63 Hz),
8.07 (1H, s), 8.96 (1H, d, J=7.32 Hz)
[0312] ES-MS; m/z: 539 (M.sup.++1)
Example 16
2-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido--
[1,2-a]pyrimidin-3-yl)-1-cyclopropanecarboxylic acid
(A)
3-[(E)-3-Hydroxy-1-propenyl]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-
-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one
[0313]
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-ox-
o-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid (222.7 mg, 0.49
mmol) dissolved in tetrahydrofuran (8 ml) was added with
triethylamine (342 .mu.l) and ethyl chloroformate (141 .mu.l 1) at
-20.degree. C., then stirred at room temperature for 1 hour, and
subsequently added with aqueous sodium borohydride (0.8 M, 4 ml) at
room temperature. The aqueous sodium borohydride was occasionally
added until the reaction was completed, and the completion of the
reaction was confirmed by TLC. Then, the reaction solution was
added with water and extracted with chloroform and
chloroform:methanol=10:1, and the organic layer collected was dried
over magnesium sulfate and concentrated under reduced pressure. The
resulting residue was purified by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=100:1.fwdarw.60:1.fwdarw.30:1)
to recover 81 mg (37%) of the title compound and 82 mg of the
starting material.
[0314] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.83 Hz),
3.07 (1H, qu, J=6.83 Hz), 3.19 (2H, t, J=7.80 Hz), 3.36 (2H, t,
J=7.80 Hz), 3.53 (4H, t, J=4.88 Hz), 3.80 (4H, t, J=4.88 Hz), 4.35
(2H, d, J=5.85 Hz), 6.44 (1H, d, J=15.60 Hz), 6.72 (1H, s), 6.83
(1H, dd, J=1.95, 7.31 Hz), 7.00 (1H, dt, J=5.85, 15.60 Hz) 7.21
(1H, s), 8.87 (1H, d, J=7.31 Hz)
[0315] EI/MS; m/s: 441 (M.sup.++1)
(B)
3-[2-(Hydroxymethyl)cyclopropyl]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)et-
hyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one
[0316]
3-[(E)-3-Hydroxy-1'-propenyl]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)e-
thyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (81 mg, 0.18
mmol) was added with dichloromethane (3 ml) and a solution of
diethyl zinc in hexane (1.02 M, 270 .mu.l, 0.275 mmol) and
subsequently added dropwise with iodomethane (30 .mu.l, 0.366 mmol)
at room temperature. After the reaction solution was stirred for 2
hours, the reaction was stopped with saturated aqueous ammonium
chloride, and the reaction solution was extracted with chloroform.
The organic layer was dried over magnesium sulfate and concentrated
under reduced pressure. The resulting residue was purified by thin
layer silica gel chromatography (chloroform:methanol=15:1) to
obtain 61 mg (73%) of the title compound.
[0317] .sup.1H-NMR (CDCl.sub.3) .delta.: 0.90 (1H, m), 1.04 (2H,
m), 1.29 (6H, d, J=6.84 Hz), 1.52 (1H, dt, J=5.62, 7.57 Hz), 3.07
(1H, qu, J=6.84 Hz), 3.17 (2H, t, J=7.32 Hz), 3.35 (2H, t, J=7.32
Hz), 3.56 (2H, m), 3.84 (6H, m), 4.12 (1H, d, J=9.52 Hz), 4.68 (1H,
brd), 6.73 (1H, s), 6.78 (1H, dd, J=1.71, 7.32 Hz), 7.16 (1H, s),
8.80 (1H, d, J=7.32 Hz)
[0318] EI/MS; m/s: 455 (M.sup.++1)
(C)
2-[(8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]-pyrimidin-3-yl}-1-cyclopropanecarboxylic acid
[0319]
3-[2-(Hydroxymethyl)cyclopropyl]-8-[2-(4-isopropyl-1,3-thiazol-2-y-
l)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (55 mg, 0.121
mmol) dissolved in acetone (10 ml) was added dropwise with Jones'
reagent (130 .mu.l, 0.363 mmol) under ice cooling with and stirred
for 2 hours. Then, the reaction solution was further added with
Jones' reagent (165 .mu.l) and stirred for 2 hours. Then, the
reaction was stopped with saturated sodium thiosulfate, and the
reaction solution was extracted with chloroform. The organic layer
was dried over magnesium sulfate and concentrated under reduced
pressure. The resulting residue was purified by thin layer silica
gel chromatography (chloroform:methanol=10:1) to obtain 2.2 mg (4%)
of the title compound as yellow crystals.
[0320] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=7.07 Hz),
1.35 (1H, dt, J=4.39, 7.80 Hz), 1.63 (1H, dt, J=4.39, 8.53 Hz),
1.85 (1H, dt, J=3.90, 8.53 Hz), 2.34 (1H, dt, J=3.90, 7.80 Hz),
3.07 (1H, qu, J=7.07 Hz), 3.18 (2H, t, J=7.07 Hz), 3.35 (2H, t,
J=7.07 Hz), 3.58 (2H, m), 3.77 (6H, m), 6.72 (1H, s), 6.80 (1H, dd,
J=1.46, 7.31 Hz), 7.17 (1H, s), 8.81 (1H, d, J=7.31 Hz)
[0321] EI/MS; m/s: 469 (M.sup.++1)
Example 17
(E)-3-{8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3R)-3-hydr-
oxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoi-
c acid
(A)
N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-[(3R)-3-hydroxyhexahydro-1-pyri-
dinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
[0322] Reactions were performed in the same manner as in Example 8,
(E) by using
N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-py-
rido[1,2-a]pyrimidine-8-carboxamide (300 mg, 0.871 mmol) and
(R)-(+)-3-hydroxypiperidine (530 mg, 5.226 mmol) to obtain 241.8 mg
(65%) of the title compound.
[0323] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.34 (9H, s), 1.57 (1H,
m), 1.76 (1H, m), 1.96 (2H, m), 3.61 (3H, m), 3.90 (2H, m), 5.69
(1H, s), 6.60 (1H, s), 7.31 (1H, dd, J=1.71, 7.32 Hz), 7.76 (1H,
s), 8.86 (1H, d, J=7.32 Hz)
[0324] EI/MS; m/s: 428 (M.sup.++1)
(B)
(3R)-1-[8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-3-formyl--
4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl]hexahydro-3-pyridinyl form
ate
[0325] Reactions were performed in the same manner as in Example 7,
(F) by using
N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-[(3R)-3-hydroxyhexahydro--
1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (295
mg, 0.690 mmol) and phosphorus oxychloride (130 .mu.l, 1.38 mmol)
to obtain 277 mg (68%) of the title compound.
[0326] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.34 (9H, s), 1.70 (1H,
m), 1.87-2.03 (3H, m), 3.66 (2H, m), 3.91 (2H, m), 5.09 (1H, brd),
6.58 (1H, s), 7.52 (1H, dd, J=1.71, 7.32 Hz), 7.96 (1H, s), 8.01
(1H, s), 8.87 (1H, d, J=7.32 Hz), 10.14 (1H, s)
[0327] EI/MS; m/s: 484 (M.sup.++1)
(C) tert-Butyl (E)-3-[8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino)
carbonyl)-2-[(3R)-3-formyloxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a-
]pyrimidin-3-yl}-2-propenoate
[0328] Reactions were performed in the same manner as in Example 1,
(J) by using
(3R)-1-[8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino]carbonyl}-3-f-
ormyl-4-oxo-4H-pyrido-[1,2-a]pyrimidin-2-yl]hexahydro-3-pyridinyl
formate (277 mg, 0.5723 mmol), and the resulting residue was
purified by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=100:1.fwdarw.70:1.fwdarw.50:1)
to obtain 559 mg (100% or more) of the title compound as a brown
oily substance in a mixture with byproducts.
[0329] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (9H, s), 1.53 (9H,
s), 1.71-1.97 (4H, m), 3.46-3.73 (4H, m), 5.09 (1H, brd), 6.56 (1H,
s), 7.09 (1H, d, J=15.60 Hz), 7.64 (1H, dd, J=1.95, 7.31 Hz), 7.65
(1H, d, J=15.60 Hz), 8.01 (1H, s), 8.05 (1H, s), 8.82 (1H, d,
J=7.31 Hz)
[0330] EI/MS; m/s: 580 (M.sup.+-1)
(D) tert-Butyl
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3R)-3-hyd-
roxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propeno-
ate
[0331] Reactions were performed in the same manner as in Example 1,
(K) by using tert-butyl
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3R)-3-for-
myloxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-prope-
noate (559 mg, 0.961 mmol) to obtain 368 mg (69%) of the title
compound as an orange oily substance.
[0332] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.32 (9H, s), 1.52 (9H,
s), 1.77-1.90 (4H, m), 3.54-3.73 (4H, m), 4.01 (1H, brd), 6.54 (1H,
s), 7.04 (1H, d, J=15.63 Hz), 7.64 (1H, dd, J=1.95, 7.32 Hz), 7.65
(1H, d, J=15.63 Hz), 8.00 (1H, s), 8.84 (1H, d, J=7.32 Hz)
(E)
(E)-3-{8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3R)-3--
hydroxy-hexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-pro-
penoic acid
[0333] Reactions were performed in the same manner as in Example
15, (E) by using tert-butyl
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3R)-3-hyd-
roxy-hexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propen-
oate (140 mg, 0.253 mmol) as a mixture containing
triphenylphosphine oxide to obtain 42 mg (33%) of the title
compound as orange crystals.
[0334] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.36 (9H, s), 1.61 (2H,
m), 1.92 (1H, m), 2.06 (1H, m), 3.21 (1H, dd, J=8.55, 12.94 Hz),
3.36 (1H, m), 3.86 (2H, m), 4.10 (1H, d, J=12.94 Hz), 6.68 (1H, s),
7.05 (1H, d, J=15.63 Hz), 7.60 (1H, dd, J=1.95, 7.32 Hz), 7.61 (1H,
d, J=15.63 Hz), 8.05 (1H, s), 8.95 (1H, d, J=7.32 Hz) ES-MS; m/s:
498 (M.sup.++1)
Example 18
(E)-3-[2-{(3R)-3-[(Aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(tert-b-
utyl)-1,3-thiazol-2-yl]amino}carbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-y-
l]-2-propenoic acid
(A) tert-Butyl
(E)-3-[2-{(3R)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(tert--
butyl)-1,3-thiazol-2-yl]amino}carbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3--
yl]-2-propenoate
[0335] Reactions were performed in the same manner as in Example
15, (D) by using tert-butyl
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino)
carbonyl)-2-[(3R)-3-hydroxy-hexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]-
pyrimidin-3-yl}-2-propenoate (240 mg, 0.436 mmol) to obtain 254 mg
(98%) of an orange oily compound.
[0336] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.30 (9H, s), 1.49 (9H,
s), 1.69-2.17 (4H, m), 3.34 (1H, m), 3.54 (1H, m), 3.65 (1H, m),
3.87 (1H, m), 4.93 (1H, brd), 6.60 (1H, s), 7.07 (1H, d, J=15.63
Hz), 7.56 (1H, dd, J=1.95, 7.33 Hz), 7.68 (1H, d, J=15.63 Hz), 8.06
(1H, s), 8.96 (1H, d, J=7.33 Hz)
(B)
(E)-3-[2-{(3R)-3-[(Aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(te-
rt-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-
-3-yl}-2-propenoic acid
[0337] Reactions were performed in the same manner as in Example
15, (E) by using tert-butyl
(E)-3-[2-{(3R)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(tert--
butyl)-1,3-thiazol-2-yl]aminocarbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-y-
l]-2-propenoate (254 mg, 0.426 mmol) containing byproducts to
obtain 51 mg (22%) of the title compound as orange crystals.
[0338] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.35 (9H, s), 1.68 (1H,
m), 1.94 (3H, m), 3.46 (1H, m), 3.66 (3H, m), 3.98 (1H, dd, J=4.88,
13.43 Hz), 4.87 (1H, s), 6.63 (1H, s), 7.10 (1H, d, J=15.63 Hz),
7.56 (1H, dd, J=1.95, 7.33 Hz), 7.68 (1H, d, J=15.63 Hz), 8.06 (1H,
s), 8.96 (1H, d, J=7.33 Hz)
[0339] EI/MS; m/s: 541 (M.sup.++1)
Example 19
(E)-3-[2-{(3S)-3-[(Aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(tert-b-
utyl)-1,3-thiazol-2-yl]amino}carbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-y-
l]-2-p ropenoic acid
(A)
N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-[(3S)-3-hydroxyhexahydro-1-pyri-
dinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
[0340] Reactions were performed in the same manner as in Example 8,
(E) by using
N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-py-
rido[1,2-a]pyrimidine-8-carboxamide (600 mg, 1.74 mmol) and
(S)-(-)-3-hydroxypiperidine hydrochloride (360 mg, 2.61 mmol) to
obtain 463 mg (62%) of the title compound.
[0341] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (9H, s), 1.59 (1H,
brd), 1.73-1.99 (3H, m), 3.61 (3H, m), 3.93 (2H, m), 5.71 (1H, s),
6.61 (1H, s), 7.31 (1H, d, J=7.32 Hz), 7.77 (1H, s), 8.89 (1H, d,
J=7.32 Hz)
[0342] EI/MS; m/s: 428 (M.sup.++1)
(B)
(3S)-1-[8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-3-formyl--
4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl]hexahydro-3-pyridinyl
formate
[0343] Reactions were performed in the same manner as in Example 7,
(F) by using
N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-[(3S)-3-hydroxyhexahydro--
1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (463
mg, 1.08 mmol) and phosphorus oxychloride (0.3 ml, 3.25 mmol) to
obtain 600 mg (100%) of the title compound as a substance
containing dimethylformamide without purification.
[0344] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.32 (9H, s), 1.72 (1H,
m), 1.89-2.04 (3H, m), 3.68 (2H, m), 3.92 (2H, d, J=3.90 Hz), 5.09
(1H, brd), 6.59 (1H, s), 7.47 (1H, dd, J=1.95, 7.31 Hz), 7.89 (1H,
s), 8.01 (1H, s), 8.88 (1H, d, J=7.31 Hz), 10.14 (1H, s)
(C) tert-Butyl
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino]carbonyl}-2-[(3
s)-3-formyloxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl-
}-2-propenoate
[0345] Reactions were performed in the same manner as in Example 1,
(J) by using
(3S)-1-[8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-3-f-
ormyl-4-oxo-4H-pyrido-[1,2-a]pyrimidin-2-yl]hexahydro-3-pyridinyl
formate (524 mg, 1.083 mmol), and the resulting residue was
purified by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=100:1.fwdarw.70:1.fwdarw.50:1)
to obtain 742 mg (100% or more) of the title compound as a brown
oily substance in a mixture containing byproducts.
[0346] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (9H, s), 1.53 (9H,
s), 1.68-2.03 (4H, m), 3.48-3.71 (4H, m), 5.10 (1H, m), 6.57 (1H,
s), 7.09 (1H, d, J=15.63 Hz), 7.64 (1H, dd, J=1.95, 7.32 Hz), 7.65
(1H, d, J=15.63 Hz), 7.99 (1H, s), 8.06 (1H, s), 8.85 (1H, d,
J=7.32 Hz)
[0347] EI/MS; m/s: 580 (M.sup.+-1)
(D) tert-Butyl
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3
s)-3-hydroxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}--
2-propenoate
[0348] Reactions were performed in the same manner as in Example 1,
(K) by using tert-butyl
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3S)-3-for-
myloxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-prope-
noate (630 mg, 1.083 mmol) to obtain 439 mg (73%) of the title
compound as an orange oily substance.
[0349] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.34 (9H, s), 1.52 (9H,
s), 1.78-1.90 (4H, m), 3.54 (2H, brd), 3.65-3.74 (2H, m), 4.02 (1H,
brd), 6.53 (1H, s), 7.03 (1H, d, J=15.60 Hz), 7.56 (1H, d, J=7.31
Hz), 7.60 (1H, d, J=15.60 Hz), 7.99 (1H, s), 8.84 (1H, d, J=7.31
Hz)
[0350] EI/MS; m/s: 554 (M.sup.++1)
(E) tert-Butyl (E)-3-[2-{(3
S)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(tert-butyl)-1,3-t-
hiazol-2-yl]amino}carbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propen-
oate
[0351] Reactions were performed in the same manner as in Example
15, (D) by using tert-butyl
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino]carbonyl}-2-[(3S)-3-hyd-
roxy-hexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propen-
oate (140 mg, 0.2529 mmol) to obtain 131 mg (87%) of an orange oily
compound.
[0352] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.30 (9H, s), 1.49 (9H,
s), 1.70-2.00 (4H, m), 3.35 (1H, m), 3.54 (1H, d, J=12.43 Hz), 3.67
(1H, m), 3.88 (1H, m), 4.92 (1H, brd), 6.60 (1H, s), 7.05 (1H, d,
J=15.60 Hz), 7.55 (1H, dd, J=1.95, 7.31 Hz), 7.68 (1H, d, J=15.60
Hz), 8.05 (1H, s), 8.97 (1H, d, J=7.31 Hz)
[0353] EI/MS; m/s: 597 (M.sup.++1)
(F)
(E)-3-[2-{(3S)-3-[(Aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({([4-(t-
ert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidi-
n-3-yl}-2-propenoic acid
[0354] Reactions were performed in the same manner as in Example
15, (E) by using tert-butyl
(E)-3-{2-{(3S)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(tert--
butyl)-1,3-thiazol-2-yl]amino}carbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3--
yl]-2-propenoate (131 mg, 0.219 mmol) containing by products to
obtain 40 mg (3.4%) of the title compound as orange crystals.
[0355] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.35 (9H, s), 1.68 (1H,
m), 1.93 (3H, m), 3.49 (1H, m), 3.69 (2H, m), 3.96 (1H, dd, J=5.36,
12.92 Hz), 4.86 (1H, brd), 6.62 (1H, s), 7.11 (1H, d, J=15.60 Hz),
7.55 (1H, dd, J=1.95, 7.56 Hz), 7.68 (1H, d, J=15.60 Hz), 8.06 (1H,
s), 8.96 (1H, d, J=7.56 Hz)
[0356] EI/MS; m/s: 541 (M.sup.++1)
Example 20
(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3
s)-3-hydroxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}--
2-propenoic acid
[0357] Reactions were performed in the same manner as in Example
15, (E) by using
tert-butyl(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carb-
onyl)-2-[(3S)-3-hydroxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimi-
din-3-yl}-2-propenoate (50 mg, 0.090 mmol) containing
triphenylphosphine oxide as a mixture to obtain 17 mg (38%) of the
title compound as orange crystals.
[0358] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.39 (9H, s), 1.65 (2H,
m), 1.92 (1H, m), 2.04 (1H, m), 3.82-4.03 (5H, m), 6.62 (1H, s),
7.07 (1H, d, J=15.43 Hz), 7.56 (1H, d, J=7.35 Hz), 7.60 (1H, d,
J=15.43 Hz), 8.03 (1H, s), 8.95 (1H, d, J=7.35 Hz)
[0359] ES-MS; m/s: 498 (M.sup.++1)
Example 21
(E)-3-{2-[(3R)-3-(Dimethylamino)tetrahydro-1H-1-pyrrolyl]-8-[2-(4-isopropy-
l-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoi-
c acid
[0360] tert-Butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-[(4-methylphenyl)-sulf-
onyl]oxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenate (31.4
mg, 0.053 mmol) was dissolved in dimethylformamide (1 ml), added
with (3R)-(+)-3-(dimethylamino)-pyrrolidine (30.1 mg, 0.26 mmol),
and stirred at room temperature for 4 hours. The solvent was
evaporated, and the residue was purified by preparative TLC
(chloroform:methanol=10:1, v/v) to obtain 16.8 mg of yellow
oil.
[0361] The product was added with 4 N hydrochloric acid solution in
dioxane (2 ml), and stirred at room temperature for 4 hours. The
solvent was evaporated, and the residue was purified by preparative
TLC (chloroform:methanol=10:1, v/v). The residue was lyophilized to
obtain 11.3 mg (44.5% for the two steps) of the title compound as
yellow powder.
[0362] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.8 Hz),
1.68-1.80 (1H, m), 2.03-2.15 (1H, m), 2.19 (6H, s), 2.62-2.75 (1H,
m), 2.92-3.01 (1H, m), 3.14 (2H, t, J=7.7 Hz), 3.49-3.58 (1H, m),
3.62-3.78 (3H, m), 6.79 (1H, d, J=15.1 Hz), 7.07 (1H, s), 7.08 (1H,
dd, J=7.3, 1.7 Hz), 7.22 (1H, s), 7.68 (1H, d, J=15.1 Hz), 8.72
(1H, d, J=7.3 Hz)
[0363] ESI/MS; m/z: 482 (MH.sup.+)
[0364] EI/MS; m/z: 481 (M+)
[0365] FAB/MS; m/z: 482 (MH.sup.+)
[0366] H-R FAB/MS: Calcd. for C.sub.25H.sub.31N.sub.5O.sub.3S:
482.2226, Found: 482.2230
[0367] In a similar manner, the following compounds were
synthesized in which the substituent at the 2-position was
converted.
Example 22
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-[3-(oxymethyl)-piperidi-
no]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0368] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.15-1.32 (2H, m), 1.52-1.83 (5H, m), 2.85 (1H, t, J=11.4 Hz),
2.90-3.10 (2H, m), 3.16 (2H, t, J=7.3 Hz), 3.85 (1H, brd, J=11.8
Hz), 4.01 (1H, brd, J=12.0 Hz), 4.56 (1H, brs), 6.85 (1H, d, J=15.4
Hz), 7.07 (1H, s), 7.15 (1H, dd, J=7.3 Hz), 7.28 (1H, s), 7.42 (1H,
d, J=15.7 Hz), 8.75 (1H, d, J=7.1 Hz)
[0369] ESI/MS; m/z: 483 (MH.sup.+)
[0370] FAB/MS; m/z: 483 (MH.sup.+), 505 (M.sup.++Na)
[0371] Anal. Calcd. for
C.sub.25H.sub.30N.sub.4O.sub.4Si.5/4H.sub.2O: C, 50.45; H, 6.49; N,
11.09, Found: C, 50.35; H, 6.16; N, 10.68
Example 23
(E)-3-{2-[2-(Hydroxymethyl)morpholino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-
ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0372] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=7.1 Hz),
2.91-3.02 (2H, m), 3.12-3.22 (4H, m), 3.42-3.67 (2H, m), 3.75-3.82
(1H, m), 3.87-3.97 (2H, m), 4.77-4.82 (1H, m), 6.87 (1H, d, J=15.5
Hz), 7.07 (1H, s), 7.20 (1H, dd, J=7.3, 2.0 Hz), 7.34 (1H, s), 7.46
(1H, d, J=15.5 Hz), 8.79 (1H, d, J=7.3 Hz), 11.88 (1H, brs)
[0373] ESI/MS; m/z: 485 (MH.sup.+)
[0374] FAB/MS; m/z: 485 (MH.sup.+)
[0375] H-RFAB/MS: Calcd. for C.sub.24H.sub.28N.sub.4O.sub.5S:
485.1859, Found: 485.1862
Example 24
(E)-3-{2-(3-Hydroxytetrahydro-1H-1-pyrrolyl)-8-[2-(4-isopropyl-1,3-thiazol-
-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0376] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.78-2.00 (2H, m), 2.92-3.02 (1H, m), 3.10-3.18 (3H, m), 3.55-3.64
(1H, m), 3.78-2.92 (2H, m), 4.39-4.46 (1H, m), 5.00 (1H, brd, J=3.4
Hz), 6.79 (1H, d, J=15.2 Hz), 7.06 (1H, d, J=1.7 Hz), 7.07 (1H, dd,
J=7.3, 0.7 Hz), 7.18 (1H, d, J=1.7 Hz), 7.68 (1H, d, J=15.2 Hz),
8.70 (1H, d, J=7.3 Hz)
[0377] EI/MS; m/z: 436 (M.sup.+-H.sub.2O)
[0378] FAB/MS; m/z: 455 (MH.sup.+), 477 (M.sup.++Na)
[0379] H-R FAB/MS: Calcd. for C.sub.23H.sub.26N.sub.4O.sub.4S:
455.1753, Found: 455.1753
Example 25
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-[(3-pyridylmethyl-
)-amino]-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0380] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.19 (6H, d, J=6.8 Hz),
2.90-3.10 (1H, m), 3.13 (2H, t, J=7.5 Hz), 4.69 (2H, d, J=5.9 Hz),
7.06 (1H, s), 7.10 (1H, dd, J=7.3, 2.0 Hz), 7.13 (1H, d, J=14.9
Hz), 7.21 (1H, s), 7.32 (1H, dd, J=7.8, 4.9 Hz), 7.74 (1H, d,
J=14.9 Hz), 7.75 (1H, brs), 8.32-8.39 (1H, m), 8.40-8.47 (1H, m),
8.58-8.62 (1H, m), 8.73 (1H, d, J=7.3 Hz), 11.82 (1H, brs)
[0381] EI/MS; m/z: 431 (M.sup.+-CO.sub.2)
[0382] FAB/MS; m/z: 476 (MH.sup.+)
[0383] H-R FAB/MS: Calcd. for C.sub.25H.sub.25N.sub.5O.sub.3S:
476.1756, Found: 476.1757
Example 26
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidino)-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0384] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.19 (6H, d, J=6.8 Hz),
1.30-1.48 (1H, m), 1.48-1.62 (1H, m), 1.73-1.88 (1H, m), 1.88-1.98
(1H, m), 2.92-3.01 (2H, m), 3.10-3.21 (3H, m), 3.37 (2H, t, J=7.6
Hz), 3.54-3.65 (1H, m), 3.65-3.75 (1H, m), 3.84-3.92 (1H, m),
3.85-3.63 (1H, m), 6.85 (1H, d, J=15.5 Hz), 7.07 (1H, s), 7.15 (1H,
dd, J=7.4, 1.7 Hz), 7.28 (1H, brs), 7.42 (1H, d, J=15.5 Hz), 8.75
(1H, d, J=7.4 Hz)
[0385] FAB/MS; m/z: 469 (MH.sup.+)
[0386] H-R FAB/MS: Calcd. for C.sub.24H.sub.28N.sub.4O.sub.4S:
469.1910, Found: 469.1927
Example 27
(E)-3-{2-[(3R)-3-Aminotetrahydro-1H-1-pyrrolyl]-8-[2-(4-isopropyl-1,3-thia-
zol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0387] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.8 Hz),
2.00-2.10 (1H, m), 2.17-2.27 (1H, m), 2.93-3.03 (1H, m), 3.16 (2H,
t, J=7.2 Hz), 3.65-3.75 (2H, m), 3.84-3.98 (3H, m), 6.86 (1H, d,
J=15.2 Hz), 7.09 (1H, s), 7.13 (1H, d, J=7.3 Hz), 7.25 (1H, s),
7.70 (1H, d, J=15.2 Hz), 8.13-7.28 (2H, br), 8.75 (1H, d, J=7.3
Hz)
[0388] LC/MS; m/z: 454 (MH.sup.+)
[0389] FAB/MS; m/z: 454 (MH.sup.+)
[0390] H-R FAB/MS: Calcd. for C.sub.23H.sub.27N.sub.5O.sub.3S:
454.1913, Found: 454.1920
Example 28
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-piperazino-4H-pyr-
ido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0391] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.8 Hz),
2.92-3.02 (1H, m), 3.13-3.27 (6H, m), 3.21 (2H, t, J=7.2 Hz), 6.92
(1H, d, J=15.6 Hz), 7.10 (1H, s), 7.27 (1H, d, J=7.1 Hz), 7.40 (1H,
s), 7.43 (1H, d, J=15.6 Hz), 8.85 (1H, d, J=7.3 Hz), 9.17 (1H,
br)
[0392] LC/MS; m/z: 454 (MH.sup.+)
[0393] EI/MS; m/z: 453 (M+)
[0394] FAB/MS; m/z: 454 (MH.sup.+), 476 (M.sup.++Na)
[0395] H-R FAB/MS: Calcd. for C.sub.23H.sub.27N.sub.5O.sub.3S:
454.1913, Found: 454.1912
Example 29
(E)-3-{2-(3,5-cisDimethylpiperazino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-e-
thyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0396] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.9 Hz),
1.26 (3H, s), 1.27 (3H, s), 2.92-3.02 (1H, m), 3.12-3.25 (4H, m),
3.90-3.98 (2H, m), 6.90 (1H, d, J=15.7 Hz), 7.09 (1H, s), 7.26 (1H,
dd, J=7.3, 1.7 Hz), 7.42 (1H, d, J=15.7 Hz), 7.41 (1H, s), 8.83
(1H, d, J=7.3 Hz), 9.03 (1H, d, J=9.6 Hz), 9.50 (1H, br)
[0397] EI/MS; m/z: 481 (M+)
[0398] H-R EI/MS: Calcd. for C.sub.25H.sub.31N.sub.5O.sub.3S:
481.2148, Found: 481.2150
Example 30
(E)-3-{2-[4-(Dimethylamino)piperidino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-
ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0399] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.8 Hz),
1.64-1.78 (2H, m), 2.10-2.19 (2H, m), 2.73 (3H, s), 2.75 (3H, s),
2.93-3.02 (1H, m), 3.03-3.14 (2H, m), 3.19 (2H, t, J=7.2 Hz), 3.38
(2H, t, J=7.2 Hz), 4.02-4.11 (1H, m), 6.91 (1H, d, J=15.5 Hz), 7.09
(1H, s), 7.22 (1H, dd, J=7.3, 1.7 Hz), 7.34 (1H, s), 7.43 (1H, d,
J=15.5 Hz), 8.81 (1H, d, J=7.3 Hz), 10.19-10.27 (1H, m)
[0400] FAB/MS; m/z: 496 (MH.sup.+)
[0401] H-R FAB/MS: Calcd. for C.sub.26H.sub.33N.sub.5O.sub.3S:
496.2382, Found: 496.2386
Example 31
(E)-3-{2-[2-(Aminomethyl)morpholino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-e-
thyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0402] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
2.84-3.14 (5H, m), 3.20 (2H, t, J=7.1 Hz), 3.63-3.85 (3H, m),
3.85-3.92 (1H, m), 3.97-4.03 (1H, m), 6.90 (1H, d, J=15.5 Hz), 7.08
(1H, s), 7.25 (1H, d, J=7.3 Hz), 7.33 (1H, s), 7.45 (1H, d, J=15.5
Hz), 7.92 (2H, br), 8.82 (1H, d, J=7.6 Hz)
[0403] FAB/MS; m/z: 484 (MH.sup.+)
[0404] H-R EI/MS: Calcd. for C.sub.24H.sub.29N.sub.5O.sub.4S:
484.2019, Found: 484.1999
Example 32
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-[(3R)-3-(methylamino)-t-
etrahydro-1H-1-pyrrolyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0405] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.8 Hz),
2.11-2.31 (2H, m), 2.58-2.64 (3H, m), 2.92-3.02 (1H, m), 3.13-3.21
(2H, m), 3.35-3.42 (2H, m), 3.44-3.52 (1H, m), 3.65-3.75 (1H, m),
3.80-4.05 (3H, m), 6.86 (1H, d, J=15.2 Hz), 7.11 (1H, s), 7.14 (1H,
dd, J=7.3, 1.7 Hz), 7.26 (1H, s), 7.68 (1H, d, J=15.2 Hz), 8.76
(1H, d, J=7.3 Hz), 9.05-9.30 (1H, br)
[0406] FAB/MS; m/z: 468 (MH.sup.+)
[0407] H-R FAB/MS: Calcd. for C.sub.24H.sub.29N.sub.5O.sub.3S:
468.2069, Found: 468.2085
Example 33
((E)-3-{2-[(3S)-3-(Dimethylamino)tetrahydro-1H-1-pyrrolyl]-8-[2-(4-isoprop-
yl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propeno-
ic acid
[0408] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.8 Hz),
1.68-1.80 (1H, m), 2.03-2.12 (1H, m), 2.18 (6H, s), 2.64-2.73 (1H,
m), 2.92-3.03 (1H, m), 3.10-3.18 (2H, m), 2.49-2.58 (1H, m),
2.62-2.79 (3H, m), 6.78 (1H, d, J=15.1 Hz), 7.05-7.08 (2H, m), 7.22
(1H, s), 7.68 (1H, d, J=15.1 Hz), 8.71 (1H, d, J=7.3 Hz)
[0409] FAB/MS; m/z: 482 (MH.sup.+), 504 (M.sup.++Na).
[0410] H-R FAB/MS: Calcd. for C.sub.25H.sub.31N.sub.5O.sub.3S:
482.2226, Found: 482.2231
Example 34
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(4-methyl-1,4-diazepan--
1-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0411] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.8 Hz),
2.08-2.10 (1H, m), 2.12-2.37 (1H, m), 2.77 (3H, s), 2.92-3.03 (1H,
m), 3.12-3.20 (2H, m), 3.50-3.72 (5H, m), 3.75-3.87 (2H, m),
4.08-4.17 (1H, m), 6.80 (1H, d, J=15.4 Hz), 7.10 (1H, s), 7.16 (1H,
dd, J=7.3, 1.2 Hz), 7.28 (1H, s), 7.48 (1H, d, J=15.4 Hz), 8.77
(1H, d, J=7.3 Hz), 10.38 (1H, br)
[0412] FAB/MS; m/z: 482 (MH.sup.+), 504 (M.sup.++Na)
[0413] H-R FAB/MS: Calcd. for C.sub.25H.sub.31N.sub.5O.sub.3S:
482.2226, Found: 482.2234
Example 35
(E)-3-{2-(4-Aminopiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-o-
xo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0414] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=7.1 Hz),
1.58-1.72 (2H, m), 1.97-2.08 (2H, m), 2.93-3.03 (1H, m), 3.06-3.17
(2H, m), 3.17-3.23 (2H, m), 3.23-3.55 (3H, m), 3.60-3.75 (2H, m),
6.91 (1H, d, J=15.5 Hz), 7.15 (1H, s), 7.21 (1H, d, J=7.1 Hz), 7.34
(1H, s), 7.42 (1H, d, J=15.5 Hz), 8.19 (2H, br), 8.80 (1H, d, J=7.3
Hz)
[0415] FAB/MS; m/z: 468 (MH.sup.+)
[0416] H-R FAB/MS: Calcd. for C.sub.24H.sub.29N.sub.5O.sub.3S:
468.2069, Found: 468.2069
Example 36
(E)-3-{2-[4-(Hydroxymethyl)piperidino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-
ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0417] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.12-1.35 (2H, m), 1.68-1.82 (3H, m), 2.92-3.07 (3H, m), 3.12-3.21
(2H, m), 3.95-4.03 (2H, m), 4.52-4.57 (1H, m), 6.87 (1H, d, J=15.5
Hz), 7.07 (1H, s), 7.16 (1H, d, J=6.6 Hz), 7.28 (1H, s), 7.41 (1H,
d, J=15.5 Hz), 8.75 (1H, d, J=7.1 Hz)
[0418] FAB/MS; m/z: 483 (MH.sup.+), 505 (M.sup.++Na)
[0419] H-R FAB/MS: Calcd. for C.sub.25H.sub.30N.sub.4O.sub.4S:
483.2066, Found: 483.2064
Example 37
(E)-3-{2-(3-Aminopiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-o-
xo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0420] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.8 Hz),
1.58-1.72 (2H, m), 1.77-1.88 (1H, m), 2.00-2.14 (1H, m), 2.92-3.05
(1H, m), 3.03-3.55 (8H, m), 6.91 (1H, d, J=15.5 Hz), 7.13 (1H, s),
7.24 (1H, d, J=6.8 Hz), 7.37 (1H, s), 7.45 (1H, d, J=15.5 Hz), 8.25
(3H, br), 8.82 (1H, d, J=6.8 Hz)
[0421] FAB/MS; m/z: 468 (MH.sup.+)
[0422] H-R FAB/MS: Calcd. for C.sub.24H.sub.29N.sub.5O.sub.3S:
468.2069, Found: 468.2073
Example 38
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-[3-(methylamino)-piperi-
dino]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0423] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.8 Hz),
1.55-1.78 (2H, m), 1.78-1.89 (1H, m), 2.05-2.20 (1H, m), 2.62 (3H,
s), 2.92-3.03 (1H, m), 3.05-3.55 (8H, m), 3.98-4.07 (1H, m), 6.91
(1H, d, J=15.5 Hz), 7.11 (1H, s), 7.24 (1H, d, J=7.3 Hz), 7.38 (1H,
s), 7.44 (1H, d, J=15.5 Hz), 8.82 (1H, d, J=7.3 Hz), 8.90 (1H, br),
9.07 (1H, br)
[0424] EI/MS; m/z: 481 (M+)
[0425] FAB/MS; m/z: 482 (MH.sup.+)
[0426] H-R FAB/MS: Calcd. for C.sub.25H.sub.31N.sub.5O.sub.3S:
482.2226, Found: 482.2244
Example 39
(E)-3-{2-[3-(Dimethylamino)piperidino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-
ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0427] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.52-1.80 (2H, m), 1.82-1.93 (1H, m), 2.14-2.23 (1H, m), 2.49 (6H,
s), 2.80-2.90 (1H, m), 2.90-3.01 (2H, m), 3.01-3.12 (1H, m),
3.17-3.24 (2H, m), 3.32-3.40 (2H, m), 4.02-4.12 (1H, m), 4.27-4.36
(1H, m), 6.74 (1H, s), 6.83 (1H, dd, J=7.3, 1.7 Hz), 7.08 (1H, d,
J=15.6 Hz), 7.19 (1H, s), 7.56 (1H, d, J=15.6 Hz), 8.85 (1H, d,
J=7.3 Hz)
[0428] EI/MS; m/z: 495 (M+)
[0429] FAB/MS; m/z: 496 (MH.sup.+)
[0430] H-R FAB/MS: Calcd. for C.sub.26H.sub.33N.sub.5O.sub.3S:
496.2382, Found: 496.2383
Example 40
(E)-3-{2-[3-(Aminocarbonyl)piperidino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-
-ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0431] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.55-1.67 (2H, m), 1.67-1.84 (1H, m), 1.88-2.00 (1H, m), 2.40-2.50
(1H, m), 2.90-3.12 (3H, m), 3.12-3.22 (2H, m), 3.81-3.91 (1H, m),
4.00-4.12 (1H, m), 6.86 (1H, d, J=15.5 Hz), 6.89 (1H, s), 7.07 (1H,
s), 7.17 (1H, d, J=7.1 Hz), 7.29 (1H, br), 7.34 (1H, s), 7.41 (1H,
d, J=15.5 Hz), 8.76 (1H, d, J=7.1 Hz), 11.89 (1H, br)
[0432] FAB/MS; m/z: 496 (MH.sup.+)
[0433] H-R FAB/MS: Calcd. for C.sub.25H.sub.29N.sub.5O.sub.4S:
496.2019, Found: 496.2018
Example 41
(E)-3-{2-[4-(Aminocarbonyl)piperidino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-
-ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0434] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.60-1.76 (2H, m), 1.76-1.85 (2H, m), 2.35-2.46 (1H, m), 2.92-3.09
(3H, m), 3.12-3.20 (2H, m), 3.92-4.00 (2H, m), 6.82 (1H, s), 6.87
(1H, d, J=15.5 Hz), 7.07 (1H, s), 7.17 (1H, dd, J=7.3, 1.7 Hz),
7.22-7.33 (2H, m), 7.42 (1H, d, J=15.5 Hz), 8.77 (1H, d, J=15.5
Hz), 11.88 (1H, br)
[0435] FAB/MS; m/z: 496 (MH.sup.+)
[0436] H-R FAB/MS: Calcd. for C.sub.25H.sub.29N.sub.5O.sub.4S:
496.2019, Found: 496.2015
Example 42
(E)-3-{2-[(7
S)-7-Amino-5-azaspiro[2,4]hept-5-yl]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)e-
thyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0437] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.70-1.90 (3H, m),
1.00-1.09 (1H, m), 1.20 (6H, d, J=6.9 Hz), 2.91-3.02 (1H, m),
3.13-3.22 (2H, m), 3.22-3.28 (1H, m), 3.62-3.75 (1H, m), 3.77-3.85
(1H, m), 4.19-4.32 (2H, m), 6.87 (1H, d, J=15.2 Hz), 7.08 (1H, s),
7.14 (1H, d, J=6.9, 2.2 Hz), 7.25 (1H, s), 7.68 (1H, d, J=15.2 Hz),
8.16 (2H, br), 8.75 (1H, d, J=6.9 Hz)
[0438] FAB/MS; m/z: 480 (MH.sup.+)
[0439] H-R FAB/MS: Calcd. for C.sub.25H.sub.29N.sub.5O.sub.3S:
480.2069, Found: 480.2062
Example 43
(E)-3-{2-[(3S,4S)-3-Amino-4-(fluoromethyl)tetrahydro-1H-1-pyrrolyl]-8-[2-(-
4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}--
2-propenoic acid
[0440] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.9 Hz),
2.83-3.07 (2H, m), 3.12-3.20 (2H, m), 3.34-3.42 (2H, m), 3.65-3.83
(2H, m), 3.87-4.10 (3H, m), 4.62-4.70 (1H, m), 4.72-4.81 (1H, m),
6.88 (1H, d, J=15.3 Hz), 7.09 (1H, s), 7.14 (1H, dd, J=7.3, 1.7
Hz), 7.27 (1H, s), 7.68 (1H, d, J=15.3 Hz), 8.29 (2H, br), 8.75
(1H, d, J=7.3 Hz)
[0441] FAB/MS; m/z: 486 (MH.sup.+)
[0442] H-R FAB/MS: Calcd. for C.sub.24H.sub.28FN.sub.5O.sub.3S:
486.1975, Found: 486.1974
Example 44
(E)-3-{2-[(3R)-3-Piperidino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-o-
xo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0443] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.19 (6H, d, J=6.9 Hz),
1.30-1.60 (2H, m), 1.73-1.83 (1H, m), 1.83-1.96 (1H, m), 2.90-3.00
(2H, m), 3.08-3.21 (3H, m), 3.52-3.61 (1H, m), 3.63-3.72 (1H, m),
3.82-3.91 (1H, m), 4.85-4.93 (1H, m), 6.84 (1H, d, J=15.4 Hz), 7.07
(1H, s), 7.14 (1H, d, J=6.9 Hz), 7.27 (1H, s), 7.41 (1H, d, J=15.4
Hz), 8.74 (1H, d, J=7.8 Hz), 11.85 (1H, br).
[0444] FAB/MS; m/z: 469 (MH.sup.+)
[0445] H-R FAB/MS: Calcd. for C.sub.24H.sub.28N.sub.4O.sub.4S:
469.1910, Found: 469.1901
Example 45
(E)-3-{2-[(3S)-3-Hydroxypiperidino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-et-
hyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0446] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.31-1.61 (2H, m), 1.74-1.85 (1H, m), 1.85-1.98 (1H, m), 2.90-3.00
(2H, m), 3.08-3.21 (3H, m), 3.53-3.63 (1H, m), 3.63-3.75 (1H, m),
3.83-3.92 (1H, m), 4.86-4.95 (1H, m), 6.85 (1H, d, J=15:7 Hz), 7.07
(1H, s), 7.15 (1H, d, J=6.6 Hz), 7.28 (1H, s), 7.42 (1H, d, J=15.7
Hz), 8.75 (1H, d, J=7.3 Hz), 11.88 (1H, br)
[0447] FAB/MS; m/z: 469 (MH.sup.+)
[0448] H-R FAB/MS: Calcd. for C.sub.24H.sub.28N.sub.4O.sub.4S:
469.1910, Found: 469.1921
Example 46
(E)-3-{2-(3-Amino-1-azetanyl)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4--
oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0449] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.8 Hz),
2.93-3.03 (1H, m), 3.13-3.23 (2H, m), 3.43-3.53 (2H, m), 3.65-3.85
(2H, m), 4.25-4.35 (2H, m), 4.50-4.58 (1H, m), 6.92 (1H, d, J=15.2
Hz), 7.10 (1H, s), 7.16 (1H, d, J=7.6 Hz), 7.28 (1H, s), 7.50 (1H,
d, J=15.2 Hz), 8.49 (1H, br), 8.77 (1H, d, J=7.1 Hz)
[0450] FAB/MS; m/z: 440 (MH.sup.+)
[0451] H-R FAB/MS: Calcd. for C.sub.22H.sub.25N.sub.5O.sub.3S:
440.1756, Found: 440.1768
Example 47
(E)-3-{2-(4-Fluoropiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4--
oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0452] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.8 Hz),
1.75-1.88 (2H, m), 1.93-2.10 (2H, m), 2.91-3.01 (1H, m), 3.14-3.21
(2H, m), 3.32-3.40 (2H, m), 3.40-3.52 (2H, m), 3.52-3.68 (2H, m),
4.83-4.92 (0.5H, m), 4.95-5.04 (0.5H, m), 6.88 (1H, d, J=15.6 Hz),
7.07 (1H, s), 7.19 (1H, dd, J=7.1, 1.5 Hz), 7.33 (1H, s), 7.44 (1H,
d, J=15.6 Hz), 8.79 (1H, d, J=7.1 Hz), 11.91 (1H, br)
[0453] FAB/MS; m/z: 470 (MH.sup.+)
[0454] H-R FAB/MS: Calcd. for C.sub.24H.sub.27FN.sub.4O.sub.3S:
470.1788, Found: 470.1779
Example 48
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-oxopiperidino)-
-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0455] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.8 Hz),
2.91-3.01 (1H, m), 3.15-3.22 (2H, m), 3.30-3.41 (6H, m), 3.79-3.87
(4H, m), 6.91 (1H, d, J=15.4 Hz), 7.07 (1H, s), 7.22 (1H, dd,
J=7.3, 1.8 Hz), 7.37 (1H, s), 7.52 (1H, d, J=15.4 Hz), 8.81 (1H, d,
J=7.3 Hz), 11.94 (1H, br)
[0456] FAB/MS; m/z: 467 (MH.sup.+)
[0457] H-R FAB/MS: Calcd. for C.sub.24H.sub.26N.sub.4O.sub.4S:
467.1753, Found: 467.1765
Example 49
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-{4-[(2R,3R,4S,5S,-
6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-2-pyranyl]-piperazino}-
-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0458] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.35 (6H, d, J=6.8 Hz),
3.12-3.23 (2H, m), 3.25-3.43 (4H, m), 3.53-3.90 (18H, m), 7.10 (1H,
d, J=15.7 Hz), 7.18 (1H, s), 7.35 (1H, dd, J=7.1,2.4 Hz), 7.42 (1H,
s), 7.57 (1H, d, J=15.7 Hz), 8.94 (1H, d, J=7.1 Hz)
[0459] LC-MS; m/z: 616 (MH.sup.+)
Example 50
(E)-3-[8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-{[(2R,3
R,4 S,5
R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-2-pyranyl]oxy}--
piperidino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0460] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (6H, d, J=6.8 Hz),
1.70-1.92 (2H, m), 1.92-2.10 (2H, m), 2.98-3.10 (1H, m), 3.17-3.25
(2H, m), 3.36-3.58 (7H, m), 3.68-3.78 (2H, m), 3.82-3.98 (3H, m),
4.00-4.12 (1H, m), 4.39 (1H, d, J=7.3 Hz), 6.95 (1H, d, J=15.6 Hz),
6.96 (1H, s), 7.04 (1H, dd, J=7.3, 1.7 Hz), 7.21 (1H, s), 7.60 (1H,
d, J=15.6 Hz), 8.79 (1H, d, J=7.3 Hz)
[0461] FAB/MS; m/z: 631 (MH.sup.+)
[0462] H-R FAB/MS: Calcd. for C.sub.30H.sub.38N.sub.4O.sub.9S:
631.2438, Found: 631.2485
Example 51
(E)-3-{2-[cis3,4-Dihydroxyhexahydro-1-pyridinyl]-8-[2-(4-isopropyl-1,3-thi-
azol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0463] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.19 (6H, d, J=7.1 Hz),
1.60-1.72 (1H, m), 1.77-1.88 (1H, m), 2.90-3.01 (1H, m), 3.12-3.20
(2H, m), 3.35-3.42 (2H, m), 3.45-3.66 (3H, m), 3.72-3.80 (1H, m),
4.57-4.60 (1H, m), 4.60-4.70 (1H, m), 6.83 (1H, d, J=15.5 Hz), 7.06
(1H, s), 7.13 (1H, d, J=7.6 Hz), 7.26 (1H, s), 7.42 (1H, d, J=15.5
Hz), 8.73 (1H, d, J=7.1 Hz)
[0464] FAB/MS; m/z: 485 (MH.sup.+)
[0465] H-R FAB/MS: Calcd. for C.sub.24H.sub.28N.sub.4O.sub.5S:
485.1859, Found: 485.1882
Example 52
3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido--
[1,2-a]pyrimidin-3-yl}-2-propanoic acid
(A) tert-Butyl
3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrim-
idin-3-yl}-2-propanoate
[0466] tert-Butyl
(E)-3-{8-[2-(4-isoprolyl-1,3-thiazol-2-yl)ethyl]-2-m
orpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenate (29.8
mg, 0.058 mmol) was dissolved in methanol (20 ml), added with 10%
palladium/carbon (6.0 mg) and stirred at room temperature under
hydrogen flow for 4 hours and 30 minutes. After the catalyst was
removed by filtration, the solvent was evaporated and the residue
was purified by preparative TLC (chloroform:methanol=30:1, v/v) to
obtain the title compound (8.0 mg, 26.7%) as a pale yellow oily
substance.
[0467] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.43 (9H, s), 2.62-2.70 (2H, m), 2.87-2.93 (2H, m), 3.02-3.12 (1H,
m), 3.16-3.23 (2H, m), 3.32-3.47 (6H, m), 3.80-3.86 (4H, m), 6.73
(1H, s), 6.82 (1H, dd, J=7.3, 1.7 Hz), 7.22 (1H, s), 8.81 (1H, d,
J=7.3 Hz)
(B)
3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyr-
ido[1,2-a]-pyrimidin-3-yl}-2-propanoic acid
[0468] The tert-Butyl
3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrim-
idin-3-yl}-2-propanoate (8.0 mg, 0.016 mmol) obtained in (A) was
added with 4 N hydrochloric acid in dioxane (1 ml), stirred at room
temperature for 3 hours, further added with 4 N hydrochloric acid
in dioxane (1 ml), and stirred for further 4 hours. The solvent was
evaporated, and the residue was purified by preparative TLC
(chloroform:methanol=10:1, v/v) and lyophilized from dioxane to
obtain the title compound (4.3 mg, 60.4%) as pale yellow
powder.
[0469] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.9 Hz),
2.76 (2H, t, J=6.9 Hz), 2.92 (2H, t, J=6.9 Hz), 3.02-3.12 (1H, m),
3.18-3.25 (2H, m), 3.3.4-3.56 (6H, m), 3.78-3.86 (4H, m), 6.73 (1H,
s), 6.88 (1H, dd, J=7.3, 1.7 Hz), 7.26 (1H, s), 8.82 (1H, d, J=7.1
Hz)
[0470] LC/MS; m/z: 457 (MH.sup.+), 455 (M.sup.+-1)
[0471] EI/MS; m/z: 456 (MH.sup.+)
[0472] H-R EI/MS: Calcd. for C.sub.23H.sub.28N.sub.4O.sub.4S:
456.1831, Found: 456.1848
Example 53
(E)-3-{2-(4,4-Dimethylhexahydropyrazin-4-ium-1-yl)-8-[2-(4-isopropyl-1,3-t-
hiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0473]
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(4-methyl)piper-
azino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid (19.9
mg, 0.043 mmol) was dissolved in dimethylformamide (1 ml), added
dropwise with methyl iodide (0.1 ml, 1.61 mmol), sealed with a
stopper and left in a refrigerator for 14 hours. The solvent and
excessive reagents were evaporated, and the residue was lyophilized
from dioxane/water to obtain the title compound (29.7 mg,
quantitative).
[0474] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.21 (6H, d, J=6.9 Hz),
2.55 (6H, s), 2.91-3.02 (1H, m), 3.15-3.26 (2H, m), 3.45-3.55 (4H,
m), 3.82-3.92 (4H, m), 6.93 (1H, d, J=15.5 Hz), 7.09 (1H, s), 7.29
(1H, d, J=7.1 Hz), 7.41 (1H, s), 7.45 (1H, d, J=15.5 Hz), 8.14 (1H,
br), 8.85 (1H, d, J=7.3 Hz)
[0475] FAB/MS; m/z: 482 (M+)
[0476] H-R FAB/MS: Calcd. for C.sub.25H.sub.32N.sub.5O.sub.3S:
482.2226, Found: 482.2216
Example 54
(E)-3-{2-{(3R)-3-[(Aminocarbonyl)oxy}piperidino}-8-[2-(4-isopropyl-1,3-thi-
azol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
(A) tert-Butyl
(E)-3-{2-[(3R)-3-hydroxyhexahydro-1-pyridinyl]-8-[2-(4-isopropyl-1,3-thia-
zol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenate
[0477] tert-Butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-[(4-methylphenyl)-sulf-
onyl]oxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenate (111.4
mg, 0.19 mmol) was dissolved in dimethylformamide (3 ml), added
dropwise with triethylamine (130.4 .mu.l, 0.93 mmol), added with
R-(+)-3-hydroxypiperidine hydrochloride (128.7 mg, 0.93 mmol), and
stirred at room temperature for 17 hours. The solvent was
evaporated, and then the residue was purified by preparative TLC
(chloroform:methanol=30:1, v/v) to obtain the title compound (91.4
mg, 93.2%) as yellow oil.
[0478] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.51 (9H, s), 1.72-1.95 (4H, m), 3.01-3.11 (1H, m), 3.16-3.23 (2H,
m), 3.32-3.40 (2H, m), 3.49-3.68 (3H, m), 3.88-3.97 (1H, m),
3.97-4.07 (1H, m), 6.74 (1H, s), 6.86 (1H, d, J=7.3 Hz), 7.03 (1H,
d, J=15.6 Hz), 7.19 (1H, s), 7.49 (1H, d, J=15.6 Hz), 8.85 (1H, d,
J=7.3 Hz)
(B) tert-Butyl
(E)-3-{2-(3R)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl-8-[2-(4-isoprop-
yl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propena-
te
[0479] The tert-Butyl
(E)-3-{2-[(3R)-3-hydroxyhexahydro-1-pyridinyl]-8-[2-(4-isopropyl-1,3-thia-
zol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenate
(38.9 mg, 0.074 mmol) obtained in (A) was dissolved in ethyl
acetate (3 ml), added with trichloroacetyl isocyanate (9.7 .mu.l,
0.082 mmol) under ice cooling, and stirred at the same temperature
for 1 hour. The reaction solution was further added with
trichloroacetyl isocyanate (9.7 .mu.l, 0.082 mmol), stirred at the
same temperature for further 1 hour, and added with
chloroform/methanol (10:1, v/v, 6 ml), and the solvent was
evaporated. The residue was dissolved in methanol (1.5 ml), added
with water (0.2 ml) and sodium formate (9.6 mg, 0.14 mmol) stirred
at room temperature for 2 hours and 30 minutes. The mixture was
further added with sodium formate (9.6 mg, 0.14 mmol), and stirred
at room temperature for further 20 hours. The solvent was
evaporated, and the residue was purified by preparative TLC
(chloroform:methanol=30:1, v/v) to obtain the title compound (74.9
mg, quantitative) as yellow solid.
[0480] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.9 Hz),
1.50 (9H, s), 1.80-2.10 (4H, m), 3.02-3.12 (1H, m), 3.15-3.23 (2H,
m), 3.23-3.40 (3H, m), 3.45-3.63 (1H, m), 3.65-3.77 (2H, m),
4.75-4.85 (1H, m), 6.73 (1H, s), 6.85 (1H, dd, J=7.3, 1.7 Hz), 7.08
(1H, d, J=15.7 Hz), 7.22 (1H, s), 7.73 (1H, d, J=15.7 Hz), 8.86
(1H, d, J=7.1 Hz)
(C)
(E)-3-{2-{(3R)-3-[(Aminocarbonyl)oxyhexahydro-1-pyridinyl}-8-[2-(4-iso-
propyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-pro-
penic acid
[0481] The tert-Butyl
(E)-3-{2-(3R)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl-8-[2-(4-isoprop-
yl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propena-
te (74.9 mg, 0.074 mmol) obtained in (B) was dissolved in 4 N
hydrochloric acid solution in dioxane and stirred at room
temperature for 5 hours. After the solvent was evaporated, the
residue was purified by preparative TLC (chloroform:methanol=10:1,
v/v) and lyophilized from dioxane to obtain the title compound
(17.6 mg, 67.5%) as yellow powder.
[0482] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.55-1.70 (2H, m), 1.80-1.90 (1H, m), 1.90-2.02 (1H, m), 2.90-3.01
(1H, m), 3.13-3.20 (2H, m), 3.30-3.42 (3H, m), 3.45-3.60 (2H, m),
3.80-3.88 (1H, m), 4.54-4.62 (1H, m), 6.49 (2H, br), 6.87 (1H, d,
J=15.4 Hz), 7.07 (1H, s,), 7.17 (1H, dd, J=7.3, 1.7 Hz), 7.32 (1H,
s), 7.44 (1H, d, J=15.4 Hz), 8.76 (1H, d, J=7.3 Hz), 11.89 (1H,
br)
[0483] FAB/MS; m/z: 512 (MH.sup.+)
[0484] H-R FAB/MS: Calcd. for C.sub.25H.sub.29N.sub.5O.sub.5S:
512.1968, Found: 512.1970
Example 55
(E)-3-{2-{(3S)-3-[(Aminocarbonyl)oxy]piperidino}-8-[2-(4-isopropyl-1,3-thi-
azol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0485] The title compound was synthesized in the same manner as in
Example 54.
[0486] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.53-1.70 (2H, m), 1.80-1.90 (1H, m), 1.90-2.02 (1H, m), 2.91-3.01
(1H, m), 3.13-3.20 (2H, m), 3.30-3.42 (3H, m), 3.45-3.62 (2H, m),
3.80-3.88 (1H, m), 4.53-4.63 (1H, m), 6.49 (2H, br), 6.87 (1H, d,
J=15.4 Hz), 7.07 (1H, s,), 7.17 (1H, dd, J=7.3, 1.7 Hz), 7.32 (1H,
s), 7.44 (1H, d, J=15.4 Hz), 8.76 (1H, d, J=7.3 Hz), 11.89 (1H,
br)
[0487] FAB/MS; m/z: 512 (MH.sup.+)
[0488] H-R FAB/MS: Calcd. for C.sub.25H.sub.29N.sub.5O.sub.5S:
512.1968, Found: 512.1968
Example 56
(E)-3-[2-{4-[(Aminocarbonyl)oxy]hexahydro-1-pyridinyl)-8-[2-(4-isopropyl-1-
,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0489] The title compound was synthesized in the same manner as in
Example 54.
[0490] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.20 (6H, d, J=6.9 Hz),
1.57-1.70 (2H, m), 1.91-2.01 (2H, m), 2.91-3.01 (1H, m), 3.13-3.20
(2H, m), 3.27-3.40 (4H, m), 3.72-3.82 (2H, m), 4.69-4.78 (1H, m),
6.50 (2H, br), 6.86 (1H, d, J=15.4 Hz), 7.07 (1H, s), 7.18 (1H, dd,
J=7.3, 2.0 Hz), 7.32 (1H, s), 7.44 (1H, d, J=15.4 Hz), 8.77 (1H.d,
J=7.3 Hz), 11.90 (1H, br)
[0491] FAB/MS; m/z: 512 (MH.sup.+)
[0492] H-R FAB/MS: Calcd. for C.sub.25H.sub.29N.sub.5O.sub.5S:
512.1968, Found: 512.1964
Example 57
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-3-[2-(2H-1,2,3,4-te-
trazol-5-yl)acetyl]-4H-pyrido[1,2-a]pyrimidin-4-one
(A) Ethyl
2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetate
[0493] Ethyl 2-(1H-1,2,3,4-tetrazol-5-yl)acetate (5.0 g, 32.0 mmol)
was dissolved in dimethylformamide (20 ml), added with potassium
carbonate (5.75 g, 41.6 mmol). The mixture was further added
dropwise with 4-methoxybenzyl chloride (5.21 ml, 38.4 mmol) under
ice cooling and stirred at the same temperature for 1 hour and 30
minutes and at room temperature for 15 hours. The solvent was
evaporated, and the residue was diluted with toluene, washed with
water and saturated brine, and dried over anhydrous sodium sulfate.
Then, the solvent was evaporated and the residue was purified by
silica gel column chromatography (hexane:ethyl acetate=2:1, v/v) to
obtain the title compound (3.78 g, 42.7%) as colorless oil.
[0494] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.25 (3H, t, J=7.1 Hz),
3.79 (3H, s), 3.94 (2H, s), 4.19 (2H,q, J=7.1 Hz), 5.68 (2H, s),
6.82-6.92 (2H, m), 7.28-7.38 (2H, m)
(B) 2-[2-(4-Methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetic acid
[0495] The ethyl
2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetate (2.15 g,
7.78 mmol) obtained in (A) was dissolved in
tetrahydrofuran/methanol (3:1, v/v, 60 ml), added dropwise with a
solution of lithium hydroxide (359.2 mg, 8.56 mmol) in water (15
ml) under ice cooling and then stirred at room temperature for 2
hours. The solvent was evaporated, and the residue was added with 1
N aqueous hydrochloric acid to obtain pH of about 1. The solution
was extracted with ethyl acetate, and the organic layer was washed
with saturated brine and dried over anhydrous sodium sulfate. Then,
the solvent was evaporated to obtain the title compound (1.91 g,
98.8%).
[0496] .sup.1H-NMR (CDCl.sub.3): 3.79 (3H, s), 3.99 (2H, s), 5.68
(2H, s), 6.85-6.95 (2H, m), 7.29-7.39 (2H, m)
(C) 2-[2-(4-Methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]ethanoyl
chloride
[0497] The 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetic
acid (262.0 mg, 1.05 mmol) obtained in (B) was added dropwise with
thionyl chloride (615.9 v 1, 8.44 mmol) under ice cooling and
stirred at room temperature for 30 minutes. Excessive regents were
evaporated to obtain the title compound (0.27 g, quantitative) as
pale yellow oil.
(D)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-3-{2-[2-(4-methoxybenzyl)-2H-
-1,2,3,4-tetrazol-5-yl]acetyl}-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-on-
e
[0498] The 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]ethanoyl
chloride (0.27 g, 1.05 mmol) obtained in (C) was dissolved in
methylene chloride (3 ml), added dropwise with pyridine (170.2
.mu.l, 2.10 mmol) under ice cooling, and added dropwise with a
solution of
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido-[1,2-a]p-
yrimidin-4-one (80.9 mg, 0.21 mmol) in methylene chloride (3 ml).
The reaction solution was stirred at room temperature for 23 hours,
then further added with a solution of
2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]ethanoyl chloride
(0.27 g, 1.05 mmol) in methylene chloride (2 ml) and pyridine
(170.2 .mu.l, 2.10 mmol) under ice cooling. Further, the reaction
solution was added with the same amounts of the acid chloride and
pyridine twice every 24 hours, and stirred at room temperature. The
solvent was evaporated, and the residue was added with saturated
aqueous sodium hydrogencarbonate and extracted with ethyl acetate.
The organic layer was washed with saturated brine and dried over
anhydrous sodium sulfate. The solvent was evaporated and the
residue was purified by preparative TLC (hexane:ethyl acetate=1:1,
v/v and chloroform:methanol=30:1, v/v) to obtain the title compound
(10.1 mg, 7.8%) as yellow oil.
[0499] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
3.02-3.12 (1H, m), 3.12-3.20 (2H, m), 3.31-3.38 (2H, m), 3.60-3.75
(8H, m), 3.79 (3H, s), 4.68 (2H, s), 5.66 (2H, s), 6.72 (1H, dd,
J=7.3, 1.5 Hz), 6.73 (1H, s), 6.86 (2H, d, J=8.6 Hz), 7.03 (1H, s),
7.29 (2H, d, J=8.6 Hz), 8.71 (1H, d, J=7.3 Hz)
(E)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-3-[2-(2H-1,2,3,-
4-tetrazol-5-yl)acetyl]-4H-pyrido[1,2-a]pyrimidin-4-one
[0500] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-{2-[2-(4-methoxybenzyl)-2H-1,-
2,3,4-tetrazol-5-yl]acetyl}-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one
(8.9 mg, 0.014 mmol) obtained in (D) was dissolved in
trifluoroacetic acid (5 ml) and stirred at room temperature for 18
hours. The solvent was evaporated, and the residue was purified by
preparative TLC (chloroform:methanol=10:1, v/v) and lyophilized
from dioxane to obtain the title compound (4.8 mg, 67.0%) as pale
yellow powder.
[0501] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.9 Hz),
3.01-3.12 (1H, m), 3.17-3.23 (2H, m), 3.32-3.40 (2H, m), 3.55-3.63
(4H, m), 3.67-3.76 (4H, m), 4.75 (2H, s), 6.74 (1H, s), 6.80 (1H,
d, J=7.3 Hz), 7.07 (1H, s), 8.73 (1H, d, J=7.3 Hz)
[0502] FAB/MS; m/z: 495 (MH.sup.+)
[0503] H-R FAB/MS: Calcd. for C.sub.23H.sub.26N.sub.8O.sub.3S:
495.1927, Found: 495.1955
Example 58
(E)-3-(8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino]carbonyl}-2-{3-[(dimethy-
lamino)carbonyl]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propen-
oic acid
(A)
N.sup.8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-{3-[(dimethylamino)carbony-
l]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
[0504]
N.sup.8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-
-pyrido[1,2-a]-pyrimidine-8-carboxamide (301.9 mg, 0.88 mmol) was
suspended in dimethylformamide (6 ml) and acetonitrile (12 ml),
added dropwise with diisopropylethylamine (1.83 ml, 10.5 mmol) and
diphenyl chlorophosphate (545.1 .mu.l, 2.63 mmol) at -10.degree. C.
under an argon flow, and stirred at the same temperature for 5
minutes and at room temperature for 15 minutes. The reaction
solution was cooled to -10.degree. C. again, added dropwise with a
solution of 3-[(dimethylamino)carbonyl]piperidine trifluoroacetic
acid salt (1.18 g, 4.38 mmol) in dimethylformamide (5 ml), and
stirred at room temperature for 1 hour and at about 80.degree. C.
for 2 hours. The reaction solution was heated to about 100.degree.
C., heated for 30 minutes with stirring, then added with
diisopropylethylamine (1.83 ml, 10.5 mmol), and further heated at
100.degree. C. for 3 hours and 30 minutes with stirring. After
cooling, the solution was added with saturated aqueous sodium
hydrogencarbonate and extracted with chloroform. The organic layer
was washed with saturated brine and dried over anhydrous sodium
sulfate and the solvent was evaporated. The residue was purified by
silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=50:1.fwdarw.20:1, v/v) and
preparative TLC (chloroform:methanol=20:1, v/v) to obtain the title
compound (85.9 mg, 20.3%) as yellow orange oil.
[0505] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (9H, s), 1.42-1.62
(1H, m), 1.70-2.08 (3H, m), 2.57-3.20 (3H, m), 2.99 (3H, s), 3.12
(3H, s), 4.03-4.90 (2H, m), 5.69 (1H, s), 6.60 (1H, s), 7.36-7.22
(1H, m), 7.89 (1H, s), 8.97 (1H, d, J=7.3 Hz)
[0506] LC-MS; m/z: 483 (MH.sup.+)
(B)
N.sup.8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-{3-[(dimethylamino)carbony-
l]piperidino}-3-formyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
[0507] Dimethylformamide (2 ml) was added dropwise with phosphorus
oxychloride (24.9 .mu.l, 0.27 mmol) under ice cooling, and stirred
at room temperature for 30 minutes. The reaction solution was
cooled with ice again, added dropwise with a solution of the
N.sup.8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-{3-[(dimethylamino)carbonyl]--
piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (85.9
mg, 0.18 mmol) obtained in (A) in dimethylformamide (2 ml) and
stirred at the same temperature for 2 hours. The reaction solution
was added with saturated aqueous sodium hydrogencarbonate and
extracted with chloroform. The organic layer was washed with
saturated brine and dried over anhydrous sodium sulfate, and the
solvent was evaporated to obtain the title compound (84.2 mg,
quantitative) as yellow oil.
[0508] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.34 (9H, s), 1.57-2.10
(4H, m), 2.89 (3H, s), 2.97 (3H, s), 3.00-3.28 (3H, m), 4.10-4.45
(2H, m), 6.59 (1H, s), 7.35-7.45 (1H, m), 7.82 (1H, s), 8.95 (1H,
s), 8.86 (1H, d, J=7.3 Hz), 10.12 (1H, s)
[0509] ESI/MS; m/z: 511 (MH.sup.+)
(C) Methyl
(E)-3-(8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-{-
3-[(dimethyl-amino)carbonyl]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3--
yl)-2-propenoate
[0510] The
N.sup.8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-{3-[(dimethylamino)carbonyl]--
piperidino}-3-formyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
(84.2 mg, 0.18 mmol) obtained in (B) was dissolved in
tetrahydrofuran (10 ml), added with lithium chloride (45.3 mg, 1.07
mmol), and added dropwise with
bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl)phosphonate (112.9
.mu.l, 0.53 mmol) and 1,8-diazabicyclo-[5,4,0]undec-7-ene (73.4
.mu.l, 0.53 mmol). After the reaction solution was stirred at room
temperature for 2 hours, the solvent was evaporated, and the
residue was purified by preparative TLC (chloroform:methanol=20:1,
v/v) to obtain the title compound (63.7 mg, 68.2%) as a mixture of
orange oil and solid.
[0511] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (9H, s), 1.56-1.70
(1H, m), 1.70-2.00 (3H, m), 2.92-3.20 (3H, m), 2.99 (3H, s), 3.19
(3H, s), 3.78 (3H, s), 3.97-4.03 (1H, m), 4.22-4.30 (1H, m), 6.60
(1H, s), 7.10 (1H, d, J=15.6 Hz), 7.45 (1H, dd, J=7.3, 1.7 Hz),
7.49 (1H, d, J=15.6 Hz), 7.85 (1H, d, J=1.7 Hz), 8.96 (1H, d, J=7.3
Hz)
(D)
(E)-3-(8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-{3-[(dim-
ethylamino)-carbonyl]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-p-
ropenoic acid
[0512] The methyl
(E)-3-(8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-{3-[(dimeth-
ylamino)carbonyl]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-prope-
noate (63.7 mg, 0.11 mmol) obtained in (C) was dissolved in
methanol (10 ml), added dropwise with 1 N aqueous sodium hydroxide
(562.0 .mu.l, 0.56 mmol), and stirred at room temperature for 1
hour. The reaction solution was further added with 1 N aqueous
sodium hydroxide (5.62 ml, 5.62 mmol), stirred at room temperature
for 2 hours, further added with 1 N aqueous sodium hydroxide (2.81
ml, 2.81 mmol), and stirred at room temperature for 3 hours. The
reaction solution was adjusted to about pH 2 with 1 N hydrochloric
acid aqueous solution and extracted with chloroform/methanol (10:1,
v/v). The organic layer was washed with saturated brine and dried
over anhydrous sodium sulfate, and the solvent was evaporated. The
residue was purified by preparative TLC (chloroform:methanol=20:1,
v/v) and lyophilized from dioxane to obtain the title compound
(37.6 mg, 38.5%, for the three steps) as yellow orange powder.
[0513] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.31 (9H, s), 1.60-1.80
(3H, m), 1.85-1.94 (1H, m), 2.84 (3H, s), 2.97-3.05 (1H, m), 3.12
(3H, s), 3.30-3.45 (2H, m), 3.95-4.03 (1H, m), 4.08-4.15 (1H, m),
6.82-6.95 (1H, m), 6.93 (1H, d, J=15.6 Hz), 7.44 (1H, d, J=15.6
Hz), 7.60-7.67 (1H, m), 8.12-8.18 (1H, m), 8.90 (1H, d, J=7.3
Hz)
[0514] FAB/MS; m/z: 553 (MH.sup.+)
[0515] H-R FAB/MS: Calcd. for C.sub.27H.sub.32N.sub.6O.sub.5S:
553.2233, Found: 553.2236
Example 59
(E)-3-[8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-4-oxo-2-piperi-
dino-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoic acid
[0516] The title compound was synthesized in the same manner as in
Example 58.
[0517] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.31 (9H, s), 1.62-1.72
(6H, m), 3.53-3.62 (4H, m), 6.82-6.92 (1H, m), 6.93 (1H, d, J=15.6
Hz), 7.45 (1H, d, J=15.6 Hz), 7.57-7.62 (1H, m), 8.14-8.20 (1H, m),
8.89 (1H, d, J=7.3 Hz)
[0518] FAB/MS; m/z: 482 (MH.sup.+)
[0519] H-R FAB/MS: Calcd. for C.sub.24H.sub.27N.sub.5O.sub.4S:
482.1862, Found: 482.1844
Example 60
(E)-3-(8-({[4-(tert-Butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-{3-[(methyla-
mino)carbonyl]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-propenoi-
c acid
[0520] The title compound was synthesized in the same manner as in
Example 58.
[0521] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.31 (9H, s), 1.58-1.80
(3H, m), 1.89-1.97 (1H, m), 2.59 (3H, d, J=4.4 Hz), 3.18-3.20 (2H,
m), 3.30-3.42 (2H, m), 3.90-3.97 (1H, m), 4.11-4.18 (1H, m),
6.79-6.89 (1H, m), 6.93 (1H, d, J=15.6 Hz), 7.43 (1H, d, J=15.6
Hz), 7.60-7.66 (1H, m), 7.77-7.83 (1H, m), 8.19-8.26 (1H, m), 8.90
(1H, d, J=7.6 Hz)
[0522] FAB/MS; m/z: 539 (MH.sup.+)
[0523] H-R FAB/MS: Calcd. for C.sub.26H.sub.30N.sub.6O.sub.5S:
539.2077, Found: 539.2112
Example 61
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyr-
ido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A)
2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]py-
rimidin-4-one
[0524] 2-Amino-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridine
(9.8 g) and bis(2,4,6-trichlorophenyl) malonate (18 g) were
refluxed by heating in xylene for 30 minutes and left stand for
cooling. The reaction mixture was added with ether, and the
deposited crystals were collected by filtration, washed with ethyl
acetate and dried to obtain the title compound (10.3 g). The
reaction solution was combined and the solvent was evaporated. The
residue was purified by silica gel column chromatography to further
obtain the title compound (1.5 g).
[0525] .sup.1H-NMR (CDCl.sub.3): 1.29 (6H, d, J=6.8 Hz), 3.06 (1H,
m), 3.34 (2H, m), 3.38 (2H, m), 5.34 (1H, s), 6.74 (1H, s), 7.10
(1H, dd, J=7.1,1.7 Hz), 7.37 (1H, s), 9.02 (1H, d, J=7.1 Hz)
(B)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-a-
]pyrimidin-4-one
[0526] The
2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]-pyri-
midin-4-one (500 mg) obtained in (A) was dissolved in methylene
chloride (20 ml), added with triethylamine (0.26 ml) and
p-toluenesulfonyl chloride (360 mg) and stirred for 24 hours under
nitrogen atmosphere. The reaction solution was added with
morpholine (0.83 ml) and stirred for 12 hours, and the solvent was
evaporated. The residue was purified by silica gel column
chromatography to obtain the title compound (273 mg).
[0527] .sup.1H-NMR (CDCl.sub.3): 1.30 (s, 3H), 1.33 (s, 3H), 3.07
(m, 1H), 3.18 (m, 2H), 3.48 (m, 2H), 3.67 (m, 4H), 3.79 (m, 4H),
5.59 (s, 1H), 6.77 (s, 1H), 6.78 (d, 1H), 7.11 (s, 1H), 8.80 (d,
1H)
(C)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido-
[1,2-a]-pyrimidine-3-carbaldehyde
[0528] Dimethylformamide (10 ml) was added with phosphorus
oxychloride (0.60 ml) under ice cooling, stirred for 30 minutes,
then added with the
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-a]py-
rimidin-4-one (1.0 g) obtained in (B), stirred for 1 hour, and
added with saturated aqueous sodium hydrogencarbonate to adjust the
reaction solution to pH of about 8. The reaction solution was
extracted with ethyl acetate, and the organic layer was washed with
saturated brine and dried over sodium sulfate. The solvent was
evaporated under reduced pressure to obtain the title compound
(1.07 g).
[0529] .sup.1H-NMR (CDCl.sub.3): 1.31 (s, 3H), 1.33 (s, 3H), 3.10
(m, 1H), 3.22 (m, 2H), 3.42 (m, 2H), 3.73 (m, 4H), 3.81 (m, 4H),
6.80 (s, 1H), 6.82 (d, 1H), 7.09 (s, 1H), 8.75 (d, 1H), 10.11 (s,
1H)
(D) tert-Butyl
(E)-3-(8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]pyrimidin-3-yl)-2-propenoate
[0530] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,-
2-a]pyrimidine-3-carbaldehyde (110 mg) obtained in (C) and
(tert-butoxy-carbonylmethylene)triphenylphosphorane (441 mg) were
stirred in tetrahydrofuran (5 ml) at 80.degree. C. for 15 hours.
After the solvent was evaporated, the residue was purified by
silica gel column chromatography to obtain the title compound (150
mg) as yellow powder.
[0531] .sup.1H-NMR (CDCl.sub.3): 1.29 (6H, d, J=6.8 Hz), 1.51 (9H,
s), 3.05 (1H, m), 3.20 (2H, m), 3.37 (2H, m), 3.60 (4H, m), 3.83
(4H, m), 6.73 (1H, s), 6.85 (1H, d, J=6.8 Hz), 7.05 (1H, d, J=15.4
Hz), 7.20 (1H, s), 7.50 (1H, d, J=15.4 Hz), 8.87 (1H, d, J=7.1
Hz)
(E)
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-
-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0532] The tert-butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-propenoate (39 mg) obtained in (D) was
stirred in formic acid (1 ml) for 4.5 hours, and the solvent was
evaporated under reduced pressure to obtain the title compound (30
mg).
[0533] .sup.1H-NMR (CD.sub.3OD): 1.26 (6H, d, J=6.8 Hz), 3.03 (1H,
m), 3.20 (2H, m), 3.31 (2H, m), 3.56 (4H, m), 3.79 (4H, m), 6.94
(1H, d, J=15.6 Hz), 6.96 (1H, s), 7.05 (1H, d, J=6.6 Hz), 7.21 (1H,
s), 7.55 (1H, d, J=15.6 Hz), 8.76 (1H, d, J=7.1 Hz)
[0534] The compounds of Examples 62 to 77 mentioned below were
synthesized in the same manner as in Example 61.
Example 62
(E)-3-(2-Morpholino-4-oxo-8-{2-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-ethy-
l}-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-propenoic acid
[0535] .sup.1H-NMR (CD.sub.3OD) .delta.: 3.26 (m, 2H), 3.50 (m,
2H), 3.61 (m, 4H), 3.81 (m, 4H), 6.68 (d, J=15.6 Hz, 1H), 7.12 (d,
1H), 7.32 (s, 1H), 7.62 (d, J=16 Hz, 1H), 8.03 (s, 1H), 8.84 (d,
1H)
[0536] MS (ES+) m/z 481 (M.sup.++1)
Example 63
(E)-3-{8-[2-(4-tert-Butyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0537] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.31 (s, 9H), 3.19 (t,
2H), 3.35 (t, 2H), 3.59 (m, 4H), 3.79 (m, 4H), 6.72 (s, 1H), 6.85
(d, 1H), 7.07 (d, J=16 Hz, 1H), 7.18 (s, 1H), 7.62 (d, J=16 Hz,
1H), 8.84 (d, 1H)
[0538] MS (ES+) m/z 469 (M.sup.++1); MS (ES-) m/z 467
(M.sup.+-1)
Example 64
(E)-3-{8-(2-[4-(1-Methylcyclopropyl)-1,3-thiazol-2-yl]ethyl)-2-morpholino--
4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0539] .sup.1H-NMR (CD.sub.3OD) .delta.:0.70 (m, 2H), 1.03 (m, 2H),
1.41 (s, 3H), 3.18 (t, 2H), 3.37 (t, 2H), 3.59 (m, 4H), 3.80 (m,
4H), 6.92 (s, 1H), 6.98 (d, J=16 Hz, 1H), 7.08 (s, 1H), 7.25 (s,
1H), 7.60 (d, J=16 Hz, 1H), 8.82 (d, 1H)
[0540] MS (ES+) m/z 467 (M.sup.++1); MS (ES-) m/z 465
(M.sup.+-1)
Example 65
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-carboxypiperidino)-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0541] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.26 (d, 6H), 2.38 (m,
1H), 2.55 (m, 1H), 2.67 (m, 1H), 2.82 (m, 1H), 3.08 (m, 1H), 3.12
(m, 2H), 3.39 (m, 3H), 3.56 (m, 2H), 3.82 (m, 2H), 3.92 (m, 1H),
6.75 (s, 1H), 6.84 (d, 1H), 7.07 (d, J=14 Hz, 1H), 7.21 (s, 1H),
7.33 (s, 1H), 7.20 (s, 1H), 7.65 (m, 2H), 8.82 (d, 1H)
[0542] MS (ES+) m/z 497 (M.sup.++1); MS (ES-) m/z 495
(M.sup.+-1)
Example 66
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(4-carboxypiperidino)-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0543] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (d, 6H), 2.00 (m,
2H), 2.13 (m, 2H), 2.62 (m, 1H), 3.10 (m, 3H), 3.20 (m, 2H), 3.39
(m, 2H), 4.08 (m, 2H), 6.75 (s, 1H), 6.83 (d, 1H), 7.08 (d, J=15.6
Hz, 1H), 7.22 (s, 1H), 7.69 (d, J=15.6 Hz, 1H), 8.86 (d, 1H)
[0544] MS (ES+) m/z 497 (M.sup.++1); MS (ES-) m/z 495
(M.sup.+-1)
Example 67
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(1,2,3,4-tetrahyd-
ro-2-isoquinolinyl)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0545] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (d, 6H), 2.95 (m,
1H), 3.12 (m, 2H), 3.23 (m, 2H), 3.56 (t, 2H), 3.88 (t, 2H), 4.81
(s, 2H), 6.88 (m, 2H), 7.11 (d, J=15 Hz, 1H), 7.19 (m, 6H), 7.79
(d, J=15 Hz, 1H), 8.86 (d, 1H)
[0546] MS (ES+) m/z 501 (M.sup.++1)
Example 68
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-hydroxy-3-meth-
ylpiperidino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0547] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.12 (s, 3H), 1.23 (d,
6H), 1.65 (m, 2H), 1.97 (m, 1H), 3.08 (m, 1H), 3.2 (m, 3H), 3.39
(m, 4H), 3.68 (m, 2H), 6.95 (d, J=14 Hz, 1H), 6.98 (s, 1H), 7.02
(d, 1H), 7.21 (s, 1H), 7.62 (d, J=14 Hz, 1H), 8.78 (d, 1H)
[0548] MS (ES+) m/z 483 (M.sup.++1); MS (ES-) m/z 481
(M.sup.+-1)
Example 69
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-cyano-piperidi-
no)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0549] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.30 (d, 6H), 1.65 (m,
1H), 1.90 (m, 2H), 2.00 (m, 1H), 2.98 (m, 1H), 3.08 (m, 1H), 3.22
(m, 2H), 3.40 (m, 2H), 3.52 (m, 1H), 3.65 (m, 1H), 3.83 (m, 1H),
4.18 (m, 1H), 6.75 (s, 1H), 6.92 (d, 1H), 7.11 (d, J=15.6 Hz, 1H),
7.25 (s, with CDCl.sub.3, 1H), 7.63 (d, J=15.6 Hz, 1H), 8.88 (d,
1H)
[0550] MS (ES+) m/z 478 (M.sup.++1); MS (ES-) m/z 476
(M.sup.+-1)
Example 70
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-cyano-piperidi-
no)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0551] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (d, 6H), 2.04 (m,
4H), 2.95 (m, 1H), 3.21 (m, 3H), 3.55 (m, 4H), 3.79 (m, 2H), 6.92
(m, 2H), 7.08 (d, J=15.6 Hz, 1H), 7.26 (1Hs, with CHCl.sub.3, 1H),
7.62 (d, J=15.6 Hz, 1H), 8.89 (d, 1H)
[0552] MS (ES+) m/z 478 (M.sup.++1)
Example 71
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-cyano-morpholi-
no)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0553] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (d, 6H), 3.05 (m,
1H), 3.22 (t, 2H), 3.40 (t, 2H), 3.46 (m, 1H), 3.7-4.0 (m, 4H),
4.08 (m, 1H), 4.72 (m, 1H), 6.74 (s, 1H), 6.97 (d, 1H), 7.14 (d,
J=15.6 Hz, 1H), 7.28 (s, 1H), 7.67 (d, J=15.6 Hz, 1H), 8.90 (d,
1H)
[0554] MS (ES+) m/z 480 (M.sup.++1); MS (ES-) m/z 478
(M.sup.+-1)
Example 72
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-aminocarbonyl-pipera-
zino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0555] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.25 (d, 6H), 3.02 (m,
1H), 3.2-3.4 (m, with CHD.sub.2OD), 4.24 (m, 1H), 6.96 (s, 1H),
7.04 (d, J=16 Hz, 1H), 7.14 (m, 1H), 7.37 (s, 1H), 7.58 (d, J=16
Hz, 1H), 8.84 (d, 1H)
[0556] MS (ES+) m/z 497 (M.sup.++1)
Example 73
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-carboxypiperazino)-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0557] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.23 (d, 6H), 3.02 (m,
1H), 3.15-3.42 (m, with CHD.sub.2OD), 3.62 (m, 1H), 3.95 (m, 1H),
4.75 (m, 1H), 6.96 (s, 1H), 7.05 (m, 2H), 7.37 (m, 2H), 8.82 (d,
1H)
[0558] MS (ES+) m/z 520 (M.sup.++Na); MS (ES-) m/z 496
(M.sup.+-1)
Example 74
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-cyanopiperazino)-4-o-
xo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0559] .sup.1H-NMR (300 MHz, CD.sub.3OD) .delta.: 1.23 (d, 6H),
3.02 (m, 1H), 3.15-3.42 (m, with CHD.sub.2OD), 3.71 (m, 1H), 3.92
(m, 1H), 4.12 (m, 1H), 6.81 (s, 1H), 7.00 (m, 2H), 7.25 (m, 1H),
7.52 (d, J=16 Hz, 1H), 8.82 (d, 1H)
Example 75
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-carboxymorpholino)-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0560] .sup.1H-NMR (CDCl.sub.3+CD.sub.3OD) .delta.: 1.22 (d, 6H),
3.0 (m, 1H), 3.14 (t, 2H), 3.31 (m, 4H), 3.73 (m, 2H), 4.02 (m,
1H), 4.12 (m, 2H), 6.70 (s, 1H), 6.88 (d, 1H), 6.97 (d, J=15.6 Hz,
1H), 7.21 (s, 1H), 7.53 (d, J=15.6 Hz, 1H), 8.78 (d, 1H).
[0561] MS (ES+) m/z 499 (M.sup.++1)
Example 76
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-aminocarbonyl-morpho-
lino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0562] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.30 (d, 6H), 3.0-3.2 (m,
5H), 3.47 (m, 2H), 3.81 (m, 2H), 4.02 (m, 1H), 4.21 (m, 1H), 4.42
(m, 1H), 6.82 (s, 1H), 6.92 (d, 1H), 7.08 (d, J=15.6 Hz, 1H), 7.26
(s, with CHCl.sub.3, 1H), 7.64 (d, J=15.6 Hz, 1H), 8.87 (d, 1H)
[0563] MS (ES+) m/z 498 (M.sup.++1); MS (ES-) m/z 496
(M.sup.+-1)
Example 77
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl-4-oxo-2-([(2S,3
R,4R,5 S,6
S)-3,4,5,6-tetrahydroxytetrahydro-2H-2-pyranyl]methylamino)-4H-pyrido[1,2-
-a]-pyrimidin-3-yl}-2-propenoic acid
[0564] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.23 (d, 6H), 3.02 (m,
1H), 3.18 (m, 2H), 3.4 (m, 3H), 3.75 (m, 1H), 3.98 (m, 1H), 4.5
& 5.12 (2 doublets, mixture of anomers, 1H), 6.98 (s, 1H), 7.02
(m, 2H), 7.18 (s, 1H), 7.73 (d, J=16 Hz, 1H), 8.75 (d, 1H)
[0565] MS (ES+) m/z 547 (M.sup.++1); MS (ES-) m/z 545
(M.sup.+-1)
Example 78
(E)-3-{2-[4-((2S)-2-Amino-5-{[amino(imino)methyl]amino}pentanoyl)-piperazi-
no]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-
-a]-pyrimidin-3-yl}-2-propenoic acid
[0566] tert-Butyl
(E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-2-piperaz-
ino-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (10 mg, 0.0197
mmol) and N-.alpha., .omega.-1,
.omega.-2-tri-tert-butoxycarbonyl-L-arginine (BOC-Arg,
(BOC).sub.2OH, 14 mg, 0.0295 mmol) were added with methylene
chloride (1 ml). The mixture was further added with
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC
HCl, 11 mg, 0.0591 mmol) and stirred at room temperature overnight.
The reaction solution was diluted with methylene chloride, washed
with 5% aqueous citric acid, saturated aqueous sodium
hydrogencarbonate and saturated brine, and dried over sodium
sulfate. The solvent was evaporated under reduced pressure, and
then the residue was added with trifluoroacetic acid (1 ml) and
stirred in the dark for 1 hour. The reaction solution was added
with toluene, and the solvent was evaporated under reduced
pressure. The residue was purified by medium pressure column
chromatography (Amberkron column, gradient 100% 0.1% TFA in
H.sub.2O to 100% CH.sub.3CN over 80 minutes, 3 ml/minute) to obtain
the title compound (7.0 mg).
[0567] .sup.1H-NMR (CD.sub.3OD): 1.34 (d, 6H), 1.70 (m, 2H), 1.90
(m, 2H), 3.10 (m, 1H), 3.70 (m, 8H), 3.92 (m, 1H), 4.54 (t, 1H),
7.08 (d, 1H), 7.28 (s, 1H), 7.52 (d, 1H), 7.55 (m, 2H), 7.66 (d,
1H), 7.72 (d, 1H), 8.93 (d, 1H)
[0568] MS (ES+): 631 (M+Na)
[0569] The compounds of Examples 79 to 91 mentioned below were
synthesized in the same manner as in Example 78.
Example 79
(E)-3-{2-[4-((2S)-2-Amino-5-[[amino(imino)methyl]amino)pentanoyl)-piperazi-
no]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-p-
yrimidin-3-yl}-2-propenoic acid
[0570] .sup.1H-NMR (CD.sub.3OD): 1.26 (d, 6H), 1.70 (m, 2H), 1.90
(m, 2H), 3.03 (m, 1H), 3.20-3.42 (m, 7H), 3.50-3.80 (m, 8H), 3.90
(m, 1H), 4.53 (t, 1H), 6.98 (s, 1H), 7.05 (d, 1H), 7.15 (d, 1H),
7.30 (s, 1H), 7.64 (d, 1H), 8.87 (d, 1H)
[0571] MS (ES+): 610
Example 80
(E)-3-{2-[4-((2S)-2-Amino-5-{[amino(imino)methyl]amino}pentanoyl)-piperazi-
no]-8-[(E)-2-(4-tert-butyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]--
pyrimidin-3-yl}-2-propenoic acid
[0572] .sup.1H-NMR (CD.sub.3OD): 1.29 (s, 9H), 1.69 (m, 2H), 1.88
(m, 2H), 3.10-3.50 (m, 5H), 3.50-3.80 (m, 10H), 3.90 (m, 2H), 4.53
(m, 1H), 6.96 (s, 1H), 7.05 (d, 1H), 7.16 (d, 1H), 7.30 (s, 1H),
7.65 (d, 1H), 8.88 (d, 1H)
[0573] MS (ES+): 624
Example 81
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-dimethylamino--
ethylaminocarbonylpiperidino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0574] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H), 1.80
(m, 4H), 2.05 (m, 1H), 2.65 (m, 1H), 2.94 (s, 6H), 3.05 (m, 2H),
3.15-3.25 (m, 4H), 3.42 (t, 2H), 3.58 (t, 2H), 4.10 (m, 2H), 6.98
(d, J=15.6 Hz, 1H), 7.03 (s, 1H), 7.06 (dd, 1H), 7.23 (s, 1H), 7.58
(d, J=15.6 Hz, 1H), 8.80 (d, 1H)
[0575] MS (ES+) m/z 567 (M.sup.++1)
Example 82
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-dimethylamino--
ethylaminocarbonylpiperidino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0576] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H), 1.88
(m,4H), 2.53 (m, 1H), 2.94 (s,6H), 3.02 (m, 1H), 3.0-3.25 (m, 6H),
3.41 (t, 2H), 3.55 (t, 2H), 4.15 (m, 2H), 6.97 (m, 2H), 7.04 (dd,
1H), 7.22 (s, 1H), 7.60 (d, J=15.6 Hz, 1H), 8.80 (d, 1H)
[0577] MS (ES+) m/z 567 (M.sup.++1)
Example 83
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-dimethylamino--
acetylpiperazino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0578] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.23 (d, 6H), 2.95 (s,
6H), 3.02 (m, 1H), 3.2-3.35 (m, with CHD.sub.2OD), 3.42 (m, 1H),
3.58 (m, 1H), 3.63 (m, 2H), 3.80 (m, 1H), 4.28 (s, 2H), 6.96 (s,
1H), 7.05 (d, J=13 Hz, 1H), 7.14 (d, 1H), 7.29 (s, 1H), 7.62 (d,
J=13 Hz, 1H), 8.85 (d, 1H)
Example 84
(E)-3-{8-[2-(4(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(aminoethyl-thi-
oethylamino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0579] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26(d, J=7 Hz, 6H), 2.85
(m, 4H), 3.02 (m, 1H), 3.2 (m, 4H), 3.40 (t, 2H), 3.78 (t, 2H),
6.99 (m, 2H), 7.11 (d, J=15.6 Hz, 1H), 7.15 (s, 1H), 7.73 (d,
J=15.6 Hz, 1H), 8.78 (d, 1H)
[0580] MS (ES+) m/z 488 (M.sup.++1)
Example 85
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-aminopropyl-am-
inocarbonylpiperidino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0581] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H), 1.84
(m, 3H), 2.06 (m, 1H), 2.68 (m, 1H), 2.93 (m, 2H), 3.02 (m, 2H),
3.2-3.3 (m, with CD.sub.3OD), 3.42 (m, 3H), 4.08 (m, 2H), 6.9-7.02
(m, 2H), 7.07 (dd, 1H), 7.25 (s, 1H), 7.58 (d, J=15.6 Hz, 1H), 8.81
(d, 1H)
[0582] MS (ES+) m/z 553 (M.sup.++1)
Example 86
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-aminoethyl-ami-
nocarbonylpiperidino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0583] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H), 1.79
(m, 3H), 2.06 (m, 1H), 2.68 (m, 1H), 3.0-3.1 (m, 4H), 3.15-3.28 (m,
3H), 3.45 (m, 4H), 4.1 (m, 2H), 6.97 (d, J=15.6 Hz, 1H), 7.06 (m,
2H), 7.25 (s, 1H), 7.58 (d, J=15.6 Hz, 1H), 8.79 (d, 1H)
[0584] MS (ES+) m/z 539 (M.sup.++1)
Example 87
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-[(tetrahydro-1-
H-2-pyrrolylmethyl)amino]carbonylpiperidino)-4H-pyrido[1,2-a]pyrimidin-3-y-
l}-2-propenoic acid
[0585] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H), 1.79
(m, 4H), 2.04 (m, 4H), 2.68 (m, 1H), 2.9-3.1 (m, 2H), 3.15-3.35 (m,
with CD.sub.3OD), 3.35-3.55 (m, 4H), 3.68 (m, 1H), 4.1 (m, 2H),
6.99 (m, 2H), 7.08 (d, 1H), 7.25 (s, 1H), 7.59 (d, J=15.6 Hz, 1H),
8.81 (d, 1H)
[0586] MS (ES+) m/z 579 (M.sup.++1)
Example 88
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-aminomethyl-ca-
rbonylpiperazino)-4H-pyrido[1,2-alpyrimidin-3-yl}-2-propenoic
acid
[0587] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H), 3.02
(m, 1H), 3.23 (t, 2H), 3.42 (t, 2H), 3.62 (m, 6H), 3.78 (m, 2H),
3.99 (s, 2H), 6.98 (s, 1H), 7.02 (d, J=15.6 Hz, 1H), 7.13 (d, 1H),
7.27 (s, 1H), 7.63 (d, J=15.6 Hz, 1H), 8.84 (d, 1H)
[0588] MS (ES+) m/z 511 (M.sup.++1)
Example 89
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-prolyl-piperaz-
ino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0589] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H),
1.9-2.1 (m, 3H), 2.52 (m, 1H), 3.02 (m, 1H), 3.25 (t, 2H), 3.42 (t,
2H), 3.5-3.9 (m, 10H), 4.68 (m, 1H), 6.97 (s, 1H), 7.03 (d, J=15.6
Hz, 1H), 7.14 (d, 1H), 7.28 (s, 1H), 7.63 (d, J=15.6 Hz, 1H), 8.83
(d, 1H, d)
[0590] MS (ES+) m/z 551 (M.sup.++1)
Example 90
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-lysyl-piperazi-
no)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0591] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H), 1.51
(m, 2H), 1.72 (m, 2H), 1.90 (m, 2H), 2.95 (m, 2H), 3.02 (m, 1H),
3.25 (t, 2H), 3.42 (t, 2H), 3.5-3.8 (m, 7H), 3.95 (m, 1H), 4.50 (m,
1H), 6.98 (s, 1H), 7.04 (d, J=15.6 Hz, 1H), 7.14 (d, 1H), 7.28 (s,
1H), 7.64 (d, J=15.6 Hz, 1H), 8.85 (d, 1H)
[0592] MS (ES+) m/z 582 (M.sup.++1)
Example 91
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-ornithyl-piper-
azino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0593] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (d, J=7 Hz, 6H), 1.80
(m, 2H), 1.92 (m, 2H), 2.99 (m, 3H), 3.22 (t, 2H), 3.42 (t, 2H),
3.5-3.8 (m, 7H), 3.94 (m, 1H), 4.58 (m, 1H), 6.99 (s, 1H), 7.04 (d,
J=15.6 Hz, 1H), 7.14 (d, 1H), 7.28 (s, 1H), 7.64 (d, J=15.6 Hz,
1H), 8.85 (d, 1H)
[0594] MS (ES+) m/z 568 (M.sup.++1)
Example 92
(E)-3-{2-(4-[2-(4-Aza-1-azoniabicyclo[2.2.2]oct-1-yl)acetyl]piperazino)-8--
[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3--
yl}-2-propenoic acid
(A) tert-Butyl
(E)-3-{2-[4-(2-chloroacetyl)piperazino]-8-[2-(4-isopropyl-1,3-thiazol-2-y-
l)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0595] tert-Butyl
(E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-piperazino-4-
H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (206 mg, 0.405 mmol)
was dissolved in methylene chloride (8 ml), added with
triethylamine (170 ml) and chloroacetyl chloride (64 ml) at
-78.degree. C., and then stirred overnight at room temperature in
the dark. The reaction solution was diluted with methylene
chloride, washed with water, 5% aqueous citric acid, saturated
aqueous sodium hydrogencarbonate and then with saturated brine, and
the solution was dried over magnesium sulfate. Then, the solvent
was evaporated under reduced pressure. The residue was purified by
silica gel column chromatography to obtain the title compound (260
mg).
[0596] .sup.1H-NMR (CDCl.sub.3): 1.28 (d, 6H), 1.51 (s, 9H), 3.06
(m, 1H), 3.21 (m, 2H), 3.37 (m, 2H), 3.62 (brm, 6H), 3.78 (brm,
2H), 4.10 (s, 2H), 6.72 (s, 1H), 6.89 (d, 1H), 7.07 (d, 1H), 7.24
(d, 1H), 7.49 (d, 1H), 8.88 (d, 1H)
(B) tert-Butyl
(E)-3-{2-[4-(2-iodoacetyl)piperazino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-
-ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0597] The tert-butyl
(E)-3-{2-[4-(2-chloroacetyl)piperazino]-8-[2-(4-isopropyl-1,3-thiazol-2-y-
l)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (240
mg, 0.405 mmol) obtained in (A) and NaI (300 mg, 2.03 mmol) were
refluxed by heating in acetone (8 ml) for 3 hours in the dark. The
reaction solution was cooled, then diluted with methylene chloride,
washed with water and saturated brine, and dried over sodium
sulfate. Then, the solvent was evaporated under reduced pressure to
obtain the title compound (226 mg) as a yellow amorphous
substance.
[0598] .sup.1H-NMR (CDCl.sub.3): 1.28 (d, 6H), 1.52 (s, 9H), 3.10
(m, 1H), 3.22 (m, 2H), 3.38 (m, 2H), 3.60 (m, 4H), 3.79 (s, 2H),
6.73 (s, 1H), 6.90 (d, 1H), 7.08 (d, 1H), 7.50 (d, 1H), 8.88 (d,
1H)
(C)
(E)-3-{2-(4-[2-(4-Aza-1-azoniabicyclo[2.2.2]oct-1-yl)acetyl]piperazino-
)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidi-
n-3-yl}-2-propenoic acid
[0599] The tert-butyl
(E)-3-{2-[4-(2-iodoacetyl)piperazino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-
ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (226 mg,
0.33 mmol) obtained in (B) and 1,4-diazabicyclo[2.2.2]octane (187
mg, 1.67 mmol) were stirred overnight in tetrahydrofuran (9 ml)
under nitrogen atmosphere, then the solvent was evaporated, and the
residue was stirred in trifluoroacetic acid (TFA, 4 ml) for 1 hour.
The solvent was evaporated under reduced pressure, and the residue
was purified by medium pressure reverse phase chromatography
(Amberkron column, gradient 100% 0.1% TFA in H.sub.2O to 100%
CH.sub.3CN over 80 minutes, 3 ml/minute) to obtain the title
compound (150 mg, 75%, for the two steps).
[0600] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.27 (d, 6H), 3.02 (m,
1H), 3.26 (t, 2H), 3.43 (t, 2H), 3.62 (m, 5H), 3.78 (m, 6H), 4.43
(s, 2H), 7.00 (s, 1H), 7.02 (d, J=15.6 Hz, 1H), 7.13 (d, J=7 Hz,
1H), 7.29 (s, 1H), 7.63 (d, J=15.6 Hz, 1H), 8.85 (d, J=7 Hz,
1H)
[0601] MS (ES+) m/z 606 (M.sup.++1)
[0602] The compounds of Examples 93 to 97 mentioned below were
synthesized in the same manner as in Example 92.
Example 93
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(4-[2-(1-methyl-1H-imid-
azol-3-ium-3-yl)acetyl]piperazino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-
-propenoic acid
[0603] .sup.1H-NMR (CDCl.sub.3+CD.sub.3OD) .delta.: 1.23 (d, J=7
Hz, 6H), 3.02 (m, 1H), 3.17 (t, 2H), 3.34 (t, 2H), 3.57 (m, 2H),
3.6-3.8 (m, 6H), 3.92 (s, 3H), 5.40 (s, 2H), 6.72 (s, 1H), 6.88 (d,
J=7.2 Hz, 1H), 7.00 (d, J=15.6 Hz, 1H), 7.20 (m, 2H), 7.37 (s, 1H),
7.55 (d, J=15.6 Hz, 1H), 8.81 (d, J=7.2 Hz, 1H), 9.24 (s, 1H)
[0604] MS (ES+) m/z 576 (M.sup.++1)
Example 94
(E)-3-{2-{4-[2-(1-Azabicyclo[2.2.2]oct-1-yl)acetyl]piperazino-8-[2-(4-isop-
ropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-prop-
enoic acid
[0605] .sup.1H-NMR (CD.sub.3OD): 1.26 (d, 6H), 2.05 (brm, 7H), 2.19
(m, 1H), 3.03 (m, 1H), 3.22 (m, 2H), 3.39 (m, 2H), 3.61 (brm, 6H),
3.67 (m, 8H), 4.26 (s, 2H), 6.97 (s, 1H), 6.99 (d, 1H), 7.12 (d,
1H), 7.28 (s, 1H), 7.62 (d, 1H), 8.86 (d, 1H)
[0606] MS (ES+): 605
Example 95
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-[2-(1-pyridini-
um)acetyl]piperazino)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0607] .sup.1H-NMR (CD.sub.3OD): 1.27 (d, 6H), 3.02 (m, 1H), 3.25
(m, 2H), 3.40 (m, 2H), 5.80 (s, 2H), 6.98 (s, 1H), 7.02 (d, 1H),
7.17 (d, 1H), 7.31 (s, 1H), 7.65 (d, 1H), 8.20 (m, 2H), 8.65 (m,
1H), 8.88 (m, 2H)
[0608] MS (ES+): 573
Example 96
(E)-3-{2-(4-[2-(1-Azabicyclo[2.2.2]oct-1-yl)butanoyl]piperazino)-8-[2-(4-i-
sopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-p-
ropenoic acid
[0609] .sup.1H-NMR (CD.sub.3OD): 1.25 (d, 6H), 2.07 (m, 1H), 2.58
(m, 1H), 3.02 (m, 1H), 3.20-3.80 (m, 24H), 6.99 (s, 1H), 7.02 (d,
1H), 7.12 (d, 1H), 7.28 (s, 1H), 7.64 (d, 1H), 8.86 (d, 1H)
Example 97
(E)-3-{2-(4-[2-(4-Aza-1-azoniabicyclo[2.2.2]oct-1-yl)acetyl]piperazino-8-(-
2-[4-(tert-butyl)-1,3-thiazol-2-yl]ethyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin--
3-yl}-2-propenoic acid
[0610] .sup.1H-NMR (CD.sub.3OD): 1.29 (s, 9H), 3.20-3.41 (m, 5H),
3.50-3.79 (m, 20H), 4.39 (s, 2H), 6.96 (s, 1H), 7.02 (d, 1H), 7.13
(d, 1H), 7.29 (s, 1H), 7.64 (d, 1H), 8.86 (d, 1H)
[0611] MS (ES+): 620
Example 98
N-((E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H--
pyrido[1,2-a]pyrimidin-3-yl}-2-propenoyl)methanesulfonamide
[0612]
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-ox-
o-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid (24 mg) was
dissolved in dimethylformamide (2 ml), added with
methanesulfonamide (15 mg), dimethylaminopyridine (20 mg) and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (31
mg), and then the mixture was stirred at room temperature for 24
hours. The reaction solution was added with ethyl acetate and
hexane, washed with 0.2 M hydrochloric acid, and dried over sodium
over sodium sulfate, and the solvent was evaporated under reduced
pressure. The residue was purified by silica gel column
chromatography to obtain the title compound (14 mg) as yellow
powder.
[0613] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.21 (d, 6H), 3.02 (m,
1H), 3.15 (m, 2H), 3.19 (s, 3H), 3.36 (m, 2H), 3.53 (m, 4H), 3.70
(m, 4H), 6.78 (s, 1H), 6.86 (d, 1H), 6.92 (d, J=16 Hz, 1H), 7.17
(s, 1H), 7.53 (d, J=16 Hz, 1H), 8.67 (d, 1H)
[0614] MS (ES+) m/z 532 (M.sup.++1)
Example 99
N-((E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-
-pyrimidin-3-yl}-2-propenoyl)methanesulfonamide
[0615] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (d, 6H), 3.04 (m,
1H), 3.11 (s, 3H), 3.37 (m, 4H), 6.73 (s, 1H), 7.19 (d, J=7 Hz,
1H), 7.32 (d, J=14 Hz, 1H), 7.59 (s, 1H), 7.72 (d, J=14 Hz, 1H),
8.48 (s, 1H), 9.08 (d, J=7 Hz, 1H)
[0616] MS (ES+) m/z 447 (M.sup.++1); MS (ES-) m/z 445
(M.sup.+-1)
Example 100
N-((E)-3-[8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H--
pyrido[1,2-a]pyrimidin-3-yl]-2-propenoyl)-3-amino-1-propanesulfonamide
(A)
N-((E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-
-4H-pyrido-[1,2-a]pyrimidin-3-yl]-2-propenoyl)-3-(tert-butoxycarbonylamino-
)-1-propane-sulfonamide
[0617]
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-ox-
o-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid (53 mg) was
dissolved in dimethylformamide (2 ml), added with
3-(N-tert-butoxycarbonylamino)propanesulfonamide (55 mg) and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (67
mg), and the mixture was stirred at room temperature for 24 hours.
The reaction solution was added with ethyl acetate and hexane,
washed with 0.2 M hydrochloric acid, and dried over sodium sulfate,
and the solvent was evaporated under reduced pressure. The residue
was purified by silica gel column chromatography to obtain the
title compound (32 mg) as yellow powder.
[0618] .sup.1H-NMR (300 MHz) .delta.: 1.22 (d, J=7.2 Hz, 6H), 1.40
(s, 9H), 1.90-2.05 (m, 2H), 3.00-3.80 (m, 17H), 6.70 (s, 1H), 6.85
(d, J=7.5 Hz, 1H), 7.20 (s, 1H), 7.35 (d, J=15.4 Hz, 1H), 7.65 (d,
J=15.4 Hz, 1H), 9.00-9.10 (m, 2H)
(B)
N-((E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-
-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoyl)-3-amino-1-propanesulfonamid-
e
[0619] The
N-((E)-3-[(8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4-
H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoyl)-3-(tert-butoxycarbonylamino)-1-
-propane-sulfonamide (32 mg) obtained in (A) was dissolved in
trifluoroacetic acid (2 ml) and stirred for 40 minutes. The solvent
was evaporated under reduced pressure, and the residue was purified
by medium pressure reverse phase column chromatography to obtain
the title compound (quantitative).
[0620] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.25 (d, 6H), 2.18 (m,
2H), 3.02 (m, 1H), 3.1-3.45 (m, with CHD.sub.2OD), 3.60 (m, 4H),
3.80 (m, 4H), 6.98 (s, 1H), 7.12 (s, 1H), 7.16 (d, J=16 Hz, 1H),
7.26 (s, 1H), 7.75 (d, J=16 Hz, 1H), 8.82 (d, 1H)
[0621] MS (ES+) m/z 575 (M.sup.++1); MS (ES-) m/z 573
(M.sup.+-1)
Example 101
(E)-3-[(8-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-morpholino-4--
oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) tert-Butyl
(E)-3-[8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-{[(4-methyl-p-
henyl)sulfonyl]oxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0622]
4-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridinamine
(100 mg, 0.408 mmol) was dissolved in xylene (1.2 ml), added with
trichlorophenyl malonate (208 mg, 0.448 mmol), and then the mixture
was refluxed by heating for 1.3 hours. The reaction mixture was
added with n-hexane, and the deposited solid was collected by
filtration. Dimethylformamide (110 .mu.l) was added with phosphorus
oxychloride (190 .mu.l, 2.04 mmol) under ice cooling and stirred at
room temperature for 30 minutes. The mixture was added with the
solid dissolved in dichloromethane (3.0 ml) under ice cooling, and
stirred at room temperature for 1.5 hours. The reaction mixture was
added with saturated aqueous sodium hydrogencarbonate and extracted
with chloroform. The organic layer was dried over magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was suspended in anhydrous tetrahydrofuran (4.0 ml), added
with (tert-butoxycarbonylmethylene)triphenyl-phosphorane (460 mg,
1.22 mmol), and stirred at 80.degree. C. for 5 days. The reaction
solution was concentrated, and then the residue was purified by
silica gel column chromatography
(chloroform:methanol=100:0.fwdarw.100:10, v/v) and thin layer
chromatography (chloroform:methanol=10:1, v/v). The resulting
compound was dissolved in anhydrous tetrahydrofuran (600 .mu.l) and
dimethylformamide (600 .mu.l), added with 4-dimethylaminopyridine
(10.2 mg, 0.0831 mmol) and p-toluenesulfonyl chloride (13.4 mg,
0.0703 mmol), and stirred at room temperature for 2 hours. The
reaction mixture was added with water and extracted with
chloroform. The organic layer was dried over magnesium sulfate, and
the solvent was evaporated under reduced pressure. The residue was
purified by thin layer chromatography (n-hexane:ethyl acetate=2:1,
v/v) to obtain the title compound (9.0 mg, 3.7%).
[0623] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.37 (6H, d, J=6.8 Hz),
1.51 (9H, s), 2.48 (3H, s), 3.14-3.21 (1H, m), 7.03 (1H, s), 7.18
(1H, d, J=15.9 Hz), 7.38-7.42 (4H, m), 7.52 (1H, d, J=1.5 Hz), 7.56
(1H, d, J=16.1 Hz), 7.67 (1H, d, J=15.9 Hz), 8.05 (2H, d, J=8.3
Hz), 9.02 (1H, d, J=7.6 Hz)
(B) tert-Butyl
(E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-morpholino-4--
oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0624] The tert-butyl
(E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-{[(4-methylph-
enyl)sulfonyl]oxy}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
(9.0 mg, 0.0152 mmol) obtained in (A) was dissolved in
dimethylformamide (0.75 ml), added with morpholine (13.2 .mu.l,
0.152 mmol), and stirred overnight at room temperature. The
reaction mixture was concentrated, and then the residue was
purified by thin layer chromatography (n-hexane:ethyl acetate=1:1,
v/v) to obtain the title compound (6.7 mg, 87%).
[0625] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (6H, d, J=6.8 Hz),
1.52 (9H, s), 3.12-3.19 (1H, m), 3.62-3.64 (4H, m), 3.73-3.75 (4H,
m), 6.97 (1H, s), 7.08 (1H, d, J=15.9 Hz), 7.16 (1H, dd, J=1.5, 7.6
Hz), 7.34-7.38 (2H, m), 7.50 (2H, d, J=15.9 Hz), 8.91 (1H, d, J=7.6
Hz)
(C)
(E)-3-{8-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-morpholino-
-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0626] The tert-butyl
(E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-morpholino-4--
oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (6.7 mg, 0.0132
mmol) obtained in (B) was dissolved in 1,4-dioxane (260 .mu.l),
added with 4 N hydrochloric acid solution in 1,4-dioxane (260
.mu.l), and stirred at room temperature for 7 hours. The reaction
solution was concentrated, and the residue was purified by thin
layer chromatography (chloroform:methanol=10:1, v/v) to obtain the
title compound (4.8 mg, 81%).
[0627] .sup.1H-NMR (CDCl.sub.3+CD.sub.3OD) .delta.: 1.36 (6H, d,
J=6.8 Hz), 3.13-3.20 (1H, m), 3.67 (4H, t, J=4.4 Hz), 3.86 (4H, t,
J=4.4 Hz), 7.04 (1H, d, J=15.6 Hz), 7.07 (1H, s), 7.33 (1H, dd,
J=1.6, 7.5 Hz), 7.40 (1H, d, J=16.2 Hz), 7.47 (1H, d, J=6.6 Hz),
7.58 (1H, d, J=16.2 Hz), 7.62 (1H, d, J=15.6 Hz), 8.89 (1H, d,
J=7.5 Hz)
[0628] FAB-MS; m/z: 453 (M.sup.++1)
[0629] FAB-HRMS; Calcd. for
C.sub.23H.sub.25O.sub.4N.sub.4S+H.sup.+: 453.1597, Found:
453.1602
Example 102
(E)-3-{2-(3-Hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-e-
thenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) 4-Isopropyl-1,3-thiazole-2-carbaldehyde
[0630] (4-Isopropyl-1,3-thiazol-2-yl)methanol (5.20 g, 33.0 mmol)
was dissolved in methylene chloride (100 ml), added with pyridinium
dichromate (14.9 g, 39.7 mmol), and stirred at room temperature for
19 hours stirred. After insoluble solids were removed, the reaction
solution was evaporated, and the residue was purified by silica gel
column chromatography (chloroform) to obtain the title compound
(3.32 g, 65%).
[0631] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.37 (6H, d, J=6.8 Hz),
3.18-3.25 (1H, m), 7.34 (1H, s), 9.98 (1H, s)
(B) tert-Butyl
N-4-[2-hydroxy-2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridylcarbamate
[0632] tert-Butyl N-(4-methyl-2-pyridyl)carbamate (6.24 g, 30.0
mmol) was dissolved in anhydrous tetrahydrofuran (100 ml), added
with n-butyl lithium (1.59 M in n-hexane, 47.1 ml, 74.9 mmol) at
-78.degree. C. under argon atmosphere, and then stirred at room
temperature for 1.5 hours. The reaction solution was cooled to
-78.degree. C. again, then added with a solution of the
4-isopropyl-1,3-thiazole-2-carbaldehyde (4.65 g, 30.0 mmol)
obtained in (A) in anhydrous tetrahydrofuran (50.0 ml), and then
the mixture was stirred for 3 hours. The reaction mixture was added
with saturated aqueous ammonium chloride, warmed to room
temperature, and then extracted with ethyl acetate. The organic
layer was dried over magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography (n-hexane:ethyl
acetate=3:1.fwdarw.1:1, v/v) to obtain the title compound (5.42 g,
50%).
[0633] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.53 (9H, s), 3.03-3.11 (2H, m), 3.28-3.32 (2H, m), 5.24 (1H, dd,
J=4.2, 8.5 Hz), 6.82 (1H, d, J=0.7 Hz), 6.85 (1H, dd, J=1.6, 5.2
Hz), 7.90 (1H, s), 8.10 (1H, s), 8.14 (1H, d, J=5.2 Hz)
[0634] ESI-MS; m/z: 364 (M.sup.++1)
(C) tert-Butyl
N-4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridylcarbamate
[0635] The tert-butyl
N-4-[2-hydroxy-2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridyl-carbamate
(5.30 g, 14.6 mmol) obtained in (B) was dissolved in anhydrous
tetrahydrofuran (100 ml), added with triethylamine (5.08 ml, 36.5
mmol)+ and methanesulfonyl chloride (1.35 ml, 17.5 mmol), and then
the mixture was stirred at room temperature for 1 hour. After
insoluble solids were removed, the reaction solution was washed
with tetrahydrofuran, and the solvent was evaporated under reduced
pressure. The residue was dissolved in toluene (100 ml), added with
1,8-diazabicyclo[5.4.0]undec-7-ene (10.9 ml, 72.9 mmol), and
refluxed by heating for 30 minutes. The reaction solution was
concentrated, then added with 1 N hydrochloric acid and extracted
with chloroform. The organic layer was washed with saturated
aqueous sodium hydrogencarbonate and dried over magnesium sulfate,
and the solvent was evaporated under reduced pressure. The residue
was purified by silica gel column chromatography (n-hexane:ethyl
acetate=5:1.fwdarw.3:1, v/v) to obtain the title compound (3.76 g,
75%).
[0636] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.34 (6H, d, J=6.8 Hz),
1.56 (9H, s), 3.07-3.18 (1H, m), 6.87 (1H, s), 7.07 (1H, dd, J=1.2,
5.1 Hz), 7.31 (1H, d, J=16.1 Hz), 7.50 (1H, d, J=16.1 Hz), 8.12
(1H, s), 8.25 (1H, s), 8.26 (1H, s)
(D)
4-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridinamine
[0637] The tert-butyl
N-4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridylcarbamate
(3.75 g, 10.9 mmol) obtained in (C) was dissolved in
dichloromethane (50.0 ml), added with trifluoroacetic acid (50.0
ml), and then the mixture was stirred at room temperature for 30
minutes. The reaction solution was concentrated, then neutralized
with saturated aqueous sodium hydrogencarbonate, and extracted with
chloroform. The organic layer was dried over magnesium sulfate, and
then the solvent was evaporated under reduced pressure to obtain
the title compound (2.65 g, 100%).
[0638] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.34 (6H, d, J=6.8 Hz),
3.09-3.16 (1H, m), 4.67 (1H, br s), 6.57 (1H, s), 6.80 (1H, dd,
J=1.3, 5.5 Hz), 6.87 (1H, s), 7.18 (1H, d, J=16.1 Hz), 7.37 (1H, d,
J=16.1 Hz), 8.04 (1H, d, J=5.5 Hz)
(E)
2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido-
[1,2-a]-pyrimidin-4-one
[0639] The
4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridinamine
(2.65 g, 10.8 mmol) obtained in (D) was dissolved in toluene (100
ml), added with trichlorophenyl malonate (5.50 g, 11.9 mmol), and
refluxed by heating for 1.5 hours. After the reaction mixture was
concentrated, the deposited solid was collected by filtration and
washed with n-hexane and ether to obtain the title compound (3.14
g, 93%) as yellow solid.
[0640] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.37 (6H, d, J=6.8 Hz),
3.14-3.21 (1H, m), 5.41 (1H, s), 7.05 (1H, s), 7.40 (1H, dd, J=1.5,
7.4 Hz), 7.46 (1H, d, J=16.1 Hz), 7.51 (1H, d, J=1.5 Hz), 7.66 (1H,
d, J=16.1 Hz), 9.09 (1H, d, J=7.4 Hz)
(F)
2-(3-Hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethe-
nyl]-4H-pyrido[1,2-a]pyrimidin-4-one
[0641] The
2-hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido[1,-
2-a]-pyrimidin-4-one (1.00 g, 3.19 mmol) obtained in (E) was
dissolved in anhydrous tetrahydrofuran (15.0 ml) and anhydrous
dimethylformamide (15.0 ml), added with 4-dimethylaminopyridine
(585 mg, 4.79 mmol) and p-toluenesulfonyl chloride (730 mg, 3.83
mmol), and then the mixture was stirred at room temperature for 50
minutes. Subsequently, the reaction solution was added with
3-hydroxypiperidine (646 mg, 6.38 mmol) and stirred at room
temperature for 16 hours, and then added with 3-hydroxypiperidine
(968 mg, 9.57 mmol) and stirred at 60.degree. C. for 1.5 hours.
After the reaction mixture was concentrated, the residue was
purified by silica gel column chromatography
(chloroform:methanol=100:0.fwdarw.100:1.fwdarw.100:2.fwdarw.100:5.fwdarw.-
100:10, v/v) to obtain the title compound (865 mg, 68%).
[0642] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=7.1 Hz),
1.54-1.72 (1H, m), 1.86-2.01 (3H, m), 3.11-3.21 (1H, m), 3.39-3.45
(1H, m), 3.55 (1H, dd, J=7.1,13.2 Hz), 3.73-3.78 (1H, m), 3.85-3.89
(1H, m), 4.00 (1H, dd, J=3.1,12.9 Hz), 5.65 (1H, m), 6.94 (1H, m),
7.03 (1H, dd, J=2.0, 7.6 Hz), 7.32 (1H, d, J=16.1 Hz), 7.45 (1H, d,
J=16.1 Hz), 8.82 (1H, d, J=7.3 Hz)
[0643] ESI-MS; m/z: 397 (M.sup.++1)
(G) tert-Butyl
(E)-3-{2-(3-formyloxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)--
1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0644] Dimethylformamide (15.0 ml) was added with phosphorus
oxychloride (608 .mu.l, 6.52 mmol) under ice cooling and stirred at
room temperature for 40 minutes. The mixture was added to a
solution of the
2-(3-hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl-
]-4H-pyrido[1,2-a]pyrimidin-4-one (862 mg, 2.17 mmol) obtained in
(F) in dimethylformamide (15.0 ml) under ice cooling, and then the
mixture was stirred at room temperature for 1.5 hours. The reaction
mixture was added with saturated aqueous sodium hydrogencarbonate
and extracted with chloroform. The organic layer was dried over
magnesium sulfate, and the solvent was evaporated under reduced
pressure. The residue was suspended in anhydrous tetrahydrofuran
(20 ml) and anhydrous N,N-dimethylformamide (10 ml), added with
(tert-butoxycarbonyl-methylene)triphenylphosphorane (1.64 g, 4.35
mmol), and stirred at 50.degree. C. for 16 hours. The reaction
mixture was concentrated, and the residue was purified by silica
gel column chromatography (n-hexane:ethyl acetate
10:1.fwdarw.5:1.fwdarw.3:1.fwdarw.2:1, v/v) to obtain the title
compound (488 mg, 41%).
[0645] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.52 (9H, s), 1.72-1.75 (1H, m), 1.81-1.85 (1H, m), 1.94-2.03 (2H,
m), 3.12-3.18 (1H, m), 3.51-3.60 (2H, m), 3.71 (1H, dd, J=6.3, 13.4
Hz), 3.82 (1H, dd, J=3.1,13.4 Hz), 5.13-5.16 (1H, m), 6.97 (1H, s),
7.07 (1H, d, J=15.6 Hz), 7.15 (1H, dd, J=1.7, 7.6 Hz), 7.34-7.37
(2H, m), 7.49 (1H, d, J=16.1 Hz), 7.51 (1H, d, J=15.6 Hz), 8.10
(1H, s), 8.89 (1H, d, J=7.6 Hz)
[0646] ESI-MS; m/z: 551 (M.sup.++1)
(H) tert-Butyl
(E)-3-{2-(3-hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1--
ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0647] The tert-butyl
(E)-3-{2-(3-formyloxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)--
1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (184
mg, 0.334 mmol) obtained in (G) was dissolved in methanol (3.0 ml),
added with 1 N aqueous sodium hydroxide (1.0 ml), and then the
mixture was stirred at room temperature for 10 minutes. The
reaction mixture was added with 1 N hydrochloric acid (1.0 ml) and
extracted with chloroform. The organic layer was dried over
magnesium sulfate and the solvent was evaporated under reduced
pressure. The residue was purified by silica gel column
chromatography (n-hexane:ethyl acetate=2:1.fwdarw.2:1.fwdarw.1:2,
v/v) to obtain the title compound (174 mg, 100%).
[0648] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.52 (9H, s), 1.68-1.89 (4H, m), 3.12-3.18 (1H, m), 3.55-3.66 (3H,
m), 3.93-3.96 (1H, m), 4.03 (1H, br s), 6.97 (1H, s), 7.06 (1H, d,
J=15.6 Hz), 7.16 (1H, dd, J=1.6, 7.5 Hz), 7.34 (1H, d, J=16.1 Hz),
7.34 (1H, d, J=1.6 Hz), 7.49 (1H, d, J=16.1 Hz), 7.50 (1H, d,
J=15.6 Hz), 8.89 (1H, d, J=7.5 Hz)
[0649] ESI-MS; m/z: 523 (M.sup.++1)
(I)
(E)-3-{2-(3-Hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-
-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0650] The tert-Butyl
(E)-3-{2-(3-hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1--
ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (43.4
mg, 0.0830 mmol) obtained in (H) was dissolved in 1,4-dioxane (200
.mu.l), added with 4 N hydrochloric acid solution in 1,4-dioxane,
and stirred at room temperature for 3.5 hours. The reaction
solution was concentrated, and the residue was purified by thin
layer chromatography
(chloroform:methanol:water=10:1:0.fwdarw.8:3:0.1.fwdarw.7:3:1, v/v)
to obtain the title compound (18.9 mg, 49%).
[0651] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.29 (6H, d, J=6.6 Hz),
1.42-1.47 (1H, m), 1.55-1.59 (1H, m), 1.81 (1H, m), 1.90-1.95 (1H,
m), 2.97-3.74 (4H, m), 3.89-3.92 (1H, m), 4.95 (1H, br s), 6.89
(1H, d, J=15.1 Hz), 7.42-7.46 (2H, m), 7.54-7.62 (3H, m), 7.87 (1H,
d, J=16.6 Hz), 8.76 (1H, d, 7.8 Hz)
[0652] ESI-MS; m/z: 467 (M.sup.++1)
Example 103
(E)-3-(2-{3-[(Aminocarbonyl)oxy]piperidino}-8-[(E)-2-(4-isopropyl-1,3-thia-
zol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
(A) tert-Butyl
(E)-3-(2-{3-[(aminocarbonyl)oxy]piperidino}-8-[(E)-2-(4-isopropyl-1,3-thi-
azol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0653] tert-Butyl
(E)-3-{2-(3-hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1--
ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (138
mg, 0.264 mmol) was dissolved in ethyl acetate (2.6 ml), added with
trichloroacetyl isocyanate (62.6 .mu.l, 0.528 mmol) under ice
cooling, and then the mixture was stirred at room temperature for
15 minutes. The reaction mixture was concentrated, dissolved in
methanol (5.0 ml) and water (0.5 ml), and then added with sodium
formate (71.8 mg, 1.06 mmol), and stirred overnight at room
temperature. The reaction mixture was further added with chloroform
(3.0 ml) and sodium formate (71.8 mg, 1.06 mmol) and stirred
overnight. The reaction mixture was concentrated, and the residue
was purified by silica gel column chromatography
(chloroform:methanol=100:0.fwdarw.100:1.fwdarw.100:2, v/v) to
obtain the title compound (150 mg, 100%).
[0654] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.50 (9H, s), 1.70-2.04 (4H, m), 3.11-3.18 (1H, m), 3.27-3.33 (1H,
m), 3.52-3.56 (1H, m), 3.68-3.74 (2H, m), 4.85 (1H, br s), 5.15
(2H, br s), 6.97 (1H, s), 7.11 (1H, d, J=15.6 Hz), 7.15 (1H, dd,
J=1.8, 7.6 Hz), 7.34 (1H, d, J=16.5 Hz), 7.37 (1H, s), 7.49 (1H, d,
J=16.5 Hz), 7.72 (1H, d, J=15.6 Hz), 8.89 (1H, d, J=7.6 Hz)
[0655] ESI-MS; m/z: 566 (M.sup.++1)
(B)
(E)-3-(2-{3-[(Aminocarbonyl)oxy]piperidino)-8-[(E)-2-(4-isopropyl-1,3--
thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0656] The tert-butyl
(E)-3-(2-{3-[(aminocarbonyl)oxy]piperidino}-8-[(E)-2-(4-isopropyl-1,3-thi-
azol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
obtained in (B) was dissolved in 1,4-dioxane (100 .mu.l), added
with 4 N hydrochloric acid solution in 1,4-dioxane (400 .mu.l), and
stirred at room temperature for 15 hours. The reaction solution was
further added with 4 N hydrochloric acid solution in 1,4-dioxane
(400 .mu.l) and stirred at room temperature for 7 hours. The
reaction solution was concentrated, and the residue was subjected
to azeotropy with toluene. The product was added with saturated
aqueous sodium hydrogencarbonate, neutralized with phosphate buffer
(pH 7-8), and extracted with a mixture of chloroform/methanol
(10:1, v/v). The organic layer was dried over magnesium sulfate,
and the solvent was evaporated under reduced pressure. The residue
was purified by thin layer chromatography
(chloroform:methanol=20:1, v/v) to obtain the title compound (8.1
mg, 36%).
[0657] .sup.1H-NMR (CDCl.sub.3+CD.sub.3OD) .delta.: 1.35 (6H, d,
J=7.1 Hz), 1.71 (1H, m), 1.90-1.96 (3H, m), 3.12-3.19 (1H, m),
3.38-3.40 (1H, m), 3.58-3.81 (3H, m), 4.87 (1H, br s), 6.99 (1H,
s), 7.11 (1H, d, J=15.6 Hz), 7.21 (1H, d, J=7.7 Hz), 7.35 (1H, d,
J=16.1 Hz), 7.40 (1H, s), 7.52 (1H, d, J=16.1 Hz), 7.76 (1H, d,
J=15.6 Hz), 8.88 (1H, d, J=7.7 Hz)
[0658] ESI-MS; m/z: 510 (M.sup.++1)
Example 104
2-(3-Hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-
-3-[(E)-2-(1H-1,2,3,4-tetrazol-5-yl)-1-ethenyl]-4H-pyrido[1,2-a]pyrimidin--
4-one
(A) tert-Butyl
(E)-3-[2-[(3-acetyloxy)piperidino]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl-
)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0659] tert-Butyl
(E)-3-{2-(3-formyloxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)--
1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (115
mg, 0.209 mmol) was dissolved in methanol (2.0 ml), added with 1 N
aqueous sodium hydroxide (627 .mu.l), and stirred at room
temperature for 10 minutes. The reaction solution was added with 1
N hydrochloric acid (627 .mu.l) and extracted with chloroform. The
organic layer was dried over magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was dissolved in
dichloromethane (2.0 ml), added with 4-dimethylaminopyridine (51.0
mg, 0.418 mmol) and acetic anhydride (29.6 .mu.l), and then the
mixture was stirred at room temperature for 10 minutes. The
reaction mixture was added with 1 N hydrochloric acid and extracted
with chloroform. The organic layer was dried over magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography
(n-hexane:ethyl acetate=5:1.fwdarw.3:1.fwdarw.2:1, v/v) to obtain
the title compound (121 mg, quantitative).
[0660] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.52 (9H, s), 1.70-1.78 (2H, m), 1.90-2.02 (2H, m), 2.06 (3H, s),
3.12-3.19 (1H, m), 3.47-3.52 (1H, m), 3.61 (2H, dd, J=7.1, 13.2
Hz), 3.88 (1H, dd, J=3.3, 13.2 Hz), 4.96-5.00 (1H, m), 6.96 (1H,
s), 7.06 (1H, d, J=15.6 Hz), 7.13 (1H, dd, J=2.0, 7.6 Hz),
7.33-7.37 (2H, m), 7.48 (1H, d, J=16.1 Hz), 7.50 (1H, d, J=15.6
Hz), 7.50 (1H, d, J=15.6 Hz), 8.89 (1H, d, J=7.6 Hz)
[0661] ESI-MS; m/z: 565 (M.sup.++1)
(B)
1-(3-{(E)-3-[(2-Cyanoethyl)amino]-3-oxo-1-propenyl}-8-[(E)-2-(4-isopro-
pyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)-3-p-
iperidyl acetate
[0662] The tert-Butyl
(E)-3-{2-[(3-acetyloxy)piperidino]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl-
)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
(121 mg, 0.214 mmol) obtained in (A) was dissolved in 1,4-dioxane
(1.0 ml), added with 4 N hydrochloric acid solution in 1,4-dioxane,
and then the mixture was stirred overnight at room temperature. The
reaction mixture was concentrated, and the residue was suspended in
dichloromethane (2.0 ml), added with 2-cyanoethylamine (79 .mu.l,
1.07 mmol), BOPCl (109 mg, 0.429 mmol) and diisopropylethylamine
(187 .mu.l, 1.07 mmol), and stirred for 1 hour. The reaction
solution was further added with 2-cyanoethylamine (79 .mu.l, 1.07
mmol), BOPCl (109 mg, 0.429 mmol) and diisopropylethylamine (187
.mu.l, 1.07 mmol) and stirred overnight. The reaction mixture was
added with saturated aqueous sodium hydrogencarbonate and extracted
with a mixture of chloroform/methanol (10:1, v/v). The organic
layer was dried over magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by
column chromatography (chloroform:methanol,
100:0.fwdarw.100:1.fwdarw.100:2, v/v) to obtain the title compound
(53.3 mg, 48%).
[0663] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.70-1.79 (2H, m), 1.90-1.93 (1H, m), 2.01-2.04 (1H, m), 2.06 (3H,
s), 2.71 (2H, t, J=6.5 Hz), 3.11-3.18 (1H, m), 3.46-3.51 (1H, m),
3.56-3.68 (4H, m), 3.92 (1H, dd, J=3.1,13.1 Hz), 4.95-5.00 (1H, m),
6.58-6.61 (1H, m), 6.96 (1H, s), 7.13 (1H, d, J=7.6 Hz), 7.25 (1H,
d, J=15.1 Hz), 7.31-7.34 (2H, m), 7.47 (1H, d, J=16.4 Hz), 7.47
(1H, d, J=15.1 Hz), 7.52 (1H, d, J=15.1 Hz), 8.83 (1H, d, J=7.6
Hz)
[0664] ESI-MS; m/z: 561 (M.sup.++1)
(C)
1-(3-{(E)-2-[1-(2-Cyanoethyl)-1H-1,2,3,4-tetrazol-5-yl]-1-ethenyl)-8-[-
(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyri-
midin-2-yl)-3-piperidyl acetate
[0665] The
1-(3-{(E)-3-[(2-cyanoethyl)amino]-3-oxo-1-propenyl}-8-[(E)-2-(4-isopropyl-
-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)-3-pipe-
ridyl acetate (57.3 mg, 0.102 mmol) obtained in (B) was suspended
in acetonitrile (3.0 ml), added with sodium azide (13.3 mg, 0.204
mmol) and trifluoromethanesulfonic acid anhydride (25.8 .mu.l,
0.153 mmol) under ice cooling, and then the mixture was stirred at
room temperature for 1 hour. The reaction mixture was further added
with sodium azide (13.3 mg, 0.204 mmol) and
trifluoromethanesulfonic acid anhydride (25.8 .mu.l, 0.153 mmol),
and stirred for 3 hours. The reaction mixture was added with
saturated aqueous sodium hydrogencarbonate and extracted with
chloroform, and the organic layer was dried over magnesium sulfate.
The solvent was evaporated under reduced pressure, and the residue
was purified by thin layer chromatography (hexane:ethyl
acetate=1:2.fwdarw.1:3.fwdarw.0:1, v/v) to obtain the title
compound (26.8 mg, 45%).
[0666] .sup.1H-NMR (CDCl.sub.3) b: 1.36 (6H, d, J=6.9 Hz),
1.73-1.80 (4H, m), 2.04 (3H, s), 3.10 (2H, t, J=7.0 Hz), 3.13-3.19
(1H, m), 3.57-3.73 (3H, m), 3.91 (1H, dd, J=2.8, 13.1 Hz), 4.69
(2H, t, J=7.0 Hz), 4.95-4.98 (1H, m), 6.97 (1H, s), 7.17 (1H, dd,
J=1.5, 7.5 Hz), 7.36 (1H, d, J=1.5 Hz), 7.36 (1H, d, J=16.0 Hz),
7.50 (1H, d, J=16.0 Hz), 7.75 (1H, d, J=15.3 Hz), 7.83 (1H, d,
J=15.3 Hz), 8.86 (1H, d, J=7.5 Hz)
(D)
2-(3-Hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethe-
nyl]-3-[(E)-2-(1H-1,2,3,4-tetraazol-5-yl)-1-ethenyl]-4H-pyrido[1,2-a]pyrim-
idin-4-one
[0667] The
1-(3-{(E)-2-[1-(2-cyanoethyl)-1H-1,2,3,4-tetraazol-5-yl]-1-ethenyl}-8-[(E-
)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimi-
din-2-yl)-3-piperidyl acetate (25.9 mg, 0.0442 mmol) obtained in
(C) was suspended in methanol (0.5 ml) and anhydrous
tetrahydrofuran (1.0 ml), added with sodium methoxide (4.8 mg,
0.0884 mmol) under ice cooling, and then stirred for 4 hours. The
reaction solution was further added with sodium methoxide (4.8 mg,
0.0884 mmol) and stirred for 1 hour. The reaction mixture was added
with saturated aqueous ammonium chloride and extracted with
chloroform, and the organic layer was dried over magnesium sulfate.
Then, the solvent was evaporated under reduced pressure, and the
residue was purified by thin layer chromatography
(chloroform:methanol=10:1, v/v) to obtain the title compound (12.7
mg, 59%).
[0668] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.32 (6H, d, J=7.1 Hz),
1.56-1.61 (1H, m), 1.67-1.71 (1H, m), 1.89-1.92 (1H, m), 2.03-2.07
(1H, m), 3.08-3.19 (2H, m), 3.45 (1H, s), 3.76-3.80 (1H, m),
3.84-3.88 (1H, m), 4.00 (1H, dd, J=2.9, 12.9 Hz), 7.19 (1H, s),
7.34-7.36 (2H, m), 7.39 (1H, d, J=16.4 Hz), 7.51 (1H, d, J=16.1
Hz), 7.57 (1H, d, J=16.4 Hz), 7.74 (1H, d, J=16.1 Hz), 8.76 (1H, d,
J=7.6 Hz)
[0669] ESI-MS; m/z: 491 (M.sup.++1)
Example 105
(E)-3-{2-[(3R)-3-Hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3-t-
hiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
(A) tert-Butyl
(E)-3-{2-[(3R)-3-Formyloxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,-
3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propeno-
ate
[0670]
2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-py-
rido[1,2-a]-pyrimidin-4-one (500 mg, 1.60 mmol) was treated in the
same manner as in Example 102, (F) and (G) to obtain the title
compound (488 mg, 56%).
[0671] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.52 (9H, s), 1.73-1.75 (1H, m), 1.83-1.85 (1H, m), 1.95-2.03 (2H,
m), 3.13-3.17 (1H, m), 3.54-3.60 (2H, m), 3.71 (1H, dd, J=6.2, 13.5
Hz), 3.82 (1H, dd, J=3.2, 13.5 Hz), 5.14-5.16 (1H, m), 6.97 (1H,
s), 7.07 (1H, d, J=15.6 Hz), 7.14 (1H, dd, J=1.6, 7.6 Hz),
7.34-7.37 (2H, m), 7.49 (1H, d, J=16.0 Hz), 7.51 (1H, d, J=15.6
Hz), 8.10 (1H, s), 8.89 (1H, d, J=7.6 Hz)
(B) tert-Butyl
(E)-3-{2-[(3R)-3-Hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3--
thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoat-
e
[0672] The tert-butyl
(E)-3-{2-[(3R)-3-formyloxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,-
3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propeno-
ate (488 mg, 0.886 mmol) obtained in (A) was treated in the same
manner as in Example 102, (H) to obtain the title compound (373 mg,
81%).
[0673] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.52 (9H, s), 1.82-1.88 (4H, m), 3.11-3.18 (1H, m), 3.54-3.67 (3H,
m), 3.95-3.98 (1H, m), 4.03 (1H, br s), 6.97 (1H, s), 7.05 (1H, d,
J=15.7 Hz), 7.16 (1H, dd, J=1.8, 7.6 Hz), 7.34 (1H, d, J=16.1 Hz),
7.34 (1H, s), 7.49 (1H, d, J=16.1 Hz), 7.50 (1H, d, J=15.7 Hz),
8.89 (1H, d, J=7.6 Hz)
(C)
(E)-3-{2-[(3R)-3-Hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1-
,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propen-
oic acid
[0674] tert-Butyl
(E)-3-{2-[(3R)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3--
thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoat-
e (105 mg, 0.201 mmol) obtained in (B) was treated in the same
manner as in Example 102, (I) to obtain the title compound (64.0
mg, 68%).
[0675] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.27 (6H, d, J=6.8 Hz),
1.40-1.45 (1H, m), 1.54-1.57 (1H, m), 1.80-1.83 (1H, m), 1.89-1.93
(1H, m), 2.96-3.19 (2H, m), 3.60 (1H, m), 3.88-3.90 (1H, m), 4.92
(1H, br s), 6.87 (1H, d, J=15.5 Hz), 7.40 (1H,S), 7.43 (1H, d,
J=15.5 Hz), 7.54 (1H, d, J=16.1 Hz), 7.58-7.59 (2H, m), 7.85 (1H,
d, J=16.1 Hz), 8.74 (1H, d, 8.1 Hz)
Example 106
(E)-3-{2-[(3S)-3-Hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3-t-
hiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
(A) tert-Butyl
(E)-3-{2-[(3S)-3-formyloxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,-
3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propeno-
ate
[0676]
2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-py-
rido[1,2-a]-pyrimidin-4-one (500 mg, 1.60 mmol) was treated in the
same manner as in Example 102, (F) and (G) to obtain the title
compound (164 mg, 19%).
[0677] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.9 Hz),
1.52 (9H, s), 1.73-1.75 (1H, m), 1.81-1.85 (1H, m), 1.96-2.05 (2H,
m), 3.11-3.18 (1H, m), 3.54-3.57 (2H, m), 3.70 (1H, dd, J=6.5, 13.1
Hz), 3.82 (1H, d, J=13.5 Hz), 5.15 (1H, m), 6.96 (1H, s), 7.06 (1H,
d, J=15.4 Hz), 7.14 (1H, dd, J=1.6, 7.4 Hz), 7.32-7.36 (2H, m),
7.48 (1H, d, J=15.9 Hz), 7.51 (1H, d, J=15.4 Hz), 8.10 (1H, s),
8.87 (1H, d, J=7.4 Hz)
(B) tert-Butyl
(E)-3-{2-[(3S)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3--
thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoat-
e
[0678] The tert-butyl
(E)-3-{2-[(3S)-3-formyloxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,-
3-thiazol-2-yl)-1-ethenyl]-4-oxo
4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (164 mg, 0.298 mmol)
obtained in (A) was treated in the same manner as in Example 102,
(H) to obtain the title compound (156 mg, 100%).
[0679] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.52 (9H, s), 1.81-1.91 (4H, m), 3.11-3.18 (1H, m), 3.60-3.63 (3H,
m), 3.86-3.89 (1H, m), 4.02 (1H, brs), 6.97 (1H, s), 7.04 (1H, d,
J=15.6 Hz), 7.13 (1H, dd, J=1.7, 7.6 Hz), 7.31 (1H, d, J=1.7 Hz),
7.32 (1H, d, J=16.0 Hz), 7.48 (1H, d, J=16.0 Hz), 7.49 (1H, d,
J=15.6 Hz), 8.87 (1H, d, J=7.6 Hz)
(C)
(E)-3-{2-[(3S)-3-Hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1-
,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propen-
oic acid
[0680] The tert-butyl
(E)-3-{2-[(3S)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3--
thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoat-
e (72.7 mg, 0.139 mmol) obtained in (B) was treated in the same
manner as in Example 102, (I) to obtain the title compound (35.5
mg, 55%).
[0681] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.42-1.45 (1H, m), 1.56-1.59 (1H, m), 1.81-1.85 (1H, m), 1.93-1.95
(1H, m), 2.97-3.20 (3H, m), 3.62 (1H, m), 3.69-3.74 (1H, m),
3.89-3.92 (1H, m), 4.90 (1H, br s), 6.89 (1H, d, J=15.4 Hz),
7.42-7.46 (1H, m), 7.55 (1H, d, J=16.2 Hz), 7.61-7.62 (2H, m), 7.87
(1H, d, J=16.2 Hz), 8.76 (1H, d, 7.6 Hz), 11.84 (1H, br s)
Example 107
(E)-3-(2-{(3R)-3-[(Aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-[(E)-2-(4-is-
opropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-
-2-propenoic acid
[0682] The tert-butyl
(E)-3-{2-[(3R)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3--
thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoat-
e (109 mg, 0.209 mmol) was treated in the same manner as in Example
103, (A) and (B) to obtain the title compound (89.7 mg, 84%).
[0683] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.29 (6H, d, J=6.9 Hz),
1.66 (2H, m), 1.88-1.98 (2H, m), 3.05-3.12 (1H, m), 3.36-3.54 (3H,
m), 3.86 (1H, d, J=10.0 Hz), 4.60 (1H, m), 6.47 (2H, br s), 6.90
(1H, d, J=15.2 Hz), 7.42 (1H, s), 7.45 (1H, d, J=15.2 Hz), 7.55
(1H, d, J=16.2 Hz), 7.62-7.64 (2H, m), 7.88 (1H, d, J=16.2 Hz),
8.77 (1H, d, J=7.3 Hz), 11.90 (1H, br s)
Example 108
(E)-3-(2-{(3S)-3-[(Aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-[(E)-2-(4-is-
opropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-
-2-propenoic acid
[0684] The tert-butyl
(E)-3-{2-[(3S)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3--
thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoat-
e (83.6 mg, 0.160 mmol) was treated in the same manner as in
Example 103 (A) and (B) to obtain the title compound (59.4 mg,
73%).
[0685] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.29 (6H, d, J=6.6 Hz),
1.66 (2H, m), 1.88 (1H, m), 1.98 (1H, m), 3.06-3.13 (1H, m),
3.43-3.51 (3H, m), 3.86 (1H, d, J=11.7 Hz), 4.61 (1H, m), 6.47 (2H,
brs), 6.90 (1H, d, J=15.6 Hz), 7.42 (1H, s), 7.46 (1H, d, J=15.6
Hz), 7.55 (1H, d, J=16.1 Hz), 7.62-7.64 (2H, m), 7.88 (1H, d,
J=16.1 Hz), 8.77 (1H, d, J=7.3 Hz), 11.90 (1H, brs)
Example 109
(E)-3-(2-{3-[(Dimethylamino)carbonyl]piperidino}-8-[(E)-2-(4-isopropyl-1,3-
-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-propenoi-
c acid
(A)
N3,N3-Dimethyl-1-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}-3-piperidinecarboxamide
[0686] The
2-hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido-[1-
,2-a]pyrimidin-4-one (164 mg, 0.523 mmol) obtained in Example 101,
(E) was dissolved in anhydrous tetrahydrofuran (2.5 ml) and
anhydrous dimethylformamide (2.5 ml), added with
4-dimethylaminopyridine (83.0 mg, 0.680 mmol) and p-toluenesulfonyl
chloride (110 mg, 0.576 mmol), and then the mixture was stirred at
0.degree. C. for 3 hours. Subsequently, the reaction solution was
added with triethylamine (729 .mu.l, 5.23 mmol) and
N3,N3-dimethyl-3-piperidinecarboxamide trifluoroacetic acid salt
(707 mg, 2.62 mmol) and stirred at 0.degree. C. for 1 hour, at room
temperature for 30 minutes and at 60.degree. C. for 19 hours. Then,
the reaction solution was added with triethylamine (40.0 .mu.l,
0.287 mmol) and N3,N3-dimethyl-3-piperidinecarboxamide
trifluoroacetic acid salt (400 mg, 1.48 mmol) and stirred at
60.degree. C. for 5 hours. The reaction mixture was concentrated,
added with saturated aqueous ammonium chloride, and then extracted
with chloroform. The organic layer was dried over sodium sulfate,
and the solvent was evaporated under reduced pressure. The residue
was purified by silica gel column chromatography
(chloroform:methanol=100:1.fwdarw.100:3, v/v) to obtain the title
compound (168 mg, 71%).
[0687] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.36 (6H, d, J=6.4 Hz),
1.52-1.62 (1H, m), 1.73 (1H, s), 1.81-1.97 (3H, m), 2.70-2.76 (1H,
m), 2.99 (3H, s), 3.14 (3H, s), 3.04-3.18 (2H, m), 4.35 (1H, m),
4.65 (1H, m), 5.63 (1H, s), 6.95 (1H, s), 7.03 (1H, d, J=7.3 Hz),
7.23 (1H, s), 7.32 (1H, d, J=16.1 Hz), 7.45 (1H, d, J=16.1 Hz),
8.82 (1H, d, J=7.3 Hz)
(B) tert-Butyl
(E)-3-(2-{3-[(dimethylamino)carbonyl]piperidino}-8-[(E)-2-(4-isopropyl-1,-
3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-propeno-
ate
[0688] Dimethylformamide (3.0 ml) was added with phosphorus
oxychloride (104 .mu.l, 1.12 mmol) under ice cooling and stirred at
room temperature for 30 minutes. This was added to the
N3,N3-dimethyl-1-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-ox-
o-4H-pyrido[1,2-a]pyrimidin-2-yl]-3-piperidinecarboxamide (168 mg,
0.372 mmol) obtained in (A) and dissolved in dimethylformamide (4.0
ml) under ice cooling, and stirred at room temperature for 2 hours.
The reaction mixture was concentrated, added with saturated aqueous
sodium hydrogencarbonate, and then extracted with chloroform. The
organic layer was dried over sodium sulfate, and the solvent was
evaporated under reduced pressure. The residue was suspended in
anhydrous tetrahydrofuran (3 ml) and anhydrous
N,N-dimethylformamide (3 ml), added with
(tert-butoxycarbonylmethylene)triphenylphosphorane (280 mg, 0.744
mmol), and stirred at 50.degree. C. for 37 hours. The reaction
mixture was further added with
(tert-butoxycarbonylmethylene)triphenylphosphorane (280 mg, 0.744
mmol), stirred at 80.degree. C. for 5 hours, and then concentrated,
and the residue was purified by silica gel column chromatography
(chloroform:methanol=100:1.fwdarw.100:2, v/v) to obtain the title
compound (167 mg, 78%).
[0689] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.36 (6H, d, J=6.8 Hz),
1.51 (9H, s), 1.65-1.68 (1H, m), 1.81-1.84 (1H, m), 1.89-1.94 (2H,
m), 2.98 (3H, s), 3.04-3.17 (4H, m), 3.22 (3H, s), 4.05 (1H, m),
4.24 (1H, m), 6.96 (1H, s), 7.06 (1H, d, J=15.6 Hz), 7.25 (1H, d,
J=7.6), 7.34 (1H, d, J=16.1 Hz), 7.46 (1H, s), 7.47 (1H, d, J=16.1
Hz), 7.52 (1H, d, J=15.6), 8.89 (1H, d, J=7.6 Hz)
(C)
(E)-3-(2-{3-[(Dimethylamino)carbonyl]piperidino}-8-[(E)-2-(4-isopropyl-
-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-prop-
enoic acid
[0690] The tert-butyl
(E)-3-(2-{3-[(dimethylamino)carbonyl]piperidino}-8-[(E)-2-(4-isopropyl-1,-
3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propeno-
ate (71.0 mg, 0.123 mmol) obtained in (B) was added with
trifluoroacetic acid (3.0 ml) and stirred at room temperature for 2
hours. The trifluoroacetic acid in the reaction mixture was
evaporated under reduced pressure, and the residue was neutralized
with 0.1 N sodium hydroxide and phosphate buffer (pH 7-8) and
extracted with chloroform. The organic layer was dried over sodium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by thin layer chromatography
(chloroform:methanol and chloroform:methanol:water, 8:3:1, v/v,
lower layer) to obtain the title compound (39.0 mg, 61%).
[0691] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.64 (1H, m), 1.72 (2H, m), 1.87 (1H, m), 2.84 (3H, s), 3.04 (2H,
m), 3.07-3.11 (2H, m), 3.15 (3H, s), 3.92 (1H, m), 4.08 (1H, m),
6.89 (1H, d, J=15.4), 7.42 (1H, s), 7.43 (1H, d, J=15.4 Hz), 7.56
(1H, d, J=16.1 Hz), 7.60 (1H, s), 7.62 (1H, d, J=7.8 Hz), 7.87 (1H,
d, J=16.1 Hz), 8.77 (1H, d, J=7.8 Hz)
[0692] EI-MS; m/z: 522 (M.sup.++1)
Example 110
(E)-3-(8-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-{3-[(methylami-
no)carbonyl]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-2-propenoic
acid
(A)
N3-Methyl-1-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo--
4H-pyrido-[1,2-a]pyrimidin-2-yl)-3-piperidinecarboxamide
[0693]
2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-py-
rido[1,2-a]-pyrimidin-4-one (157 mg, 0.501 mmol) was dissolved in
anhydrous tetrahydrofuran (2.5 ml) and anhydrous dimethylformamide
(2.5 ml), added with 4-dimethylamino-pyridine (80.0 mg, 0.651 mmol)
and p-toluenesulfonyl chloride (105 mg, 0.551 mmol), and stirred at
0.degree. C. for 1.5 hours. Subsequently, the reaction mixture was
added with triethylamine (698 .mu.l, 5.01 mmol) and
N3-methyl-3-piperidinecarboxamide hydrochloride (448 mg, 2.50
mmol), and then the mixture was stirred at 60.degree. C. for 5.5
hours. The reaction mixture was concentrated, added with saturated
aqueous ammonium chloride, and then extracted with chloroform. The
organic layer was dried over sodium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography
(chloroform:methanol=100:2.fwdarw.100:3, v/v) to obtain the title
compound (174 mg, 79%).
[0694] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=6.8 Hz),
1.60 (1H, m), 1.73 (1H, m), 1.94 (1H, m), 2.02-2.05 (1H, m),
2.36-2.38 (1H, m), 2.83 (3H, d, J=4.9), 3.13-3.20 (2H, m), 3.59
(1H, dd, J=8.8, 13.7), 4.00 (1H, m), 4.24 (1H, m), 5.62 (1H, s),
6.95 (1H, s), 7.05 (1H, d, J=7.8 Hz), 7.27 (1H, s), 7.33 (1H, d,
J=16.1 Hz), 7.46 (1H, d, J=16.1 Hz), 8.83 (1H, d, J=7.8 Hz)
(B) tert-Butyl
(E)-3-(8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-{3-[(methylam-
ino)carbonyl]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoat-
e
[0695] Dimethylformamide (3.0 ml) was added with phosphorus
oxychloride (111 .mu.l, 1.19 mmol) under ice cooling and stirred at
room temperature for 30 minutes. The mixture was added to the
N3-methyl-1-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H--
pyrido[1,2-a]pyrimidin-2-yl)-3-piperidinecarboxamide (174 mg, 0.398
mmol) obtained in (A) and dissolved in dimethylformamide (4.0 ml)
under ice cooling, and then the mixture was stirred at room
temperature for 2 hours. The reaction mixture was concentrated,
added with saturated aqueous sodium hydrogencarbonate, and then
extracted with chloroform. The organic layer was dried over sodium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was suspended in anhydrous tetrahydrofuran (3 ml) and
dimethylformamide (3 ml), added with
(tert-butoxycarbonylmethylene)triphenylphosphorane (449 mg, 1.19
mmol) and stirred at 75.degree. C. for 24 hours. The reaction
mixture was concentrated, and the residue was purified by silica
gel column chromatography (chloroform:methanol=100:0.fwdarw.100:3,
v/v) to obtain the title compound (192 mg, 86%).
[0696] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (6H, d, J=7.1 Hz),
1.54 (9H, m), 1.65-1.68 (1H, m), 1.85-1.90 (1H, m), 1.95-2.00 (2H,
m), 2.77 (3H, d, J=4.6), 2.82 (1H, m), 2.92 (1H, m), 3.11-3.17 (2H,
m), 3.90-4.00 (1H, m), 4.45-4.50 (1H, m), 6.97 (1H, s), 7.09 (1H,
d, J=15.6 Hz), 7.12 (1H, d, J=1.7), 7.30 (1H, d, J=1.7 Hz), 7.34
(1H, d, J=16.1 Hz), 7.40-7.70 (2H, m), 8.86 (1H, d, J=7.3 Hz)
(C)
(E)-3-(8-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-{3-[(methy-
lamino)-carbonyl]piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-prope-
noic acid
[0697] The tert-butyl
(E)-3-(8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-{3-[(methylam-
ino)carbonyl]piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoat-
e (192 mg, 0.341 mmol) obtained in (B) was added with
trifluoroacetic acid (5.0 ml) and stirred at room temperature for
1.5 hours. After the reaction was completed, the trifluoroacetic
acid was evaporated under reduced pressure, and the residue was
neutralized with 0.1 N sodium hydroxide and phosphate buffer (pH
7-8) and extracted with chloroform. The organic layer was dried
over sodium sulfate, and the solvent was evaporated under reduced
pressure. The residue was purified by thin layer chromatography
(chloroform:methanol and chloroform:methanol:water=8:3:1, v/v,
lower layer) to obtain the title compound (49.0 mg, 28%).
[0698] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.62-1.71 (2H, m), 1.77 (1H, m), 1.90 (1H, m), 2.58 (3H, d, J=4.6
Hz), 3.05-3.13 (3H, m), 3.27 (1H, m), 3.89 (1H, m), 4.08 (1H, m),
6.89 (1H, d, J=15.6 Hz), 7.42 (1H, s), 7.42 (1H, d, J=15.6 Hz),
7.54 (1H, d, J=16.1 Hz), 7.62 (1H, d, J=7.6 Hz), 7.67 (1H, s), 7.79
(1H, s), 7.88 (1H, d, J=16.1 Hz), 8.77 (1H, d, J=7.6 Hz)
[0699] EI-MS; m/z: 508 (M.sup.++1)
Example 111
8-(E)-2-[4-(tert-Butyl)-1,3-thiazol-2-yl]-1-ethenyl-3-(2H-1,2,3,4-tetraazo-
l-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
(A) [4-(tert-Butyl)-1,3-thiazol-2-yl]methanol
[0700] Ethyl thiooxamate (4.94 g, 37.1 mmol) was dissolved in
anhydrous ethanol (250 ml), added with 1-bromopinacolone (4.99 ml,
37.1 mmol), and refluxed by heating for 4 hours. The reaction
mixture was concentrated, neutralized with saturated aqueous sodium
hydrogencarbonate, and extracted with ethyl acetate. The organic
layer was dried over sodium sulfate, and then the solvent was
evaporated under reduced pressure. The residue was dissolved in
anhydrous ethanol (200 ml), added with sodium hydroboride (2.10 g,
55.6 mmol), and stirred at room temperature for 16 hours. The
reaction solution was further added with sodium borohydride (500
mg, 13.2 mmol) and stirred at room temperature for 4 hours, and
then the solvent was evaporated under reduced pressure. The residue
was cooled to -78.degree. C., and the resulting white solid was
taken by filtration to obtain the title compound (2.77 g, 44%).
[0701] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (9H, s), 4.92 (2H,
s), 6.86 (1H, s)
(B) 4-(tert-Butyl)-1,3-thiazol-2-carbaldehyde
[0702] [4-(tert-Butyl)-1,3-thiazol-2-yl]methanol (2.77 g, 16.2
mmol) obtained in (A) was dissolved in methylene chloride (45 ml),
added with pyridinium dichromate (12.2 g, 32.3 mmol), and stirred
at room temperature for 13.5 hours. After insoluble solids were
removed, the reaction solution was evaporated, and the residue was
purified by silica gel column chromatography (dichloromethane) to
obtain the title compound (2.71 g, 99%).
[0703] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.40 (9H, s), 7.36 (1H,
s), 9.98 (1H, s)
(C) tert-Butyl
N-(4-{2-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-hydroxyethyl}-2-pyridyl)-carb-
amate
[0704] tert-Butyl N-(4-methyl-2-pyridyl)carbamate (3.11 g, 14.9
mmol) was dissolved in anhydrous tetrahydrofuran (50 ml), added
with n-butyl lithium (1.59 M in n-hexane, 19.7 ml, 31.3 mmol) at
-78.degree. C. under argon atmosphere, and stirred at room
temperature for 1.5 hours. The reaction mixture was cooled to
-78.degree. C. again, then added with a solution of the
4-(tert-butyl)-1,3-thiazol-2-carbaldehyde (2.30 g, 13.6 mmol)
obtained in (B) in anhydrous tetrahydrofuran (10 ml), and stirred
for 30 minutes. The reaction mixture was added with saturated
aqueous ammonium chloride, warmed to room temperature and extracted
with chloroform. The organic layer was dried over sodium sulfate,
and the solvent was evaporated under reduced pressure. The residue
was purified by silica gel column chromatography (n-hexane:ethyl
acetate=2:1.fwdarw.1:1, v/v) to obtain the title compound (2.29 g,
45%).
[0705] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.32 (9H, s), 1.53 (9H,
s), 3.08 (1H, dd, J=8.4, 13.8 Hz), 3.29 (1H, dd, J=4.2, 13.8), 5.23
(1H, dd, J=4.2, 8.4 Hz), 6.83 (1H, s), 6.85 (1H, dd, J=1.5, 5.1
Hz), 7.67 (1H, s), 7.87 (1H, s), 8.13 (1H, d, J=5.1 Hz)
(D) tert-Butyl
N-(4-(E)-{2-[4-(tert-butyl)-1,3-thiazol-2-yl]-1-ethenyl}-2-pyridyl)-carba-
mate
[0706] The tert-butyl
N-(4-{2-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-hydroxyethyl]-2-pyridyl)carba-
mate (1.80 g, 4.77 mmol) obtained in (C) was dissolved in anhydrous
tetrahydrofuran (20 ml), added with triethylamine (2.33 ml, 16.7
mmol) and methanesulfonyl chloride (738 .mu.l, 9.54 mmol), and
stirred at 0.degree. C. for 3.5 hours. After insoluble solids were
removed, the reaction mixture was washed with tetrahydrofuran, and
the solvent was evaporated under reduced pressure. The residue was
dissolved in toluene (30 ml), added with
1,8-diazabicyclo[5.4.0]undec-7-ene (1.07 ml, 7.15 mmol), and
refluxed by heating for 1 hour. The reaction mixture was
concentrated, and the residue was purified by silica gel column
chromatography (n-hexane:ethyl acetate=3:1.fwdarw.2:1, v/v) to
obtain the title compound (1.23 g, 72%).
[0707] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.37 (9H, s), 1.55 (9H,
s), 6.89 (1H, s), 7.08 (1H, dd, J=1.5, 5.4 Hz), 7.29 (1H, d, J=16.4
Hz), 7.51 (1H, d, J=16.4 Hz), 8.12 (1H, s), 8.09 (1H, s), 8.21 (1H,
d, J=5.4 Hz)
(E)
4-(E)-2-[4-(tert-Butyl)-1,3-thiazol-2-yl]-1-ethenyl-2-pyridinamine
[0708] The tert-butyl
N-(4-(E)-2-[4-(tert-butyl)-1,3-thiazol-2-yl]-1-ethenyl-2-pyridyl)-carbama-
te (585 mg, 1.63 mmol) obtained in (D) was dissolved in
trifluoroacetic acid (15 ml) and stirred at room temperature for 1
hour. The reaction mixture was concentrated, neutralized with
saturated aqueous sodium hydrogencarbonate, and extracted with
chloroform. The organic layer was dried over sodium sulfate, and
the solvent was evaporated under reduced pressure to obtain the
title compound (422 mg, 100%).
[0709] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.38 (9H, s), 6.62 (1H,
s), 6.84 (1H, d, J=6.0 Hz), 6.93 (1H, s), 7.17 (1H, d, J=16.2 Hz),
7.42 (1H, d, J=16.2 Hz), 7.92 (1H, d, J=6.0 Hz)
(F)
8-(E)-2-[4-(tert-Butyl)-1,3-thiazol-2-yl]-1-ethenyl-3-(2H-1,2,3,4-tetr-
aazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0710] Ethyl
3-(dimethylamino)-2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetraazol-5-yl]-2-pro-
penoate (150 mg, 0.453 mmol) was dissolved in propionic acid (2.0
ml), added to the
4-(E)-2-[4-(tert-butyl)-1,3-thiazol-2-yl]-1-ethenyl-2-pyridinamine
(98.0 mg, 0.378 mmol) obtained in (E), and refluxed by heating for
3 hours. The reaction mixture was concentrated, and the residue was
purified by silica gel column chromatography (chloroform) to obtain
the title compound (175 mg, 93%).
[0711] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.40 (9H, s), 3.79 (3H,
s), 5.81 (2H, s), 6.89 (2H, d, J=8.3 Hz), 7.02 (1H, s), 7.41 (1H,
d, J=16.2 Hz), 7.42 (2H, d, J=8.3 Hz), 7.46 (1H, d, J=7.5 Hz), 7.60
(1H, d, J=16.2 Hz), 7.74 (1H, s), 9.21 (1H, d, J=7.5 Hz), 9.21 (1H,
s)
(G)
8-(E)-2-[4-(tert-Butyl)-1,3-thiazol-2-yl]-1-ethenyl-3-(2H-1,2,3,4-tetr-
aazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0712] The
8-(E)-2-[4-(tert-butyl)-1,3-thiazol-2-yl]-1-ethenyl-3-(2H-1,2,3,4-tetraaz-
ol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one (170 mg, 0.340 mmol)
obtained in (F) was added with trifluoroacetic acid (4.0 ml) and
stirred at 60.degree. C. for 3 hours. After the reaction was
completed, the trifluoroacetic acid was evaporated under reduced
pressure, and the residue was neutralized with 0.1 N sodium
hydroxide and phosphate buffer (pH 7-8) and extracted with
chloroform. The organic layer was dried over sodium sulfate, and
the solvent was evaporated under reduced pressure. The yellow solid
deposited from the residue was collected by filtration to obtain
the title compound (20.0 mg, 15%).
[0713] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.35 (9H, s), 7.47 (1H,
s), 7.67 (1H, d, J=16.1 Hz), 8.03 (1H, d, J=16.1 Hz), 8.04 (1H, d,
J=1.9 Hz), 8.13 (1H, d, J=1.9 Hz), 9.11 (1H, d, J=7.3 Hz), 9.17
(1H, s)
[0714] EI-MS; m/z: 380 (M.sup.++1)
Example 112:
(E)-3-[8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(tetrahydro-3-fu-
ranylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) tert-Butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(tetrahydro-3-fu-
ranylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0715] tert-Butyl
(E)-3-(2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrid-
o[1,2-a]pyrimidin-3-yl}-2-propenoate (17 mg) was added with
dimethylformamide (3 ml), diisopropylethylamine (500 ml) and
3-(iodomethyl)tetrahydrofuran (50 ml), and then the mixture was
stirred at 80.degree. C. for 16 hours. The reaction mixture was
added with ethyl acetate and saturated brine, and the organic layer
was further washed twice with saturated brine and dried over
magnesium sulfate. After the solvent was evaporated under reduced
pressure, the residue was purified by silica gel column
chromatography to obtain the title compound (14 mg).
[0716] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=7.1 Hz),
1.52 (9H, s), 1.75 (1H, m), 2.16 (1H, m), 2.82 (1H, m), 3.07 (1H,
m), 3.26 (2H, m), 3.39 (2H, m), 3.71 (1H, m), 3.80 (1H, m), 3.92
(2H, m), 4.42 (2H, m), 6.74 (1H, s), 7.02 (1H, m), 7.13 (1H, d,
J=15.8 Hz), 7.34 (1H, s), 7.91 (1H, d, J=15.8 Hz), 8.99 (1H, d,
J=7.3 Hz)
(B)
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(tetrahydro-3-
-furanyl-methoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0717] The tert-butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(tetrahydro-3-fu-
ranylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (10 mg)
obtained in (A) was dissolved in methylene chloride (1 ml) and
formic acid (1 ml), and then the mixture was stirred for 5 hours.
After the solvent was evaporated under reduced pressure, the
residue was purified by silica gel column chromatography to obtain
the title compound (14 mg).
[0718] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.6 Hz),
1.79 (1H, m), 2.16 (1H, m), 2.83 (1H, m), 3.07 (1H, m), 3.26 (2H,
m), 3.39 (2H, m), 3.73 (2H, m), 3.81 (1H, m), 3.93 (2H, m), 4.42
(2H, m), 6.73 (1H, s), 7.02 (1H, m), 7.15 (1H, d, J=15.8 Hz), 7.33
(1H, s), 8.05 (1H, d, J=15.8 Hz), 8.99 (1H, d, J=6.5 Hz)
Example 113
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-3-[(E)-2-(1H-1,2,3,4-tetrazol-5--
yl)-1-ethenyl]-2-(tetrahydro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-4-
-one
(A)
(E)-2-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(tetrahydro-3-
-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-1-ethenylcyanide
[0719]
(E)-2-{2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4-
H-pyrido-[1,2-a]pyrimidin-3-yl}-1-ethenylcyanide (100 mg) was added
with dimethylformamide (5 ml), diisopropylethylamine (500 ml) and
3-(iodomethyl)tetrahydrofuran (200 ml), and then the mixture was
stirred at 80.degree. C. for 2 hours and further stirred overnight
at room temperature. After the reaction mixture was distributed
between chloroform and water, the organic layer was dried over
magnesium sulfate. After the solvent was evaporated under reduced
pressure, the residue was purified by silica gel column
chromatography to obtain the title compound (51 mg).
[0720] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.78 (1H, m), 2.16 (1H, m), 2.79 (1H, m), 3.05 (1H, m), 3.29 (2H,
m), 3.38 (2H, m), 3.71 (1H, m), 3.82 (1H, m), 3.93 (2H, m), 4.42
(2H, m), 6.74 (1H, s), 6.68 (1H, d, J=16.3 Hz), 7.07 (1H, d, J=7.3
Hz), 7.37 (1H, s), 7.64 (1H, d, J=16.3 Hz), 8.97 (1H, d, J=7.3
Hz)
(B)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-3-[(E)-2-(1H-1,2,3,4-tetrazo-
l-5-yl)-1-ethenyl]-2-(tetrahydro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimid-
in-4-one
[0721] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.80 (1H, m), 2.18 (1H, m), 2.86 (1H, m), 3.08 (1H, m), 3.27 (2H,
m), 3.42 (2H, m), 3.80 (2H, m), 3.96 (2H, m), 4.47 (2H, m), 6.76
(1H, s), 7.04 (1H, m), 7.34 (1H, s), 7.90 (1H, d, J=16.3 Hz), 8.04
(1H, d, J=16.3 Hz), 8.99 (1H, d, J=7.0 Hz)
Example 114
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(2-pyridyl-methox-
y)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0722] .sup.1H-NMR (CD.sub.3OD-CDCl.sub.3) .delta.: 1.42 (6H, d,
J=6.8 Hz), 3.29 (1H, m), 3.40 (2H, m), 3.77 (2H, m), 5.96 (2H, s),
7.18 (1H, d, J=15.9 Hz), 7.37 (1H, m), 7.44 (1H, s), 7.80 (1H, s),
8.02 (1H, d, J=15.9 Hz), 8.07 (1H, m), 8.31 (1H, m), 8.68 (1H, m),
8.92 (1H, m), 9.04 (1H, d, J=7.3 Hz)
Example 115
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-pyridyl-methox-
y)-4H-pyridol 1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0723] .sup.1H-NMR (CD.sub.3OD-CDCl.sub.3) .delta.: 1.42 (6H, d,
J=6.8 Hz), 3.29 (1H, m), 3.45 (2H, m), 3.83 (2H, m), 5.85 (2H, s),
7.07 (1H, d, J=15.9 Hz), 7.39 (1H, d, J=7.3 Hz), 7.46 (1H, s), 7.78
(1H, s), 7.93 (1H, d, J=15.9 Hz), 8.18 (1H, m), 8.82 (2H, m), 9.01
(1H, d, J=7.1 Hz), 9.24 (1H, s)
Example 116
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-pyridyl-methox-
y)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0724] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.35 (6H, d, J=6.8 Hz),
3.29 (1H, m), 3.37 (2H, m), 3.70 (2H, m), 5.97 (2H, s), 7.16 (1H,
d, J=15.9 Hz), 7.38 (1H, d, J=7.0 Hz), 7.52 (2H, s), 8.08 (1H, d,
J=15.9 Hz), 8.20 (2H, m), 8.88 (2H, m), 9.06 (1H, d, J=7.0 Hz)
Example 117
(E)-3-{8-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-2-(tetrahy-
dro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
(A)
8-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-(tetrahydro-3-fur-
anyl-methoxy)-4H-pyrido[1,2-a]pyrimidin-4-one
[0725]
2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-py-
rido[1,2-a]-pyrimidin-4-one (210 mg, 0.670 mmol) was suspended in
dimethylformamide (6.0 ml), added with diisopropylethylamine (600
.mu.l) and 3-(iodomethyl)tetrahydrofuran (334 .mu.l), and stirred
overnight at 80.degree. C. The reaction solution was further added
with diisopropylethylamine (600 .mu.l) and
3-(iodomethyl)tetrahydrofuran (334 .mu.l) and stirred overnight at
80.degree. C. The reaction mixture was concentrated, and the
residue was purified by silica gel column chromatography
(chloroform:methanol=100:0 100:1.fwdarw.100:2.fwdarw.100:5, v/v) to
obtain the title compound (277 mg, quantitative).
(B) tert-Butyl
(E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-2-(tetrah-
ydro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0726] Dimethylformamide (3.0 ml) was added with phosphorus
oxychloride (187 .mu.l, 2.02 mmol) under ice cooling and stirred at
room temperature for 30 minutes. The mixture was added to
8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-(tetrahydro-3-furany-
lmethoxy)-4H-pyrido[1,2-a]pyrimidin-4-one (277 mg) obtained in (A)
and dissolved in dimethylformamide (3.0 ml) under ice cooling, and
then the mixture was stirred at room temperature for 4 hours. The
reaction mixture was added with saturated aqueous sodium
hydrogencarbonate and extracted with chloroform. The organic layer
was dried over magnesium sulfate, and the solvent was evaporated
under reduced pressure. The residue was suspended in anhydrous
tetrahydrofuran (6.0 ml) and anhydrous N,N-dimethylformamide (3.0
ml), added with (tert-butoxycarbonyl-methylene)triphenylphosphorane
(505 mg, 1.34 mmol) and stirred at 50.degree. C. for 16 hours. The
reaction mixture was concentrated, and then the residue was
purified by silica gel column chromatography (n-hexane:ethyl
acetate, 5:1.fwdarw.3:1.fwdarw.2:1.fwdarw.1:1, v/v) to obtain the
title compound (215 mg, 61%).
[0727] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.36 (6H, d, J=6.8 Hz),
1.53 (9H, s), 1.80 (1H, dt, J=7.3, 12.8 Hz), 2.12-2.21 (1H, m),
2.80-2.87 (1H, m), 3.12-3.19 (1H, m), 3.73 (1H, dd, J=5.4, 8.8 Hz),
3.81 (1H, dd, J=7.7, 15.2 Hz), 3.91-3.97 (2H, m), 4.44-4.47 (2H,
m), 6.99 (1H, s), 7.16 (1H, d, J=16.3 Hz), 7.31 (1H, d, J=1.8, 7.5
Hz), 7.39 (1H, d, J=16.2 Hz), 7.48 (1H, d, J=1.5 Hz), 7.54 (1H, d,
J=16.2 Hz), 7.92 (1H, d, J=16.3 Hz), 9.04 (1H, d, J=7.5 Hz)
[0728] ESI-MS; m/z: 524 (M.sup.++1)
(C)
(E)-3-{8-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-2-(tet-
rahydro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0729] The tert-butyl
(E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-2-(tetrah-
ydro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
(101 mg, 0.193 mmol) obtained in (B) was dissolved in 1,4-dioxane
(1.6 ml), added with 4 N hydrochloric acid in 1,4-dioxane (3.2 ml),
and then the mixture was stirred at room temperature for 16.25
hours. The reaction solution was concentrated, added with saturated
aqueous sodium hydrogencarbonate, neutralized with phosphate buffer
(pH 7-8), and then extracted with a mixture of chloroform/methanol
(10:1, v/v). The organic layer was dried over magnesium sulfate,
and then the solvent was evaporated under reduced pressure. The
residue was purified by thin layer chromatography
(chloroform:methanol=20:1, v/v) to obtain the title compound (77.1
mg, 86%).
[0730] .sup.1H-NMR (CDCl.sub.3+CD.sub.3OD) .delta.: 1.36 (6H, d,
J=6.8 Hz), 1.17-1.85 (1H, m), 2.13-2.22 (1H, m), 2.82-2.89 (1H, m),
3.13-3.19 (1H, m), 3.74 (1H, dd, J=5.4, 8.8 Hz), 3.82 (1H, dd,
J=7.7, 15.5 Hz), 3.93-3.98 (2H, m), 4.44-4.52 (2H, m), 7.01 (1H,
s), 7.16 (1H, d, J=15.9 Hz), 7.36-7.41 (2H, m), 7.50 (1H, s), 7.57
(1H, d, J=16.1 Hz), 8.03 (1H, d, J=15.9 Hz), 9.03 (1H, d, J=7.3
Hz)
[0731] ESI-MS; m/z: 468 (M.sup.++1)
Example 118
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-3-(1H-1,2,3,4-tetra-
zol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
(A)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-3-[(4-methoxybenzy-
l)tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one
[0732] 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine
(50 mg) and diethyl 2-[1-(4-methoxybenzyl)tetrazol-5-yl]malonate
(141 mg) were heated to 150.degree. C. in bromobenzene with
stirring for 4 hours. After the solvent was evaporated, the residue
was purified by silica gel column chromatography to obtain the
title compound (73 mg) as cream solid.
[0733] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.22 (d, J=6.6 Hz, 6H),
3.02 (m, 1H), 3.20-3.40 (m, 4H), 3.70 (s, 3H), 5.80 (s, 2H), 6.70
(s, 1H), 6.80 (bs, 2H), 7.00 (s, 1H), 7.30-7.50 (m, 3H), 9.00 (bs,
1H)
[0734] MS(-), m/z, 502 (M-H.sup.+)
(B)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-tosyloxy-3-[(4-methoxybenz-
yl)tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one
[0735] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-3-[(4-methoxybenzyl)--
tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one (73 mg) obtained in
(A) was dissolved in methylene chloride (2 ml), added with
dimethylaminopyridine (5 mg), triethylamine (40 ml) and
p-toluenesulfdnyl chloride (83 mg) at 0.degree. C., and then the
mixture was stirred at room temperature for 6 hours. The reaction
solution was directly purified by silica gel column chromatography
to obtain the title compound (61 mg, 64%) as pale yellow
powder.
[0736] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.22 (d, J=6.6 Hz, 6H),
2.42 (s, 3H), 3.05 (m, 1H), 3.25-3.32 (m, 4H), 3.80 (s, 3H), 5.75
(s, 2H), 6.75 (s, 1H), 6.85 (d, J=7.2 Hz, 2H), 7.15 (d, J=7.5 Hz,
1H), 7.24 (d, J=7.2 Hz, 2H), 7.35 (d, J=7.2 Hz, 2H), 7.42 (s, 1H),
7.90 (d, J=7.2 Hz, 2H), 9.01 (d, J=7.5 Hz, 1H)
(C)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-3-(1-p-methoxyb-
enzyl-1,2,3,4-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0737] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-tosyloxy-3-[(4-methoxybenzyl)-
-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one (61 mg) obtained in
(B) was dissolved in tetrahydrofuran (1 ml), added with morpholine
(40 ml) at room temperature, and stirred overnight at the same
temperature. After the solvent was evaporated under reduced
pressure, the residue was purified by silica gel column
chromatography to obtain the title compound (31 mg, 59%).
[0738] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (d, J=6.6 Hz, 6H),
3.06 (m, 1H), 3.30-3.70 (m, 12H), 3.78 (s, 3H), 5.76 (s, 2H), 6.72
(s, 1H), 6.77 (d, J=7.5 Hz, 1H), 6.86 (d, J=7.2 Hz, 2H), 7.14 (s,
1H), 7.36 (d, J=7.2 Hz, 2H), 8.88 (m, J=7.5 Hz, 1H)
(D)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-3-(1H-1,2,3,4-t-
etrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0739] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-3-(1-p-methoxy-ben-
zyl-1,2,3,4-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one (10 mg)
obtained in (C) was dissolved in trifluoroacetic acid (1 ml) and
added with anisole (50 ml), and then stirred at room temperature
for 4 hours. After the solvent was evaporated, the residue was
purified by silica gel column chromatography to obtain the title
compound (7 mg) as yellow powder.
[0740] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.25 (d, 6H), 3.04 (m,
1H), 3.22 (t, 2H), 3.38 (t, 2H), 3.66 (m, 4H), 3.82 (m, 4H), 6.73
(s, 1H), 6.89 (m, 1H), 7.22 (m, 1H), 8.83 (d, 1H)
[0741] MS (ES-) m/z 451 (M.sup.+-1)
[0742] In the following Examples 119 to 121, synthesis was
performed in the same manner as in Example 118.
Example 119
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-pyridylmethoxy)-3-(1H-1,2,3-
,4-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0743] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.21 (d, 6H), 2.98 (m,
1H), 3.25 (t, 2H), 3.36 (t, 2H), 5.73 (s, 2H), 6.71 (s, 1H), 7.16
(d, 1H), 7.31 (m, 1H), 7.42 (s, 1H), 8.10 (d, 1H), 8.41 (d, 1H),
8.69 (s, 1H), 8.99 (d, 1H)
[0744] MS (ES+) m/z 475 (M.sup.++1); MS (ES-) m/z 473
(M.sup.+-1)
Example 120
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-dimethylamino-3-(1H-1,2,3,4-te-
trazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0745] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.24 (d, 6H), 2.95 (s,
6H), 3.01 (m, 1H), 3.21 (t, 2H), 3.41 (t, 2H), 6.95 (s, 1H), 7.00
(m, 1H), 7.23 (s, 1H), 8.80 (d, 1H)
[0746] MS (ES+) m/z 512 (M.sup.++1); MS (ES-) m/z 510
(M.sup.+-1)
Example 121
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(4-cyanopiperidino)-3-(1H-1,2,-
3,4-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0747] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.33 (d, 6H), 2.02 (m,
2H), 2.10 (m, 2H), 2.95 (m, 1H), 3.20 (m, 4H), 3.45 (m, 2H), 3.62
(m, 1H), 3.79 (m, 2H), 6.82 (s, 1H), 6.90 (d, 1H), 7.18 (s, 1H),
8.85 (d, 1H)
[0748] MS (ES-) m/z 476 (M.sup.++1); 474 (M.sup.+-1)
Example 122
4-Isopropyl-2-(2-(3-[([(4-methylphenyl)sulfonyl]aminocarbonyl)amino]-4-oxo-
-4H-pyrido[1,2-a]pyrimidin-8-yl)ethyl)-1,3-thiazole
(A) tert-Butyl
N-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimi-
din-3-ylcarbamate
[0749] 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine
(300 mg) and methyl
2-(t-butoxycarbonyl)amino-3-dimethylaminopropenoate (445 mg) were
added with xylene (2 ml) and heated at 140.degree. C. for 6.5 hours
with stirring. After the solvent was evaporated, the residue was
purified by silica gel column chromatography to obtain the title
compound (200 mg) as yellow powder.
[0750] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.21 (d, J=6.9 Hz, 6H),
3.01 (m, 1H), 3.22 (t, J=7.8 Hz, 2H), 3.37 (t, J=7.8 Hz, 2H), 6.72
(s, 1H), 6.96 (d, J=7.2 Hz, 1H), 7.25 (s, 1H), 7.47 (s, 1H), 8.83
(d, J=7.5 Hz, 1H), 9.14 (s, 1H)
[0751] MS(+), m/z, 415 (M+H.sup.+), 829 (2M+H.sup.+)
(B)
3-Amino-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyri-
midin-4-one
[0752] The tert-butyl
N-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrimi-
din-3-ylcarbamate (200 mg) obtained in (A) was treated with 2 ml of
trifluoroacetic acid at room temperature for 1 hour, and the
solvent was evaporated under reduced pressure. The residue was
dissolved in ethyl acetate, washed with saturated sodium
hydrogencarbonate and dried over sodium sulfate. The solvent was
evaporated under reduced pressure, and the residue was purified by
silica gel column chromatography to obtain the title compound
(quantitative) as yellow powder.
[0753] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (d, J=6.9 Hz, 6H),
3.06 (m, 1H), 3.23 (t, J=7.8 Hz, 2H), 3.39 (t, J=7.8 Hz, 2H), 6.75
(s, 1H), 6.95 (d, J=7.5 Hz, 1H), 7.50 (s, 1H), 7.47 (s, 1H), 7.94
(s, 1H), 8.80 (d, J=7.5 Hz, 1H)
[0754] MS(+), m/z, 315 (M+H.sup.+)
(C)
4-Isopropyl-2-(2-3-[([(4-methylphenyl)sulfonyl]aminocarbonyl)amino]-4--
oxo-4H-pyrido[1,2-a]pyrimidin-8-ylethyl)-1,3-thiazole
[0755] The
3-amino-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]-pyrimi-
din-4-one (44 mg) obtained in (B) and p-toluenesulfonyl isocyanate
(42 mg) were dissolved in toluene (0.5 ml) and refluxed by heating
for 2.5 hours. After the solvent was evaporated, the residue was
purified by silica gel column chromatography to obtain the title
compound (33 mg) as white powder.
[0756] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.26 (d, 6H), 2.41 (s,
3H), 3.05 (m, 1H), 3.25 (t, 2H), 3.39 (t, 2H), 6.73 (s, 1H), 7.19
(dd, 1H), 7.31 (d, 1H), 7.56 (s, 1H), 7.96 (d, 1H), 8.71 (s, 1H),
9.04 (d, 1H), 9.39 (s, 1H)
[0757] MS (ES+) m/z 411 (M.sup.++1)
Example 123
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-py-
rimidin-3-yl}-2-propenoic acid
(A) Ethyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-
[1,2-a]-pyrimidin-3-yl}-2-propenoate
[0758] 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine
(200 mg), diethyl 4-dimethylaminomethyleneglutaconate (265 mg) was
added with bromobenzene (2 ml) and heated at 120.degree. C. for 1
hour and at 160.degree. C. for 4 hours with stirring. The residue
was purified by silica gel column chromatography to obtain the
title compound (20 mg) as white powder.
[0759] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20-1.40 (m, 9H), 3.05
(m, 1H), 3.32 (t, J=6.6 Hz, 2H), 3.40 (t, J=6.6 Hz, 2H), 4.27 (q,
J=7.2 Hz, 2H), 6.73 (s, 1H), 7.11 (d, J=7.2 Hz, 1H), 7.18 (d,
J=15.9 Hz, 1H), 7.51 (s, 1H), 7.66 (d, J=15.9 Hz, 1H), 8.45 (s,
1H), 9.08 (s, 1H) MS(+), m/z, 398 (M+H.sup.+), 420 (M+Na.sup.+),
MS(-), m/z, 396 (M-H.sup.+)
(B)
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a-
]pyrimidin-3-yl}-2-propenoic acid
[0760] The ethyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]p-
yrimidin-3-yl}-2-propenoate (15 mg) obtained in (A) was dissolved
in tetrahydrofuran (1 ml) and methanol (0.5 ml), added with a
solution of 8 mg of lithium hydroxide dissolved in 0.5 ml of water,
and stirred at room temperature for 3.5 hours, and the solvent was
concentrated under reduced pressure. The residue was distributed
between ether and water, and the aqueous layer was separated, made
pH 3 with hydrochloric acid, extracted with ethyl acetate, and
dried over sodium sulfate. After the solvent was evaporated, the
residue was purified by silica gel column chromatography to obtain
the title compound.
[0761] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.21 (d, 6H), 2.41 (s,
3H), 3.00 (m, 1H), 3.25 (t, 2H), 3.34 (t, 2H), 6.67 (s, 1H),
7.06-7.19 (m, 2H), 7.48 (s, 1H), 7.68 (d, J=16 Hz, 1H), 8.40 (s,
1H), 9.03 (d, J=7.5 Hz, 1H)
[0762] MS (ES+) m/z 370 (M.sup.++1); MS (ES-) m/z 368
(M.sup.+-1)
Example 124
2-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimi-
din-3-yloxy}acetic acid
(A) Ethyl
2-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-
-a]-pyrimidin-3-yloxy)acetate
[0763] 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine
(100 mg) and ethyl
2-ethoxycarbonylmethoxy-3-methoxy-3-dimethylaminopropenoate (150
mg) were heated at 140.degree. C. in xylene (1 ml) for 7 hours with
stirring. After the solvent was evaporated under reduced pressure,
the residue was purified by silica gel column chromatography to
obtain the title compound (41 mg).
[0764] .sup.1H-NMR(CDCl.sub.3, 300 MHz) .delta.: 1.20-1.30 (m, 9H),
3.04 (m, 1H), 3.23 (t, J=7.8 Hz, 2H), 3.40 (t, J=7.8 Hz, 2H), 4.25
(q, J=7.2 Hz, 2H), 4.86 (s, 2H), 6.72 (s, 1H), 6.98 (d, J=7.5 Hz,
1H), 7.45 (s, 1H), 8.29 (s, 1H), 8.90 (d, J=7.5 Hz, 1H)
[0765] MS(+), m/z, 401 (M+H.sup.+)
(B)
2-(8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyr-
imidin-3-yloxy)acetic acid
[0766] The ethyl
2-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrim-
idin-3-yloxy)acetate (41 mg) obtained in (A) was dissolved in
tetrahydrofuran (1 ml) and methanol (300 ml), added with a solution
of lithium hydroxide (5 mg) dissolved in water (300 ml), and then
the mixture was stirred at room temperature for 1 hour, and the
solvent was concentrated under reduced pressure. The residue was
distributed between ether and water, and the aqueous layer was
separated and made pH 3 with hydrochloric acid, and then extracted
with ethyl acetate. The organic layer was dried over sodium
sulfate. After the solvent was evaporated, the residue was purified
by silica gel column chromatography to obtain the title compound
(quantitative).
[0767] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.23 (d, 6H), 3.00 (m,
1H), 3.21 (t, 2H), 3.40 (t, 2H), 4.54 (s, 2H), 6.96 (s, 1H), 7.18
(d, 1H), 7.38 (s, 1H), 8.12 (s, 1H), 8.85 (d, 1H)
[0768] MS (ES-) m/z 372 (M.sup.+-1)
Example 125
5-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimi-
din-3-yl)-2,3-dihydro 1,3,4-oxadiazol-2-one
[0769] Methyl
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimidi-
n-3-carboxylate (22 mg) and hydrazine (4 ml) were refluxed by
heating in methanol (3 ml) for 2.5 hours under nitrogen atmosphere.
The reaction mixture was further added with hydrazine (10 ml) and
refluxed by heating for 2 days. After the reaction mixture was
cooled, insoluble solids were collected by filtration and suspended
in methylene chloride (5 ml). The suspension was added with
diphosgene (7 ml) and stirred for 30 minutes. Insoluble solids were
removed by filtration, and the reaction mixture was concentrated to
obtain the title compound (11 mg).
[0770] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.36 (s, 3H), 1.39 (s,
3H), 3.22 (m, 1H), 3.53 (m, 2H), 3.77 (m, 2H); 7.58 (s, 1H); 7.75
(d, 1H), 7.91 (s, 1H), 8, 84 (s, 1H), 9.31 (d, 1H)
[0771] MS (ES+) m/z 384 (M.sup.++1); MS (ES-) m/z 382
(M.sup.+-1)
Example 126
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-py-
rimidin-3-yl)-2-methyl-2-propenoic acid
(A) tert-Butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-p-
yrimidin-3-yl}-2-methyl-2-propenoate
[0772] tert-Butyl 2-(diethylphosphono)propionate (70 mg) was
dissolved in tetrahydrofuran (5 ml), added with sodium hydride (60%
in oil, 40 mg), and stirred for 10 minutes. The reaction mixture
was added with
8-(2-(4-isopropyl-1,3-thiazol-2-yl)-ethyl)-4-oxo-4H-pyrido[1,2-a]pyrimidi-
ne-3-carbaldehyde (56 mg), stirred for 10 minutes and added with
acetic acid (0.2 ml), and then distributed between ethyl acetate
and saturated aqueous sodium hydrogencarbonate. The organic layer
was concentrated, and the residue was purified by silica gel column
chromatography to obtain the title compound (70 mg) as yellow
oil.
[0773] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.27 (d, 6H), 1.51 (s,
9H), 2.07 (s, 3H), 3.05 (m, 1H), 3.3-3.5 (m, 4H), 6.72 (s, 1H),
7.07 (d, 1H), 7.52 (s, 1H), 7.68 (s, 1H), 8.41 (s, 1H), 9.00 (s,
1H)
(B)
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a-
]pyrimidin-3-yl]-2-methyl-2-propenoic acid
[0774] The tert-butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]p-
yrimidin-3-yl}-2-methyl-2-propenoate (70 mg) obtained in (A) was
dissolved in trifluoroacetic acid (1 ml) and stirred at room
temperature for 1 hour, and then the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography to obtain the title compound (21 mg).
[0775] .sup.1H-NMR (CDCl.sub.3+CD.sub.3OD) .delta.: 1.25 (d, 6H),
2.10 (s, 3H), 3.04 (m, 1H), 3.28 (t, 2H), 3.35-3.45 (m, with
CD.sub.3OD), 6.74 (s, 1H), 7.15 (d, 1H), 7.59 (s, 1H), 7.79 (s,
1H), 8.45 (s, 1H), 9.01 (d, 1H)
Example 127
(E)-2-(3-Chloroethyl)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4-
H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0776] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (d, 6H), 2.10 (m,
2H), 2.70 (m, 2H), 3.05 (m, 1H), 3.30 (t, 2H), 3.40 (t, 2H), 3.60
(m, 2H), 6.75 (s, 1H), 7.10 (d, 1H), 7.54 (s, 1H), 7.94 (s, 1H),
8.51 (s, 1H), 9.03 (d, 1H)
[0777] MS (ES+) m/z 446 (M.sup.++1); MS (ES-) m/z 444
(M.sup.+-1)
Example 128
(E)-3-{8-[2-(4-Isopropyl)-1,3-thiazol-2-yl]ethyl]-4-oxo-2-phenyl-4H-pyrido-
[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A)
2-Trifluoromethanesulfonyloxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl-
]-4H-pyrido[1,2-a]pyrimidin-4-one
[0778]
2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2--
a]-pyrimidin-4-one (400 mg) and DMAP (310 mg) were dissolved in
methylene chloride (8 ml), added with trifluoromethanesulfonic
anhydride (427 ml) at -78.degree. C., and then the mixture was
stirred overnight while the reaction temperature was gradually
returned to room temperature. The reaction mixture was added with
0.2 M hydrochloric acid (50 ml) and extracted with methylene
chloride, and the organic layer was dried over sodium sulfate.
After the solvent was evaporated, the residue was purified by
silica gel column chromatography to obtain the title compound (499
mg, 88%).
[0779] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.22 (d, J=7.5 Hz, 6H),
3.10 (m, 1H), 3.25-3.40 (m, 4H), 6.10 (s, 1H), 6.75 (s, 1H), 7.18
(d, J=7.5 Hz, 1H), 7.55 (s, 1H), 8.95 (d, J=7.5 Hz, 1H)
(B)
2-Phenyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyr-
imidin-4-one
[0780] The
2-trifluoromethanesulfonyloxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-
H-pyrido[1,2-a]pyrimidin-4-one (82 mg) obtained in (A),
phenylboronic acid (45 mg), palladium tetrakistriphenylphosphine
(11 mg), potassium bromide (24 mg) and potassium carbonate (38 mg)
were stirred at 85.degree. C. overnight in dioxane (4 ml) under a
nitrogen flow. The reaction mixture was cooled and added with water
(20 ml) and extracted with ethyl acetate, and then the organic
layer was dried over sodium sulfate. The solvent was evaporated
under reduced pressure, and the residue was purified by silica gel
column chromatography to obtain the title compound (65 mg, 94%) as
white powder.
[0781] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.22 (d, J=7.5 Hz, 6H),
3.00-3.10 (m, 1H), 3.30-3.50 (m, 4H), 6.72 (s, 1H), 6.85 (s, 1H),
6.99 (d, J=7.5 Hz, 1H), 7.46-7.56 (m, 5H), 8.20-8.40 (m, 1H), 8.96
(d, J=7.5 Hz, 1H)
(C) tert-Butyl
(E)-3-{2-phenyl-4-oxo-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido-
[1,2-a]pyrimidin-3-yl]-2-propenoate
[0782] Dimethylformamide (1 ml) and phosphorus oxychloride (25 ml)
were mixed under ice cooling and stirred at room temperature for 30
minutes. The mixture was added with a solution of the
2-phenyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyrimi-
din-4-one (65 mg) obtained in (B) and dissolved in
dimethylformamide (1 ml) and stirred at room temperature for 1 hour
and at 95.degree. C. for 1.5 hours on an outer bath. The reaction
mixture was cooled and then added with ethyl acetate and hexane.
Then, the organic layer was washed with saturated aqueous sodium
hydrogencarbonate and water and dried over magnesium sulfate, and
the solvent was evaporated under reduced pressure. The residue was
added with tetrahydrofuran (2.5 ml) and dimethylformamide (0.5 ml),
further added with
(tert-butoxycarbonylmethylidene)triphenylphosphorane (240 mg), and
stirred at 80.degree. C. for 10 hours. The solvent was evaporated
under reduced pressure, and the residue was purified by silica gel
column chromatography to obtain the title compound (18 mg).
[0783] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.22 (d, J=7.5 Hz, 6H),
3.00-310 (m, 1H), 3.30-3.50 (m, 4H), 6.82 (s, 1H), 6.99 (d, J=7.5
Hz, 1H), 7.40-7.66 (m, 7H), 8.05-8.10 (m, 1H), 8.95 (d, J=7.5 Hz,
1H)
(D)
(E)-3-{8-[2-(4-Isopropyl)-1,3-thiazol-2-yl]ethyl}-4-oxo-2-phenyl-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0784] The tert-butyl
(E)-3-{2-phenyl-4-oxo-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido-
[1,2-a]pyrimidin-3-yl}-2-propenoate (18 mg) obtained in (C) was
added with trifluoroacetic acid (1 ml) and stirred at room
temperature for 2 hours. The solvent was evaporated under reduced
pressure, and the residue was purified by silica gel column
chromatography to obtain the title compound (15 mg) as yellow
powder.
[0785] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.25 (d, 6H), 3.05 (m,
1H), 3.28 (t, 2H), 3.39 (t, 2H), 6.75 (s, 1H), 7.12 (d, 1H), 7.39
(d, J=16 Hz, 1H), 7.50 (m, 3H), 7.58 (m, 3H), 7.72 (d, J=16 Hz,
1H), 9.05 (d, 1H)
Example 129
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-pyridyl)-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-pyridyl)-4H-pyrido[1,2--
a]pyrimidin-4-one
[0786]
2-Trifluoromethanesulfonyloxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)e-
thyl]-4H-pyrido[1,2-a]pyrimidin-4-one (499 mg), pyridine-3-boronic
acid 1,3-propanediol cyclic ester (364 mg), palladium
tetrakistriphenylphosphine (65 mg), potassium bromide (146 mg) and
potassium carbonate (231 mg) were added with dioxane (8 ml) and
stirred overnight at 85.degree. C. under nitrogen atmosphere. The
reaction mixture was cooled and then added with ethyl acetate.
Insoluble solids were removed by filtration, and the solvent of the
filtrate was evaporated. The residue was purified by silica gel
column chromatography to obtain the title compound (400 mg).
[0787] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.18 (d, J=7.2 Hz, 6H),
2.98 (m, 1H), 3.05-3.30 (m, 4H), 6.66 (s, 1H), 6.75 (s, 1H), 7.02
(dd, J=7.5, 1.8 Hz, 1H), 7.38 (dd, J=7.5, 7.8 Hz, 1H), 7.49 (d,
J=1.2 Hz, 1H), 8.30 (dt, J=7.5, 1.8 Hz, 1H), 8.55 (dd, J=7.5, 1.2
Hz, 1H), 8.86 (d, J=7.8 Hz, 1H), 9.11 (d, J=1.2 Hz, 1H).
(B) Methyl
(E)-3-(8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-pyr-
idyl)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0788] Phosphorus oxychloride (367 ml) was added to
dimethylformamide (5 ml) under ice cooling and stirred at the same
temperature for 10 minutes. The mixture was added with the
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-pyridyl)-4H-pyrido-[1,2-a]-
pyrimidin-4-one (336 mg) obtained in (A) and stirred at 950C for
1.5 hours. The mixture was cooled, then slowly added with sodium
carbonate and extracted with ethyl acetate. The organic layer was
dried over sodium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography to obtain yellow powder (58 mg). The resulting
powder was dissolved in tetrahydrofuran (2.5 ml) and
dimethylformamide (0.5 ml), added with methyl
(triphenylphosphoranylidene)acetate (240 mg) and stirred at
90.degree. C. for 10 hours. After the solvent was evaporated under
reduced pressure, the residue was purified by silica gel column
chromatography to obtain the title compound (19 mg) as yellow
powder.
[0789] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.22 (d, J=7.5 Hz, 6H),
3.05 (m, 1H), 3.30-3.50 (m, 4H), 3.75 (s, 3H), 6.88 (s, 1H), 7.15
(dd, J=7.2, 2.1 Hz, 1H), 7.40-7.60 (m, 4H), 7.93 (dt, J=7.8, 1.8
Hz, 1H), 8.75 (dd, J=5.1,1.5 Hz, 1H), 8.87 (d, J=1.8 Hz, 1H), 9.08
(d, J=7.5 Hz, 1H)
(C)
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-pyridyl)-4-
H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0790] The methyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-pyridyl)-4H-p-
yrido[1,2-a]pyrimidin-3-yl}-2-propenoate obtained in (B) was
dissolved in tetrahydrofuran (2 ml) and methanol (0.5 ml), added
with a solution (0.5 ml) containing lithium hydroxide (5.5 mg) and
stirred at room temperature for 1-hour. The solvent was evaporated
under reduced pressure, and the residue was distributed between
water and diethyl ether. The aqueous layer was separated, made pH
4-5 with hydrochloric acid, and then extracted with ethyl acetate.
The organic layer was dried over sodium sulfate, and the solvent
was evaporated. The residue was purified by silica gel column
chromatography to obtain the title compound (6.9 mg) as yellow
powder.
[0791] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.18 (d, 6H), 2.95 (m,
1H), 3.21 (t, 2H), 3.32 (t, 2H), 6.67 (s, 1H), 7.15 (d, 1H), 7.23
(d, J=13 Hz, 1H), 7.41 (d, J=13 Hz, 1H), 7.48 (s, 1H), 7.55 (m,
1H), 8.01 (m, 1H), 8.65 (m, 1H), 8.76 (s, 1H), 8.98 (d, 1H)
[0792] MS (ES+) m/z 447 (M.sup.++1); MS (ES-) m/z 445
(M.sup.+-1)
Example 130
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(4-pyridyl)-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0793] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.25 (d, 6H), 3.02 (m,
1H), 3.2-3.5 (m, with CHD.sub.2OD), 6.87 (s, 1H), 7.33 (d, J=16 Hz,
1H), 7.38 (m, 1H), 7.45 (d, J=16 Hz, 1H), 7.59 (m, 2H), 7.72 (s,
1H), 8.72 (m, 2H), 9.13 (d, 1H)
[0794] MS (ES+) m/z 447 (M.sup.++1); MS (ES-) m/z 445
(M.sup.+-1)
Example 131
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyr-
ido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoic acid
(A) Ethyl
(E)-3-[8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4--
oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-methyl-2-propenoate
[0795] Under nitrogen atmosphere, triethyl 2-phosphonopropionate
(155 mg, 0.65 mmol) was dissolved in tetrahydrofuran (2 ml), added
with n-butyl lithium (1 M, 0.65 ml) at -78.degree. C., and stirred
at the same temperature for 20 minutes. The reaction mixture was
added with a solution of
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,-
2-a]pyrimidine-3-carbaldehyde (50 mg) dissolved in tetrahydrofuran
(1 ml). The cooling bath was removed, and the reaction mixture was
warmed to room temperature and stirred overnight at room
temperature. The reaction mixture was added with saturated aqueous
sodium hydrogencarbonate and extracted with ethyl acetate. The
organic layer was dried over magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography to obtain the title compound (14
mg).
[0796] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20-1.30 (m, 9H), 1.79
(s, 3H), 2.95 (m, 1H), 3.11 (t, J=7.5 Hz, 2H), 3.29 (t, J=7.5 Hz,
2H), 3.48 (t, J=4.8 Hz, 4H), 3.66 (t, J=4.8 Hz, 4H), 4.05-4.15 (m,
2H), 6.66 (s, 1H), 6.75 (d, J=7.5 Hz, 1H), 7.12 (s, 1H), 7.45 (s,
1H), 8.75 (d, J=7.5 Hz, 1H)
(B)
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-
-pyrido-[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoic acid
[0797] The ethyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoate (14 mg) obtained
in (A) was dissolved in tetrahydrofuran (4 ml) and methanol (1 ml),
added with a solution of lithium hydroxide (1.4 mg) in water (1 ml)
and stirred at room temperature for 1.5 hours. The reaction mixture
was added with water and washed with ether, and then the aqueous
layer was made acidic with diluted hydrochloric acid and extracted
with ethyl acetate. The organic layer was dried over magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (4.4 mg) as yellow powder.
[0798] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.24 (d, 6H), 1.86 (s,
3H), 3.05 (m, 1H), 3.19 (t, 2H), 3.38 (t, 2H), 3.58 (m, 4H), 3.74
(m, 4H), 6.74 (s, 1H), 6.82 (d, 1H), 7.20 (s, 1H), 7.63 (s, 1H),
8.83 (d, 1H)
[0799] MS (ES+) m/z 469 (M.sup.++1); MS (ES-) m/z 467
(M.sup.+-1)
Example 132
(E)-2-Methyl-3-(8-{2-[4-(1-methylcyclopropyl)-1,3-thiazol-2-yl]ethyl}-2-mo-
rpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0800] .sup.1H-NMR (CDCl.sub.3) .delta.: 0.75 (m, 2H), 1.14 (m,
2H), 1.42 (s, 3H), 1.88 (s, 3H), 3.18 (t, 2H), 3.34 (t, 2H), 3.59
(m, 4H), 3.76 (m, 4H), 6.73 (s, 1H), 6.81 (d, 1H), 7.22 (s, 1H),
7.63 (s, 1H), 8.82 (d, 1H)
[0801] MS (ES+) m/z 481
Example 133
(E)-3-{8-[2-(4-tert-Butyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoic acid
[0802] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.35 (s, 9H), 1.85 (s,
3H), 3.20 (t, 2H), 3.36 (t, 2H), 3.58 (m, 4H), 3.75 (m, 4H), 6.73
(s, 1H), 6.81 (d, 1H), 7.20 (s, 1H), 7.61 (s, 1H), 8.81 (d, 1H)
[0803] MS (ES+) m/z 483 (M.sup.++1); MS (ES-) m/z 481
(M.sup.+-1)
Example 134
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-aminopyrrolidino-4-o-
xo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoic acid
[0804] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.20 (d, 6H), 1.59 (s,
3H), 1.95 (m, 1H), 2.23 (m, 1H), 2.98 (m, 1H), 3.10 (m, 2H), 3.35
(m, 2H), 3.43 (m, 1H), 3.62 (m, 2H), 3.75 (m, 2H), 6.88 (m, 2H),
7.08 (s, 1H), 7.36 (s, 1H), 8.62 (d, 1H)
[0805] MS (ES+) m/z 468 (M.sup.++1)
Example 135
(Z)-2-Fluoro-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-o-
xo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) Ethyl
(Z)-2-fluoro-3-[8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydr-
oxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate
[0806] 2-Fluoro-2-phosphonoacetic acid triethyl ester (384 mg) was
dissolved in tetrahydrofuran (3 ml) and dimethylformamide (1.5 ml),
added with n-butyl lithium (1.6 M, 1 ml) at -78.degree. C. under
nitrogen atmosphere, and then the mixture was stirred at the same
temperature for 20 minutes. The reaction mixture was added with a
solution of
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrido[1,2-a-
]-pyrimidine-3-carbaldehyde (108 mg) dissolved in tetrahydrofuran
(2 ml). The reaction temperature was gradually raised to room
temperature, and the reaction mixture was stirred overnight at the
same temperature. The reaction mixture was added with water and
extracted with methylene chloride, and the organic layer was dried
over magnesium sulfate. Then, the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography to obtain the title compound (35 mg) as a mixture of
(E)- and (Z)-isomers.
[0807] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20-1.30 (m, 9H), 3.05
(m, 1H), 3.20-3.30 (m, 4H), 4.05-4.15 (m, 2H), 6.70-6.80 (m, 2H),
7.14 (d, J=7.5 Hz, 1H), 7.41 (s, 1H), 9.00-9.05 (m, 1H) MS(+), m/z,
382 (M+H.sup.+); MS(-), m/z, 380 (M-H.sup.+)
(B) Ethyl
(Z)-2-fluoro-3-(8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morp-
holino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0808] The ethyl
2-fluoro-3-(8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H--
pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (35 mg) obtained in (A)
was dissolved in methylene chloride (2 ml), added with
triethylamine (35 ml) and tosyl chloride (46 mg) under ice cooling,
and then the mixture was stirred overnight at room temperature. The
reaction mixture was added with morpholine (49 ml) and further
stirred for 4 hours. After the solvent was evaporated under reduced
pressure, the residue was purified by silica gel column
chromatography to obtain yellow powder (28 mg). This was dissolved
in methylene chloride (1 ml), added with a trace amount of iodine,
and then the mixture was stirred at room temperature for 30
minutes, and the solvent was evaporated to obtain the title
compound.
[0809] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20-1.30 (m, 9H), 3.05
(m, 1H), 3.20 (t, J=7.8 Hz, 2H), 3.36 (t, J=7.8 Hz, 2H), 3.55-3.80
(m, 8H), 4.20-4.35 (m, 2H), 6.70-6.82 (m, 2H), 7.19 (d, J=7.5 Hz,
1H), 7.35 (d, J=36.9 Hz, 1H), 8.75-8.85 (m, 1H)
(C)
(Z)-2-Fluoro-3-[8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-
-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0810] The ethyl
(Z)-2-fluoro-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4--
oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (28 mg) obtained
in (B) was dissolved in tetrahydrofuran (2 ml) and methanol (0.5
ml), added with a solution of lithium hydroxide (5 mg) in water
(0.5 ml), and then the mixture was stirred at room temperature for
1 hour. The reaction mixture was added with water and washed with
ether. Then, the aqueous layer was made acidic with diluted
hydrochloric acid and extracted with ethyl acetate. The organic
layer was dried over magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography to obtain the title compound (26
mg) as yellow powder.
[0811] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.24 (d, 6H), 3.03 (m,
1H), 3.18 (t, 2H), 3.37 (t, 2H), 3.62 (m, 4H), 3.72 (m, 4H),
6.88-7.0 (m, 3H), 7.18 (s, 1H), 8.72 (d, 1H)
[0812] MS (ES+) m/z 473 (M.sup.++1); MS (ES-) m/z 471
(M.sup.+-1)
Example 136
(Z)-2-Fluoro-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxy-pip-
eridino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0813] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.2-1.4 (m, 7H), 1.52 (m,
2H), 1.80 (m, 1H), 2.0 (m, 1H), 3.0 (m, 2H), 3.2 (t, 2H), 3.38 (t,
2H), 3.65 (m, 1H), 3.9 (m, 1H), 4.15 (m, 1H), 6.97 (m, 2H), 7.15
(d, J=36 Hz, 1H), 7.15 (s, 1H), 8.66 (d, 1H)
Example 137
(Z)-2-Fluoro-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-aminocarbon-
ylmorpholino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0814] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.24 (d, 6H), 3.0 (m, 2H),
3.2 (m, 3H), 3.38 (t, 2H), 3.68 (m, 1H), 4.0 (m, 3H), 4.46 (d, 1H),
6.97 (s, 1H), 7.03 (d, 1H), 7.13 (s, 1H), 7.19 (d, J=36 Hz, 1H),
7.25 (s, 1H), 8.75 (d, 1H)
[0815] MS (ES-) m/z 514 (M.sup.+-1)
Example 138
(Z)-2-Fluoro-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-cyanomorpho-
lino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0816] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.22 (d, 6H), 3.0 (m, 1H),
3.15 (m, 2H), 3.25 (m, 4H), 3.70-4.0 (m, 4H), 4.26 (dd, 1H), 6.72
(s, 1H), 6.81 (d, 1H), 6.85 (d, J=36 Hz, 1H), 7.16 (s, 1H), 8.72
(d, 1H)
[0817] MS (ES-) m/z 496 (M.sup.+-1)
Example 139
(Z)-2-Fluoro-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-(4-amino-methy-
lcarbonylpiperazino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0818] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.22 (d, 6H), 3.02 (m,
1H), 3.21 (t, 2H), 3.39 (t, 2H), 3.53 (m, 2H), 3.65 (m, 6H), 3.98
(s, 2H), 6.98 (s, 1H), 7.05 (d, 1H), 7.22 (s, 1H), 7.26 (d, J=37
Hz, 1H), 8.77 (d, 1H)
[0819] MS (ES+) m/z 529 (M.sup.++1); MS (ES-) m/z 527
(M.sup.+-1)
Example 140
(Z)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyr-
ido[1,2-a]pyrimidin-3-yl}-2-methoxy-2-propenoic acid
(A) Ethyl
(Z)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4--
oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-methoxy-2-propenoate
[0820] 2-Methoxy-2-phosphonoacetic acid triethyl ester (92 mg) was
dissolved in tetrahydrofuran (1 ml), added with n-butyl lithium
(1.6 M, 0.23 ml) at -78.degree. C. under nitrogen atmosphere, and
then the mixture was stirred at the same temperature for 30
minutes. The reaction mixture was added with a solution of
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,-
2-a]pyrimidine-3-carbaldehyde (50 mg) dissolved in tetrahydrofuran
(1 ml). The reaction temperature was gradually raised to room
temperature, and the reaction mixture was stirred overnight at the
same temperature. The reaction mixture was added with water and
extracted with methylene chloride. The organic layer was dried over
magnesium sulfate, and the solvent was evaporated under reduced
pressure. The residue was purified by silica gel column
chromatography to obtain the title compound.
[0821] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20-1.30 (m, 9H), 3.05
(m, 1H), 3.15-3.35 (m, 4H), 3.50 (s, 3H), 3.55-3.70 (m, 8H),
4.05-4.15 (m, 2H), 6.70-6.80 (m, 2H), 7.14 (s, 1H), 7.21 (s, 1H),
8.78 (d, J=7.5 Hz, 1H)
(B)
(Z)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-
-pyrido-[1,2-a]pyrimidin-3-yl}-2-methoxy-2-propenoic acid
[0822] The ethyl
(Z)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]pyrimidin-3-yl}-2-methoxy-2-propenoate obtained in (A)
was dissolved in tetrahydrofuran (2 ml) and methanol (0.5 ml),
added with a solution of lithium hydroxide (5 mg) in water (0.5
ml), and then the mixture was stirred at room temperature for 2.5
hours. The reaction mixture was added with water and washed with
ether, and then the aqueous layer was made acidic with diluted with
hydrochloric acid and extracted with ethyl acetate. The organic
layer was dried over magnesium sulfate, and the solvent was
evaporated under reduced pressure to obtain the title compound (6
mg, 10% for the two steps) as yellow powder.
[0823] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.23 (d, 6H), 3.02 (m,
1H), 3.19 (t, 2H), 3.38 (t, 2H), 3.55 (s, 3H), 3.62 (m, 4H), 3.70
(m, 4H), 6.95 (s, 1H), 6.99 (m, 2H), 7.18 (s, 1H), 8.74 (d, 1H)
[0824] MS (ES+) m/z 485 (M.sup.++1); MS (ES-) m/z 483
(M.sup.+-1)
Example 141
5-(1-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyri-
do[1,2-a]pyrimidin-3-yl]methylidene)-1,3-thiazolidine-2,4-dione
[0825]
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-py-
rido[1,2-a]-pyrimidine-3-carbaldehyde (18 mg) and
2,4-thiazolidinedione (53 mg) were added with benzene (10 ml),
piperidine (one drop) and acetic acid (two drops) and refluxed by
heating for 3 hours in a vessel provided with a Dean-Stark trap.
After the solvent was evaporated under reduced pressure, the
residue was purified by silica gel column chromatography to obtain
the title compound (17 mg) as yellow powder.
[0826] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.26 (d, 6H), 3.01 (m,
1H), 3.22 (t, 2H), 3.38 (t, 2H), 3.63 (m, 4H), 3.80 (m, 4H), 6.73
(s, 1H), 6.87 (d, 1H), 7.23 (s, 1H), 7.78 (s, 1H), 8.80 (d, 1H)
[0827] MS (ES-) m/z 510 (M.sup.+-1)
Example 142
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-4-oxo-4H-pyrido-
[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) tert-Butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-4-oxo-4H-pyrid-
o[1,2-a]pyrimidin-3-yl}-2-propenoate
[0828] tert-Butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrid-
o[1,2-a]pyrimidin-3-yl}-2-propenoate (20 mg) and triethylamine (63
ml) were dissolved in dimethylformamide (1.5 ml) and stirred at
room temperature for 20 minutes under nitrogen atmosphere. The
reaction mixture was added with dimethyl sulfate (4.3 ml) and
stirred in the dark for 2 days. The reaction mixture was further
added with dimethyl sulfate (4.3 ml) and stirred for 2 days in the
same manner. The reaction mixture was added with water and
extracted with ethyl acetate. The organic layer was washed with 1%
aqueous solution of lithium chloride and dried over magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (6.7 mg) as yellow powder. The starting material
(7.6 mg) was also recovered.
[0829] .sup.1H-NMR (CDCl.sub.3): 1.28 (s, 3H), 1.29 (s, 3H), 1.51
(s, 9H), 3.07 (m, 1H), 3.21 (m, 2H), 3.42 (m, 2H), 4.06 (s, 3H),
6.74 (s, 1H), 7.01 (d, 1H), 7.11 (d, 1H), 7.37 (s, 1H), 7.94 (d,
1H), 9.00 (d, 1H)
(B)
(E)-3-[8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-4-oxo-4H-py-
rido[1,2-a]-pyrimidin-3-yl}-2-propenoic acid
[0830] The tert-butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-4-oxo-4H-pyrid-
o[1,2-a]pyrimidin-3-yl]-2-propenoate (6.7 mg) obtained in (A) was
treated with trifluoroacetic acid (0.5 ml) in the dark for 30
minutes, and then the solvent was evaporated. The residue was added
with methanol and methylene chloride, and insoluble matters were
collected by filtration to obtain the title compound (7.2 mg).
[0831] .sup.1H-NMR (CDCl.sub.3): 1.30 (s, 3H), 1.32 (s, 3H), 3.11
(m, 1H), 3.31 (m, 2H), 3.45 (m, 2H), 4.07 (s, 3H), 6.77 (s, 1H),
7.05 (d, 1H), 7.18 (d, 1H), 7.39 (s, 1H), 8.10 (d, 1H), 9.02 (d,
1H)
[0832] MS (ES-): 398
Example 143
(Z)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-4-oxo-4H-pyrido-
[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0833]
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-4-oxo-4-
H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid (1 mg) was
dissolved in CDCl.sub.3 (0.5 ml) and irradiated with light from a
fluorescent lamp for 19 hours. The solvent was evaporated to obtain
the title compound (1 mg).
[0834] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (s, 3H), 1.29 (s,
3H), 3.12 (m, 1H), 3.38 (m, 2H), 3.61 (m, 2H), 4.06 (s, 3H), 6.19
(d, 1H), 6.80 (d, 1H), 6.90 (s, 1H), 7.05 (d, 1H), 7.40 (d, 1H),
7.50 (s, 1H), 9.04 (d, 1H)
[0835] MS (ES-): 398
Example 144
(E)-3-[(8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrid-
o[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0836] tert-Butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrid-
o[1,2-a]pyrimidin-3-yl}-2-propenoate (15 mg) was treated with
formic acid (1 ml) in the dark for 1 hour, and added with toluene.
The solvent was evaporated under reduced pressure to obtain the
title compound (22 mg).
[0837] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.18 (s, 3H), 1.21 (s,
3H), 2.99 (m, 1H), 3.23-3.40 (m, 4H), 6.82 (d, 1H), 7.10 (s, 1H),
7.20 (s, 1H), 7.42 (d, 1H), 7.85 (d, 1H), 8.91 (d, 1H)
[0838] MS (ES-): 384
Example 145
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-9-methoxy-2-morphol-
ino-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) 3-Methoxy-4-methyl-2-nitropyridine
[0839] 3-Hydroxy-4-methyl-2-nitropyridine (5 g) was dissolved in
dimethylformamide (50 ml), added with cesium carbonate (11.6 g) and
methyl iodide (13.7 g), and then the mixture was stirred overnight
at room temperature. The reaction mixture was added with ethyl
acetate and hexane, washed with water and dried over magnesium
sulfate, and then the solvent was evaporated under reduced pressure
to obtain the title compound (quantitative).
[0840] .sup.1H-NMR (CDCl.sub.3) .delta.: 2.30 (s, 3H), 3.78 (s,
3H), 7.27 (d, J=4.8 Hz, 1H), 7.98 (d, J=4.8 Hz, 1H)
(B) 2-Amino-3-methoxy-4-methylpyridine
[0841] The 3-methoxy-4-methyl-2-nitropyridine (1 g) obtained in (A)
was dissolved in methanol (50 ml), added with 5% Pd/C (200 mg), and
stirred at a pressure of 40 psi for 2 hours under hydrogen
atmosphere. After the catalyst was removed by filtration, the
solvent was evaporated under reduced pressure to obtain the title
compound (850 mg) as yellow oil.
[0842] .sup.1H-NMR (CDCl.sub.3) .delta.: 2.20 (s, 3H), 3.70 (s,
3H), 4.6 (s, 2H), 6.45 (d, J=4.8 Hz, 1H), 7.85 (d, J=4.8 Hz,
1H)
(C) 2-(tert-Butoxycarbonylamino)-3-methoxy-4-methylpyridine
[0843] The 2-amino-3-methoxy-4-methylpyridine (850 mg) obtained in
(B) was dissolved in tert-butanol (10 ml), added with di-tert-butyl
dicarbonate (2 g), and stirred at room temperature for 72 hours.
After the solvent was evaporated under reduced pressure, the
residue was purified by silica gel column chromatography to obtain
the title compound (1.1 g).
[0844] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.52 (s, 9H), 2.27 (s,
3H), 3.75 (s, 3H), 4.6 (s, 1H), 6.78 (d, J=4.8 Hz, 1H), 8.05 (d,
J=4.8 Hz, 1H)
(D) tert-Butyl
N-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-methoxy-2-pyridylcarbamate
[0845] The 2-(tert-butoxycarbonylamino)-3-methoxy-4-methylpyridine
(2.84 g) obtained in (C) was dissolved in anhydrous tetrahydrofuran
(50 ml) and added dropwise with n-butyl lithium (1.6 M, 19 ml) at
-78.degree. C. under nitrogen atmosphere. Then, the reaction
temperature was raised to room temperature. The reaction mixture
was cooled to -78.degree. C. again, added dropwise with a solution
of 2-bromomethyl-4-isopropylthiazole (3.94 g) dissolved in
tetrahydrofuran (10 ml) and stirred at the same temperature for 1
hour. Then, the reaction mixture was added with water and extracted
with ethyl acetate. The organic layer was dried over sodium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (4.1 g).
[0846] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20 (d, J=6.9 Hz, 6H),
1.45 (s, 9H), 2.95-3.20 (m, 5H), 3.67 (s, 3H), 6.60 (s, 1H), 6.70
(d, J=4.8 Hz, 1H), 8.05 (d, J=4.8 Hz, 1H)
(E)
2-Amino-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-methoxypyridine
[0847] The tert-butyl
N-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-methoxy-2-pyridylcarbamate
(4.1 g) obtained in (D) was added with trifluoroacetic acid (20 ml)
at room temperature and stirred overnight. Then, the reaction
mixture was added with 50 ml of water and 5 ml of 6 M hydrochloric
acid and washed with ether. The aqueous layer was carefully added
with sodium hydrogencarbonate to make pH of the aqueous layer
weakly alkaline, and then extracted with ethyl acetate. The organic
layer was dried over sodium sulfate, and the solvent was evaporated
under reduced pressure to obtain the title compound (2.7 g).
[0848] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.20 (d, J=6.9 Hz, 6H),
3.00-3.30 (m, 5H), 3.70 (s, 3H), 4.6 (s, 2H), 6.50 (s, 1H), 6.70
(d, J=4.8 Hz, 1H), 7.75 (d, J=4.8 Hz, 1H)
(F)
2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-4H-pyrid-
o[1,2-a]-pyrimidin-4-one
[0849] The
2-amino-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-methoxypyridine
(2.35 g) obtained in (E) and bis-2,4,6-trichlorophenyl malonate
(4.3 g) were refluxed by heating for 1 hour in toluene (25 ml), and
then the solvent was evaporated under reduced pressure. The residue
was purified by silica gel column chromatography to obtain the
title compound (2.8 g).
[0850] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (d, J=6.9 Hz, 6H),
2.95-3.05 (m, 1H), 3.30-3.40 (m, 4H), 3.95 (s, 3H), 5.35 (s, 1H),
6.70 (s, 1H), 7.00 (d, J=7.2 Hz, 1H), 8.82 (d, J=7.2 Hz, 1H)
(G)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-2-morpholino-4H-py-
rido[1,2-a]-pyrimidin-4-one
[0851] The
2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-4H-pyrido-[-
1,2-a]pyrimidin-4-one (1.77 g) obtained in (F) was dissolved in
methylene chloride (40 ml), added with triethylamine (1.5 ml) and
tosyl chloride (1.96 g) under ice cooling, and then the mixture was
stirred at room temperature. After disappearance of the starting
material was observed, the reaction mixture was added with
morpholine (2.2 ml) and stirred overnight. After the solvent was
evaporated under reduced pressure, the residue was purified by
silica gel column chromatography to obtain the title compound (0.99
g) as yellow powder.
[0852] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (d, J=6.9 Hz, 6H),
3.00-3.10 (m, 1H), 3.20 (t, J=7.2 Hz, 2H), 3.30 (t, J=7.2 Hz, 2H),
3.65-3.80 (m, 8H), 4.00 (s, 3H), 5.60 (s, 1H), 6.65-6.70 (m, 2H),
8.80 (d, J=7.2 Hz, 1H)
(H)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-2-morpholino-4-oxo-
-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde
[0853] Dimethylformamide (2 ml) was added with phosphorus
oxychloride (0.6 ml) under ice cooling and stirred at room
temperature for 20 minutes. This mixture was cooled again with ice,
and added with a solution of the
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-2-morpholino-4H-pyrid-
o[1,2-a]pyrimidin-4-one (0.99 g) obtained in (G) in methylene
chloride (10 ml). The reaction mixture was stirred at room
temperature for 3 hours, added with water, then added with
saturated aqueous sodium hydrogencarbonate and extracted with
methylene chloride. After the organic layer was dried over sodium
sulfate, the solvent was evaporated and the residue was purified by
silica gel column chromatography to obtain the title compound (1.54
g).
[0854] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (d, J=6.9 Hz, 6H),
3.00-3.10 (m, 1H), 3.20 (t, J=7.2 Hz, 2H), 3.30 (t, J=7.2 Hz, 2H),
3.70-3.85 (m, 8H), 3.95 (s, 3H), 6.75 (d, J=7.5 Hz, 1H), 8.00 (s,
1H), 8.55 ((d, J=7.5 Hz), 10.05 (s, 1H)
(I) tert-Butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-9-methoxy-2-morpho-
lino-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0855] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-2-morpholino-4-oxo-4H-
-pyrido[1,2-a]pyrimidine-3-carbaldehyde (300 mg) obtained in (H)
was dissolved in tetrahydrofuran (4 ml) and dimethylformamide (1
ml), added with (tert-butoxy-carbonylmethylene)triphenylphosphorane
(767 mg), and stirred at 80.degree. C. for 15 hours. After the
solvent was evaporated, the residue was purified by silica gel
column chromatography to obtain the title compound (209 mg) as
yellow powder.
[0856] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.25 (d, J=6.9 Hz, 6H),
1.5 (s, 9H), 3.00-3.10 (m, 1H), 3.20-3.35 (m, 4H), 3.60-3.85 (m,
8H), 4.00 (s, 3H), 6.70 (s, 1H), 6.80 (d, J=7.5 Hz, 1H), 7.05 (d,
J=15.3 Hz, 1H), 7.50 (d, J=15.3 Hz, 1H), 8.65 (d, J=7.5 Hz, 1H)
(J)
(E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-9-methoxy-2-mor-
pholino-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0857] The tert-butyl
(E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-9-methoxy-2-morpho-
lino-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (209 mg) obtained
in (I) was dissolved in trifluoroacetic acid (2 ml) and stirred at
room temperature for 30 minutes. The solvent was evaporated under
reduced pressure to obtain the title compound (180 mg) as yellow
powder.
[0858] .sup.1H-NMR (CDCl.sub.3) .delta. 1.22 (d, 6H), 3.00 (m, 1H),
3.16 (m, 2H), 3.25 (t, 2H), 3.55 (m, 4H), 3.78 (m, 4H), 3.98 (s,
3H), 6.68 (s, 1H), 6.94 (d, J=16 Hz, 1H), 7.58 (d, J=16 Hz, 1H),
8.58 (d, 1H)
[0859] MS (ES+) m/z 485 (M.sup.++1), MS (ES-) m/z 483
(M.sup.+-1)
Example 146
5-((Z)-1-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-
-pyrimidin-3-yl)methylidene)-1,3-thiazolidine-2,4-dione
(A) Methyl
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a-
]-pyrimidine-3-carboxylate
[0860] 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine
(497 mg) and dimethyl methoxymethylenemalonate (425 mg) were
dissolved in methylene chloride, and stirred at 90.degree. C. for 2
hours while the solvent was evaporated. The reaction mixture was
added with propionic acid (0.5 ml) and heated at 160C for 10 hours
with stirring. The reaction mixture was cooled, then added with
ethyl acetate, washed with saturated sodium hydrogencarbonate and
dried over sodium over sodium sulfate. The solvent was evaporated
under reduced pressure, and the residue was purified by silica gel
column chromatography to obtain the title compound (416 mg).
[0861] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (s, 3H), 1.31 (s,
3H), 3.06 (m, 1H), 3.35 (m, 2H), 3.40 (m, 2H), 3.99 (s, 3H), 6.75
(s, 1H), 7.20 (d, 1H), 7.60 (s, 1H), 9.07 (s, 1H), 9.19 (d, 1H)
(B)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimi-
dine-3-carbaldehyde
[0862] The methyl
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimidi-
n-3-carboxylate (660 mg) obtained in (A) was dissolved in
tetrahydrofuran (30 ml), added dropwise with diisopropylaluminum
hydride (1 M solution in tetrahydrofuran, 9.2 ml) at -78.degree.
C., and then the mixture was stirred for 2 hours at the same
temperature. The reaction mixture was added with saturated aqueous
ammonium chloride (1 ml), then added with 12% aqueous hydrochloric
acid, and stirred at room temperature for 1 hour. After insoluble
solids were removed by filtration through a Celite layer, the
solvent of the filtrate was evaporated, and the residue was
dissolved in methylene chloride. This solution was added with
active manganese dioxide (1.2 g) and stirred at room temperature
for 16 hours. Then, insoluble matters were removed by filtration to
obtain the title compound (390 mg) as yellow powder.
[0863] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.27 (d, 6H), 3.05 (m,
1H), 3.3-3.5 (m, 4H), 6.74 (s, 1H), 7.25 (d, 1H), 7.63 (s, 1H),
8.87 (s, 1H), 9.16 (d, 1H), 10.36 (s, 1H)
(C)
5-((Z)-1-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,-
2-a]-pyrimidin-3-yl}methylidene)-1,3-thiazolidine-2,4-dione
[0864] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-
e-3-carbaldehyde (70 mg) obtained in (B) and 2,4-thiazolidinedione
(360 mg) were added with benzene (10 ml), piperidine (one drop) and
acetic acid (two drops) and refluxed by heating for 1 hour in a
vessel provided with a Dean-Stark trap. After the solvent was
evaporated under reduced pressure, the residue was purified by
silica gel column chromatography to obtain the title compound (62
mg) as yellow powder.
[0865] .sup.1H-NMR (CDCl.sub.3+CD.sub.3OD) .delta.: 1.22 (d, 6H),
3.00 (m, 1H), 3.2-3.4 (m, with CD.sub.3OD), 6.72 (s, 1H), 7.18 (d,
1H), 7.51 (s, 1H), 7.86 (s, 1H), 8.42 (s, 1H), 8.98 (d, 1H)
[0866] MS (ES+) m/z 427 (M.sup.++1), MS (ES-) m/z 425
(M.sup.+-1)
Example 147
3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimi-
din-3-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one
(A)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimi-
dine-3-carboxamide
[0867] A mixture of methyl
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrimidi-
ne-3-carboxylate (400 mg), concentrated aqueous ammonia (6 ml) and
methanol (9 ml) was stirred overnight. Insoluble solids were
collected by filtration to obtain the title compound (117 mg). The
reaction mixture was concentrated and the residue was purified by
silica gel column chromatography to further obtain the title
compound (69 mg).
[0868] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (s, 3H), 1.31 (s,
3H), 3.09 (m, 1H), 3.39 (m, 2H), 3.48 (m, 2H), 5.73 (brs, 1H), 6.79
(s, 1H), 7.29 (d, 1H), 7.66 (s, 1H), 8.71 (brs, 1H), 9.14 (d, 1H),
9.30 (s, 1H)
[0869] MS (ES+) m/z 343 (M.sup.++1), MS (ES-) m/z 341
(M.sup.+-1)
(B)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimi-
dine-3-carbonitrile
[0870] A mixture of the
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-
e-3-carboxamide (186 mg) obtained in (A), p-toluenesulfonyl
chloride (207 mg) and pyridine (0.18 ml) was stirred overnight in
methylene chloride. The mixture was added with triethylamine (0.2
ml), further stirred for 2 days, and diluted with methylene
chloride. This mixture was washed with saturated aqueous sodium
hydrogencarbonate and saturated brine, and dried over sodium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (98 mg). The starting material was also
recovered (73 mg).
[0871] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (s, 3H), 1.31 (s,
3H), 3.09 (m, 1H), 3.37 (m, 2H), 3.49 (m, 2H), 6.79 (s, 1H), 7.31
(d, 1H), 7.65 (s, 1H), 8.58 (s, 1H), 9.09 (d, 1H)
[0872] MS (ES+) m/z 325 (M.sup.++1), MS (ES-) m/z 323
(M.sup.+-1)
(C)
3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyr-
imidin-3-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one
[0873] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-
e-3-carbonitrile (35 mg) obtained in (B), hydroxylamine (9 mg) and
triethylamine (28 ml) were refluxed overnight by heating in
ethanol. After the reaction mixture was cooled, the solvent was
evaporated under reduced pressure, and the residue was purified by
silica gel column chromatography to obtain an oxim compound (22
mg). This compound (11 mg), 1,1'-carbodiimidazole (5 mg) and
pyridine (2 ml) were dissolved in tetrahydrofuran (0.5 ml),
refluxed by heating for 45 minutes, and stirred overnight at room
temperature. The reaction mixture was concentrated, and the residue
was purified by silica gel column chromatography to obtain the
title compound (1.6 mg).
[0874] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.26 (s, 3H), 1.30 (s,
3H), 3.08 (m, 1H), 3.40 (m, 4H), 6.75 (s, 1H), 7.18 (brm, 1H), 7.70
(brs, 1H), 9.08 (brm, 1H)
[0875] MS (ES+) m/z 384 (M.sup.++1), MS (ES-) m/z 382
(M.sup.+-1)
Example 148
2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-(1H-1,2,3,4-tetrazol-
-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0876]
2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-[2-(4-methox-
ybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one
(30 mg) was added with anisole (0.15 ml) and trifluoroacetic acid
(1 ml) and stirred at room temperature for 20 hours. After the
solvent was evaporated under reduced pressure, the residue was
added with methanol and toluene and the solvents were evaporated
again under reduced pressure. The residue was added with methanol
and methylene chloride, and the deposited crystals were collected
by filtration to obtain the title compound (15 mg).
[0877] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.25 (s,3H), 1.28 (s,3H),
3.04 (m, 1H), 3.35 (m, 2H), 3.46 (m, 2H), 7.04 (s, 1H), 7.31 (s,
1H), 7.45 (d, 1H), 9.11 (d, 1H)
[0878] MS (ES+) m/z 384 (M.sup.++1)
Example 149
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-3-(1H-1,2,3,4-tetrazol-
-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
(A)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-3-[2-(4-methoxyben-
zyl)-2H-1,2,3,4-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one
[0879]
2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-[2-(4-methox-
ybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one
(24 mg) was dissolved in dimethylformamide (1.5 ml), added with
triethylamine (1.6 ml) and dimethyl sulfate (22 ml) and stirred
overnight at room temperature. The reaction mixture was further
added with dimethyl sulfate (5 ml), stirred for 4 hours, and then
added with water and extracted with ethyl acetate. After the
organic layer was dried over sodium sulfate, the solvent was
evaporated under reduced pressure, and the residue was purified by
silica gel column chromatography to obtain the title compound (5
mg).
[0880] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (s, 3H), 1.33 (s,
3H), 3.09 (m, 1H), 3.29 (m, 2H), 3.44 (m, 2H), 3.79 (s, 3H), 4.03
(s, 3H), 5.79 (s, 2H), 6.79 (s, 1H), 6.88 (d, 2H), 7.02 (d, 1H),
7.41 (d, 2H), 9.02 (d, 1H)
[0881] MS (ES+) m/z 518 (M.sup.++1), MS (ES-) m/z 516
(M.sup.+-1)
(B)
8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-3-(1H-1,2,3,4-tetr-
azol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
[0882] The
8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-3-[2-(4-methoxy-benzy-
l)-2H-1,2,3,4-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one (5 mg)
obtained in (A) was added with trifluoroacetic acid (0.3 ml) and
anisole (0.1 ml) and stirred for 2 days. The solvent was evaporated
under reduced pressure, and the residue was added with hexane and
ethyl acetate. Insoluble solids were collected by filtration and
dried to obtain the title compound (1.2 mg).
[0883] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.30 (s, 3H), 1.32 (s,
3H), 3.12 (m, 1H), 3.37 (m, 2H), 3.49 (m, 2H), 4.29 (s, 3H),
6.79,(s, 1H), 7.53 (s, 1H), 9.10 (d, 1H)
[0884] MS (ES+) m/z 398 (M.sup.++1), MS (ES-) m/z 396
(M.sup.+-1)
Example 150
(E)-3-{2-Carboxymethylthio-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-
-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) tert-Butyl
(E)-3-[2-[(diphenoxyphosphoryl)oxy]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-e-
thyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0885] tert-Butyl
(E)-3-[8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrid-
o[1,2-a]pyrimidin-3-yl}-2-propenoate (80 mg) was suspended in
methylene chloride (40 ml), added with triethylamine (0.13 ml) and
diphenylphosphoryl chloride (0.15 ml), and then the mixture was
stirred at room temperature for 16 hours. The reaction mixture was
washed with saturated aqueous sodium hydrogencarbonate, 5% aqueous
hydrochloric acid and saturated brine, and then dried over sodium
sulfate and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (104 mg).
[0886] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.26 (d, 6H), 1.51 (s,
9H), 3.05 (m, 1H), 3.2-3.4 (m, 4H), 6.73 (s, 1H), 7.1-7.5 (m, 13H),
7.75 (d, J=15.8 Hz, 1H), 8.96 (d, 1H)
(B) tert-Butyl
(E)-3-{2-(tert-butoxycarbonylmethylthio)-8-[2-(4-isopropyl-1,3-thiazol-2--
yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0887] The tert-butyl
(E)-3-{2-[(diphenoxyphosphoryl)oxy]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)et-
hyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (62 mg)
obtained in (A) was dissolved in dimethylformamide (1 ml) and added
dropwise with a solution of lithium sulfide in ethanol (0.1 g/ml)
until the starting material disappeared. Separately, tert-butyl
bromoacetate (0.04 ml) was dissolved in dimethylformamide (1 ml),
added with sodium iodide (69 mg), and then stirred at room
temperature for 40 minutes. These two of solutions were mixed and
stirred at room temperature for 2 hours. The reaction mixture was
distributed between ethyl acetate and water, and the organic layer
was dried. The solvent was evaporated, and the residue was purified
by silica gel column chromatography to obtain the title compound
(19 mg).
[0888] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (d, 6H), 1.45 (s,
9H), 1.53 (s, 9H), 3.06 (m, 1H), 3.2-3.4 (m, 4H), 3.93 (s, 2H),
6.73 (s, 1H), 6.99 (d, 1H), 7.24 (d, J=15.6 Hz, overlapped with
CHCl.sub.3, 1H), 7.32 (s, 1H), 7.78 (d, J=15.6 Hz, 1H), 8.95 (d,
1H)
(C)
(E)-3-{2-Carboxymethylthio-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-
-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0889] The tert-butyl
(E)-3-{2-(tert-butoxycarbonylmethylthio)-8-[2-(4-isopropyl-1,3-thiazol-2--
yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (19
mg) obtained in (B) was dissolved in methylene chloride (2 ml),
added with triethylsilane (0.5 ml) and trifluoroacetic acid (0.5
ml), and then the mixture was stirred at room temperature for 5
hours. After the solvent was evaporated under reduced pressure, the
residue was purified by silica gel column chromatography to obtain
the title compound (4 mg) as yellow powder.
[0890] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.18 (d, 6H), 2.96 (m,
1H), 3.15 (m, 2H), 3.25 (m, 1H), 3.91 (d, 2H), 6.69 (s, 1H), 6.99
(d, 1H), 7.15 (d, J=15 Hz, 1H), 7.31 (s, 1H), 7.77 (d, J=15 Hz,
1H), 8.83 (d, J=7 Hz, 1H)
[0891] MS (ES+) m/z 460 (M.sup.++1), MS (ES-) m/z 458
(M.sup.+-1)
Example 151
(E)-3-{2-Methylthio-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyr-
ido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0892] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.21 (d, 6H), 2.56 (s,
3H), 3.00 (m, 1H), 3.19 (m, 2H), 3.31 (m, 2H), 6.69 (s, 1H), 6.99
(d, 1H), 7.19 (d, J=15 Hz, 1H), 7.36 (s, 1H), 7.83 (d, J=15 Hz,
1H), 8.87 (d, J=7 Hz, 1H)
Example 152
(E)-3-{2-Aminocarbonylmethylthio-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-ethyl-
]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
[0893] .sup.1H-NMR (CDCl.sub.3+CD.sub.3OD) .delta.: 1.23 (d, 6H),
3.02 (m, 1H), 3.1-3.5 (m, with CD.sub.3OD), 3.88 (d, 2H), 6.74 (s,
1H), 7.06 (d, 1H), 7.15 (d, J=16 Hz, 1H), 7.41 (s, 1H), 7.74 (d,
J=16 Hz, 1H), 8.89 (d, J=8 Hz, 1H)
[0894] MS (ES+) m/z 458 (M.sup.++1)
Example 153
(E)-3-{2-[2-(Aminoethylthiomethyl)-3-pyridylthio]-8-[2-(4-isopropyl-1,3-th-
iazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0895] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.22 (d, 6H), 3.02 (m,
1H), 3.15-3.4 (m, with CHD.sub.2OD), 6.95 (s, 1H), 7.02 (s, 1H),
7.28 (d, 1H), 7.32 (d, J=16 Hz, 1H), 7.52 (dd, 1H), 8.02 (d, J=16
Hz, 1H), 8.10 (d, 1H), 8.72 (m, 1H), 8.98 (d, 1H)
Example 154
1-Ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihyd-
ro[1,8]naphthylidine-3-carboxylic acid
(A) Ethyl
1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-
-1,4-dihydro[1,8]naphthylidine-3-carboxylate
[0896] [(4-Isopropyl-1,3-thiazol-2-yl)methyl](triphenyl)phosphonium
bromide (723 mg, Chem. Pharm. Bull., 1977, 25, 349-352) was
suspended in tetrahydrofuran (20 ml), added dropwise with n-butyl
lithium (1.6 M, 1.2 mmol) at -20.degree. C. under nitrogen
atmosphere, and stirred at the same temperature for 20 minutes. The
reaction mixture was added with a solution of ethyl
1-ethyl-7-formyl-4-oxo-1,4-dihydro-[1,8]naphthylidine-3-carboxylate
(316 mg) dissolved in tetrahydrofuran, and stirred for 2 hours. The
reaction mixture was added with saturated aqueous ammonium chloride
and extracted with ethyl acetate. After the organic layer was
dried, the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (456 mg).
[0897] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 1.35 (d, 6H),
1.41 (t, 3H), 1.53 (t, 3H), 3.15 (m, 1H), 4.39 (q, 2H), 4.52 (q,
2H), 6.94 (s, 1H), 7.44 (d, J=15.8 Hz, 1H), 7.47 (d, 1H), 7.94 (d,
J=15.8 Hz, 1H), 8.63 (s, 1H), 8.73 (d, 1H)
(B)
1-Ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-d-
ihydro[1,8]-naphthylidine-3-carboxylic acid
[0898] The ethyl
1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihy-
dro[1,8]naphthylidine-3-carboxylate (120 mg) obtained in (A) and
lithium hydroxide (26 mg) were added with methanol (10 ml) and
water (5 ml), and then the mixture was stirred at room temperature
for 16 hours. After the methanol was evaporated, pH of the residue
was made 6 by using 5% hydrochloric acid, and insoluble substance
was collected by filtration and dried to obtain the title compound
(80 mg).
[0899] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 1.39 (d, 6H),
1.61 (t, 3H), 3.25 (m, 1H), 4.69 (q, 2H), 7.05 (s, 1H), 7.62
(m,2H), 8.13 (d, J=16 Hz, 1H), 8.80 (d, J=8 Hz, 1H), 8.94 (s,
1H)
[0900] MS (ES+) m/z 370 (M.sup.++1), MS (ES-) m/z 368
(M.sup.+-1)
Example 155
1-Ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-3-(1H-1,2,3,4-t-
etrazol-5-yl)-1,4-dihydro[1,8]naphthylidin-4-one
(A)
1-Ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-d-
ihydro[1,8]-naphthylidine-3-carboxamide
[0901] Eethyl
1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihy-
dro[1,8]naphthylidine-3-carboxylate (160 mg) was added with 25%
aqueous ammonia (20 ml) and isopropanol (3 ml) and heated at
100.degree. C. for 16 hours in a Parr acid digestion bomb. After
the reaction mixture was cooled, the solvent was evaporated to
obtain the title compound (148 mg).
[0902] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 1.36 (d, 6H),
1.56 (t, 3H), 3.18 (m, 1H), 4.61 (q, 2H), 5.75 (brs, 1H)6.97 (s,
1H), 7.47 (d, J=15.8 Hz, 1H), 7.51 (d, 1H), 7.98 (d, J=15.8 Hz,
1H), 8.75 (d, 1H), 8.95 (s, 1H), 9.56 (brs, 1H)
(B)
1-Ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-d-
ihydro[1,8]-naphthylidine-3-carbonitrile
[0903] The
1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihy-
dro[1,8]naphthylidine-3-carboxamide (32 mg) obtained in (A) was
dissolved in 1,2-dichloroethane, added with benzenesulfonyl
chloride (0.12 ml), pyridine (0.18 ml) and dimethylaminopyridine
(several pieces), and then the mixture was stirred at 40.degree. C.
for 24 hours. The reaction mixture was diluted with
1,2-dichloroethane, then washed with 5% hydrochloric acid,
saturated aqueous sodium hydrogencarbonate and saturated brine, and
then dried and the solvent was evaporated under reduced pressure.
The residue was purified by silica gel column chromatography to
obtain the title compound (19 mg).
[0904] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 1.36 (d, 6H),
1.56 (t,3H), 3.18 (m, 1H), 4.56 (q,2H), 6.99 (s, 1H), 7.45 (d,
J=15.8 Hz, 1H), 7.51 (d, 1H), 7.98 (d, J=15.8 Hz, 1H), 8.20 (s,
1H), 8.69 (d, 1H)
(C)
1-Ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-3-(1H-1,2,3-
,4-tetrazol-5-yl)-1,4-dihydro[1,8]naphthylidin-4-one
[0905] The
1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihy-
dro[1,8]naphthylidine-3-carbonitrile (32 mg) obtained in (B) was
dissolved in tetrahydrofuran (20 ml), added with sodium azide (100
mg), ammonium chloride (200 mg) and stirred at 80.degree. C. for 2
hours. The reaction mixture was added with water and adjusted to pH
8 with saturated aqueous sodium hydrogencarbonate, and the
tetrahydrofuran was evaporated. The residue was added with five
drops of 25% aqueous ammonia, and insoluble solids were removed by
filtration. The filtrate was adjusted to pH 7 with 12% aqueous
hydrochloric acid, loaded on a HP-20 reverse phase column,
sufficiently washed with water, and then eluted with
water/acetonitrile/aqueous ammonia (80:20:0.2, v/v). After the
solvent was evaporated, the residue was added with tert-butyl
methyl ketone, and insoluble substance was taken by filtration and
dried to obtain the title compound (13 mg) as yellow powder.
[0906] .sup.1H-NMR (300 MHz, CDCl.sub.3+CD.sub.3OD) .delta.: 1.24
(d, 6H), 1.50 (t, 3H), 3.02 (m, 1H), 4.61 (q, 2H), 6.92 (s, 1H),
7.40 (d, J=15.8 Hz, 1H), 7.51 (d, J=8 Hz, 1H), 7.91 (d, J=15.8 Hz,
1H), 8.66 (d, J=8 Hz, 1H), 9.04 (s, 1H)
[0907] MS (ES+) m/z 394 (M.sup.++1), MS (ES-) m/z 392
(M.sup.+-1)
Example 156
(E)-3-{7-Fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl-
)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid
(A) N1-(4-Methyl-5-nitro-2-pyridyl)acetamide
[0908] 4-Methyl-5-nitro-2-pyridinamine (3.69 g, 2.41 mmol) was
added with acetic anhydride (10 ml) and stirred at 130.degree. C.
for 1.5 hours. The reaction mixture was left stand for cooling, and
then added with distilled water (5.4 ml) at 0.degree. C., heated to
130.degree. C., and stirred for 45 minutes. The reaction mixture
was left stand for cooling and concentrated, and the deposited
crystals were collected by filtration and washed with distilled
water to obtain the title compound (4.71 g, quantitative).
[0909] .sup.1H-NMR (CDCl.sub.3) .delta.: 2.26 (3H, s), 2.70 (3H,
s), 8.19 (1H, br), 8.23 (1H, s), 8.95 (1H, s)
[0910] MS; m/z: MH.sup.-194
(B) N1-(5-Amino-4-methyl-2-pyridyl)acetamide
[0911] The N1-(4-methyl-5-nitro-2-pyridyl)acetamide (4.70 g, 24.1
mmol) obtained in (A) was dissolved in ethanol (150 ml), added with
10% palladium/carbon (0.95 g) and subjected to catalytic reduction
overnight at 1 atm under hydrogen atmosphere. The catalyst was
removed by filtration and washed with ethanol. The filtrate was
concentrated and the resulting residue was purified by silica gel
column chromatography (chloroform.fwdarw.chloroform:methanol=100:5)
to obtain the title compound (4.10 g, quantitative) as brown
solid.
[0912] .sup.1H-NMR (CD.sub.3OD) .delta.:2.11 (3H, s), 2.18 (3H, s),
7.61 (1H, s), 7.70 (1H, s)
(C) 6-(Acetylamino)-4-methyl-3-pyridinediazonium
tetrafluoroborate
[0913] The N1-(5-amino-4-methyl-2-pyridyl)acetamide (8.00 g, 48.4
mmol) obtained in (B) was dissolved in tetrafluoroboric acid (160
ml) and slowly added dropwise with an aqueous solution (40 ml) of
sodium nitrite (3.51 g, 50.8 mmol) at -20.degree. C. under nitrogen
atmosphere. The reaction mixture was further stirred at -10.degree.
C. for 1 hour and added with diethyl ether (800 ml), and the
deposited white solid was collected by filtration and washed with
diethyl ether to obtain the title compound (14.7 g,
quantitative).
(D) N1-(5-Fluoro-4-methyl-2-pyridyl)acetamide
[0914] Toluene (280 ml) heated at 100.degree. C. with stirring was
added with the 6-(acetylamino)-4-methyl-3-pyridinediazonium
tetrafluoroborate (12.8 g, 48.4 mmol) obtained in (C) and further
refluxed by heating for 1 hour. After the reaction mixture was left
stand for cooling and the solvent was evaporated, the residue was
diluted with chloroform and washed with 1 N aqueous sodium
hydroxide. The organic layer was dried over anhydrous magnesium
sulfate, then the solvent was evaporated and the resulting residue
was purified by silica gel column chromatography
(chloroform:methanol=100:1) to obtain the title compound (3.48 g,
43%) as yellow solid.
[0915] .sup.1H-NMR (CDCl.sub.3) .delta.: 2.19 (3H, s), 2.32 (3H,
s), 7.93 (1H, br), 7.98 (1H, s), 8.08 (1H, d, J=5.6 Hz)
[0916] MS; m/z: (MH.sup.+) 169
(E) 5-Fluoro-4-methyl-2-pyridinamine
[0917] The N1-(5-fluoro-4-methyl-2-pyridyl)acetamide (4.25 g, 25.3
mmol) obtained in (D) was dissolved in ethanol (3 ml), added with 6
M aqueous hydrochloric acid (3 ml) and refluxed by heating for 1
hour and 30 minutes. The reaction mixture was left stand for
cooling and the solvent was concentrated. The resulting residue was
dissolved in distilled water, and the system was made basic with 1
N aqueous sodium hydroxide and extracted twice with chloroform. The
organic layer was dried over anhydrous magnesium sulfate and the
solvent was evaporated to obtain the title compound (2.82 g, 88%)
as solid.
[0918] .sup.1H-NMR (CD.sub.3OD) .delta.: 2.19 (3H, s), 6.45 (1H,
m), 7.65 (1H, m)
[0919] ES-MS; m/z: (MH.sup.+) 127
(F) tert-Butyl N-(5-fluoro-4-methyl-2-pyridyl)carbamate
[0920] The 5-fluoro-4-methyl-2-pyridinamine (2.82 g, 22.4 mmol)
obtained in (E) was dissolved in tert-butanol (100 ml), slowly
added dropwise with a solution of di-tert-butyl dicarbonate (5.12
g, 23.5 mmol) in tetrahydrofuran (10 ml) over 1 hour, and then the
mixture was stirred at room temperature. The deposited substance
was removed by filtration, and the reaction mixture was
concentrated. The resulting residue was purified by silica gel
column chromatography (chloroform) to obtain the title compound
(3.17 g, 66%) as white solid.
[0921] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.53 (9H, s), 2.30 (3H,
s), 7.74 (1H, br), 7.83 (1H, d, J=5.8 Hz), 7.99 (1H, d, J=1.2
Hz)
[0922] MS; m/z: (MH.sup.+) 227
(G) tert-Butyl
N-{5-fluoro-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridyl]carbamate
[0923] The tert-butyl N-(5-fluoro-4-methyl-2-pyridyl)carbamate
(75.6 mg, 0.334 mmol) obtained in (F) was dissolved in
tetrahydrofuran (2 ml) and added dropwise with n-butyl lithium (1.5
M solution in hexane, 0.468 ml, 0.702 mmol) at -78.degree. C. under
argon atmosphere. The reaction mixture was warmed to room
temperature, stirred for 1 hour, cooled to -78.degree. C. again,
added dropwise with a solution of
2-(bromomethyl)-4-isopropyl-1,3-thiazole (84.6 mg, 0.384 mmol) in
tetrahydrofuran (2 ml), and then warmed to room temperature. The
reaction mixture was added with water and extracted twice with
ethyl acetate. The organic layer was dried over anhydrous magnesium
sulfate, and the solvent was evaporated. The resulting residue was
purified by silica gel column chromatography (chloroform: ethyl
acetate=100:1) to obtain the title compound (40.0 mg, 33%).
[0924] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (6H, d, J=7.1 Hz),
1.54 (9H, s), 3.09 (1H, m), 3.15 (2H, m), 3.32 (2H, m), 6.71 (1H,
s), 7.90 (1H, d, J=5.6 Hz), 8.05 (1H, d, J=1.5 Hz)8.23 (1H, br)
[0925] MS; m/z: (MH.sup.+) 366
(H)
5-Fluoro-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridinamine
[0926] The tert-butyl
N-{5-fluoro-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridyl]-carbamat-
e (393 mg, 1.08 mmol) obtained in (G) was dissolved in methylene
chloride (10 ml), added with trifluoroacetic acid (10 ml) under ice
cooling, and stirred overnight at room temperature. The reaction
mixture was concentrated, and the resulting residue was dissolved
in chloroform and washed with 1 N aqueous sodium hydroxide. The
organic layer was dried over anhydrous magnesium sulfate and the
solvent was evaporated. The resulting residue was purified by
silica gel column chromatography (chloroform:methanol=100:2) to
obtain the title compound (40.0 mg, 33%) as an oil.
[0927] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
3.05 (3H, m), 3.27 (2H, m), 6.32 (1H, m), 6.72 (1H, m), 7.84 (1H,
m)
(I)
7-Fluoro-2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H--
pyrido[1,2-a]-pyrimidin-4-one
[0928] The
5-fluoro-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridinamine
(310 mg, 1.15 mmol) obtained in (H) was dissolved in xylene (2.5
ml), added with di(2,4,6-trichlorophenyl)malonate (568 mg, 1.23
mmol), and refluxed by heating for 30 minutes. The reaction mixture
was left stand for cooling and then concentrated, and the resulting
residue was purified by silica gel column chromatography
(chloroform:methanol=100:1) to obtain the title compound (325 mg,
84%) as yellow solid.
[0929] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.27 (6H, d, J=6.8 Hz),
3.05 (1H, m), 3.40 (4H, m), 5.40 (1H, s), 6.75 (1H, s), 7.40 (1H,
d, J=5.9 Hz), 9.00 (1H, d, J=4.6 Hz)
[0930] MS; m/z: (MH.sup.+) 334, (MH.sup.-) 332
(J)
7-Fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)et-
hyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-4-one
[0931] The
7-fluoro-2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyr-
ido[1,2-a]pyrimidin-4-one (150 mg, 0.450 mmol) obtained in (I) was
dissolved in a mixed solvent of tetrahydrofuran (3 ml) and
dimethylformamide (1 ml), added with p-toluenesulfonyl chloride
(129 mg, 0.675 mmol) and 4-dimethylaminopyridine (60.5 mg, 0.494
mmol), and then the mixture was stirred at room temperature for 2
hours. The reaction mixture was diluted with chloroform, washed
with water and dried over anhydrous magnesium sulfate. The solvent
was evaporated and the resulting residue was dissolved in
dimethylformamide (3 ml), added with 3-hydroxypiperidine (310 mg,
2.25 mmol) and triethylamine (0.3 ml) and stirred at 80.degree. C.
for 2 hours. The reaction mixture was left stand for cooling,
diluted with chloroform, washed with water and dried over anhydrous
magnesium sulfate. Then, the solvent was evaporated and the
resulting residue was purified by preparative TLC
(chloroform:methanol=100:3) to obtain the title compound (147 mg,
79%) as yellow solid.
[0932] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.56 (1H, m), 1.64 (1H, m), 1.86 (1H, m), 1.99 (1H, m), 3.07 (1H,
m), 3.21 (2H, m), 3.34 (1H, m), 3.36 (2H, m), 3.38 (1H, m), 3.82
(1H, m), 3.98 (1H, m), 5.66 (1H, s), 6.73 (1H, s), 7.11 (1H, d,
J=6.6 Hz), 8.70 (1H, d, J=5.4 Hz)
(K)
1-[7-Fluoro-3-formyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4-
H-pyrido-[1,2-a]pyrimidin-2-yl)-3-piperidyl formate
[0933] Dimethylformamide (3 ml) was added with phosphorus
oxychloride (0.083 ml, 0.882 mmol) under ice cooling and stirred
for 30 minutes. The mixture was added with a solution of the
7-fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl-
]-4-oxo-4H-pyrido[1,2-a]pyrimidin-4-one (147 mg, 0.353 mmol)
obtained in (J) in dimethylformamide (2 ml), warmed to room
temperature, and then stirred for 1 hour. The reaction mixture was
further added with phosphorus oxychloride (0.083 ml, 0.882 mmol)
and stirred for 30 minutes. The reaction mixture was added with
saturated aqueous sodium hydrogencarbonate and extracted twice with
ethyl acetate. The organic layer was dried over anhydrous magnesium
sulfate, and the solvent was evaporated. The resulting residue was
purified by silica gel column chromatography
(chloroform.fwdarw.chloroform:methanol=400:1) and further purified
by preparative TLC (chloroform:methanol=100:1) to obtain the title
compound (145 mg, 87%) as yellow oil.
[0934] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (6H, d, J=6.8 Hz),
1.69 (1H, m), 1.85 (1H, m), 1.89 (1H, m), 2.02 (1H, m), 3.06 (1H,
m), 3.25 (2H, m), 3.37 (2H, m), 3.63 (2H, m), 3.78 (1H, dd, J=13.7
and 6.6 Hz), 3.88 (1H, dd, J=13.7 and 3.2 Hz), 5.06 (1H, m), 6.74
(1H, s), 7.10 (1H, d, J=6.6 Hz), 7.98 (1H, s), 8.69 (1H, d, J=5.4
Hz), 10.1 (1H, s)
(L) tert-Butyl
(E)-3-{7-fluoro-2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl-
)-ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0935] The
1-{7-fluoro-3-formyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-p-
yrido[1,2-a]pyrimidin-2-yl]-3-piperidyl formate (145 mg, 0.307
mmol) obtained in (K) was dissolved in tetrahydrofuran (5 ml),
added with tert-butoxycarbonylmethylene-triphenylphosphorane (1.38
g, 3.68 mmol) and refluxed by heating for 2 days. The reaction
mixture was concentrated, and the resulting residue was purified by
preparative TLC (chloroform:methanol=100:4) to obtain the title
compound (147 mg, 84%) as yellow solid.
[0936] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (6H, d, J=6.9 Hz),
1.51 (9H, s), 1.73 (1H, m), 1.85 (1H, m), 1.99 (2H, m), 3.06 (1H,
m), 3.26 (2H, m), 3.38 (2H, m), 3.48 (1H, m), 3.52 (1H, m), 3.65
(1H, m), 3.74 (1H, m), 5.12 (1H, m), 6.73 (1H, s), 7.05 (1H, d,
J=15.5 Hz), 7.21 (1H, d, J=6.9 Hz), 7.48 (1H, d, J=15.5 Hz), 8.07
(1H, s), 8.80 (1H, d, J=5.4 Hz)
(M) tert-Butyl
(E)-3-[7-fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-y-
l)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0937] The tert-butyl
(E)-3-{7-fluoro-2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl-
)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (147 mg,
0.258 mmol) obtained in (L) was dissolved in methanol (3 ml), added
with sodium methoxide (33.6 mg, 0.618 mmol), and then stirred at
room temperature for 9 hours. The reaction mixture was added with
distilled water and extracted with chloroform (twice). The organic
layer was dried over anhydrous magnesium sulfate, and the solvent
was evaporated. The resulting residue was purified by preparative
TLC (chloroform:methanol=100:5) to obtain the title compound (91.6
mg, 65%).
[0938] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.27 (6H, d, J=6.8 Hz),
1-51 (9H, s), 1.60 (2H, m), 1.83 (2H, m), 3.05 (1H, m), 3.26 (2H,
m), 3.38 (2H, m), 3.53 (1H, m), 3.57 (2H, m), 3.73 (1H, m), 3.87
(1H, m), 4.01 (1H, m), 6.73 (1H, s), 7.03 (1H, d, J=15.6 Hz), 7.21
(1H, d, J=6.6 Hz), 7.48 (1H, d, J=15.6 Hz), 8.81 (1H, d, J=5.6
Hz)
(N)
(E)-3-{7-Fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol--
2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0939] The tert-butyl
(E)-3-{7-fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-y-
l)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (43.6
mg, 0.0803 mmol) obtained in (M) was dissolved in 4 N hydrochloric
acid/dioxane (3 ml) and stirred at room temperature for 2 hours.
The reaction mixture was concentrated and the resulting residue was
purified by preparative TLC (chloroform:methanol=10:1) to obtain
the title compound (35.6 mg, 91%) as lyophilized product.
[0940] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.27 (6H, d, J=6.8 Hz),
1.54 (1H, m), 1.71 (1H, m), 1.87 (2H, m), 3.06 (1H, m), 3.23 (2H,
m), 3.37 (2H, m), 3.45 (1H, m), 3.62 (3H, m), 3.99 (1H, m), 6.73
(1H, s), 7.00 (1H, d, J=15.4 Hz), 7.18 (1H, d, J=6.6 Hz), 7.56 (1H,
d, J=15.4 Hz), 8.73 (1H, d, J=4.9 Hz)
[0941] MS; m/z: (MH.sup.+) 487, (MH.sup.-) 485
Example 157
(E)-3-{2-{3-[(Aminocarbonyl)oxy]piperidino}-7-fluoro-8-[2-(4-isopropyl-1,3-
-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
(A) tert-Butyl
(E)-3-[2-{3-[(aminocarbonyl)oxy]piperidino}-7-fluoro-8-[2-(4-isopropyl-1,-
3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0942] The tert-butyl
(E)-3-{7-fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-y-
l)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (48.0
mg, 0.0885 mmol) obtained in Example 156, (M) was dissolved in
ethyl acetate (3 ml), added with trichloroacetyl isocyanate (0.052
ml, 0.442 mmol) and stirred at room temperature for 1 hour. The
reaction mixture was added with methanol:chloroform (1:10, 10 ml)
and concentrated, and the resulting residue was dissolved in a
mixed solvent of methanol (3 ml) and distilled water (1 ml), added
with sodium formate (12.0 mg, 0.177 mmol) and stirred overnight at
room temperature. The solution was further added with sodium
formate (12.0 mg, 0.177 mmol), stirred for 5 hours and then
concentrated, and the resulting residue was purified by preparative
TLC (chloroform:methanol=100:5) to obtain the title compound (71.3
mg, quantitative) as lyophilized product.
[0943] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.27 (6H, d, J=6.8 Hz),
151 (9H, s), 1.78 (1H, m), 1.84-2.00 (3H, m), 3.06 (1H, m), 3.26
(2H, m), 3.27 (1H, m), 3.39 (2H, m), 3.52 (1H, m), 3.66 (2H, m),
4.81 (1H, m), 4.90 (1H,br), 6.70 (1H,br), 6.74 (1H, s), 7.08 (1H,
d, J=15.6 Hz), 7.26 (1H, d, J=6.8 Hz), 7.68 (1H, d, J=15.6 Hz),
8.81 (1H, d, J=5.4 Hz)
[0944] MS; m/z: (MH.sup.+) 586, (MH.sup.-) 584
(B)
(-3-[2-[3-[(Aminocarbonyl)oxy]piperidino}-7-fluoro-8-[2-(4-isopropyl-1-
,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic
acid
[0945] The tert-butyl
(E)-3-{2-{3-[(aminocarbonyl)oxy]piperidino}-7-fluoro-8-[2-(4-isopropyl-1,-
3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
(51.8 mg, 0.0884 mmol) obtained in (A) was dissolved in 4 N
hydrochloric acid in dioxane (3 ml) and stirred at room
temperature. The reaction mixture was concentrated and the
resulting residue was purified by preparative TLC
(chloroform:methanol=10:1) to obtain the title compound (26.8 mg,
57%) as lyophilized product.
[0946] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.25 (6H, d, J=6.8 Hz),
1.68 (1H, m), 1.82 (1H, m), 1.97 (2H, m), 3.02 (1H, m), 3.25 (2H,
m), 3.41 (2H, m), 3.48 (1H, m), 3.57 (1H, m), 3.66 (1H, m), 3.77
(1H, m), 4.73 (1H, m), 6.94 (1H, d, J=15.6 Hz), 6.97 (1H, s), 7.29
(1H, d, J=6.8 Hz), 7.55 (1H, d, J=15.6 Hz), 8.71 (1H, d, J=5.6
Hz)
[0947] MS; m/z: (MH.sup.+) 530, (MH.sup.-) 528
Example 158
3-{2-(3-Formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo--
4H-pyrido[1,2-a]pyrimidin-3-yl}propanoic acid
(A) Methyl
(E)-3-{2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-y-
l)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate
[0948]
1-(3-Formyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyr-
ido[1,2-a]pyr imidin-2-yl)-3-piperidylformate (94.0 mg, 0.207 mmol)
and bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl)phosphonoate
(0.131 ml, 0.620 mmol) were dissolved in tetrahydrofuran (2 ml),
added with DBU (0.085 ml, 0.620 mmol) and lithium chloride (26.3
mg, 0.620 mmol), and then the mixture was stirred at room
temperature for 1 hour.
[0949] The reaction mixture was concentrated and the obtained
residue was purified by preparative TLC (chloroform:methanol=100:2)
to obtain the title compound (80.9 mg, 76%).
[0950] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.28 (6H, d, J=6.8 Hz),
1.74-2.00 (4H, m), 3.07 (1H, m), 3.20 (2H, t, J=7.8 Hz), 3.36 (2H,
t, J=7.8 Hz), 3.54 (2H, m), 3.67 (1H, m), 3.76 (1H, m), 3.77 (3H,
s), 5.14 (1H, m), 6.73 (1H, s), 6.84 (1H, dd, J=7.3 and 1.7 Hz),
7.10 (1H, d, J=15.6 Hz), 7.20 (1H, s), 7.62 (1H, d, J=15.6 Hz),
8.09 (1H, s), 8.85 (1H, d, J=7.3 Hz)
(B) Methyl
3-{2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)et-
hyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]propanoate
[0951] The methyl
(E)-3-(2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-ethyl]--
4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (80.9 mg, 0.158
mmol) obtained in (A) was dissolved in ethanol (3 ml), added with
5% palladium/carbon (30 mg) and stirred at 1 atm for 2 days under
hydrogen atmosphere. The catalyst was removed by filtration, and
the filtrate was concentrated. The resulting residue was purified
by preparative TLC (chloroform:methanol=100:2) to obtain the title
compound (23.1 mg, 28%).
[0952] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.29 (6H, d, J=6.8 Hz),
1.74-2.03 (4H, m), 3.07 (1H, m), 3.20 (2H, t, J=7.8 Hz), 2.73 (2H,
m), 2.93 (2H, m), 3.15 (1H, m), 3.20 (2H, m), 3.30 (2H, m), 3.35
(2H, m), 3.37 (2H, m), 3.68 (3H, s), 5.12 (1H, m), 6.72 (1H, s),
6.81 (1H, d, J=7.3 Hz), 7.20 (1H, s), 7.26 (1H, s), 8.07 (1H, s),
8.79 (1H, d, J=7.3 Hz)
[0953] MS; m/z: 513 (MH.sup.+), 511 (MH.sup.-)
(C)
3-(2-(3-Formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4--
oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl]propanoic acid
[0954] The methyl
3-{2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-
-4H-pyrido[1,2-a]pyrimidin-3-yl}propanoate (23.1 mg, 0.0451 mmol)
obtained in (B) was dissolved in a mixed solution of methanol,
tetrahydrofuran and water (1:1:1, 3 ml), added with lithium
hydroxide monohydrate (3.8 mg, 0.0901 mmol), and stirred overnight
at room temperature. The reaction mixture was added with 1 N
hydrochloric acid (0.091 ml) to neutralize the system, and then the
solvent was evaporated. The resulting residue was purified by
preparative TLC (chloroform:methanol=10:1) to obtain the title
compound (15.0 mg, 71%) as lyophilized product.
[0955] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.26 (6H, d, J=6.8 Hz),
1.51 (1H, m), 1.67 (1H, m), 1.84 (1H, m), 1.99 (1H, m), 2.64 (2H,
m), 2.90 (2H, m), 2.95-3.08 (3H, m), 3.20 (2H, t, J=7.3 Hz), 3.40
(2H, t, J=7.3 Hz), 3.57 (1H, m), 3.78 (2H, m), 6.96 (1H, s), 7.03
(1H, dd, J=7.3 and 2.0 Hz), 7.21 (1H, s), 8.74 (1H, d, J=7.3
Hz)
[0956] MS; m/z: 471 (MH.sup.+), 469 (MH.sup.-)
Example 159
1-(2-Fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-3-(1H-
-1,2,3,4-tetrazol-5-yl)-1,4-dihydro-4-quinolinone
(A) Ethyl
1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethe-
nyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylate
[0957] Ethyl
7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro-3-qu-
inolinecarboxylate (368 mg, 1.00 mmol) was dissolved in
dimethylformamide (6 ml), added with potassium carbonate (276 mg,
2.00 mmol) and 1-bromo-2-fluoroethane (0.223 ml, 3.00 mmol), and
then the mixture was stirred overnight at 65.degree. C. The
reaction mixture was left stand for cooling and then diluted with
ethyl acetate. The organic layer was washed with water and dried
over anhydrous magnesium sulfate, and the solvent was evaporated.
The resulting residue was purified by silica gel column
chromatography (chloroform.fwdarw.chloroform:methanol=100:1) to
obtain the title compound (254 mg, 61%) as colorless transparent
oil.
[0958] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.34 (6H, d, J=7.1 Hz),
1.39 (3H, t, J=7.1 Hz), 3.13 (1H, m), 4.36 (2H,q), 4.54 (2H, ddd,
J=24.9, 4.6 and 4.4 Hz), 4.85 (2H, ddd, J=46.6, 4.6 and 4.4 Hz),
6.86 (1H, s), 7.40 (2H, s), 7.43 (1H, s), 7.57 (1H, dd, J=8.5 and
1.2 Hz), 8.43 (1H, s), 8.47 (1H, dd, J=8.5 and 2.0 Hz)
[0959] MS; m/z: (MH.sup.+) 415
(B)
1-(2-Fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-
-oxo-1,4-dihydro-3-quinolinecarboxylic acid
[0960] The ethyl
1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-ox-
o-1,4-dihydro-3-quinolinecarboxylate (254 mg, 0.613 mmol) obtained
in (A) was dissolved in a mixed solution of methanol,
tetrahydrofuran and water (1:1:1), added with 1 N aqueous sodium
hydroxide (1.23 ml, 1.23 mmol), and then the mixture was stirred at
room temperature for 8 hours. The reaction mixture was added with 1
N hydrochloric acid (1.23 ml, 1.23 mmol) to neutralize the system,
and extracted with chloroform. The organic layer was dried over
anhydrous magnesium sulfate, and the solvent was evaporated to
obtain the title compound (174 mg, 73%) as yellow solid.
(C)
1-(2-Fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-
-oxo-1,4-dihydro-3-quinolinecarboxamide
[0961] The
1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-ox-
o-1,4-dihydro-3-quinolinecarboxylic acid (174 mg, 0.450 mmol)
obtained in (B) was dissolved in dimethylformamide (3 ml), added
with triethylamine (0.126 ml, 0.900 mmol) and ethyl chloroformate
(0.086 ml, 0.900 mmol) under ice cooling, and then the mixture was
stirred for 1 hour. The reaction mixture was warmed to room
temperature, stirred for 30 minutes and further stirred at
0.degree. C. for 1 hour. The reaction mixture was added with
concentrated aqueous ammonia (0.15 ml) and stirred overnight at
room temperature. The reaction mixture was diluted with ethyl
acetate and washed successively with aqueous citric acid, saturated
aqueous sodium hydrogencarbonate and saturated brine and dried over
anhydrous magnesium sulfate. Then, the solvent was evaporated to
obtain the title compound (164 mg, 94%) as pale yellow solid.
[0962] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.36 (6H, d, J=6.8 Hz),
3.17 (1H, m), 4.59 (2H, ddd, J=23.9, 4.9 and 4.6 Hz), 4.87 (2H,
ddd, J=46.4, 4.9 and 4.6 Hz), 5.75 (1H,br), 6.92 (1H, s), 7.28 (1H,
m), 7.47 (2H, s), 7.69 (1H, d, J=8.6 Hz), 8.54 (1H, d, J=8.6 Hz),
8.79 (1H, s), 9.66 (1H, br)
[0963] MS; m/z: (MH.sup.+) 386
(D)
1-(2-Fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-
-oxo-1,4-dihydro-3-quinolinecarbonitrile
[0964] A solution of dimethylformamide (0.109 ml, 1.40 mmol) in
acetonitrile (2 ml) was added with oxalyl chloride (0.111 ml, 1.28
mmol) under ice cooling, stirred at the same temperature for 15
minutes, and then added with a solution of the
1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-ox-
o-1,4-dihydro-3-quinolinecarboxamide (164 mg, 0.425 mmol) obtained
in (C) in acetonitrile (3 ml). The mixture was stirred at the same
temperature for 10 minutes. This mixture was added with pyridine
(0.206 ml, 2.55 mmol) and stirred at the same temperature for 10
minutes and further at room temperature for 2 hours. The reaction
mixture was added with a solution of dimethylformamide (0.109 ml,
1.40 mmol) and oxalyl chloride (0.111 ml, 1.28 mmol) in
acetonitrile (1 ml) prepared beforehand at 0.degree. C., then added
with pyridine (0.206 ml, 2.55 mmol), and stirred at room
temperature for 1 hour. The reaction mixture was added with ethyl
acetate and washed with aqueous citric acid, saturated aqueous
sodium hydrogencarbonate and saturated brine. The organic layer was
dried over anhydrous magnesium sulfate, and the solvent was
evaporated. The resulting residue was purified by preparative TLC
(chloroform:methanol=100:7) to obtain the title compound (179 mg,
quantitative) as pale yellow as solid.
[0965] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.36 (6H, d, J=7.1 Hz),
3.15 (1H, m), 4.52 (2H, ddd, J=24.6, 4.6 and 4.4 Hz), 4.85 (2H,
ddd, J=46.6, 4.6 and 4.4 Hz), 6.93 (1H, s), 7.43 (1H, s), 7.46 (2H,
s), 7.69 (1H, dd, J=8.5 and 1.2 Hz), 8.03 (1H, s), 8.49 (1H, d,
J=8.6 Hz)
(E)
1-(2-Fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-3-
-(1H-1,2,3,4-tetrazol-5-yl)-1,4-dihydro-4-quinolinone
[0966] A solution of aluminum chloride (55.7 mg, 0.418 mmol) in
dimethylformamide (1 ml) was added with sodium azide (81.5 mg, 1.25
mmol) under ice cooling, and then stirred at room temperature for
15 minutes. Then, the reaction mixture was added with a solution of
the
1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-ox-
o-1,4-dihydro-3-quinolinecarbonitrile (51.2 mg, 0.139 mmol)
obtained in (D) in dimethylformamide (1 ml) and stirred overnight
at 85-90.degree. C. The reaction mixture was poured into ice
water/1 N hydrochloric acid (1 ml) and stirred at room temperature
for 1.5 hours. The precipitates were collected by filtration and
recrystallized from chloroform/methanol/hexane to obtain the title
compound (15.1 mg, 26%) as colorless solid.
[0967] .sup.1H-NMR (DMSO-d.sub.6) .delta.: 1.29 (6H, d, J=7.1 Hz),
3.08 (1H, m), 4.82 (1H, m), 4.94 (2H, m), 4.95 (1H, m), 7.34 (1H,
s), 7.64 (1H, d, J=16.2 Hz), 7.84 (1H, d, J=16.2 Hz), 7.96 (1H, d,
J=8.6 Hz), 8.23 (1H, s), 8.37 (1H, d, J=8.6 Hz), 9.05 (1H, s)
[0968] LCMS; m/z: 411 (MH.sup.+)
Example 160
1-Cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-2-morpholi-
no-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
(A) Ethyl
1-cyclopropyl-6,7-difluoro-2-(methylsulfonyl)-4-oxo-1,4-dihydro--
3-quinoline-carboxylate
[0969] Ethyl
1-cyclopropyl-6,7-difluoro-2-(methylsulfanyl)-4-oxo-1,4-dihydro-3-quinoli-
necarboxylate (300 mg, 0.976 mmol), which is a known compound [J.
Heterocyclic Chem., 27, 839 (1990)], was dissolved in methylene
chloride (6 ml), added with metachloroperformic acid (755 mg, 2.93
mmol) and stirred overnight. The reaction mixture was diluted with
chloroform and washed successively with saturated aqueous sodium
hydrogencarbonate and sodium hydrogensulfite. The organic layer was
dried over anhydrous sodium sulfate, and the solvent was
evaporated. The resulting residue was developed by silica gel
column chromatography (hexane:ethyl acetate=2:1) to obtain the
title compound (140 mg, 39%) as white solid. The resulting compound
was further developed (chloroform:methanol=100:1) to obtain ethyl
1-cyclopropyl-6,7-difluoro-2-(methylsulfinyl)-4-oxo-1,4-dihydro-3-q-
uinoline-carboxylate (101 mg, 29%) as colorless transparent oil.
Sulfone compound (title compound)
[0970] .sup.1H-NMR (CDCl.sub.3) .delta.: 0.88 (2H, m), 1.39 (3H, t,
J=7.1 Hz), 1.44 (2H, m), 3.56 (3H, s), 3.92 (1H, m), 4.43 (2H,q,
J=7.1 Hz), 7.63 (1H, dd, J=11.5 and 6.4 Hz), 8.01 (1H, dd, J=9.8
and 8.6 Hz)
[0971] ES-MS; m/z: 372 (MH.sup.+)
Sulfoxide Compound
[0972] .sup.1H-NMR (CDCl.sub.3) .delta.: 0.99 (2H, m), 1.39 (3H, t,
J=6.9 Hz), 1.46 (2H, m), 3.16 (3H, s), 4.42 (3H, m), 7.66 (1H, dd,
J=11.3 and 6.4 Hz), 8.13 (1H, t, J=9.3 Hz)
[0973] ES-MS; m/z: 356 (MH.sup.+)
(B) Ethyl
1-cyclopropyl-6,7-difluoro-2-morpholino-4-oxo-1,4-dihydro-3-quin-
oline-carboxylate
[0974] The ethyl
1-cyclopropyl-6,7-difluoro-2-(methylsulfonyl)-4-oxo-1,4-dihydro-3-quinoli-
necarboxylate (140 mg, 0.377 mmol) obtained in (A) was dissolved in
tetrahydrofuran (5 ml), added with morpholine (0.0395 ml, 0.452
mmol), N,N-diisopropylethylamine (0.131 ml, 0.754 mmol) and
magnesium bromide diethyl etherate (389 mg, 1.51 mmol), and then
the mixture was refluxed by heating for 2 hours. The reaction
mixture was diluted with ethyl acetate and washed with water. The
organic layer was dried over magnesium sulfate, and the solvent was
evaporated under reduced pressure. The resulting residue was
purified by preparative TLC (chloroform:methanol=100:5) to obtain
the title compound (89.2 mg, 62%).
[0975] .sup.1H-NMR (CDCl.sub.3) .delta.: 0.80 (2H, m), 1.40 (3H, t,
J=7.1 Hz), 1.41 (2H, m), 3.14 (1H, m), 3.36 (4H, t, J=4.4 Hz), 3.84
(4H, t, J=4.4 Hz), 4.38 (2H,q, J=7.1 Hz), 7.47 (1H, dd, J=11.7 and
6.4 Hz), 8.01 (1H, dd, J=10.0 and 9.0 Hz)
(C) Ethyl
1-cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]--
2-morpholino-4-oxo-1,4-dihydro-3-quinolinecarboxylate
[0976] (4-Isopropyl-1,3-thiazol-2-yl)methanol (37.0 mg, 0.235 mmol)
was dissolved in dimethylformamide (2 ml), added with 18-crown-6
(68.4 mg, 0.259 mmol) and sodium hydride (95%, 6.5 mg, 0.259 mmol),
and stirred for 10 minutes under argon atmosphere. The reaction
mixture was added with a solution of the ethyl
1-cyclopropyl-6,7-difluoro-2-morpholino-4-oxo-1,4-dihydro-3-quinolinecarb-
oxylate (89.0 mg, 0.235 mmol) obtained in (B) in dimethylformamide
(1 ml), and stirred at room temperature for 1 hour. Then, the
reaction mixture was added with aqueous ammonium chloride and
extracted with ethyl acetate. The organic layer was dried over
magnesium sulfate, and the solvent was evaporated under reduced
pressure. The resulting residue was purified by preparative TLC
(chloroform:methanol=100:5, v/v) to obtain the title compound (102
mg, 84%).
[0977] .sup.1H-NMR (CDCl.sub.3) .delta.: 0.68 (2H, m), 1.29 (2H,
m), 1.32 (6H, d, J=6.8 Hz), 1.39 (3H, t, J=7.1 Hz), 3.05 (1H, m),
3.11 (1H, m), 3.32 (4H, t, J=4.4 Hz), 3.82 (4H, t, J=4.4 Hz), 4.39
(2H,q, J=7.1 Hz), 5.52 (2H, s), 6.97 (1H, s), 7.27 (1H, d, J=7.3
Hz), 7.93 (1H, d, J=11.2 Hz)
[0978] ES-MS; m/z: 516 (MH.sup.+)
(D)
1-Cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-2-morp-
holino-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
[0979] A solution of aluminum chloride (266 mg, 2.00 mmol) in
1,2-dichloroethane (4 ml) was added with dimethyl sulfide (0.293
ml, 4.00 mmol) and stirred at 0.degree. C. for 30 minutes. Then,
the reaction mixture was added with ethyl
1-cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-2-morphol-
ino-4-oxo-1,4-dihydro-3-quinolinecar boxylate (51.5 mg, 0.0999
mmol) and refluxed overnight by heating. The reaction mixture was
left stand for cooling, diluted with chloroform, washed with 1 N
hydrochloric acid, and dried over anhydrous magnesium sulfate. The
solvent was evaporated and the obtained residue was purified by
preparative TLC (chloroform:methanol=10:1) to obtain the title
compound (1.3 mg, 3%).
[0980] .sup.1H-NMR (CDCl.sub.3) .delta.: 0.58 (2H, m), 1.17 (2H,
m), 1.33 (6H, d, J=6.8 Hz), 3.11 (1H, m), 3.29 (1H, m), 3.52 (4H,
m), 4.00 (4H, m), 5.55 (2H, s), 6.97 (1H, s), 7.28 (1H, d, J=6.8
Hz), 7.90 (1H, d, J=10.7 Hz)
[0981] LCMS; m/z: 487 (M)
Example 161
(Z)-3-(1-Cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-4-o-
xo-1,4-dihydro-3-quinolyl)-2-propeonic acid
(A)
1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxamide
[0982]
1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic
acid (1.00 g, 3.77 mmol) was dissolved in dimethylformamide (15
ml), added with triethylamine (0.788 ml, 5.66 mmol) and ethyl
chloroformate (0.538 ml, 5.66 mmol) under ice cooling, and stirred
for 1 hour. The reaction mixture was warmed to room temperature,
stirred for 30 minutes, and further stirred at 0.degree. C. for 1
hour. The reaction mixture was added with concentrated aqueous
ammonia (0.75 ml) and stirred overnight at room temperature. The
reaction mixture was diluted with ethyl acetate and washed
successively with aqueous citric acid, saturated aqueous sodium
hydrogencarbonate and saturated brine. The organic layer was dried
over anhydrous magnesium sulfate, and the solvent was evaporated to
obtain the title compound (1.23 g, quantitative) as white
solid.
[0983] .sup.1H-NMR (CD.sub.3OD) .delta.: 1.21 (2H, m), 1.42 (2H,
m), 3.56 (1H, m), 7.88 (1H, dd, J=11.2 and 6.4 Hz), 8.25 (1H, dd,
J=10.5 and 8.5 Hz), 8.88 (1H, s)
(B)
1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile
[0984] A solution of dimethylformamide (0.712 ml, 9.19 mmol) in
acetonitrile (10 ml) was added with oxalyl chloride (0.729 ml, 8.36
mmol) under ice cooling, stirred at the same temperature for 15
minutes, added with a solution of the
1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxamide
(1.23 g, 4.18 mmol) obtained in (A) in acetonitrile (10 ml) and
stirred at the same temperature for 10 minutes. This mixture was
added with pyridine (1.35 ml, 16.7 mmol), stirred at the same
temperature for 10 minutes, and then stirred overnight at room
temperature. The reaction mixture was added with ethyl acetate,
washed successively with aqueous citric acid, saturated aqueous
sodium hydrogencarbonate and saturated brine, and dried over
anhydrous magnesium sulfate to obtain the title compound (714 mg,
77%) as pale yellow solid.
[0985] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.16 (2H, m), 1.42 (2H,
m), 3.47 (1H, m), 7.78 (1H, dd, J=11.0 and 6.4 Hz), 8.16 (1H, s),
8.21 (1H, dd, J=10.0 and 8.6 Hz)
[0986] MS; m/z: 247 (MH.sup.+)
(C)
1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarbaldehyde
[0987] The
1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile
(150 mg, 0.609 mmol) obtained in (B) was dissolved in a mixed
solution of acetic acid, water and pyridine (1:1:2, 4 ml), added
with Raney Nickel (catalytic amount) and sodium phosphinate
monohydrate (258 mg, 2.44 mmol), and then the mixture was stirred
overnight at 60.degree. C. The reaction mixture was left stand for
cooling and the catalyst was removed by filtration through a Celite
layer and washed with hot ethanol. The reaction mixture was
concentrated, then diluted with chloroform, and washed with aqueous
copper sulfate. The organic layer was dried over anhydrous
magnesium sulfate to obtain the title compound (97.0 mg, 64%) as
pale yellow solid.
[0988] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.18 (2H, m), 1.39 (2H,
m), 3.47 (1H, m), 7.78 (1H, dd, J=11.2 and 6.3 Hz), 8.27 (1H, dd,
J=10.2 and 8.8 Hz), 8.42 (1H, s), 10.37 (1H, s)
[0989] LCMS; m/z: 250 (MH.sup.+)
(D) tert-Butyl (E)- and
(Z)-3-(1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolyl)-2-propeno-
ate
[0990] The
1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarbaldehyde
(97.0 mg, 0.389 mmol) obtained in (C) was dissolved in a mixed
solvent of dimethylformamide and tetrahydrofuran (2:1, 3 ml), added
with (tert-butoxycarbonyl-methylene)triphenylphosphorane (176 mg,
0.467 mmol), and stirred at 70.degree. C. for 11 hours. The
reaction mixture was concentrated, and the resulting residue was
separated and purified by preparative TLC
(chloroform:methanol=100:5) to obtain Z-isomer of the title
compound (68.7 mg, 51%) and E-isomer of the title compound (32.9
mg, 29%) as pale yellow solids.
(Z-Isomer) Rf=Higher
[0991] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.23 (2H, m), 1.32 (2H,
m), 1.50 (9H, s), 3.43 (1H, m), 5.86 (1H, d, J=13.2 Hz), 7.27 (1H,
d, J=13.2 Hz), 7.71 (1H, dd, J=11.5 and 6.4 Hz), 8.22 (1H, dd,
J=10.0 and 9.1 Hz), 9.36 (1H, s)
[0992] MS; m/z: 348 (MH.sup.+)
(E-Isomer) Rf=Lower
[0993] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.11 (2H, m), 1.33 (2H,
m), 1.52 (9H, s), 3.43 (1H, m), 7.14 (1H, d, J=15.8 Hz), 7.39 (1H,
d, J=15.8 Hz), 7.70 (1H, dd, J=11.5 and 6.3 Hz), 7.88 (1H, s), 8.24
(1H, dd, J=10.5 and 8.5 Hz)
[0994] MS; m/z: 348 (MH.sup.+)
(E) tert-Butyl
(Z)-3-(1-cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-4--
oxo-1,4-dihydro-3-quinolyl)-2-propenoate
[0995] (4-Isopropyl-1,3-thiazol-2-yl)methanol (31.1 mg, 0.198 mmol)
was dissolved in dimethylformamide (1 ml), added with 18-crown-6
(57.5 mg, 0.218 mmol) and sodium hydride (95%, 5.5 mg, 0.218 mmol),
and then the mixture was stirred for 15 minutes under argon
atmosphere. The reaction mixture was added with a solution of the
tert-butyl
(Z)-3-(1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolyl)-2-propeno-
ate (68.7 mg, 0.198 mmol) obtained in (D) in dimethylformamide (1
ml) and stirred at room temperature for 2 hours. Then, the reaction
mixture was added with aqueous ammonium chloride and extracted with
chloroform. The organic layer was dried over magnesium sulfate, and
the solvent was evaporated under reduced pressure. The obtained
residue was purified by preparative TLC (chloroform:methanol=100:1)
to obtain the title compound (52.4 mg, 55%).
[0996] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.15 (2H, m), 1.29 (2H,
m), 1.33 (3H, d, J=6.8 Hz), 1.50 (9H, s), 3.11 (1H, m), 3.36 (1H,
m), 5.58 (2H, s), 5.82 (1H, d, J=12.9 Hz), 6.97 (1H, s), 7.27 (1H,
d, J=12.9 Hz), 7.55 (1H, d, J=6.8 Hz), 8.11 (1H, d, J=11.5 Hz),
9.32 (1H, s)
(F)
(Z)-3-(1-Cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-
-4-oxo-1,4-dihydro-3-quinolyl)-2-propeonic acid
[0997] The
(Z)-3-(1-cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-4--
oxo-1,4-dihydro-3-quinolyl)-2-propenoate (52.4 mg, 0.108 mmol)
obtained in (E) was dissolved in 4 N hydrochloric acid in dioxane
(2 ml) and stirred overnight. The reaction mixture was
concentrated, and the deposited solid was collected by filtration
using ether to obtain the title compound (54.3 mg, quantitative) as
pale yellow solid.
[0998] .sup.1H-NMR (CD.sub.3OD/CDCl.sub.3) .delta.: 1.36 (3H, d,
J=7.10 Hz), 1.53 (2H, m), 1.73 (2H, m), 3.18 (1H, m), 4.38 (1H, m),
5.90 (2H, s), 6.77 (1H, d, J=9.6 Hz), 7.26 (1H, s), 8.25 (1H, d,
J=9.6 Hz), 8.41 (2H, m), 9.79 (1H, s)
[0999] ES-MS; m/z: 427 (MH.sup.-)
Example 162:
(E)-3-(1-Cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-4--
oxo-1,4-dihydro-3-quinolyl)-2-propeonic acid
(A) tert-Butyl
(E)-3-(1-Cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-4--
oxo-1,4-dihydro-3-quinolyl)-2-propenoate
[1000] (4-Isopropyl-1,3-thiazol-2-yl)methanol (19.5 mg, 0.124 mmol)
was dissolved in dimethylformamide (1 ml), added with 18-crown-6
(35.8 mg, 0.135 mmol) and sodium hydride (95%, 3.4 mg, 0.135 mmol),
and stirred for 15 minutes under argon atmosphere. The reaction
mixture was added with a solution of tert-butyl
(E)-3-(1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolyl)-2-propeno-
ate (39.2 mg, 0.124 mmol) in dimethylformamide (1 ml) and stirred
at room temperature for 3 hours. Then, the reaction mixture was
added with aqueous ammonium chloride and extracted with chloroform.
The organic layer was dried over magnesium sulfate, and the solvent
was evaporated under reduced pressure. The resulting residue was
purified by preparative TLC (chloroform:methanol=100:1) to obtain
the title compound (44.7 mg, 82%).
[1001] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.03 (2H, m), 1.30 (2H,
m), 1.31 (3H, d, J=6.8 Hz), 1.51 (9H, s), 3.11 (1H, m), 3.36 (1H,
m), 5.57 (2H, s), 6.96 (1H, s), 7.12 (1H, d, J=15.8 Hz), 7.37 (1H,
d, J=15.8 Hz), 7.53 (1H, d, J=6.8 Hz), 7.79 (1H, s), 8.10 (1H, d,
J=11.2 Hz)
(B)
(E)-3-(1-Cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-
-4-oxo-1,4-dihydro-3-quinolyl)-2-propeonic acid
[1002] The
(E)-3-(1-cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-4--
oxo-1,4-dihydro-3-quinolyl)-2-propenoate (44.7 mg, 0.0992 mmol)
obtained in (A) was dissolved in 4 N hydrochloric acid in dioxane
(2 ml) and stirred overnight. The reaction mixture was
concentrated, and the deposited solid was collected by filtration
using ether to obtain the title compound (32.9 mg, 83%) as pale
yellow solid.
[1003] .sup.1H-NMR (CD.sub.3OD/CDCl.sub.3) .delta.: 1.14 (2H, m),
1.33 (3H, d, J=5.6 Hz), 1.38 (2H, m), 3.15 (1H, m), 3.56 (1H, m),
5.66 (2H, s), 7.13 (1H, d, J=15.6 Hz), 7.17 (1H, s), 7.60 (1H, d,
J=15.6 Hz), 7.75 (1H, d, 6.9 Hz), 8.04 (1H, d, J=11.2 Hz), 8.25
(1H, s)
[1004] ES-MS; m/z: 429 (MH.sup.+)
Test Example 1
Effect of combined use with antimicrobial agent on multidrug
resistant Pseudomonas aeruginosa
[1005] As multidrug resistant Pseudomonas aeruginosa, Pseudomonas
aeruginosa PAM 1723 strain highly expressing the drug efflux pump
was used. As antimicrobial drugs for the combinational uses,
levofloxacin (LVFX) as a quinolone antibacterial agent and
aztreonam (AZT) as a monobactam antibiotic were used. Each of the
compounds shown in Table 1 with Example No., which falls within the
compounds of the present invention, was subjected to the
measurement of its minimum concentration (.mu.g/ml) that was
required to enhance the antibacterial activity of levofloxacin when
the test compound was used in combination with levofloxacin applied
at a concentration of 1/4, or 1/8 or less of the minimum inhibitory
concentration against the PAM 1723 strain. As for aztreonam, a
minimum concentration (.mu.g/ml) of each text compound was measured
that was required to enhance its antibacterial activity when the
test compound was used in combination with azthreonam at a
concentration of 1/8 or less of the MIC. Effects as combinational
uses for 18 hours was indicated for each of the drugs. Effects were
determined by visually observing the turbidity of the medium. The
Muller-Hinton broth (MHB, Difco) was used as a medium, and the
inoculum of the bacteria was 1.times.10.sup.6 CFU/ml. As clearly
shown in Table 1, the compounds of the present invention exhibited
effect on the drug resistant Pseudomonas aeruginosa in the
combinational uses mainly by inhibiting resistance due to the drug
efflux pump, and accordingly, it can be concluded that the class of
compounds are expected to be useful clinically. TABLE-US-00001
TABLE 1 Example No. MPC4 LVFX MPC8 LVFX MPC8 AZT 5 0.5 8 8 10 2 16
4 18 .ltoreq.0.25 1 0.5 26 0.25 1 1 78 0.5 1 1 94 4 16 16 98 1 4 4
104 0.24 1 0.5 117 1 4 4 130 2 8 8 135 4 16 8 141 0.25 16 2 152 2 8
4 155 0.25 2 2 Example No. Chemical Formula 5 ##STR22## 10
##STR23## 18 ##STR24## 26 ##STR25## 78 ##STR26## 94 ##STR27## 98
##STR28## 104 ##STR29## 117 ##STR30## 130 ##STR31## 135 ##STR32##
141 ##STR33## 152 ##STR34## 155 ##STR35##
Test Example 2
Synergistic Effect of Combined Use of a Drug Efflux Pump Inhibitor
and Plural Antibacterial Agents
[1006] By using a drug efflux pump inhibitor in combination with
two or more types of antibacterial agents that can be substrates of
the drug efflux pump, strong synergistic effect can be obtained and
thus an effective therapeutic method can be provided for treatment
of infectious diseases caused by Pseudomonas aeruginosa
Antibacterial agents for combination include antibacterial agents
excreted by Pseudomonas aeruginosa Mex type drug efflux pump such
as quinolones, .beta.-lactams, tetracyclines, macrolides,
chloramphenicol, sulfonamides, trimethoprim, .beta.-lactamase
inhibitors and so forth.
(1) Effect of Combined Used of a Pump Inhibitor, Levofloxacin
(LVFX) and Meropenem (MEPM) Evaluated by the Three-Dimensional
Checker Board Method
[1007] The effect was measured by the three-dimensional checker
board method by using Pseudomonas aeruginosa wild strain PAM 1020.
The test strain was inoculated into Mueller-Hinton broth containing
LVFX, MEPM (at 11 concentration levels and 0 .mu.g/ml) and the
compound of Example 26 (40-0.625 .mu.g/ml and 0 .mu.g/ml) at a
concentration of 10.sup.6 CFU/ml and cultured at 37.degree. C. for
18 hours. Then, MIC was measured for sole and combined use.
Measurement was performed by the checker board method and FIC index
was calculated according to the following equation. FIC
index=a/a0+b/b0+c/c0 wherein a0: MIC for Agent A used alone, a: MIC
for Agent A when Agents A, B and C are used in combination, b0: MIC
for Agent B used alone, b: MIC for Agent B when Agents A, B and C
are used in combination, c0: MIC for Agent C used alone, c: MIC for
Agent C when Agents A, B and C are used in combination.
[1008] It was determined that there was synergistic effect when FIC
index was 0.75 or less, additive effect or weak synergistic effect
when the index was more than 0.75 but not more than 1.125, no
effect of combined use when the index was more than 1.125 but not
more than 3.0, and antagonistic effect when the index was more than
3.0.
[1009] The results are shown in the following table. As for the
effect of MEPM on the combined use of two types of drugs, LVFX and
the compound of Example 26, effects of the addition of MEPM were
clearly observed for all of effective concentrations of the
compound of Example 26 (0.625-40 .mu.g/ml). As for the effect of
combined use of three types of drugs, apparent effects of the
addition of MEPM were observed for all of effective concentrations
of the compound of Example 26 (0.625-40 .mu.g/ml).
[1010] MIC values of the used agents for the PAM 1020 strain were
0.25 .mu.g/ml for LVFX, 80 .mu.g/ml or more for the compound of
Example 26, and 0.5 .mu.g/ml for MEPM. TABLE-US-00002 FIC index
provided by combined use of 3 types of drugs FIC index 0.016 0.0313
0.0625 0.125 0.25 (MEPM LVFX (MEPM LVFX (MEPM LVFX (MEPM LVFX (MEPM
LVFX Compound of conc. conc. conc. conc. conc. conc. conc. conc.
conc. conc. Example 26 .mu.g/ml) (.mu.g/ml) .mu.g/ml) (.mu.g/ml)
.mu.g/ml) (.mu.g/ml) .mu.g/ml) (.mu.g/ml) .mu.g/ml) (.mu.g/ml) 40
1.031 0.125 1.0625 0.125 0.750 0.0313 -- -- -- -- 20 0.781 0.125
0.8125 0.125 0.500 0.0313 -- -- -- -- 10 0.656 0.125 0.6875 0.125
0.500 0.0625 0.766 0.0039 -- -- 5 0.594 0.125 0.625 0.125 0.438
0.0625 0.563 0.0156 -- -- 2.5 1.063 0.25 0.59375 0.125 0.656 0.125
0.500 0.0313 -- -- 1.25 1.047 0.25 1.07813 0.25 0.641 0.125 0.563
0.0625 -- -- 0.625 1.039 0.25 1.07031 0.25 1.133 0.25 0.781 0.125
1.063 0.0078 0 1.031 0.25 1.0625 0.25 1.125 0.25 1.250 0.25 1.5
2
Test Example 3
Effect of Combined Use of Drug Efflux Pump Inhibitor and
Disinfectant
[1011] By using a drug efflux pump inhibitor in combination with a
disinfectant that can be a substrate of the drug efflux pump,
effect of combined use can be achieved and an effective
disinfection method can be provided.
[1012] Effects of a combined use of a drug efflux pump inhibitor
and alkyldiaminoethylglycine hydrochloride (AEG, trade name: Tego
51) or chlorhexidine gluconate (CHG, trade name: Hibiten) on
Pseudomonas aeruginosa PAM 1723 (a strain highly expressing
MexAB-OprM drug efflux pump) was determined by the broth dilution
method. The compound of Example 26 was added at a final
concentration of 10 .mu.g/ml to Mueller-Hinton broth (MHB)
containing a disinfectant at a concentration after 2-fold serial
dilution. The amount of the test bacteria inoculated was
1.times.10.sup.6 CFU/ml, and after standing cultivation at
37.degree. C. for 18 hours, the culture was observed by visual
inspection. The minimum concentration that gave no turbidity as in
the control of MHB was determined as MIC.
[1013] The results are shown in the following table. Evaluation of
the effect of the combined use of the disinfectant and the compound
of Example 26 revealed that the activities of AEG and CHG on PAM
1723 were enhanced by two times and four times, respectively, by
the combined use with 10 .mu.g/ml of the compound of Example 26.
TABLE-US-00003 MIC (.mu.g/ml) AEG CHG Single Combined Combined
Strain use use Ratio* Single use use Ratio* PAM 64 32 2 16 4 4 1723
*Ratio of MIC values for single use of the disinfectant and
combined use with the compound of Example 26
* * * * *